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Abstract
Health technology assessments require reliable estimates of relative treatment
effects for a given patient population, to inform decision making. Standard
network meta-analysis (NMA) and indirect comparisons combine aggregate
data (AgD) from multiple studies on treatments of interest, assuming that any
treatment effect modifiers are balanced across populations. This assumption
can be relaxed if individual patient data (IPD) are available from all studies,
using an IPD network meta-regression (NMR). However, in many cases IPD
are only available from one or a subset of studies.
Recently proposed methods for population-adjusted indirect comparisons
aim to adjust for differences between one IPD study and one AgD study.
However, the resulting comparison is only valid in the AgD study population
without additional assumptions, and the methods cannot be extended to
larger treatment networks. Meta-regression approaches can be used in larger
networks, but typically incur aggregation bias.
In this thesis, webeginby reviewing the literature onpopulation adjustment
and related problems, giving a critique of current methods. We review
applications of current methods in the published literature and in National
Institute for Health and Care Excellence technology appraisals. Motivated
by these reviews we propose a general method, Multilevel Network Meta-
Regression (ML-NMR), that overcomes some of the disadvantages of current
approaches and reduces to AgD NMA and IPD NMR as special cases. We
discuss the computational aspects of implementingML-NMR, before applying
to a real example of plaque psoriasis treatments. The ML-NMR framework is
then extended to handle more general likelihoods, illustrated with an artificial
example of survival outcomes and a reanalysis of the plaque psoriasis example
incorporating multiple outcomes. An extensive simulation study is conducted
to assess the performance of ML-NMR and current methods in a range of
scenarios and under various failures of assumptions. We conclude with a
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Health technology assessments and appraisals require reliable estimates of
the relative effectiveness of all relevant treatments or interventions for a given
patient population, to inform decision making. In the United Kingdom, the
National Institute for Health and Care Excellence (NICE) operates a technology
appraisal (TA) process in which a company submits evidence on the clinical
and cost effectiveness of their treatment compared to other relevant treatments.
However, it is rare that all relevant treatments have been compared head-to-
head in a single randomised controlled study; instead, the evidence base is
often comprised of several studies, each comparing a subset of the treatments
of interest.
When head-to-head evidence is not available, but two treatments of interest
have been studied against a common comparator (e.g. placebo or standard care),
a standard indirect comparison may be performed using published aggregate
data (AgD) from each study (Bucher et al. 1997; Glenny et al. 2005). With
larger numbers of treatments and studies, a network meta-analysis (NMA) is
the standard approach, of which indirect comparison is a simple special case
(Ades 2003; Dias et al. 2011c; Hasselblad 1998; Higgins and Whitehead 1996;
Lu and Ades 2004, 2006). NMA combines direct evidence (i.e. head-to-head)
and indirect evidence (i.e. via a common comparator) in a coherent manner,
and allows any two treatments in the network to be compared regardless of
whether they were involved in the same head-to-head study. We introduce
NMA in greater detail in Section 1.2.
Wemake a distinction between prognostic variables, which affect outcomes
equally on all treatments, and effect modifiers (EMs), which alter the effect of
treatment relative to control on a chosen scale. Some variables may be both
prognostic and effect modifying, or purely one or other. Standard methods for
indirect comparison and network meta-analysis (and pairwise meta-analysis)
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respect randomisation and are thus unaffected by differences in prognostic
variables between populations. However, these methods do assume that
the distributions of any effect modifying variables do not differ between
study populations and the decision target population, so that relative effects
are constant across populations. This assumption does not always hold, as
evidenced by the frequent use of random effects meta-analysis. Methods
which relax this assumption to form population-adjusted indirect comparisons are
becoming increasingly common for submissions to reimbursement agencies
such as NICE. Effect modifying variables may be population characteristics
such as age, sex, or disease severity. Other study-level variables can also be
seen to modify treatment effect, such as differences in treatment intensity
between studies, or differences in healthcare systems by country or region. In
a health technology appraisal context the latter are typically tightly-defined;
we therefore focus on effect modification by population characteristics.
Ideally, individual patient data (IPD) would be available from all studies
to fully adjust for differences between study populations using IPD network
meta-regression (NMR) (Berlin et al. 2002; Dias et al. 2011a; Lambert et al. 2002;
Riley et al. 2010; Tudur Smith et al. 2005), as aggregate data network meta-
regression has low power to detect or adjust for effect modifying covariates and
is susceptible to ecological bias (Berlin et al. 2002; Donegan et al. 2013; Rothman
et al. 2008; Saramago et al. 2012). However, it is rarely the case that full IPD are
available. In particular, a very common scenario in the TA context is when a
company has IPD on its own trial but only publishedAgD on their competitor’s
trial, typically consisting of average treatment effects and summary patient
characteristics (e.g. mean and standard deviation for continuous characteristics,
and proportions for discrete). Population adjustment methods aim to use
the available IPD to adjust for between-trial imbalances in the distribution of
observed covariates. The development and use of these methods is motivated
by one of two reasons: either i) there is evidence for effect modification, and
these variables are distributed differently in each study population; or ii)
there is no common comparator or the relevant studies are single arm, and so
adjustment is required for all prognostic and effect modifying variables. We
describe the population adjustment scenario in greater detail in Section 1.1.
Two recently proposed methods, Matching-Adjusted Indirect Comparison
(MAIC) (Ishak et al. 2015; Signorovitch et al. 2012, 2010) and Simulated
Treatment Comparison (STC) (Caro and Ishak 2010; Ishak et al. 2015), are
becoming increasingly popular in the applied literature and in submissions
to NICE. These approaches (described in detail in Section 2.2) are based on
2
reweighting and regression adjustment ideas that date back several decades in
the surrounding literatures on standardisation, generalisation, and calibration
(reviewed in Section 2.1). MAIC and STC are primarily designed with a
simple two-study scenario in mind, where IPD on one study is used to
create a population-adjusted indirect comparison in the population of an AgD
study. As such, these methods are not easily generalisable to larger treatment
networks. Present attempts to extend MAIC to larger networks (e.g. Belger
et al. 2015b) match an IPD trial either to the population of a chosen AgD trial
in a larger network, or to the overall average population in a larger network,
and then perform an NMA on the full network including the reweighted IPD
trial. Both of these approaches make different assumptions regarding effect
modification in different parts of the network, and are thus difficult to justify:
the MAIC is predicated on the fact that EMs are present and imbalanced
between the IPD trial and AgD trial (or overall average AgD population),
whereas the ensuing NMA assumes that there are no imbalances in any EMs
in the AgD trials. MAIC and STC are also limited to providing a comparison
adjusted to the population of the AgD trial, which may not match the target
population for the decision. If effect modification is present, then relative
effect estimates must be provided for the relevant decision target population
in order to be useful for decision making.
Separately from the development of MAIC and STC, efforts have also been
made to extend the IPD network meta-regression framework to incorporate
both IPD and AgD studies (Donegan et al. 2013; Jansen 2012; Saramago et al.
2012; Sutton et al. 2008; Thom et al. 2015). These methods (described in detail
in Section 2.2) typically assume common regression coefficients at both the
individual and aggregate level, which leads to aggregation bias (a form of
ecological bias) when the model is non-linear (Rothman et al. 2008). Two
approaches have been proposed to account for this. The first is to split the
interaction effect into between-study (or aggregate-level) and within-study
(or individual-level) effects (Donegan et al. 2013; Saramago et al. 2012; Sutton
et al. 2008; Thom et al. 2015). However, in smaller networks (such as the
two-study scenario addressed by MAIC and STC) there are insufficient data
to identify the additional parameters. The second approach is to define the
aggregate-level model by integrating the individual-level model over the study
population. This avoids aggregation bias by properly relating the two levels,
and does not introduce additional parameters. So far, however, this approach
has only been derived for the simple case of binary outcomes and binary
covariates, where the integration reduces to summation (Jansen 2012).
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This thesis sets out to propose a new and general method for population-
adjusted indirect comparisons and network meta-regression combining IPD
and AgD, which can be applied to any connected network of evidence and
produce estimates in any specified target population. We generalise and build
upon the ideas of Jansen (2012) to extend to other outcomes, likelihoods, and
covariate distributions, aided by a general method for numerical integration.
We call this new approach Multilevel Network Meta-Regression (ML-NMR).
ML-NMR has the desirable property that standard IPD NMR and AgD NMA
are special cases.
In this chapter, we provide a background on indirect comparisons and
NMA, which underlie the rest of this thesis. We start by describing in greater
detail the simple two-study scenario, and the methods of standard indirect
comparison, MAIC, and STC (Section 1.1, also published as part of Phillippo
et al. 2016; Phillippo et al. 2018a). We then provide an overview of NMA and
the key concepts, including heterogeneity and inconsistency, and model fit
and comparison (Section 1.2). Finally, we summarise this chapter in Section 1.3
before outlining the structure of the remainder of this thesis (Section 1.4).
1.1 Background to population-adjusted indirect comparisons
We begin by describing a simple two-study scenario, in which a comparison
is made between two treatments investigated separately in two studies. We
distinguish between population adjustment methods that make anchored indi-
rect comparisons, where the evidence is connected by a common comparator,
and unanchored indirect comparisons, where the evidence is disconnected
due to a lack of a common comparator or single-arm studies. We make a
clear and necessary distinction between prognostic variables and effect modifiers:
prognostic variables are covariates that affect outcome; effect modifiers (also
known as predictive variables, Hingorani et al. 2013) are covariates that alter
the effect of treatment as measured on a given scale. Effect modifiers are not
necessarily also prognostic variables, and may be specific to each treatment.
Effect modifier status on one scale does not necessarily imply effect modifier
status on another scale (van Valkenhoef and Ades 2013). We assume internal
validity of the studies included in the analysis, so that the studies provide
unbiased estimates of treatment effects in their respective sample populations.
Consider the scenario in Figure 1.1 with one AB trial for which the analyst
has IPD, and one AC trial for which only published AgD are available. We
wish to estimate a comparison of the effects of treatments B and C on an
4
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A
B C
Figure 1.1 An anchored indirect comparison in a simple two-study scenario.
IPD are available for the AB study (represented by the thick line); only AgD
are available for the AC study (thin line). An anchored indirect comparison
(dotted line) compares treatments B and C via the common treatment A arms.
appropriate scale in some target population P, denoted by the parameter dBC(P).
Within the AB trial population there are parameters θA(AB), θB(AB), and θC(AB)
representing the expected outcome on each treatment (including for treatment
C, which was not studied in the AB trial). The AB trial provides estimates
ȳA(AB) and ȳB(AB) of θA(AB) and θB(AB) respectively, which are the summary
outcomes (e.g. probability of success, or mean response) on each treatment.
The parameter θC(AB) is not estimated by the AB trial. There is a parallel
system of parameters {θA(AC) , θB(AC) , θC(AC)} and estimates { ȳA(AC) , ȳC(AC)}
in the AC trial.
Having selected a suitable scale, for example a logit, log, risk difference, or
mean difference scale, we estimate the population-specific relative treatment




















Standard methods for indirect comparison make the assumption that there
is no difference in the distribution of effect modifying covariates, specific to
the chosen scale, between the population in the AB and AC trials or the target
population P, so that the population-specific relative treatment effects are
equal across populations:
dAB(AB)  dAB(AC)  dAB(P) , (1.2a)
dAC(AC)  dAC(AB)  dAC(P). (1.2b)
Under this assumption, which we call constancy of relative effects, a standard
indirect comparison estimates the relative effect of C vs. B in population P as
d̂BC(P)  d̂AC(AC) − d̂AB(AB) , (1.3)
which takes account of the fact that individuals are only randomised within
trials (Bucher et al. 1997).
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For the purposes of technology appraisal, we typically require estimates of
absolute effects (for example, as inputs to a cost-effectiveness analysis). The
final step is thus to apply these relative effects to a specified target population P
in which the summary absolute effect (such as the mean change from baseline,
or probability of response) of treatment A is ȳA(P). We can now estimate the
summary absolute effects on treatments A, B, and C in the target population,




















Suppose that, in each trial, we have information on a common set of co-
variates x. Between-trial differences in the distribution of prognostic variables
that are not effect modifiers do not affect inference, because the within-trial
randomisation means that they do not impact on the relative treatment effects.
Note that effect modifiers xEM, a subset of x, are assumed to have an additive
effect on the transformed scale. In other words, at any given value of xEM, the
conditional relative effect is γAB + βTxEM, conceptualised as an “intercept” term
(the relative effect γAB at xEM  0) plus an interaction effect βTxEM.
If there are effect modifiers and if these are distributed differently between
the populations, then the relative treatment effects dAB(AB) and dAC(AC) that
can be estimated directly from each trial are only valid for a population with
the distribution of effect modifiers observed in that trial. For example, we
would have estimates d̂AB(AB) in the AB population and d̂AC(AC) in the AC
population, but it would not be possible to identify a coherent set of estimates,
either for the population represented by the AB trial
d̂AB(AB) , d̂AC(AB) , d̂BC(AB)  d̂AC(AB) − d̂AB(AB)
(since d̂AC(AB) is not available), or for the population represented by the AC
trial
d̂AB(AC) , d̂AC(AC) , d̂BC(AC)  d̂AC(AC) − d̂AB(AC)
(since d̂AB(AC) is not available), or indeed for any other target population.
The premise of population adjustment methods such as MAIC and STC in
a connected network is to relax the constancy of relative effects assumption by
adjusting for between-trial differences in effect modifying covariates, in order
to identify a coherent set of estimates where standard methods of indirect
comparison cannot. Both methods use IPD on the AB trial to form predictions
6
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ŷA(AC), ŷB(AC) of the summary outcomes that would be observed on treatments
A and B in the AC trial. MAIC and STC, and the process by which these
predictions are obtained, are described in greater detail in Section 2.2. The





















The validity of this anchored comparison assumes that the dAB(AC) relative
effect can be reliably predicted using the IPD in the AB study given that
all effect modifying covariates are known and adjusted for, which we call
conditional constancy of relative effects.
B C
Figure 1.2 Anunanchored indirect comparison in a simple two-study scenario.
IPD are available for the B study; only AgD are available for the C study. An
unanchored indirect comparison (dotted line) compares treatments B and
C directly, without a common comparator. The studies involved may also
have other treatment arms, or be single-arm as shown here; the key difference
between Figure 1.1 is the lack of a common comparator.
In a disconnected network or where single-arm trials are involved (as
in Figure 1.2), MAIC and STC instead attempt to improve on a naïve (or
“unadjusted”) indirect comparison of arms by adjusting for any covariates that










An unanchored comparison assumes that absolute outcomes θB(C) can be
reliably predicted; this is a very strong assumption, which we call conditional
constancy of absolute effects. To be valid, all effect modifiers and prognostic
variables must be known and adjusted for. An anchored indirect comparison
should therefore always be preferred in a connected network, as it respects the
randomisation within studies and does not rely on such strong assumptions.
However, if the treatment network is disconnected or contains single-arm
studies, then there is no common comparator arm through which to make an
anchored indirect comparison, andwemay be obliged to rely on anunanchored
indirect comparison.
Table 1.1 summarises the constancy assumptions made by the different
forms of indirect comparison. These assumptions are described in greater
detail in Section 2.3.
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Table 1.1 All indirect comparisons and network meta-analyses require some
form of constancy assumption. Unanchored comparisons require a much
stronger assumption, which is widely considered impossible to meet.
















⇒ Relative effects are the
same across populations
⇒ Reliable predictions of
relative effects
⇒ Reliable predictions of
absolute effects
Valid only if No effect modifiers in
imbalance
All effect modifiers known
and adjusted for





Aggregate data IPD on at least one trial IPD on at least one trial
1.2 Background to networkmeta-analysis
When a larger network of treatments and studies is available, the standard
approach is a network meta-analysis (Ades 2003; Dias et al. 2011c; Hasselblad
1998; Higgins andWhitehead 1996; Lu and Ades 2004, 2006). NMA provides a
coherent set of relative treatment effects which is essential for decision making
(Caldwell et al. 2005), and standard indirect comparison (described above in
Section 1.1) is a simple special case. For greatest generality, we label treatments
numerically in a NMA (i.e. treatments 1, 2, 3, etc.) instead of alphabetically
as in an indirect comparison. An example treatment network is shown in
Figure 1.3.
We begin this section by describing the standard parameterisation for
writing NMAmodels, known as the baseline shift parameterisation, in which a
reference treatment arm is defined for each trial. We then describe an alterna-
tive parameterisation, which we term the reference treatment parameterisation,
that uses a single reference treatment across the entire network. We will
show that these two parameterisations are equivalent, and henceforth use
the reference treatment parameterisation for the remainder of this thesis. We
consider AgDNMA to begin with, but the same arguments apply to IPDNMA
(and, by extension, to ML-NMR as developed in Chapter 4).
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Figure 1.3 An example network of five treatments, connected by study evi-
dence (solid lines). Not all treatments are directly compared in a study, but
NMA combines all of the direct and indirect evidence in a coherent manner
allowing any two treatments to be compared.
1.2.1Baseline shi parameterisation
Consider that we have summary outcome data y• jtk available on treatment
tk in arm k of study j. The subscript • denotes that the data are summaries
over individuals; this will help to distinguish from individual-level data yi jtk ,
that we introduce later. Using the standard baseline shift parameterisation,
we write out the NMAmodel as
y• jtk ∼ π(θ• jtk ) (1.7a)




µ(t1)j for k  1
µ(t1)j + δ jt1tk for k > 1
(1.7c)
where π(·) is a suitable likelihood (e.g. Binomial, Normal, Poisson, etc.), and
g(·) is a link function transforming the expected summary outcomes θ• jtk
onto the linear predictor η• jtk . Again, we use a subscript • to help distinguish
these parameters, which relate to aggregate-level summaries, from their
counterparts introduced later, which relate to individuals. The baseline shift
parameterisation dictates the form of the linear predictor η• jtk , so that µ
(t1)
j are
study-specific baseline parameters (here we use a superscript referring to the
interpretation of the study-specific baselines with respect to the treatment t1
in arm 1), and δ jt1tk is the study-specific relative effect of treatment tk in arm k
vs. treatment t1 in arm 1.
In a fixed effect (FE) model, the study-specific relative effects are the same
across trials:
δ jt1tk  dt1tk  d1tk − d1t1 , (1.8)




dab  d1b − d1a . (1.9)
We often write dt in place of d1t , and we set d1  0. In a Bayesian analysis,
prior distributions are placed on the parameters µ(t1)j and dt .
In a random effects (RE) model, the study-specific relative effects instead
have a distribution. For trials with three or more arms the relative effects
are correlated, given a multivariate Normal with marginal distributions and
correlations given by
δ jt1tk ∼ N(dtk t1 , τ2t1tk ) ∀k > 1 (1.10a)
cor(δ jt1tk1 , δ jt1tk2 )  ψ
(t1)
tk1 tk2
∀k1 , k2 > 1. (1.10b)
The superscript (t1) on the pairwise correlation parameters by convention
denotes the treatment that the correlation between random effects is with
respect to: i.e. here the correlation is for random effects of treatments tk1 and
tk2 against t1. For trials with only two arms, the single relative effect on the
non-reference arm is univariate Normal with marginal distribution given by
(1.10a). As with the fixed effect model, we have the consistency equations
(1.9) on the treatment effects, but now we also have a set of second-order




− 2ψ(t1)tk1 tk2 τt1tk1 τt1tk2 . (1.11)
Prior distributions on the random effect variances and correlations are non-
trivial to specify, as they must jointly satisfy these consistency constraints (Lu
and Ades 2009). However, if we assume that the between-study variances are
homogeneous and equal to τ2, this implies that all the correlations are equal
to 0.5 (following (1.11), see Higgins and Whitehead 1996).
1.2.2 Reference treatment parameterisation
In the reference treatment parameterisation, the likelihood and link function
remain the same as the baseline shift parameterisation (equations (1.7a) and
(1.7b)). However, the linear predictor η• jt for study j treatment t is now
written in terms of the reference treatment, which we set to be treatment 1
without loss of generality, leading to the following NMAmodel:
y• jt ∼ π(θ• jt) (1.12a)
θ• jt  g−1(η• jt) (1.12b)
η• jt  µ
(1)
j + δ jt ∀t ≥ 1, (1.12c)
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where µ(1)j are study-specific baseline parameters for reference treatment 1
(the superscript referring to the interpretation with respect to the reference
treatment 1), and δ jt  δ j1t is the study-specific relative effect of treatment t
vs. treatment 1. The subscript k is dropped from tk in the reference treatment
parameterisation, since it is no longer necessary.
The fixed effect model is written as
δ jt  d1t , (1.13)
again often writing dt for d1t and setting d1  0. We still have the set of
consistency equations (1.9), but these are not explicitly used in writing down
the model. In a Bayesian analysis, prior distributions are placed on the
parameters µ(1)j and dt .
For the random effects model, this time every non-treatment 1 arm has a
random effect. Therefore wemust handle the correlations between the random
effects for all trials with two or more non-treatment 1 arms, not just those with
three or more arms in total. We specify the random effects to be multivariate
Normal, with marginal distributions and correlations given by
δ jt ∼ N(dt , τ2t ) ∀t > 1 (1.14a)
cor(δ ja , δ jb)  ψ(1)ab ∀a , b > 1, (1.14b)
and δ j1  0. For two-arm studies that compare a treatment t > 1 against
treatment 1, there is a single univariate Normal random effect on the non-
treatment 1 arm, with distribution given by (1.14a). We still have the second-
order consistency equations (1.11), nowwith respect to the reference treatment







ab τaτb . (1.15)
but these are not explicitly used in writing down the model; prior distributions
are therefore straightforward to specify on the τ2t parameters, since the
second-order consistency equations are then implicitly satisfied. Again, if the
homogeneous variance assumption is used this implies that all the correlations
are equal to 0.5.
1.2.3Equivalence
The standard baseline shift parameterisation (Section 1.2.1) defines a reference
arm 1 in each study, in which the treatment is t1. Study-specific baseline
parameters refer to this treatment arm, and the other treatment arms in the trial
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are compared to the treatment t1 as relative effects. The reference treatment
parameterisation (Section 1.2.2) instead defines a single reference treatment
across the entire network. Without loss of generality, we set treatment 1 to
be the reference treatment. Study-specific baseline parameters then always
refer to the reference treatment, and relative treatment effects in each trial are
always against the reference treatment—even if the trial does not include this
treatment arm. These two parameterisations are trivially equivalent when
every study has a treatment 1 arm. However, when there are trials without
a treatment 1 arm, the baseline shift parameterisation specifies a model on
a different set of relative effects to the reference treatment parameterisation.
Here, we show that the two parameterisations are indeed equivalent regardless
of the network structure (with some caveats, discussed later in Section 1.2.3.1).




j + δ jt1 . (1.16)
Intuitively, we transform the reference treatment parameterisation (where the
baselines are with respect to treatment 1) into the baseline shift parameterisa-
tion (where the baselines are with respect to treatment t1 in arm 1) simply by
adding the study-specific relative effect of treatment t1 vs. 1 to the baseline
effect of treatment 1, and vice versa.
For both the fixed and random effects models this result follows from
the property that relative effects are consistent within a study, requiring the
study-specific relative effects to “add up” within a study j (Lu and Ades 2009):
δ jtk1 tk2  δ jt1tk2 − δ jt1tk1
 δ j1tk2 − δ j1tk1 ,
(1.17)
where this relationship can be expressed with respect to the reference arm
treatment t1 or the reference treatment 1 (or indeed any other treatment).
(The first and second-order consistency relations are motivated by taking
expectations and variances respectively of both sides of (1.17).) We see that
(1.16) is the necessary relation to equate the two parameterisations:
µ(t1)j + δ jt1tk  µ
(t1)
j + δ jtk − δ jt1

(
µ(t1)j − δ jt1
)
︸         ︷︷         ︸
(1.16)
+ δ jtk
 µ(1)j + δ jtk .
(1.18)
To see that the joint random effects distribution remains the same, consider
the joint distribution of the T − 1 basic random effects (i.e. against treatment 1),
12
1.2. BACKGROUND TO NETWORK META-ANALYSIS



























In any given trial, the reference treatment parameterisation selects the nec-
essary subset of these basic random effects. By comparison, the baseline
shift parameterisation puts functional random effects on non-reference arms,
which are linear combinations of the basic random effects (a description used
previously by Lu and Ades (2006), with basic/functional terminology from
Eddy et al. (1990)). In general, the functional random effects of the baseline
shift parameterisation can be written in terms of the basic random effects as







cov(δ jt1tk1 , δ jt1tk2 )  cov(δ j1tk1 − δ j1t1 , δ j1tk2 − δ j1t1)
 cov(δ j1tk1 , δ j1tk2 ) − cov(δ j1tk1 , δ j1t1)
− cov(δ j1t1 , δ j1tk2 ) + cov(δ j1t1 , δ j1t1)
 ψ(1)tk1 tk2










To see that themean and variance of the functional random effects (1.20) are the
same as those specified in the baseline shift parameterisation (1.10) is simply a
matter of applying the first (1.9) and second-order (1.15) consistency relations,
respectively. To transform correlations with respect to treatment 1 (as used in
the reference treatment parameterisation) into correlations with respect to the
treatment in the reference arm (as used in the baseline shift parameterisation),














Thus we have equivalence of random effects NMA under the two parameteri-
sations: the reference treatment parameterisation writes out the model using
the basic random effects, whereas the baseline shift parameterisation writes
out the model using the functional random effects.
The distribution of these functional random effects can also be computed
in matrix form. Writing (1.19) in a compact manner as δ j ∼MVN(d ,Στ), we
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use the fact that
Dδ j ∼MVN(Dd ,DΣτDT) (1.23)
for any given “design” matrix D selecting the relevant contrasts, to the same
result.
Notice that the reference treatment parameterisation aligns closely with
the “auxiliary variables” approach used by Lu and Ades (2009) to find prior
configurations that satisfy the second-order consistency equations. Lu and
Ades (2009) consider expressing the random effects δ jt1tk as the sum of two
correlated Normal “auxiliary variables” (and thus the heterogeneity variances
τ2t1tk in a form analogous to (1.15)), leading to simplified prior specification
satisfying the second-order consistency equations. In this case, the auxiliary
variables are precisely the basic random effects δ j1t1 and δ j1tk , and we have
one-to-one correspondence between the formulations as described above
(which is not true for general auxiliary variables).
1.2.3.1 Caveats to equivalence
The equivalence of the two parameterisations is true up to the specification of
prior distributions on the study-specific baselines µ(t1)j or µ
(1)
j . When t1 , 1, the
baselines in the two parameterisations refer to absolute responses on different
treatments, and thus the same prior distribution has different interpretations
under the different parameterisations. It is typical to place non-informative
or weakly-informative prior distributions on the study-specific baselines, and
in this case there is unlikely to be any noticeable difference to the posterior
distribution; however, if stronger prior distributions are to be placed then the
different interpretations of the baselines should be noted, and if necessary
prior distributions may be transformed from one parameterisation to the other
via (1.16).
1.2.4 IPD networkmeta-regression
When individual patient data are available from every study, an IPD network
meta-regressionmay be performed (Berlin et al. 2002; Dias et al. 2011a; Lambert
et al. 2002; Riley et al. 2010; Tudur Smith et al. 2005). Consider that outcomes
yi jt and covariates xi jt are available for each individual i in study j on treatment
t. Using the reference treatment parameterisation, an IPD NMR model is of
14
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the form
yi jt ∼ π(θi jt) (1.24a)
θi jt  g−1(η jk(xi jt)) (1.24b)
η jk(xi jt)  µ(1)j + x
T
i jt(β1 + β2,t) + δ jt , (1.24c)
where π(·) is a suitable likelihood, and g(·) is a link function transforming the
expected outcomes θi jt onto the linear predictor η jk(xi jt). As with AgD NMA
using the reference treatment parameterisation, µ(1)j are study-specific baseline
parameters for reference treatment 1. Prognostic covariate effects are given by
β1, and effect modifier interactions with treatment are β2,t . We set β2,1  0.
Again, δ jt can either be fixed effect or random effects, except now in terms of
individual-level (conditional) relative effects γ1t . We often write γt for γ1t .
The fixed effect model is written as
δ jt  γt , (1.25)
with γ1  0. In a Bayesian analysis, prior distributions are placed on the
parameters µ(1)j and γt .
For the random effects model, we specify the random effects to be multi-
variate Normal, with marginal distributions and correlations given by
δ jt ∼ N(γt , τ2t ) ∀t > 1 (1.26a)
cor(δ ja , δ jb)  ψ(1)ab ∀a , b > 1, (1.26b)
and δ j1  0. For two-arm studies against treatment 1, there is a single univariate
Normal random effect on the non-treatment 1 arm, with distribution given
by (1.26a). Prior distributions are required for µ(1)j , γt , and τ
2
t . Again, if the
homogeneous variance assumption is used this implies that all the correlations
are equal to 0.5.
As for the AgD NMAmodel, we have consistency equations (1.9) on the
(now individual-level) relative effects γt , and for the random effects model
we also have second-order consistency (1.15) on the heterogeneity variances
τ2t . Furthermore, we now have consistency equations on the effect modifier
interaction coefficients β2,t :
β2,ab  β2,1b − β2,1a , (1.27)




Using baseline shift parameterisation, the linear predictor in the IPD NMR
model is instead written as





(β1 + β2,t1tk ) + δ jt1tk
 µ(t1)j + x
T
i jtk
(β1 + β2,tk − β2,t1) + δ jtk − δ jt1 .
(1.28)







β2,t1 + δ jt1 . (1.29)
The interpretation of the study-specific baseline parameters under the different
parameterisations is now also with respect to the reference level of the covari-
ates (typically centred for continuous covariates). We interpret the baselines
under the baseline shift parameterisation (absolute outcomes on treatment
t1) as the baselines under the reference treatment parameterisation (absolute
outcomes on treatment 1) plus the study-specific relative effect of treatment
t1 vs. treatment 1, all at the reference level of the covariates. As described in
Section 1.2.3.1, the equivalence of the two parameterisations is true up to the
specification of prior distributions on the study-specific baselines µ(t1)j or µ
(1)
j .
1.2.5 Advantages of dierent parameterisations
Both the baseline shift and reference treatment parameterisations have their
relative advantages and disadvantages.
Firstly, the baseline shift parameterisation is the standard parameterisation
for NMA in the literature, and is thus the most familiar form for those
applying and developing NMAmethods. For RE models, the baseline shift
parameterisation specifies only a single random effect for studies with only two
arms, thus avoiding the need to account for correlations in networks where
only two-arm studies are present. By comparison, the reference treatment
parameterisation specifies random effects on every non-reference treatment
arm, and so correlations between random effects are present for every network
other than a simple “star network” where every study is a single comparison
against treatment 1. For both parameterisations, correlations between random
effects—where present—are essential, and cannot be ignored. The baseline
shift parameterisation is also more obviously not a pooling over treatment
arms, since the relative effects are explicitly written out using the consistency
equations—a fact that may be less obvious when using the reference treatment
parameterisation. “Arm-based” NMAmodels that pool absolute effects over
16
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treatment arms instead of pooling relative effects have been proposed (Hong
et al. 2015), but have been criticised for not respecting randomisation (Dias
and Ades 2015). Furthermore, since the consistency equations are explicitly
written out as part of the baseline shift parameterisation, it is simpler to assess
inconsistency through unrelated mean effects or node-splitting models (see
Section 1.2.7).
On the other hand, the reference treatment parameterisation allows for
simpler implementation in code, as there is no longer a need to keep track of the
reference treatment for each study. Moreover, it is much more straightforward
to specify prior distributions for non-equal heterogeneity variances τ2t under
the reference treatment parameterisation, since the second-order consistency
equations hold simply by construction. Lastly, the reference treatment param-
eterisation allows for the inclusion of single-arm studies through a model on
the study-specific baselines µ(1)j , which is possible in this parameterisation
since these all refer to the reference treatment 1, rather than study-specific
reference treatments t1 (Thom et al. 2015). Although this is not a scenario we
consider in this thesis, we expect future development of the new methods
proposed here to proceed in this direction (see discussion in Section 9.2.7).
For the remainder of this thesis, we adopt the reference treatment parame-
terisation. We also switch to indexing treatments by k  1, . . . , K so that, for
example, individual-level data are referenced as individual i in study j on
treatment k. This also frees up t to refer to event or survival times when we
consider models for time-to-event data later in Chapter 7.
1.2.6Model fit and comparison
In a Bayesian NMA framework, model fit is often assessed using the resid-
ual deviance, and different models are often compared using the Deviance
Information Criterion (DIC) (Dias et al. 2011c; Spiegelhalter et al. 2002).
The residual deviance for a data point is defined as the deviance (−2 times
the log likelihood) under the current model, minus the deviance under a
saturated model where every data point is perfectly predicted (McCullagh
and Nelder 1989). The form of the residual deviance is dictated by the form of
the likelihood; formulae for some common likelihoods are given by Welton
et al. (2012, p. 123), and later in Table 5.1. For example, in an AgD NMA with
Binomial likelihood, y• jk ∼ Bin(N jk , p jk), the residual deviance contribution
Dres;• jk for the treatment k arm of study j is







+ (N jk − y• jk) log
(
N jk − y• jk





where ŷ• jk  N jk p jk is the predicted number of events under the model. The
total residual deviance Dres is the sum of the residual deviance contributions






Dres;• jk . (1.31)
For an IPD NMA, the residual deviance contribution for an individual i in








Dres;i jk . (1.32)
For the purposes of checking absolute model fit, we are interested in the
posterior distribution of Dres, and of the contribution from each data point
(either Dres;i jk or Dres;• jk in an AgD or IPD NMA, respectively). The posterior
mean of the residual deviance, (Dres), can be compared to the number
of independent data points to check if model fit is adequate: the two will
be approximately equal under a well-fitting model assuming approximate
Normality (which may not hold in practice, e.g. for binary data in small
samples or with event probabilities far from 0.5) (Spiegelhalter et al. 2002).
Furthermore, the posterior distributions of the residual deviance contributions
from each data point can be plotted (e.g. posterior mean and 95% Credible
Interval), to identify any poorly-fitting observations (those with contributions
much greater than 1).
To compare different models, we need to trade off goodness-of-fit against
model complexity. The DIC achieves this by penalising the residual deviance
Dres by ameasure of the effective number of parameters, pD . FollowingWelton
et al. (2012, p. 126), we calculate pD as the difference between the posterior
mean of Dres and the value of Dres calculated at the posterior mean of the
fitted values (for example, in an AgD NMA we replace ŷ• jk by ( ŷ• jk)):
pD   (Dres) − Dres

( ŷ). (1.33)
(Spiegelhalter et al. (2002) originally suggested calculating pD at the posterior
mean of the parameters; the modification of Welton et al. (2012) is more stable
in hierarchical models.) The DIC is then calculated as
DIC   (Dres) + pD . (1.34)
When comparing a set of candidate models, lower values of DIC are preferred;
typically differences of less than 3 are considered small, and differences of
more than 5 are considered substantial (Lunn et al. 2010, pp. 165–167; Dias
et al. 2018, p. 69). If differences in DIC are small we would typically prefer the
model with the smallest effective number of parameters.
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1.2.7Assessing inconsistency
A key assumption of network meta-analysis is that of consistency: that is, treat-
ment effects “add up” across the network through the consistency equations
(1.9), dbc  dac − dab for all treatments a, b, c (Higgins and Whitehead 1996;
Lu and Ades 2006). Consistency is guaranteed to hold within multi-arm trials
by design. However, when direct and indirect evidence from different studies
are available on the same comparison (e.g. direct evidence on d23 and indirect
evidence via d12 and d13) there is potential for disagreement, or inconsistency.
Checking consistency is therefore a key part of a network meta-analysis.
Inconsistency and heterogeneity are both caused by differences between
studies that alter the treatment effect, such as differences in effect modifying
covariates or outcome or treatment definitions. We consider, heterogeneity
as affecting studies on the same treatment comparison, and inconsistency as
affecting studies on different treatment comparisons. However, in networks
containing multi-arm trials this distinction is not uniquely defined, and
depends on the choice of baseline treatment. Inconsistency and heterogeneity
are therefore often examined together.
Several methods for assessing inconsistency have been proposed, including
inconsistency factors (Lu and Ades 2006), design-by-treatment interactions
(Higgins et al. 2012), unrelated mean effects (Dias et al. 2011d), and node-
splitting (Dias et al. 2010). The inconsistency factors model can be seen as a
re-parameterisation of the unrelated mean effects model, with an additional
exchangeable structure on the inconsistency parameters; however, the ex-
changeable inconsistency structure is hard to estimate well and will often be
very uncertain (Dias et al. 2011d), and the assumption that inconsistency is
exchangeable throughout the network is questionable (Higgins et al. 2012).
The inconsistency factors model can also be seen as a restricted form of the
design-by-treatment interactions model; however, the design-by-treatment
interactions model is over-parameterised unless constraints are placed on the
inconsistency parameters (Higgins et al. 2012). We thus focus on the unrelated
mean effects and node-splitting models here: the former allows for a simple
global assessment of inconsistency, and the latter provides a more powerful
and detailed assessment for each potentially inconsistent contrast in turn.
Inconsistency is assessed in IPD NMA using the very same techniques, except
that the parameters of interest are the individual-level treatment effects γk




Under the assumption of consistency, NMA models define a set of “basic”
parameters d2 , . . . , dK , which relate to relative effects against the reference
treatment 1. Prior distributions are placed on these basic parameters, and
all other contrasts are derived “functional” parameters using the consistency
equations dab  db − da for a < b ∈ {2, . . . , K}. The unrelated mean effects
(UME) model (Dias et al. 2011d) instead treats all of these parameters, basic
and functional, as unrelated parameters with independent prior distributions.
In other words, for every observed contrast dab , we assign a prior distribution
such as dab ∼ N(0, σ2d)with some appropriate prior variance σ
2
d .
Evidence for inconsistency is then based on comparing the model fit of
the unrelated mean effects model to the standard NMA model assuming
consistency, for example by comparing residual deviance (Section 1.2.6).
Comparing the residual deviance contributions from each data point under
each model can indicate where in the network inconsistencies may lie, for
example by plotting these against each other and looking for points away from
the line of equality, as in Dias et al. (2011d).
1.2.7.2 Node-splitting
Node-splitting, rather than testing for inconsistency globally, examines each
potentially inconsistent comparison in turn (Dias et al. 2010). Briefly, the
node-splitting approach splits the estimation of a chosen comparison da′b′ into
an estimate based only on direct evidence dDa′b′ and an estimate d
I
a′b′ based
on the remainder of the network (i.e. the indirect evidence). Inconsistency is
often examined at the same time as heterogeneity, and this is particularly true
of node-splitting models where different model parameterisations can shift
variation from heterogeneity to inconsistency, or vice versa. The mathematical
structure of the RE NMAmodel is unchanged, except that the random effect
for any study with a′ and b′ arms is now δ ja′b′ ∼ N(dDa′b′ , τ
2). The estimate
of dIa′b′ from the indirect evidence is computed by applying the consistency
equations to the remainder of the network in the usual manner. Notice that
here we have used the same heterogeneity variance parameter τ2 for the direct
evidence and for the rest of the network. This is not a strict requirement, but
in practice there is often not enough data to estimate separate heterogeneity
variances for the direct evidence and the rest of the network; moreover, using
the same heterogeneity variance parameter allows direct comparison with the
heterogeneity variance from the RE NMA.
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Again, inconsistency can be assessed by comparing model fit between the
standard NMA and the node-split model. Visually comparing the posterior
distributions of dDa′b′ and d
I
a′b′ allows the amount of inconsistency to be judged
directly. We can also define the inconsistency parameter ωa′b′  dDa′b′ − d
I
a′b′
and examine its posterior distribution to assess whether ωa′b′  0, for example
by computing a Bayesian p-value.
Node-splitting models are more powerful for detecting local inconsistency
in a given comparison than the unrelated mean effects model (which assesses
inconsistency across the network all at once), however there is a multiple
testing issue if several comparisons are to be checked for inconsistency in turn.
Node-splitting models also require considerably more effort in determining
potentially inconsistent comparisons and then in re-fitting a node-split model
for each, although this may be mitigated by automated methods for selecting
comparisons to split and then building and fitting the associated models
(Valkenhoef et al. 2015).
1.2.7.3Inconsistency inmeta-regression
Whenmeta-regressionmodels are fitted (either to IPD or AgD), the consistency
assumption applies to both the treatment effects dab  db − da or γab  γb − γa ,
now with respect to the covariates at zero, and to the treatment-covariate
interactions β2,ab  β2,b − β2,a (Donegan et al. 2017). This results in four
possible scenarios:
1. Consistent treatment effects at zero covariate, consistent interactions;
2. Inconsistent treatment effects at zero covariate, inconsistent interactions;
3. Inconsistent treatment effects at zero covariate, consistent interactions;
4. Consistent treatment effects at zero covariate, inconsistent interactions.
Donegan et al. (2017) suggest using a node-splitting approach to assess
consistency of treatment effects and interactions simultaneously. To illustrate,
let us consider an AgD meta-regression with a single covariate. For a chosen
comparison b′ vs. a′, we now split estimation of both treatment effects and
interactions into direct evidence, dDa′b′ and β
D
2,a′b′ respectively, and indirect
evidence from the rest of the network, dIa′b′ and β
I
2,a′b′ . The treatment effect of
b′ vs. a′ at a given value x of the covariates, estimated by the direct evidence,










These two equations define two lines as a function of x that, when plotted
together, should lie parallel (consistent interactions) and have the same inter-
cept (consistent treatment effect at zero covariate). It may be useful to define
the inconsistency parameter ωa′b′(x), in a similar manner to the node-splitting
model for standard NMA, except that the inconsistency parameter is now a
function of the covariate x:

















When plotting the posterior distribution of ωa′b′(x) against x, this should be a
flat horizontal line (consistent interactions) with intercept at zero (consistent
treatment effects at zero covariate). Donegan et al. (2017) do not suggest how
this approach might extend to interactions with multiple covariates, however
there appear to be two options. The first is to consider inconsistency for
each covariate interaction separately in turn, following exactly the approach
above for each covariate. The second is to node-split all interactions together,
replacing βD2,a′b′, β
I




2,a′b′, and x. Visualisations
would then be produced for each covariate in turn. It remains to be seen which
of these two approaches is preferred.
1.2.8 NMAwith contrast-based data
So far, we have considered theNMA scenariowhere outcome data are available
from each treatment arm, such as event counts or mean response. However, it
is also possible for outcome data to be reported as summary relative effects on
each treatment contrast, such as log odds ratios or mean differences. In this
case, the standard approach is to use a Normal likelihood and identity link
function for these data (Dias et al. 2011c; Salanti et al. 2007; Woods et al. 2010).
Letting y• jab be the observed relative effect of treatment b vs. a in study j with
standard error s jab , the NMAmodel for contrast-based data is then
y• jab ∼ N(δ jab , s2jab), (1.38)
where δ jab is the study-specific relative effect of treatment b vs. a. In studies
with three or more arms (and therefore two or more summary relative effects),
the corresponding relative effects are correlated. In such cases, a multivariate
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Normal likelihood is used to account for these correlations, with marginal
distributions given by (1.38) and covariances
cov(y• jab , y• jac)  v(a)jbc . (1.39)
If not reported, the covariance v(a)jbc between the relative effects y• jab and y• jac
for any two treatments b and c both compared to a may be derived from the









In cases where the relative effects are simple differences between mean
outcomes on each treatment, the covariance v(a)jbc is equal to the variance of
the outcome on treatment a (Dias et al. 2011c). When the variance of the
outcome on treatment a is not reported, it may be possible to impute from
those reported in other trials (Dakin et al. 2011).
Under a fixed effect model, we have
δ jab  dab  db − da (1.41)
with d1  0.
For a random effects model, studies with three or more arms have a
multivariate Normal random effects structure, with marginal distributions
and correlations given by
δ jab ∼ N(db − da , τ2ab) (1.42a)
cor(δ jab , δ jac)  ψ(a)bc , (1.42b)
and again d1  0. For two-arm studies, there is a single summary relative effect
and thus a single univariate Normal random effect, with distribution given by
(1.42a). Again, we have the second-order consistency equations (1.15) on the
heterogeneity variances, and (1.22) on the correlations. If the homogeneous
variance assumption is used this implies that all the correlations are equal to
0.5.
1.3Summary
In this chapter, we began by introducing the problem of population adjustment
in a simple two-study scenario, in which an indirect comparison is to be made
between two treatments investigated in two different studies (Section 1.1).
When the two studies share a common comparator, population adjustment
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methods are motivated by the need to adjust for differences in effect modifying
variables between the study populations, which would incur bias in a standard
indirect comparison. A standard indirect comparison relies on there being no
effect modifiers in imbalance between the study populations (the constancy of
relative effects assumption), whereas anchored population-adjusted indirect
comparisons adjust for effect modifying variables to relax this assumption,
assuming that there are no unobserved effect modifiers in imbalance (condi-
tional constancy of relative effects). When there is no common comparator (e.g.
if the studies are single-arm), unanchored population adjustment methods
aim to improve on a naïve comparison of arms by adjusting for all prognos-
tic and effect modifying variables. However, the assumption that all effect
modifiers and prognostic variables are known and have been adjusted for
(the conditional constancy of absolute effects assumption) is very strong and
difficult to justify.
We then introduced network meta-analysis, which allows larger networks
of treatments and studies to be synthesised in a coherent manner (Section 1.2).
Standard indirect comparison is a special case of NMA, and (fixed effect) NMA
relies on the same constancy of relative effects assumption as standard indirect
comparison. (A random effects NMAmakes a slightly weaker assumption—
constancy of relative effects in expectation—which means that any imbalances
in effect modifiers throughout the network are random (we discuss further
in Section 2.1.6).) In Section 1.2.1, we outlined the standard parameterisation
for writing NMA models, known as the baseline shift parameterisation, in
which a reference treatment arm is defined for each trial. The study-specific
baselines refer to the reference arm in each trial, and treatments in the other
arms of each trial are compared to this as relative effects. We then described
an alternative parameterisation in Section 1.2.2, which we term the reference
treatment parameterisation. This parameterisation uses the same reference
treatment (treatment 1) across the entire network, to which study baseline
parameters always refer to, and relative treatment effects in each trial are
always against the reference treatment—even if the trial does not include this
treatment arm. We showed that the two parameterisations are equivalent
(Section 1.2.3) and compared the relative merits of each (Section 1.2.5); we use
the reference treatment parameterisation for the remainder of this thesis.
Other parameterisations of NMAmodels have previously been considered.
For example, Lu and Ades (2004) write a model where the study-specific
baselines refer to the “average” treatment in the network. This lead to
improved computational performance within the MCMC software at the time,
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butmore recent algorithms perform equallywell with the simpler baseline shift
parameterisation and as such this parameterisation is seldom used. Previous
authors (Hawkins et al. 2015; Tu 2014) have considered models that are also
parameterised with respect to a common reference treatment 1 across the
network, but that do not account for the correlation structure between random
effects. As a result, their models are fundamentally different to the standard
baseline shift model (despite similar empirical results in some cases), and
have computational difficulties when there are trials in the network with
no treatment 1 arm. The mvmeta command in Stata has an option to use
the reference treatment parameterisation; however, this implementation uses
additional “dummy” treatment 1 arms in trials where no treatment 1 arm is
present (White 2015).
We considered approaches to assessing model fit and model comparison
(Section 1.2.6) and described the inclusion of contrast-based data in NMA
(Section 1.2.8). We also introduced IPD networkmeta-regression (Section 1.2.4)
which is the “gold-standard” approach to adjusting for imbalances in effect
modifiers throughout the network; however, IPD NMR requires IPD to be
available from every study, which is not always possible. Particular issues in
all forms of network meta-analysis (both of AgD and of IPD) are heterogeneity
and inconsistency, which are both caused by differences in effect modifying
variables between studies (either in terms of population characteristics, or
other study-level factors such as treatment or outcome definition or study
setting). Heterogeneity is assessed using random effects models (Sections 1.2.1,
1.2.2 and 1.2.4), and several approaches exist for assessing inconsistency
(Section 1.2.7). Adjusting for effect modifying variables in an IPD NMR
is likely to reduce any heterogeneity and inconsistency, however residual
heterogeneity or inconsistency indicates that differences in effect modifiers
between studies still remain. In the case of a two-study indirect comparison,
heterogeneity and inconsistency cannot be checked as there is not enough
data.
1.4Thesis overview
The remainder of this thesis is set out as follows. Chapter 2 reviews the
literature on population adjustment and closely related problems. We describe
current methods, including MAIC, STC, and NMR-based approaches, and set
out their assumptions and properties. Chapter 3 contains a systematic review
of applications of MAIC and STC in the published literature, and of population
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adjustment methods in NICE Technology Appraisals. We aim to determine
the ways in which these methods are used and whether the key assumptions
are likely to hold, to assess the adequacy of current practice. In Chapter 4, we
propose a new method for population adjustment called Multilevel Network
Meta-Regression, that aims to address the issues with current approaches.
Chapter 5 discusses the computational aspects of implementing ML-NMR
models. In Chapter 6, we apply ML-NMR to a real example network of plaque
psoriasis treatments, and compare with results fromMAIC andNMA analyses.
Chapter 7 extends the ML-NMR framework to handle general individual-level
likelihoods where the corresponding aggregate-level likelihood does not have
a known form, such as survival analysis. We apply the approach to two
examples, one with artificial survival outcomes, and another continuing with
the plaque psoriasis example to incorporate ordered categorical outcomes. In
Chapter 8, we perform an extensive simulation study to assess the performance
of ML-NMR in a range of scenarios and under various failures of assumptions,
comparing with MAIC, STC, and standard indirect comparisons. Finally, in
Chapter 9 we conclude with a discussion, including suggestions for future
research. Additional Appendices contain listings of Stan code implementing
the ML-NMR models, full tabulated results from the simulation study, and
details of the computing environments used.
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Chapter 2
Review of population adjustment
methods
Methods for adjusting treatment effects observed in one population to those
that would be observed in another population have been around for many
years. In this chapter, we review the literature on methods for population
adjustment and other related problems. This chapter was published by the
NICE Decision Support Unit as Technical Support Document 18 (Phillippo
et al. 2016; also published in abridged form, Phillippo et al. 2018a).
Population adjustment describes a scenario where individual patient data
(IPD) in one or more trials are used to adjust for between-trial differences in the
distribution of covariates that influence outcome. Recently proposed methods
for population adjustment include Matching Adjusted Indirect Comparison
(MAIC; Ishak et al. 2015; Signorovitch et al. 2010) and Simulated Treatment
Comparison (STC; Caro and Ishak 2010; Ishak et al. 2015), which are becoming
increasingly popular in submissions to regulatory/reimbursement agencies
and the wider literature. MAIC and STC are forms of propensity score
weighting and outcome regression methods, respectively. These families of
methods have previously been used to adjust treatment effects from both
randomised and non-randomised studies, under the general headings of
“standardisation”, “generalisation” or “calibration”, and the properties of
such methods have been examined in the related literatures. The novelty of
population adjustment methods such as MAIC and STC is that they apply the
classic propensity score and regression methods to the specific case of indirect
comparisons with limited availability of IPD.
Consider the simple two-study scenario introduced in Section 1.1, where
IPD are available for an AB trial comparing treatments A and B, and aggregate
27
2. REVIEW OF POPULATION ADJUSTMENT METHODS
data (AgD) are available for an AC trial comparing treatments A and C
(see Figure 1.1). The basic premise of MAIC and STC is to effect an indirect
comparison between treatments B and C in the AC study population, adjusting
for between-trial differences in baseline characteristics. Both methods use
IPD from the AB study to form predictions ŷA(AC) and ŷB(AC) of the summary
outcomes that would have been observed on treatments A and B in the AC
trial. The predicted outcomes are then used to form a population-adjusted
indirect comparison in one of two ways, depending on whether or not a
common comparator treatment is used. Firstly, the relative effect dBC(AC) may
be estimated using an anchored comparison, formed as the difference of the
relative effects against the common comparator A:
d̂BC(AC)  g( ȳC(AC)) − g( ȳA(AC)) −
(
g( ŷB(AC)) − g( ŷA(AC))
)
, (2.1)
where ȳC(AC) and ȳA(AC) are the mean outcomes observed on each treatment in
the AC trial, ŷB(AC) and ŷA(AC) are predictedmean outcomes in the AC popula-
tion using the population adjustment method, and g(·) is a link function onto
some suitable transformed linear scale. The second estimator is an unanchored
comparison (see Figure 1.2), which does not use a common comparator and is
formed as a difference in the mean absolute outcomes on each treatment:
d̂BC(AC)  g( ȳC(AC)) − g( ŷB(AC)). (2.2)
As we describe in Section 2.3, the anchored indirect comparison respects
randomisation and relaxes the assumptions made by standard indirect com-
parisons, whereas the unanchored indirect comparison requiresmuch stronger
assumptions which are very hard to meet.
If IPD are available from every study, an IPD network meta-regression may
be performed to adjust for differences in observed effect modifiers between
study populations, and is considered the “gold standard” approach (see
Section 1.2.4; Berlin et al. 2002; Dias et al. 2011a; Lambert et al. 2002; Riley et al.
2010; Tudur Smith et al. 2005). As a result, there have also been efforts to extend
IPD network meta-regression to incorporate aggregate data from published
studies (Donegan et al. 2013; Jansen 2012; Saramago et al. 2012; Sutton et al.
2008; Thom et al. 2015). Such developments have thus far proceeded in parallel
with the development of MAIC and STC, which are instead largely focused on
simple two-study indirect comparisons.
This chapter starts with a review of the earlier literature surrounding pop-
ulation adjustment, including the literature on standardisation, generalisation,
and calibration (Section 2.1). We then describe the current methods for popu-
lation adjustment including MAIC, STC, and network meta-regression based
28
2.1. EARLIER LITERATURE SURROUNDING POPULATION ADJUSTMENT
approaches, noting the similarities and differences with the previous methods
(Section 2.2). In Sections 2.3 to 2.5, we detail the particular assumptions that
are made by population adjustment methods and discuss specific issues which
arise from their practical application, focusing on the scenario of technology
appraisal. Finally, in Section 2.6 we conclude with a summary and discussion.
2.1Earlier literature surrounding population adjustment
We begin with a review of the earlier literature surrounding population
adjustment based on propensity score weighting and outcome regression. We
start with literature on approaches to standardisation, then look at a related
literature on generalisation of treatment effects, and finally at some recent
work on calibration.
2.1.1Model-based standardisation
Standardisation is amethod closely related to the kinds of adjustment proposed
byMAIC and STC. Here, the mean outcomes or responses to be predicted for a
target population P are based on those observed in an unrepresentative sample
S from P, taking into account differences in the distributions of characteristics
between the sample and full target population. In the following discussion of
the methods developed for the standardisation problem, we refer to outcomes
underdifferent treatments to remain consistentwith ourpopulation adjustment
scenario; however, in the original context of the standardisation methods, the
“treatments” are often exposure classes in an observational context, sampled
from a larger target population.
Crude direct standardisation, also known as poststratification, subclassi-
fication, or direct adjustment, is a basic method of estimating outcomes in a
target population of which the sample is an unrepresentative subpopulation,
achieved by stratifying the sample population and reweighting the sample
means within each stratum according to the population frequencies (Cochran
1968).
Suppose that the sample population of size N(S) is stratified into Z strata
or subclasses based on covariates x, with Nkz(S) subjects in each stratum z in
the sample population receiving treatment k, and Nk(S) the total number of
subjects receiving treatment k. The target population is of size N(P), with Nkz(P)
members in each stratum receiving treatment k. Let yikz denote the response
for subject i receiving treatment k in stratum z, which is only observed if the
subject is in the sample population (covariate values are however known for
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every individual in the full population). The directly standardised estimator












where individuals in strata z receiving treatment k are given weight Nkz(P)Nkz(S) .
Common issues with direct standardisation arise when some strata have small
(or zero) membership Nkz(S) in the sample population, leading to inflated (or
even infinite) weights for these strata; application is further limited by the
number of stratification variables, which must also be categorical (or at least
discretised in such a manner).
Rosenbaum (1987) proposed a modification of direct standardisation,
known as model-based direct standardisation, in which the weights are
found using a parametric model rather than observed population frequencies.
Individuals in stratum z receiving treatment k are weighted by the inverse of












The propensity score (PS) (Rosenbaum and Rubin 1983) is defined in this
context as the conditional probability that an individual from the target popula-
tion is assigned to the sample given the covariates; p(xz)  
(
(S)  1 | X  xz
)
,
where (S) is an indicator of assignment into the trial sample ((S)  1) or not
((S)  0) from the target population. Rosenbaum (1987) modelled the PS
using logistic regression on the observed covariates xz in each stratum, written





 h(xz ;α), (2.5)
where α is a vector of unknown parameters and h(·) is a known function of
the covariates, possibly including interactions or a constant term. A simple
linear model for example would be specified with h(xz ;α)  α0 + xTzα1.
When correctly specified, the propensity score is a balancing score: condi-
tioning on the PS removes any imbalance in the distribution of x between the
sample and target populations. However, incorrect specification of the model
in equation (2.5) or the presence of unmeasured effect modifiers or prognostic
variables will result in the estimator in equation (2.4) being biased.
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Greenland (1991) suggested an alternative form of model-based stan-
dardisation where, instead of modelling the propensity score, a gener-
alised linear model (GLM) is fitted to estimate the expected response θkz 
(Y | K  k ,X  xz) on treatment k conditional upon the covariates in a
stratum z:
g(θkz)  βk0 + xTzβ, (2.6)
for an appropriate link function g(·) and coefficients βk0, β. The estimated
responses θ̂kz  g−1(β̂k0 + xTz β̂) in each stratum z are then weighted by a vector




θ̂k1 , . . . , θ̂kZ
]T
. (2.7)
One key difference between this method and that of Rosenbaum (1987), is
that the vector of weights w is assumed known—in contrast to Rosenbaum’s
PS method, which estimates the weights as 1/p(xz) for each stratum z. Again,
the estimator is unbiased only if the model is correctly specified, and there are
no unmeasured effect modifiers or prognostic variables.
2.1.2Further propensity scoremethods
The propensity score, introduced by Rosenbaum and Rubin (1983), has been
used in a variety of ways to adjust for imbalances in covariates between
a sample population and a target population, of which the sample is an
unrepresentative subpopulation. PS adjustment methods in general weight
individuals or groups of individuals by the inverse of their PS. Differences
between the various methods are found in the coarseness of the weighting
applied: at the finest scale to individuals, at the coarsest scale to whole groups
or subclasses, or somewhere in between (Stuart et al. 2011). We discuss three
common methods here.
2.1.2.1Inverse propensity score weighting
Inverse propensity score weighting (IPW) applies weights at the finest possible
scale; each individual in the trial population is given their own weight. The
propensity score is defined for each individual as
p(xi)  
(
(S)i  1 | X  xi
)
, (2.8)
and the logistic regression in equation (2.5) is therefore modified so that
logit(p(xi))  h(xi ;α). The individual propensity scores (2.8) are then used in
the estimator (2.4). However, IPW can result in unstable estimates if extreme
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weights are estimated—a problem not evident in coarser weighting schemes
which stabilise the weights. Furthermore, simulation studies have shown that
IPW is heavily reliant on correct specification of the PS model, and that bias
and imprecision are increased by misspecification (Kang and Schafer 2007).
2.1.2.2 Subclassification
Subclassification is the coarsest weighting method, where individuals with
similar propensity scores are grouped and the subclass average responses
are weighted. The model-based standardisation method of Rosenbaum
(1987) sits in this category (see Section 2.1.1), as individuals in the same
stratum are assigned the same weight—equivalent to weighting their average
responses. Kang and Schafer (2007) showed that the amount of bias reduction
of subclassification methods is not as great as an IPW method with a correct
PS model; however, the estimator is more efficient and the amount of bias
reduction increases with the number of subclasses. Usually only five or
six subclasses are used (Rubin 2001), for example by the quintiles of the PS
distribution, which may not be enough for sufficient bias reduction (Stuart
et al. 2011). Subclassification is also more robust to misspecification of the PS
model than IPW.
2.1.2.3 Full matching
Full matching is a weighting method that lies between the two extremes of
IPW and subclassification in terms of coarseness of the weights. Subclasses
are formed so that each contains at least one individual from both the trial
and target populations. Rosenbaum (1991) first proposed the full matching
method, and also showed that it is the weighting method which minimises
differences in propensity scores between trial and target populations within
the subclasses.
2.1.3 Outcome regression
An alternative to PSweighting is known as outcome regression. In thismethod,
instead of modelling the propensity score and applying a weighting scheme
to the sample subjects, a model for the mean response (or outcome) given
treatment and observed covariates θk(x)  (Y | K  k ,X  x) is fitted:
g(θk(x))  m
(
k , x; β
)
(2.9)
where β is an unknownparameter, m(·) is a known function, possibly including
interactions or a constant term, and g(·) is an appropriate link function.
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Estimators of expected outcomes in treatment group k in the target population











k , xik ; β̂
))
(2.10)
These are unbiased if the outcome model is correctly specified and there are
no unmeasured covariates. Simulation studies (Kang and Schafer 2007) have
shown that estimators based on a misspecified outcome regression model
are less biased and more efficient than estimators based on a misspecified PS
model, however the associated precisions are overestimated.
Outcome regression is similar to the standardisation method proposed by
Greenland (1991), in the sense that a model for the outcome conditional on
covariates is fitted, however the methods differ in some key ways. Firstly, the
regressionmodel in equation (2.9) ismore general than that originally proposed
byGreenland in equation (2.6), which is a special casewith m(k , x; β)  βk+xTβ.
Greenland’s model-based standardisation method fits the outcome regression
at the level of mean response within a subclass, however outcome regression
fits amodel at the individual response level. Furthermore, Greenland’smethod
estimates the mean response within each subclass in the trial population and
thenweights the subclass responses by the relative frequencies of the subclasses
in the target population (equation (2.7)); outcome regression predicts the
response for each individual in a target population based on their covariate
values, and then takes the average (equation (2.10)).
2.1.4Doubly robust estimation
Both propensity score weighting/matching and outcome regression provide
methods to estimate outcomes in a target population from a sample sub-
population that differs in covariate balance. However, the estimators are
only unbiased if their respective models (for propensity score or outcome)
are correctly specified, and if there are no unmeasured effect modifiers or
prognostic variables.
Doubly robust (DR) estimators aim to reduce the impact of model mis-
specification by incorporating both outcome regression and propensity score
models into one estimator, which is consistent (and for some estimators un-
biased) if at least one of the constituent models is correct. Doubly robust
estimators can be constructed in various ways (Funk et al. 2011; Kang and
Schafer 2007; Robins et al. 2007). Robins et al. (2007) refer to DR estimators of
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yik − θ̂k (xik)
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(2.11)


















where θ̂k(x)  g−1(m(k , x; β̂)) is the outcome regression estimator of the mean
response at covariate value x, and p̂(x) is the estimated propensity score.
Note that, in the DR estimators (2.11) and (2.12) above, the first term is a
summation over every individual in the full target population (of which the
sample population is a subpopulation), and the second term is a summation
over only those individuals in the sample. (Recall that, in this standardisation
scenario, individuals not in the sample are missing outcomes yik , but covariate
values are known for every individual in the full population.) The estimator
proposed by Funk et al. (2011) is also of this form.
These estimators are consistent (they converge to the true value as sample
size increases) and unbiased when at least one of the PS or outcome models is
correct. Funk et al. (2011) show that these estimators can be rearranged into an
unbiased estimator plus an augmentation term—the product of the biases in
the PS and outcome regression models—which vanishes when either model is
correct. Robins et al. (2007) however note that DR estimators in this form do
not have the property of boundedness: when the sample population is of finite
size, the estimates do not lie in the parameter space with probability 1. This is
an issue when the parameter space is not the entire real line, for example when
fitting logistic models for the probability of an event. Robins et al. suggest
that it is primarily desirable for an estimator to display boundedness, possibly
at the expense of unbiasedness, and describe the construction of three DR
estimators, known as regression doubly-robust estimators, which have the
boundedness property. Each of these three regression DR estimators is a
modification of the outcome regression estimator in equation (2.10):
1. Modify the outcome regression model to include the inverse of the
propensity score p̂(xik)−1 as a covariate;
2. Modify the outcome regression model to use weighted least squares
(WLS), using the inverse propensity scores as weights;
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3. Modify the outcome regression model to include the propensity score
p̂(xik) as a covariate.
The first estimator (also suggested by Bang and Robins 2005), including
the inverse PS as a covariate in the outcome regression, can perform very
poorly when the inverse PS are highly variable, due to large extrapolations
being made from the sample population to the target population. The second
estimator, using the inverse PS as weights for WLS outcome regression, does
not suffer from this issue, and is expected in general to outperform the first. The
third estimator, including the propensity score as a covariate in the outcome
regression, should also fare better than the first in the case of highly variable
weights, perhaps as well as the second. Doubly robust methods “give the
analyst two chances” to specify correct models (Bang and Robins 2005), and
demonstrate little loss of efficiency in practice. If neither model is correctly
specified then the resulting estimator will be biased and inconsistent.
2.1.5Generalising treatment eects to a target population
There is substantial literature developed to generalise estimates of relative
treatment effects obtained from a RCT into a target population. The methods
used are broadly similar to the standardisation literature discussed so far,
including propensity score methods and outcome regression. Here, the quan-
tity of interest is the average relative treatment effect in the target population
(the population average treatment effect, or PATE)—in contrast to the stan-
dardisation literature, which in general is interested in standardising expected
outcomes (or absolute effects) to a target population P. Mathematically, the










where N(P) is the number of individuals in the target population, and Yi(A)
and Yi(B) are the potential outcomes for individual i on treatments A
and B respectively (one of which is unobserved); we could equivalently





, where the expectation is with respect to the joint
covariate distribution in the target population P. The PATE may be esti-







where the sum is over the N(S) individ-
uals in the sample (trial) population S, which is the usual quantity estimated
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by a RCT. Some authors (e.g. Hartman et al. 2015) focus on estimating a related
quantity for the treated population only—the population average treatment
effect on the treated (PATT), estimated from the sample average treatment
effect on the treated (SATT)—which is pertinent in some policy decisions. The
PATT and SATT are analogous to the PATE and SATE, except expectation of
treatment effect is taken only over the individuals actually assigned treatment.
In a RCT, SATE and SATT are asymptotically equal due to randomisation
(assuming sufficiently large sample size and proper randomisation).
Of particular significance in this literature are the introduction of a rigorous
decomposition of the biases in estimating PATE (Imai et al. 2008), and tests for
generalisability which provide means to verify the assumptions required.
The underlying assumptions required for generalisability and valid esti-
mation of PATE are given by several authors (Hartman et al. 2015; Stuart et al.
2011):
1. Homogeneity of outcomes on each treatment. Outcomes on treatment
and control are the same whether the individual is assigned to the trial
or not.
2. Stable unit treatment value. The outcomes of one individual are not
affected by any other individuals.
3. Strongly ignorable treatment assignment. Treatment assignment is
random and independent of sample selection from the target population
given the observed covariates. This means that there are no prognostic
factors or effect modifiers in imbalance between arms of a study.
4. Strongly ignorable sample assignment. There are no unmeasured
variables related to both sample selection and outcome and, given
observed covariates, each individual in the target population has a
non-trivial probability (i.e. not zero or one) of being selected into the
trial sample.
Assumption 1 may be violated by, for example, protocol differences in in-
clusion/exclusion criteria (Hartman et al. 2015). Assumption 2 is met by
appropriate study design, and is necessary for causal inference. Assumption 3
is met in RCTs by proper randomisation, where treatment assignment only
depends on the observed covariates. Assumption 4 is violated if there are
unmeasured effect modifiers or prognostic variables in imbalance between the
populations.
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In order to assess the assumptions required for generalisability, several
authors have proposed what are known as placebo tests, proposed by Stuart
et al. (2011) in the context of PS models and more generally by Hartman et al.
(2015). Outcomes on the placebo (or control) arm of the trial are generalised
to the target population, and then compared with the outcomes observed in
the target population. The null hypothesis is that there is no difference in the
average outcome between populations; however, tests of this null hypothesis
can have low power, particularly if conditional outcomes by subgroup are
investigated or if the outcome measure has a large variance (Hartman et al.
2015). An alternative proposition is to use the reverse null hypothesis that
there is a difference in average control outcome between populations, a test
of which will then only support generalisability if there is sufficient evidence
and sufficient power to reject the null (Hartman and Hidalgo 2011).
Placebo tests can demonstrate failures of assumptions 1, 2, and 4 above,
however they cannot ascertain which assumption or assumptions are violated,
nor can they detect multiple violations whose resulting biases cancel each
other out (Hartman et al. 2015). Furthermore, a placebo test only has capacity
to check for unobserved prognostic variables in imbalance in assumption 4 but
not for unobserved effect modifiers in imbalance. A “placebo” test comparing
observed and predicted outcomes on a common active comparator (if available)
would additionally be able to detect unobserved effect modifiers in imbalance
(but would not be able to discern whether the unobserved covariate was an
effect modifier or prognostic variable).
When PS methods are used to generalise relative treatment effects, Stuart
et al. (2011) suggest examining the difference in average propensity scores
between the trial population and target population; a difference in the mean
PS greater than 0.25 standard deviations indicates that the generalisation is
largely based on extrapolation, and will be heavily dependent on the PS model
used.
2.1.6Calibration of treatment eects
The literature reviewed thus far seeks to generalise either the outcomes
(Sections 2.1.1 to 2.1.4) or the relative treatment effects (Section 2.1.5) observed
in a sample sub-population, under some strict assumptions, to those thatwould
be observed in a target population. There has however been no attempt to
perform treatment comparisons in the target population, which is our problem
of interest. Additionally, we now wish to consider the sample and target
populations asdistinct and independent (e.g. from twonon-overlapping clinical
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trials), whereas previously the sample was considered an unrepresentative
subpopulation of the target population. Several authors have framed this as a
calibration problem, where information on treatment effects and covariates
in one population is used to estimate treatment effects in another population
with different known covariate values (Nie and Soon 2010; Nie et al. 2013;
Zhang 2009; Zhang et al. 2015), and note that it is similar to the generalisation
problem (Section 2.1.5).
The work on calibration assumes that IPD is available on both the AB and
AC trials, so the methods proposed are not strictly relevant to the problem
that MAIC and STC set out to address. However, we review this literature
here because it contains some clear statements of the assumptions made by
MAIC and STC.
Recently there has been a specific interest from the US Food and Drug
Administration (FDA) in calibration methods for the analysis of non-inferiority
studies, which compare a treatment A with an active comparator B and thus
lack a placebo arm C. When the quantity of interest is treatment effect relative
to placebo, a historical placebo-controlled trial with the active comparator may
be used to calibrate the treatment effect by estimating the placebo effect that
would be observed in the AB trial (known as a putative placebo analysis).
Calibration methods are interested in estimating the average relative
treatment effect of B vs. C in the AB population on an appropriate scale, which
can be done in one of several ways depending on the assumptions one is
willing to make. (This is in contrast with MAIC/STC, where the target of
inference is the B vs. C effect that would be observed in the AC trial if the B
arm was included.)











which requires that there are no prognostic variables or effect modifiers in
imbalance between the two populations. This is of course absurd, as there
is no randomisation between trials—only within. No accepted methods for
evidence synthesis or indirect comparison, whether population-adjusted or
not, make this impossibly strong assumption (see Table 2.1).
Another possibility is an approach based on the assumption of conditional
constancy of absolute effects (also known as treatment-specific conditional constancy
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This means that the expected absolute outcomes under treatment C are
identical between the two trial populations at any given set of covariate
values. This assumption is very strong (if not implausibly so), as it requires all
effect modifiers and prognostic variables to be available (Zhang et al. 2015).
Estimation of the indirect comparison under this assumption proceeds via one
of the previously discussedmethods (e.g. propensity scoreweighting, outcome





is estimated as ȳB(AB) in standard fashion
directly from the AB trial. The result is an unanchored comparison in the AB
population,
d̂BC(AB)  g( ŷC(AB)) − g( ȳB(AB)). (2.16)
(This is the same idea as the unanchored comparison in equation (2.2), except
that here the comparison ismade in theAB population.) Wenote that treatment-
specific conditional constancy is equivalent to ignorable sample assignment as
described in the generalisation literature (assumption 4, Section 2.1.5).
To avoid making such a strong assumption about prognostic variables,
inferences could be made instead using an assumption of constancy of relative
effects (sometimes referred to simply as constancy), meaning that the relative
C vs. A effect observed in the AC trial is identical to that which would be
observed in the AB trial:
dAC(AB)  dAC(AC). (2.17)
However, this is often questionable, as constancy of relative effects requires that
all effect modifiers (whether measured or unmeasured) are balanced between
the two trial populations. This is akin to the consistency assumption (on the
transformed scale) that is standard in NMA (Lu and Ades 2006): consistency is
assumed to hold exactly for a fixed effect analysis, and is relaxed in a random
effects analysis where consistency is only assumed to hold in expectation. The
consistency assumption in random effects models is reasonable when contrasts
are informed bymany trials, allowing the impact of effect modifiers to “balance
out”, but less so in sparse networks. Development of population adjustment
for the very sparse networks of comparisons often seen in submissions to
NICE is therefore well motivated.
Instead of making any of the three strong assumptions above, calibra-
tion methods rely on an assumption of conditional constancy of relative effects
(sometimes referred to simply as conditional constancy):
γAC(AB)(x)  γAC(AC)(x), (2.18)
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where γAC(AB)(x)  (AB)
(
g(Y(C)) − g(Y(A)) | X  x
)
is the relative condi-
tional treatment effect. This means that the relative C vs. A effect observed
in the AC trial at a given covariate value (e.g. the effect at age 55) is equal
to the C vs. A effect which would be observed in the AB trial at that same
covariate value. This assumption may be more valid, as only effect mod-
ifiers are required to be adjusted for; estimators based on the conditional
constancy of relative effects assumption respect randomisation which balances





. dAB(AB) is estimated in standard fashion from
the AB trial. The result is an anchored comparison in the AB population,
d̂BC(AB)  d̂AC(AB) − d̄AB(AB). (2.19)
(This is the same idea as the anchored comparison in equation (2.1), except
that here the comparison is made in the AB population.)
Calibration methods have been proposed in various forms: covariate
adjustment, which is a form of outcome regression (Zhang 2009); likelihood
reweighting, which is a form of PS weighting (Nie et al. 2013); and doubly
robust methods (Zhang et al. 2015). Another estimator recently proposed
by Zhang et al. (2015) is known as a conditional effect estimator, which
models the conditional relative effect γAC(AB)(x) directly rather thanmodelling
(transformed) outcomes, and may also be combined into doubly robust
estimators. We are yet to see any published applications of conditional effect
models. In practice, all of the above methods require IPD on the historical
AC trial in order to infer comparisons in the AB population; this differs from
the calibration scenarios into which MAIC and STC have been proposed,
where IPD on the AC trial are unavailable and comparisons are inferred in
the AC population. Zhang (2009) notes that covariate adjustment may be
performed using aggregate data from the AC trial if the coefficients in the
outcome regression and their covariance matrix are published, although this
seems unlikely.
2.2 Population adjustment combining IPD and AgD
The core principles of MAIC and STC remain the same as in the general
calibration literature (Section 2.1.6), however the problem scenario is modified
slightly: rather than IPD being available in all study populations, IPD are only
available in the AB trial, with AgD in the AC trial along with information on
the covariate distribution. Ideally the full joint distribution of x is known,
but frequently in practice only marginal summary statistics for each covariate
40
2.2. POPULATION ADJUSTMENT COMBINING IPD AND AGD
are known (e.g. mean and standard deviation for continuous covariates,
proportions for discrete covariates). Due to the lack of IPD from the AC trial,
standard approaches to fitting both propensity score and outcomemodels may
not be used. We outline both MAIC and STC below (Sections 2.2.1 and 2.2.2),
along with alternative approaches arising from the literature on network
meta-regression (Section 2.2.3).
2.2.1Matching-Adjusted Indirect Comparison (MAIC)
MAIC is a form of non-parametric likelihood reweighting (see Section 2.1.6),
which allows the propensity score logistic regression model to be estimated
without IPD in the AC population. The mean outcome on treatment k  A, B
in the AC target population is estimated by taking a weighted average of the






where the weight wik assigned to the i-th individual receiving treatment k is
equal to the odds of being enrolled in the AC trial vs. the AB trial. Conceptually,
this is very similar to the inverse propensity weighting method discussed in
the standardisation literature (Section 2.1.2.1). As with likelihood reweighting
(from which MAIC is derived), the weights themselves are estimated using
logistic regression as log(wik)  α0+xTikα1, where xik is the covariate vector for
the i-th individual receiving treatment k; however, the regression parameters
are not estimable using standard methods due to the lack of IPD in the AC
trial, in particular a lack of information on the joint distribution of covariates.
If the joint covariate distribution was available in the AC trial, then the
likelihood reweighting approach of Nie et al. (2013) would be feasible, with
the possibility of the sufficient statistics replacing the full IPD. Because only
marginal information is available, Signorovitch et al. (2010) propose using a
method of moments to estimate α1 so that the weights exactly balance the
mean covariate values (and any included higher order terms, for example
squared covariate values to balance the variance) between the weighted AB
population and the AC population. When x̄(AC)  0, Signorovitch et al. show
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noting that exp α̂0 cancels from the top and bottom of the fraction. Anchored
and unanchored indirect comparisons are then formed using equations (2.1)
and (2.2) respectively. Although MAIC can be used to facilitate indirect
comparisons on any scale, the MAIC literature almost exclusively performs
comparisons on the natural outcome scale (i.e. with g(·) the identity function).
Typically, standard errors for MAIC estimates are calculated using a robust
sandwich estimator (White 1980) (see the appendix of Signorovitch et al.
(2010)). Sandwich estimators are derived empirically from the data rather than
making overly strong assumptions about the weights, to account for the fact
that the weights are estimated rather than fixed and known. Signorovitch et al.
(2010) suggest that the effective sample size (ESS) of the pseudo-population














This approximate ESS is only accurate if the weights are fixed and known, or
if they are uncorrelated with outcome—neither of which is true here; as such,
this approximation is likely to be an underestimate of the true ESS (Vartivarian
and Little 2004). However, small effective sample sizes are an indication that
the weights are highly variable due to a lack of population overlap, and that
the estimate may be unstable. The distribution of weights themselves should
also be examined directly, to diagnose population overlap and to highlight any
overly influential individuals. It is not possible to apply traditional propensity
score tools for “balance checking” here, as propensity scores are only estimated
for the AB trial, and the method of moments by definition ensures covariate
balance (at least in the means, and up to the level of information published in
the AC trial).
2.2.2 Simulated Treatment Comparison (STC)
STC is a modification of covariate adjustment (see Section 2.1.6). Firstly, an













(k  B), (2.22)
where µ(AB) is an intercept term, β1 is a vector of coefficients for prognostic
variables, β2 is a vector of coefficients for effect modifiers xEM (a subvector of
the full covariate vector x), γB is the individual-level relative effect of treatment
B compared to A at x  0, and θk(AB)(x) is the expected outcome of an
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individual assigned treatment k with covariate values x which is transformed
onto a chosen linear predictor scale with link function g(·).
The model in equation (2.22) is a more general form of that given by
Ishak et al. (2015), which does not include any effect modifier terms. Ishak
et al. then form (on the natural outcome scale) either an unanchored indirect
comparison d̂BC(AC)  ȳC(AC) − ŷB(AC), or an anchored indirect comparison




, where ŷA(AC) and ŷB(AC) are




















These estimators (and hence any indirect comparison based on them) are
systematically biased whenever g(·) is not the identity function, because the
mean outcome depends on the full distribution of the covariates and not just
their mean (Ishak et al. 2015). Instead of substituting in mean covariate values,
Ishak et al. suggest that estimates are obtained by first drawing samples from
the joint covariate distribution in the AC trial and then averaging over the
predicted outcomes based on the regression model. This simulation approach
however introduces additional variation as, rather than computing an average
over the distribution of covariates in the AC population, the estimated quantity
is now the expected effect for a randomly selected individual from the AC
population (i.e. the predictive distribution), leading to an underestimate of
the precision of the final indirect comparison estimate.
Forming indirect comparisons directly on the natural outcome scale, as
advocated by the STC literature and described above, causes several problems
due to a conflict between the scale of the linear predictor and the scale of
the indirect comparison (see Section 2.3.1.2). To avoid these, we strongly
recommend that anchored and unanchored indirect comparisons are formed
on the linear predictor scale using equations (2.1) and (2.2) respectively.
Standard tools for model checking (such as AIC/DIC, examining residuals,
etc.) may be used when constructing the outcome model in the AB trial;
however (as with MAIC), additional assumptions are required to predict
outcomes in the AC population, which are difficult to test when there is little
data available.
Whilst the above formulation of STC is seen in Ishak et al. (2015) and in
all the published applications of STC to date, an earlier paper (Ishak 2014)
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suggests that an indirect comparison may be performed in the AB population
via extension to the above steps. We have not identified any applications
employing this method.
2.2.3 Network Meta-Regression
If individual patient data are available on both the AB and AC studies, a
network meta-regression using IPD is the gold standard approach (Berlin et al.
2002; Dias et al. 2011a; Lambert et al. 2002; Riley et al. 2010; Tudur Smith et al.
2005). There has, understandably, been interest in generalising network meta-
regression to situations where combinations of IPD and AgD are available in a
network of treatment comparisons; the scenario with one AB IPD study and
one AC aggregate study is then a special case. Currently, there are two main
forms of network meta-regression which combine both IPD and aggregate
data, which primarily differ in how the regression model is defined at the
individual level and at the aggregate level. We discuss both approaches here,
in the context of the two-study scenario.
The first approach (Donegan et al. 2013; Jansen 2012; Saramago et al.
2012; Thom et al. 2015) builds upon models previously proposed for pairwise
meta-regression (Riley et al. 2008; Riley and Steyerberg 2010; Sutton et al. 2008).
Two regression models are fitted simultaneously, one describing individual
level outcomes in the AB trial, and another describing the aggregate outcome


























(k  C) (2.23b)
Due to the lack of data, there are some restrictions on the more general
models which have been proposed for larger networks (Donegan et al. 2013;
Saramago et al. 2012) and for pairwise meta-regression of multiple studies
(Riley et al. 2008; Riley and Steyerberg 2010): a fixed effects model must be
used, and the treatment by effect modifier interaction coefficient β2 must be
shared between treatments B and C and between the individual and aggregate
level. This second restriction is at first glance akin to the shared effect modifier
assumption discussed later (Section 2.5), although on further inspection it
is far stronger—the effect modifier is required to act in the same manner on
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both the aggregate level and on the individual level. This assumption is only
valid if the identity link is used and all effect modifiers are accounted for (and
proper randomisation has occurred); imposing this assumption when it does
not hold results in aggregation bias (a form of ecological bias) (Berlin et al.
2002; Donegan et al. 2013; Rothman et al. 2008; Saramago et al. 2012).
The second approach derives from a type of model proposed by Jackson
et al. (2006, 2008) known as hierarchical related regression. This model avoids
the pitfalls of the first by correctly relating the individual and aggregate levels
so that aggregation bias does not occur. The basic idea is a natural one; the
aggregate data arise from averaging over a population of individuals, so the
aggregate level model arises from averaging (i.e. integrating) the individual

































where f(AC)(x) is the joint distribution of x in the AC trial population, and X is
the support of x. If the full joint distribution is not available for the AC trial (as
is likely with published data), an approximation may be used—for example by
assuming a Normal distribution (or another appropriate distribution, such as
log Normal) for continuous covariates with the reported mean and standard
deviation, and either imputing correlations between covariates from the AB
trial or assuming that they are zero. Note that this model reduces to the
gold-standard IPD network meta-regression when IPD are available for all
studies, and is equally applicable for analysing larger networks of treatments
with a mixture of IPD and aggregate data available. When used in the simple
two-study scenario, model (2.24) does require the shared effect modifier
assumption (see Section 2.5) in order to estimate the parameters due to lack of
data; however, this assumption may not be required when a larger network of
studies is available, or perhaps if external information on the effect modifiers
of treatment C is available. Model (2.24) is equivalent to model (2.23) if an
identity link is used and all effect modifiers are accounted for.
The individual level model (2.24a) here is of the same form as above in
model (2.23a). The aggregate level model (2.24b) however is found by integra-
tion of this individual level model, and therefore may not be straightforward to
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explicitly write down. Jansen (2012) describes a special case of model (2.24) for
the simple case of a binary outcome and binary covariates. When all covariates
are binary (or categorical), it is simple to rewrite the integration as a sum over

















where xz is a discrete level of the covariates, and f(AC)(xz) is simply the
proportion of AC trial individuals in the category xz . We are not currently
aware of any more general applications of model (2.24) in the literature; in
the absence of a more sophisticated approach, model (2.25) may be used to
incorporate continuous covariates by splitting them into discrete categories
(e.g. splitting ages into 5 year bands), at the expense of loss of information.
An alternative approach to avoiding aggregation bias, proposed by Ya-
maguchi et al. (2014) for pairwise meta-regression combining IPD and AgD
studies, is to use multiple imputation to generate simulated IPD for the AgD
studies. Each set of simulated IPD from the AgD studies may then be analysed
in an IPD meta-regression along with the IPD, before combining the results
using Rubin’s rules (Rubin 1987). This approach should avoid aggregation
bias, since an individual-level model is used for all studies. However, the
imputation algorithm described by Yamaguchi et al. (2014) is not immediately
applicable to indirect comparisons or larger networks, assumes covariates are
Normally distributed, and is limited to fixed effect models.
The hierarchical network meta-regression approach in model (2.24) rep-
resents an alternative class of methods to those such as MAIC and STC. The
hierarchical approach models individual-level relationships and is able to
provide internally consistent inferences at both the individual level and at an
aggregate level like a standard indirect comparison. Methods such as MAIC
and STC use IPD to predict average outcomes on study arms, and then effect
the indirect comparison at the aggregate study level. We could therefore refer
to MAIC and STC as forms of population-adjusted study-level indirect comparisons,
and the hierarchical approach as a form of population-adjusted individual-level
indirect comparison. Despite the apparent benefits of the hierarchical approach,
MAIC and (to a lesser extent) STC are the most widely used approaches in
the applied literature and in submissions to NICE (Chapter 3). We therefore
focus largely on the properties and assumptions of MAIC and STC for the
remainder of this chapter. However, we expect that these properties and
assumptions will apply to population adjustment methods in general, and in
particular those for STC will broadly apply to network meta-regression based
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approaches (including those that we go on to develop in later chapters).
2.2.4Other forms of population reweighting
The application of weights to individuals in the IPD population in order to
balance the covariate distributions between trials is a general technique which
we shall refer to as population reweighting. MAIC as described in Section 2.2.1
is currently the most widely used form of population reweighting when IPD
are only available for the AC trial.
Belger et al. (2015a,b) suggest another formof population reweighting based
on entropy balancing (Hainmueller 2012). Rather than seeking to estimate a
propensity score with which to create weights, entropy balancing methods are
designed to estimate weights by directly matching moments of the covariate
distributions (such as the mean and standard deviation). As MAIC uses the
method of moments to estimate weights, the methods up to this point are
effectively identical. However, entropy balancing methods apply an additional
constraint when estimating theweights; the optimal entropy balancingweights
are those which are as close as possible to uniform weights (that is, as close as
possible to no weighting at all). This additional constraint means that entropy
balancing methods should have equal or reduced standard error compared
to MAIC, whilst achieving the same reduction in bias. However, as we now
show, estimation of weights via entropy balancing and standard MAIC (using
the method of moments) are in fact entirely equivalent.
To see this, let us consider the objective functions that are minimised for
MAIC and for entropy balancing. As we described in Section 2.2.1, after
centring the IPD covariates around the means in the AC study (i.e. so that























(We use the normalised weights here to better show the equivalence to entropy
balancing; a set of weights can be rescaled arbitrarily without affecting the
estimate (2.20).) Entropy balancing also seeks weights that match themoments





i1 wik log(N(AB)wik). Hainmueller (2012)
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uses Lagrangemultipliers to find an unconstrained dual optimisation problem,























Comparing the objective functions (2.26) and (2.27), we see that
HEB(α)  log(HMAIC(α)) − log(N(AB)). (2.28)
Therefore, since the logarithm is a monotonic function and log(N(AB)) is
constant, the solutions of these two minimisation problems are identical.
As a result, we have shown that the MAIC weights (being identical to
entropy balancingweights) have the additional desirable property that they are
as close as possible to uniformweights (noweighting at all), in an entropy sense.
Entropy balancing performs the minimisation on the log scale which may
perform better computationally, but the estimated weights will be identical
for MAIC and entropy balancing, up to optimisation error. Whilst MAIC
and entropy balancing are mathematically identical under this formulation,
alternative loss functions could be used in the entropy balancing scheme
which may change the performance of the method. Hainmueller (2012) also
notes that other “base weights” to minimise the distance from could be
used instead of uniform weights, and this would affect the equivalence to
standard MAIC. For example, other base weights could be used to perform
non-parametric covariate adjustment (Williamson et al. 2013), or to adjust for
treatment crossover (Robins and Finkelstein 2000), prior to reweighting to
match the AC population. With non-uniform base weights w(0)ik , the entropy


























2.3. ASSUMPTIONS AND PROPERTIES OF MAIC AND STC
Setting uniform base weights w(0)ik  1/N(AB) in (2.29) recovers the formulae in
(2.27) above.
Different schemes for applying weights have also been proposed. MAIC
as described in Section 2.2.1 estimates weights for the entire AB population
at once to balance covariate distributions with the entire AC population.
Belger et al. (2015a,b) compare anchored and unanchored MAIC with other
possible approaches, which involve splitting apart trial arms and balancing
covariate distributions separately between the control arms (A) and between
the treatment arms (B and C) in the IPD and aggregate populations. The
properties of such “splitting” approaches in comparison with a more typical
population reweighting are largely unknown and require further investigation;
however, some initial simulation studies have reported performance benefits
over standard MAIC (Petto et al. 2019).
2.3Assumptions and properties of MAIC and STC in anchored
and unanchored comparisons
We now examine in detail the assumptions made by MAIC and STC which
are required to achieve a valid indirect comparison in the target population.
If these assumptions are violated, the resulting estimate may be biased. It is
critical to observe that the necessary assumptions differ between the anchored
and unanchored forms of indirect comparison (equations (2.1) and (2.2)
respectively), with the unanchored indirect comparison requiring stronger
assumptions. We do not discuss the first three core assumptions specified
in the generalisation literature (homogeneity of effects, stable unit treatment
value, and ignorable treatment assignment), as theymust generally be assumed
to hold for any form of indirect comparison or meta-analysis.
2.3.1Anchored comparisons
The MAIC and STC literature typically advocates performing indirect compar-
isons directly on the outcome scale, with g(·) the identity function in equation
(2.1) for an anchored comparison, so that





2.3.1.1MAIC, and STCwith an identity link
When making an anchored indirect comparison in the AC population on
the outcome scale as in equation (2.30), both MAIC and STC (using a linear
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outcome model with identity link) rely on an assumption of conditional
constancy of relative effects on the outcome scale—that the differences in the
relative effects that would be observed between studies are entirely accounted
for by an imbalance in the effect modifier variables xEM (see Section 2.1.6).
The implication of this assumption is that xEM must contain every effect
modifier that is in imbalance between the two studies, otherwise the indirect
comparison is still biased. Note that both effect modifiers and conditional
constancy of relative effects here are defined on the outcome scale due to the
indirect comparison being made on this scale.
STC requires the correct specification of the form of the outcome model
in order to provide unbiased estimates. When an anchored comparison is
made, an unbiased estimate is still obtained even if some or all prognostic
variables (that are not also effect modifiers) are omitted from or misspecified
in the model (and an intercept term is included). However, inclusion of
prognostic variables in the outcome model should in theory lead to more
precise estimation of the treatment effect and effect modifier parameters within
the model and the resulting indirect comparison, as a portion of the variability
is accounted for by the prognostic variables.
In the present MAIC literature (Ishak et al. 2015; Signorovitch et al. 2012,
2010), there is no discussion of which variables (prognostic and/or effect
modifying) should be included in the weighting model; the prevailing choice
in applications of MAIC to date appears to be to include as many variables
as possible, regardless of effect modifier status or level of imbalance (see
Chapter 3). However, the choice of variables to be matched/weighted on
should be carefully considered: including too many variables will reduce
the effective sample size, negatively affecting the precision of the estimate;
conversely, failure to include relevant variables will result in a biased estimate.
Therefore, for an anchored indirect comparison, the weighting model must
include all effect modifiers (both those in balance and imbalance between
the studies), but no prognostic variables. Including effect modifiers that are
already balanced in the weighting model ensures that they remain balanced
after the weighting, and there will be negligible impact on the standard error
due to their inclusion. Imbalances in prognostic variables are taken care of by
the randomisation within studies (and the subsequent “adjustment” to the
comparison with the control arms), and their inclusion in the matching model
only reduces the effective sample size.
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2.3.1.2STC with a non-identity link
In the case that STC is carried out with a non-identity link function, there
arises a conflict of scale when equation (2.30) is used to form an indirect
comparison on the natural outcome scale: the outcome model defines a
specific transformed linear predictor scale, upon which additivity is assumed
and effect modifiers and prognostic variables are defined, whereas the indirect
comparison is formed on the natural outcome scale. Effect modifier status
is mathematically demonstrable to be scale-specific (e.g. Brumback and Berg
2008), and the status of a variable as an effect modifier on one scale does
not imply (either positively or negatively) the effect modifier status on any
other scale. Therefore, performing the indirect comparison on one scale whilst
fitting the outcome model on another raises questions about the interpretation
of the model and of the indirect comparison.
The advantage of an anchored indirect comparison over an unanchored
indirect comparison is also in doubt in this case, as the aim of cancelling out
prognostic variables on the outcome scale in the anchored indirect comparison
is in contradiction with their definition on the linear predictor scale in the
outcome model. It is unclear at present whether the anchored comparison
leads to a reduction in bias and reliance on model specification or an increase,
compared to the unanchored comparison. However, it is clear that, as
prognostic variables (defined on the linear predictor scale) will not cancel
in the anchored indirect comparison (defined on the outcome scale), any
misspecification or omission of prognostic variables in the outcomemodel will
lead to a biased estimate. Therefore, an indirect comparison made using STC
with a non-identity link makes the assumption that x contains both all effect
modifiers and all prognostic variables (i.e. conditional constancy of absolute
effects) with respect to the linear predictor scale, and that the outcome model
is correctly specified.
Performing the indirect comparison on the transformed linear predictor
scale as in equation (2.1) (instead of the outcome scale) would eliminate these
concerns, and once again lead to reliance upon the weaker assumption of
conditional constancy of relative effects. This is the usual method employed
in standard indirect comparisons (Bucher et al. 1997; Dias et al. 2013a). We
discuss the choice of scale further in Section 2.3.3.
2.3.2Unanchored comparisons
Regulators are, increasingly, approving newproducts on the basis of single-arm
studies, especially in oncology (50% of all FDA accelerated oncology approvals
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in 2015 were based on single-arm trials; FDA 2016), and reimbursement
authorities are increasingly asked to assess treatments where only single-arm
studies or disconnected networks are available. In this case unanchored MAIC
or STC can be used to improve on “unadjusted” or naïve indirect comparisons
by taking into account the different distributions of prognostic factors and
effect modifiers in the two studies. (In the same way that MAIC and STC may
improve upon standard “adjusted” indirect comparison by taking account
of the distribution of effect modifiers.) However, it is essential that decision
makers understand the different sources of error that attach to standard
(“adjusted”) indirect comparisons, naïve “unadjusted” indirect comparisons,
and MAIC/STC in their anchored and unanchored forms.
If an unanchored comparison ismade (2.2), whether on the outcome scale or
transformed scale, then both MAIC and STC rely on the conditional constancy
of absolute effects assumption; the differences between absolute outcomes
that would be observed in each trial are entirely explained by imbalances
in prognostic variables and effect modifiers x with respect to the chosen
scale. Under this assumption, x must contain both every prognostic variable
and every effect modifier that is in imbalance between the two studies—an
assumption that is largely deemed unreasonable (if it were, there would be no
reason to undertake randomised controlled trials). Conditional constancy of
absolute effects may be partially assessed in a connected scenario through the
use of placebo tests using the common comparator (see Section 2.1.5). If the
conditional constancy of absolute effects assumption fails then the unanchored
estimator is invalid and an anchored estimator making use of the conditional
constancy of relative effects assumption should be used. However, such tests
cannot be used to justify an unanchored comparison for two reasons: (i)
lack of statistical power; and (ii) conditional constancy of absolute effects
is only partially assessed if the common comparator is placebo, as residual
imbalances in observed or unobserved effect modifiers cannot be evaluated.
It should also be noted that, whilst the traditional approach is to adjust
for all available variables, these may nevertheless be limited (especially in
the published aggregate data), and therefore such an approach alone is
not sufficient justification for the conditional constancy of absolute effects
assumption.
STC furthermore assumes that the outcome model is correctly specified in
both prognostic variables and effect modifiers; it is thus more burdensome to
specify an outcomemodel for an unanchored comparison than for an anchored
comparison, as the prognostic variables and their model specification become
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critical in the unanchored case. The impact of performing an unanchored
indirect comparison on a different scale to that of the linear predictor is
currently unknown, although the concerns over interpretability raised for the
anchored case in Section 2.3.1.2 still stand.
If a MAIC is to be performed, the weighting model must include every
effect modifier and prognostic variable—compared to the anchored case,
where only effect modifiers are required. An immediate consequence of this is
that an unanchored indirect comparison performed using MAIC will always
have less precision than an anchored indirect comparison using MAIC in the
presence of an imbalance of prognostic variables, and—more importantly—is
more likely to be biased given that all prognostic variables in imbalance must
be included in the weighting model as well as effect modifiers.
2.3.3Choice of scale for indirect comparisons
The standard practice for indirect comparison and network meta-analysis is
that they are made on a pre-specified transformed linear predictor scale (e.g.
on the logit scale for proportions or the log scale for rate outcomes), rather
than on the natural outcome scale (Bucher et al. 1997; Dias et al. 2013a); for
the purposes of a CEA, the resulting estimates may be back-transformed onto
the (possibly more interpretable) natural scale. The reasons for this choice
include approximate normality and the stabilisation of variance, however the
most critical reason with regards to indirect comparisons is that effects are
assumed to be linear and additive on the transformed scale. Therefore the
apparently pervasive choice amongst present applications of MAIC and STC
(see Section 3.1) to perform comparisons directly on the natural outcome scale
in the face of a more usual transformed scale is disconcerting, and somewhat
a contradiction of assumptions. Furthermore, as effect modification is defined
with respect to the scale of the comparison, variables that are effect modifiers
in standard indirect comparison might not be in MAIC/STC, and variables
which are effect modifiers in MAIC/STC may not be effect modifiers in a
standard indirect comparison analysis.
This is made most clear by STC when an outcome model is (quite cor-
rectly) specified with a non-identity link function (see Section 2.3.1.2): the
outcome model defines effects linearly and additively on the transformed
linear predictor scale, which is in direct contradiction with the subsequent
assumption of linearity and additivity on the outcome scale used by the
indirect comparison. Furthermore, the definition and interpretation of effect
modifiers and prognostic variables is entirely scale-specific, and results in
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conflicts and contradictions when the outcomemodel and indirect comparison
are on differing scales. We cannot be certain of the impact of such conflicts of
scale without comprehensive simulation studies.
Although the identification of the “correct” scale for any specific outcome
is debatable, there is a considerable literature (e.g. Deeks 2002) that shows that
relative treatment effects for binary or rate outcomes are more stable across
trials when they are expressed on logit or log scales, compared to absolute
scales such as the risk difference, meaning there are fewer effect modifiers
or that effect modification is weaker. Another concern of scale choice in the
context of indirect comparisons is that different scales can lead to reverse
conclusions, particularly for binary and rate outcomes when baseline event
rates are diverse (Norton et al. 2012). This reversal is due to the additivity
assumption not being valid on all scales (indeed, it is impossible for additivity
to hold on all scales; van Valkenhoef and Ades 2013). The choice of an
appropriate scale is therefore critical, and should be made using biological
and clinical knowledge (Caldwell et al. 2012); moreover, where a standard
scale exists for a given outcome upon which additivity is commonly accepted,
the use of an alternative scale is hard to justify.
In a decision-making context, the possibility of effect modification has
to be handled thoughtfully. The NICE Guide to the Methods of Technology
Appraisal (NICE 2013) is explicit that effect modifiers must be pre-specified
and clinically plausible, and that supporting evidence must be provided from
a thorough review of the subject area or from expert clinical opinion (see
Section 5.2.7 of the NICE Methods Guide). Moreover, although in the present
context controlling for effect modifiers is undertaken to generate less biased
population-average relative effects, the existence of an effect modifier can
change the nature of the decision problem: for example if age is considered to
be an effect modifier, it raises the possibility that a treatment that is effective at
one age might not be effective at another.
A potential and oft-cited advantage of MAIC is that it is perceived to be
“scale-free”, in the sense that the definition of the weighting model does not
require any fixed outcome scale to be chosen (Ishak et al. 2015; Signorovitch
et al. 2010). We however express caution at this notion: it is true that no
outcome model need be assumed to create the weighting model, but the
subsequent indirect comparison does assume additivity on a specific scale,
and therefore neither MAIC nor STC are “scale-free” in this important sense.
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2.3.4Impact of having access to only marginal covariate information
Thus far we have considered MAIC and STC in the scenario where, despite
not having access to IPD on the AC trial, sufficient information on the joint
covariate distribution is available. In practice even this level of detail is unlikely,
as published trials frequently report only details of the marginal covariate
distributions (e.g. mean/median and standard deviation for continuous covari-
ates, or proportion of individuals with a binary/categorical trait). This leads
to an additional assumption being required for both MAIC and STC: either
that (i) the joint distribution of covariates in the AC trial is the product of the
(published) marginal distributions, or (ii) the correlations between covariates
in the AC trial may be imputed using those observed in the AB trial.
This assumption is most explicit when STC is used. Ishak et al. (2015)
propose that, in order to create predictions into the AC population, missing
correlations between covariates in the AC population are assumed to be the
same as those observed in the AB population.
MAIC does not explicitly specify any form of outcome model, however
there is an implicit outcome model which is inferred when the indirect
comparison is formed. Specifically, effects are assumed to be additive on the
scale of the indirect comparison, as are the actions of effect modifiers and
prognostic variables. When covariate correlations are not available from the
AC population (and therefore cannot be balanced by inclusion in theweighting
model), they are assumed to be equal to the correlations amongst covariates
in the pseudo-population formed by weighting the AB population.
However, if an anchored indirect comparison is made (from either MAIC
or STC), then, due to the cancellation of prognostic variables, only correlations
amongst effect modifiers will affect the indirect comparison, and the assump-
tion of identical correlations amongst prognostic variables between the two
trial populations can be dropped. Furthermore, if there are no multi-way
treatment by effect modifier interactions in the (for MAIC, implicit) outcome
model (or any interactions at all, for an unanchored comparison), then the
estimated indirect comparison will remain unbiased even if the correlations
between covariates differ between the two trial populations.
2.3.5Choice of target population
The premise of both MAIC and STC is that the treatment effect depends on the
population. It is therefore not sufficient to use MAIC or STC to generate an
“unbiased” comparison in just any population; they only achieve this purpose
if they can produce a fair comparison in the target population for the decision.
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In general, the target population should be a UK cohort or registry study
population relevant to the clinical decision, which is unlikely to match the
population of the AC trial. However, MAIC and STC as currently proposed are
unable to achieve estimates in any population other than that of the AC study.
We present an extension in Section 2.5 which enables indirect comparisons to
be made in any target population, given an additional assumption.
The population-specific nature of MAIC and STC analyses can lead to
apparently contradictory conclusions being drawn from the same pair of trials,
simply by taking the alternate company’s perspective and swapping the roles of
the AB and AC studies, having instead IPD on the AC trial and aggregate data
on the AB trial. This problem has already arisen in analyses from competing
companies: Novartis and AbbVie presented MAIC analyses of the same two
trials comparing secukinumab and adalimumab to placebo as treatments for
ankylosing spondylitis (Betts et al. 2016; Maksymowych et al. 2016). Each
company had IPD on their own trial, but not on their competitor’s trial. The
results from each company’s MAIC appear to be in conflict, with one company
claiming significant differences in efficacy in favour of secukinumab, and the
other claiming comparable efficacy but improvements in cost effectiveness
for adalimumab. Importantly we note that, as MAIC (and STC) attempts to
produce estimates in the AC population, the two MAIC analyses are aiming
to provide estimates in two different target populations—the population of
the competitor’s trial in each case. Furthermore, the Novartis trial population
included both treatment experienced and treatment naïve patients, whereas
the AbbVie trial population included only treatment naïve patients. Due to
the lack of population overlap concerning treatment experienced patients, it
is impossible for a MAIC from AbbVie’s perspective to generate estimates
for the full Novartis trial population. However, even if both trial populations
overlapped perfectly, we would still expect there to be differing estimates
depending on which company’s perspective is taken—precisely because the
two study populations have been deemed incomparable directly due to an
imbalance in effect modifiers; if there were no such imbalance, then there
would be no need to conduct an anchored indirect comparison instead of
the usual indirect comparison. The real conflict, therefore, lies not in the
results produced by the two MAICs, but in deciding which of the two study
populations better represents the true target population. Ironically, each
company is left in the position of implicitly assuming that their competitor’s
trial is more representative than their own.
This prospect of conflicting estimates from different companies becomes
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exponentially worse as MAIC/STC is extended to multiple trials and multiple
treatments. For example in a star-like structure of AB, AC, AD, AE studies, if
each company performed a MAIC/STC using IPD available on their own trial,
and effect modification was present, they would generate among them four
incoherent sets of three pair-wise indirect comparisons, none of which could
be compared to each other.
2.3.6Sampling variation in the target population
MAIC and STC, as currently portrayed, produce estimates of mean outcomes
on each treatment in the AC study sample, rather than in the AC population.
In other words, the sampling uncertainty of the AC trial sample is ignored.
There is substantial literature on super-population average treatment effects
(SPATE), which addresses precisely this issue (for an introduction, see Imbens
and Rubin 2015, chapter 6). In the context of our calibration scenario, the
AB and AC trials are seen as samples from a larger super-population (the
true target population), and the estimates in the AC trial can be turned into
estimates in the target population by accounting for the additional sampling
variation. A notable special case occurs when the inclusion/exclusion criteria
of the AC trial match exactly the true target population and the individuals
enrolled in the AC trial are randomly sampled from the true target population;
then the point estimates provided by MAIC or STC in the sample population
are exactly carried over to the true target population, with an increase in
standard error reflecting the sampling uncertainty.
2.4Uncertainty propagation
We break down the uncertainty in the estimates resulting fromMAIC and STC
into three sources: sampling variationwithin the studies, uncertaintydue to the
imbalance in covariate distributions, and uncertainty due to estimation of the
weighting/outcome model. (We do not consider additional methodological or
structural uncertainty here, such as that arising from the choice of covariates to
adjust for, and these are not reflected in the uncertainty of the estimates.) Both
MAIC and STC fully account for the sampling variation within the studies,
and propagate this through to the final estimate.
MAIC inherently accounts for the uncertainty due to the imbalance in
covariate distributions: greater differences between the covariate distributions
lead to an increase in the variation of weights (some become larger, some
become smaller) and hence a reduction in effective sample size. Standard errors
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for MAIC estimates are typically obtained using robust sandwich estimators
(Signorovitch et al. 2010), which account for the fact that the weights are
estimated rather than fixed and known. Alternative methods for incorporating
all sources of uncertainty in MAIC include bootstrapping techniques (Efron
1979).
Whether or not STC takes into account the latter two sources of variation
depends upon how the predicted outcomes into the AC study are treated.
If the predicted outcomes are treated as fixed and known (as if they had
actually been observed), then the estimates resulting from STC will not take
into account either the uncertainty due to covariate imbalance (whichmay lead
to extrapolation if there is insufficient overlap between the two populations),
or due to the estimation of the outcome model parameters. However, if
the predicted outcomes are correctly considered along with their associated
prediction error, then the resulting estimates will account for all three sources
of variation.
2.5 Calibrating population-adjusted estimates to the correct
target population
In Section 2.3.5 it was pointed out that MAIC and STC as presently used,
althoughbased on the idea that the size of a relative treatment effect depends on
the population, do not in general succeed in generating comparisons calibrated
to the target population for the decision (unless the target population matches
the AC trial population, which is unlikely). We propose that an additional
assumption is made, which we call the shared effect modifier assumption, which
will allow relative treatment effects to be projected into any population. One of
the results of this assumption is that active-active treatment comparisons (e.g.
B vs. C) may be transported into any target population, as any effect modifiers
cancel out; indeed, the shared effect modifier assumption is required in order
for this to be possible.
2.5.1 Shared eect modifier assumption
The shared effect modifier assumption applies to a set of active treatments T ,
and states that (i) the effect modifiers of all treatments in T are the same, and
(ii) the change in treatment effect caused by each effect modifier is the same
for all treatments in T .
This assumption is not required for MAIC or STC as currently used.
However, if this assumption is deemed reasonable, then it may be leveraged
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to produce indirect comparisons in any given target population (see below).
The shared effect modifier assumption is evaluated on a clinical and biological
basis; treatments in the same class (i.e. sharing biological properties or mode
of action) are likely to satisfy the shared effect modifier assumption, and
those from different classes are not. In some circumstances, where effect
modification is an artefact of the scale of measurement (possibly indicating a
poor choice of scale), it will be valid for all active treatments. This assumption
is, in fact, commonly made when meta-regression is used (as noted by Dias
et al. 2011a). One of the reasons for assuming that treatments in the same class
have the same effect modifiers, in the absence of overwhelming evidence to
the contrary, is that relaxing this assumption could lead to seemingly perverse
decisions. For example, it is not uncommon to switch from recommending no
treatment to recommending a given treatment past a certain age, but it would
be most unusual to switch among several treatments within the same class at
various ages (say treatment B is most effective at age 50, treatment C at age 60,
and treatment D at age 70, and so on). In the present “anchored” scenario, it
is common that A is placebo or a standard treatment, and we might make the
shared effect modifier assumption for the set of treatments T  {B, C}.
2.5.2Using the shared eect modifier assumption
The shared effect modifier assumption allows us to transpose indirect com-
parisons from any population where a relative effect has been observed, such
as an AC trial, to any other population of interest P, and recreate a full set of
relative or absolute effects given an observed relative or absolute effect in the
P population. In general, we make use of the following relation concerning
the marginal relative effects for a set of treatments T for which the shared
effect modifier assumption holds:
dab(P)  dab ∀a , b ∈ T and ∀P. (2.31)
That is, the b vs. a relative effects are constant across populations for any two
active treatments a and b in T .
2.5.3Proof of shared eect modifier relationship
To see that the relation in (2.31) holds, assume additivity on an appropriate
linear predictor scale andwrite the transformed conditional absolute treatment
effects ηk(x , u) as








(k , A), (2.32)
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where x and u are vectors of observed and unobserved covariates respectively
(possibly including interactions or higher order terms), with corresponding
subvectors of effect modifiers xEM and uEM. Equation (2.32) represents the
underlying (transformed) outcome model, which cannot be estimated directly
as u are unobserved.
Using the shared effect modifier assumption on the set of treatments T ,
which means that β2,k  β2 and φ2,k  φ2 ∀k ∈ T , we rewrite the outcome
model (2.32) for k ∈ T as








(k , A). (2.33)
We are now ready to proceed in proving (2.31).
Notice that, for any two treatments a , b ∈ T , we can write the marginal
relative effects in a population P in terms of the conditional absolute effects by
using equation (2.33) and taking expectation over the population P :
dab(P)  (P)
(
ηb(x , u) − ηa(x , u)
)





EM) −(P) (βT2xEM + φT2uEM)
 γb − γa .
The right-hand side of this equation does not depend on the population P.
Therefore dab(P) is constant across populations for all a , b ∈ T .
2.5.4 Example of applying the shared eect modifier assumption
Hence, if all relative effects are known in one population (say, the AC pop-
ulation) and for another population (say P) we are given an estimate of any
single relative effect dAk(P), where k is in T , then immediately we can calcu-
late estimates of all other relative effects dAb(P), where b is in T , in the new
population via equation (2.31). Similarly, if we are given an estimate of a
single absolute effect θk(P), where k is in T , in the P population, then we can
calculate estimates of all absolute effects θb(P) and relative effects dab(P) for all
a , b in T via equation (2.31).
For example, suppose the log odds ratios in the AC population have been
estimated to be
d̂AB(AC)  1.3, d̂AC(AC)  0.8.
Furthermore, in a population P the log odds ratio for treatment B compared
to A is estimated to be d̂AB(P)  0.7. We make the shared effect modifier
assumption for treatments T  {B, C}. From the AC trial we have that
d̂BC(AC)  d̂AC(AC) − d̂AB(AC)  −0.5. Now using (2.31), we have that d̂BC(AC) 
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d̂BC(P), and the log odds ratio for treatment C compared to A is inferred to be
d̂AC(P)  d̂AB(P) + d̂BC(P)  0.2.
In practical terms for our two-study scenario, if the shared effect modifier
assumption holds for treatments B and C, then the estimated dBC marginal
relative treatment effect (whether obtained using anchored or unanchored
MAIC/STC)will be applicable to anypopulation. Notice also that if {A, B} ⊆ T
then d̂AB(AB) is valid for any population and no population adjustment is
necessary for this comparison, and similarly if {A, C} ⊆ T then d̂AC(AC) is
valid for any population.
2.6Summary
Population adjustment methods such as MAIC and STC are based upon
well-known methods dating back several decades. In this chapter we began
with a review of the earlier literature surrounding the population adjustment
scenario and other closely-related problems.
We started by considering a related problem known as standardisation
(Section 2.1.1), in which outcomes are to be predicted in (or standardised
to) a target population based on a sample population which has a different
covariate distribution. Two standardisation methods were discussed, namely
propensity score weighting (of which there are several variants; Section 2.1.2),
and outcome regression (Section 2.1.3); these methods are common across
the broader literature and within various problem settings, and may also
be combined into doubly robust methods (Section 2.1.4). Propensity score
methods seek to apply weights (the inverse propensity score) to the sample
population in order that its covariate distribution matches that of the target
population; the propensity scores are usually foundusing logistic regression for
inclusion into the target population based on the set of covariates. Outcome
regression fits a model to the outcomes on a suitable scale in the sample
population based on the set of covariates, and uses this model to predict the
outcomes that would be seen in the target population.
We then discussed more recent literature concerning another related
problem known as generalisation (Section 2.1.5), where relative treatment
effects observed in a sample population are to be generalised to a target
population. The techniques involved in such scenarios are broadly similar
to those described above in the standardisation literature. An important
contribution of the generalisation literature is the discussion of the assumptions
required for valid inference in the target population, along with methods to
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(at least partially) test these assumptions (placebo tests), and an exposition of
the biases involved in generalising treatment effects across populations.
Finally, we explored the calibration literature (Section 2.1.6), which seeks
to perform indirect comparisons between treatments studied in two different
populations, relaxing the assumptions typically made in the generalisation
literature. Treatment-specific conditional constancy (that is, conditional
constancy of absolute effects) assumes that, on a suitable scale, treatment
effects are constant across populations given a set of covariates. In practice
this is highly implausible, as the set of covariates is required to contain every
prognostic variable and effect modifier that is in imbalance between the two
populations; arguably if all of these were known then there would be no need
for RCTs. Calibration methods instead rely upon a less stringent assumption
of conditional constancy of relative effects, assuming that (again on a suitable
scale) relative treatment effects are constant across populations given a set
of effect modifiers, allowing the randomisation within studies to cancel out
the effects of any prognostic variables. The calibration literature again makes
use of the standard propensity score and outcome regression ideas. The key
difference between calibration methods and population adjustment method
such as MAIC and STC is that the standard calibration methods require the
availability of IPD in both studies. This inhibits their immediate application in
our specific problem setting where IPD is available only on the manufacturer’s
AB trial, although the assumptions, advantages, and disadvantages of the
different calibration methods carry over to MAIC and STC, since they share
the same basis in reweighting or regression adjustment.
In light of the surrounding literature on standardisation, generalisation,
and calibration, we then proceeded to describe the current methods for popu-
lation adjustment (Section 2.2) and to set out their properties and assumptions
(Section 2.3). All methods for indirect comparison—population-adjusted or
otherwise—require some form of constancy assumption with respect to the
chosen comparison scale, as described earlier by the calibration literature.
The strength of this assumption depends on whether an anchored compar-
ison (comparing relative effects via a common comparator treatment) or an
unanchored comparison (comparing absolute effects with no commmon com-
parator) is made. A standard indirect comparison or network meta-analysis
assumes constancy of relative effects, so that there are no imbalances any effect
modifiers between study populations (for random effects NMA, this is relaxed
to no imbalance on average). Anchored forms of population-adjusted indirect
comparisons rely on conditional constancy of relative effects. This means
62
2.6. SUMMARY
that the relative treatment effects are assumed constant between studies at
any given level of the effect modifiers. No assumptions are needed regarding
between-study differences in the distribution of prognostic variables, because
these are accounted for by randomisation. Unanchored population-adjusted
indirect comparisons make the much stronger assumption of conditional
constancy of absolute effects (called treatment-specific conditional constancy
by Zhang et al. (2015) in the calibration literature). Thismeans that the absolute
treatment effects are assumed constant at any given level of the effect modifiers
and prognostic variables, and all effect modifiers and prognostic variables
are required to be known. This is a far more demanding assumption, and it
is widely accepted that it is very hard to meet or even verify. Unanchored
comparisons based on disconnected networks and/or involving single-arm
studies are therefore problematic. The required constancy assumption for
each population adjustment method are summarised in Table 2.1.
In Section 2.5, we described how the shared effect modifier assumption
could be used to produce estimates for a target population other than that of
the AgD AC study. This is especially important in a decision making context
since estimates are only useful if they can be produced for the relevant decision
population, which is unlikely to be represented by the AC study. MAIC and
STC do not require the shared EM assumption to produce estimates for the AC
population, but do require the shared EM assumption to generalise estimates
to other populations. Current network meta-regression based approaches do
require the shared EM assumption in order to identify the model in a scenario
with one IPD and one AgD study. However, it is possible to relax the shared
EM assumption if IPD are available from both studies, or if enough AgD
AC studies are available. Later in Section 4.6.1, we describe more generally
how the shared EM assumption may be relaxed and assessed under our new
method (also based on network meta-regression). Table 2.1 also summarises
the use of the shared EM assumption for each population adjustment method.
In Section 2.2.3we discussed a further class ofmethods based upon network
meta-regression, with regression models defined at both the individual
and aggregate levels. Of particular interest is a method derived from the
hierarchical related regression introduced by Jackson et al. (2006, 2008), where
the aggregate-level model is an integration of the individual-level model
over the aggregate study population, although at present these models have
only been derived for the special case of binary covariates (Jansen 2012). This
method requires the same assumptions asMAIC and STC, namely that all effect
modifiers in imbalance are accounted for (conditional constancy of relative
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effects), and (in the two-study scenario) the shared effect modifier assumption.
This approach differs conceptually from MAIC and STC, in that it models
individual-level relationships and is able to provide internally consistent
inferences at both the individual level and at an aggregate level like a standard
indirect comparison. Methods such as MAIC and STC use IPD to predict
average outcomes on study arms, and then produce an indirect comparison at
the aggregate study level. We regard this as a promising approach with some
attractive properties. Most importantly: (i) it reduces to the gold-standard IPD
network meta-regression if IPD are available for all trials, and to standard AgD
NMA if no adjustment is required; (ii) it generalises naturally to connected
networks of any size, unlike MAIC and STC; and (iii) aggregation bias is
avoided by correctly relating the individual and aggregate levels of the model
through integration, unlike simpler meta-regression approaches that “plug
in” mean covariate values (Berlin et al. 2002; Rothman et al. 2008). Later
in Chapter 4, we build upon this approach to develop a general framework
for population-adjusted indirect comparisons and network meta-regression
combining IPD andAgD,which is then comparedwithMAIC and STC through
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AgD, one IPD and one AgD), with the exception of the shared effect modifier assumption which is not required if IPD are available on both studies and may also
potentially be relaxed in larger networks.




Review of applications of
population adjustmentmethods
In this chapter, we undertake two reviews of the applications of population
adjustment methods. As well as investigating the uptake of population
adjustment methods, we are interested in the ways in which these methods
are used and whether the key assumptions are likely to hold in order to
assess the adequacy of current practice, particularly for decision making.
The first (Section 3.1) is a review of applications of MAIC and STC in the
published literature, which has been published as part of NICE Decision
Support Unit Technical Support Document 18 (Phillippo et al. 2016). We
focus on MAIC and STC in this review, as they are the most commonly used
population adjustment methods at present, although other approaches based
on network meta-regression have also been proposed (see Section 2.2.3). This
review was carried out at the beginning of the PhD project. Later on in the
PhD project we wished to perform an updated review; however, to keep this
manageable we focused on applications of population adjustment methods in
NICE Technology Appraisals (TAs). Thus, in the second review (Section 3.2),
we review all NICE TAs published since 2010—whenMAIC and STCwere first
suggested in the literature (Caro and Ishak 2010; Signorovitch et al. 2010)—for
uses of any population adjustment methods. This review has been published
as Phillippo et al. (2019a). We conclude with a discussion and suggest several
key improvements to current practice, towards providing better evidence for
decision makers and greater impact for those performing such analyses.
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3.1 Published applications of MAIC and STC in the literature
In this section we review the published applications of MAIC and STC in the
literature, to examine how these new methods are being used in practice, and
how well the methodology and assumptions underlying them are understood.
Applied papers were found using a simple search amongst titles, abstracts,
and keywords for “matching-adjusted indirect comparison” and “simulated
treatment comparison” in Scopus and PubMed on 07/07/2016, by checking
citing articles of the methodological papers (Caro and Ishak 2010; Ishak et al.
2015; Signorovitch et al. 2010), and examining papers identified in a published
scoping review (Veroniki et al. 2016).
3.1.1 Applications of MAIC in the literature
In the short time since the first papers on MAIC (Signorovitch et al. 2010)
and STC (Caro and Ishak 2010) were published, the use of these methods—
particularly MAIC—has increased dramatically. In Table 3.1 we list the ten
published applications of MAIC that our search identified in the literature
up until 07/07/2016, along with particular features and properties of the
analyses, which we now discuss.
3.1.1.1 Anchored and unanchored comparisons
The majority (60%) of the analyses involved randomised controlled trials
with a common comparator. Of these, four out of six performed anchored
indirect comparisons. Three out of six analyses involved an unanchored
indirect comparison (one performed both anchored and unanchored indirect
comparisons on different outcomes). In two of these, the unanchored approach
was due to the outcome of interest being overall survival (OS) in a trial subject
to treatment switches, where the placebo arm is contaminated by individuals
crossing-over to active treatment after disease progression. Focusing on
progression free survival (PFS) rather than OS as the primary outcome avoids
this issue, although estimates of OS are typically required for economic
modelling. One analysis by Signorovitch et al. (2013b) performed an anchored
indirect comparison for PFS and an unanchored indirect comparison for OS.
Several methods to account for treatment switching in the analysis of OS are
available, including rank-preserving structural failure time models (Robins
and Tsiatis 1991), iterative parameter estimation (Branson and Whitehead
2002), and inverse probability of censoring weighting (Robins and Finkelstein
2000), yet none of the analyses made use of these approaches. (An overview
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of treatment switching methods and guidance on their use in NICE appraisals
is given by Latimer and Abrams (2014).)
An analysis by Sikirica et al. (2013) had common placebo arms between
the two trials, yet made an unanchored indirect comparison. The authors’
justification was that, in the matching procedure, weights were additionally
constrained to exactly balance placebo outcomes across trials. This method
has yet to be evaluated either formally or through simulation studies, and
its properties and performance in comparison with anchored methods are
uncertain; in particular it is unlikely that balancing placebo outcomes is
equivalent to relying on randomisation to remove residual differences due to
unobserved prognostic variables.
A sizeable proportion (40%) of analyses applied MAIC to single-arm trials,
or in situations with no common comparator. The only choice in such a
scenario is to perform an unanchored indirect comparison. As in all cases
where unanchored indirect comparisons are performed, a strong assumption
is made that all prognostic variables and all effect modifiers are accounted for
and correctly specified—an assumption largely considered to be implausibly
strong. The published applications of unanchored MAIC acknowledge the
possibility of residual bias due to unobserved prognostic variables and effect
modifiers; however, it is not made clear that the accuracy of the resulting
estimates is entirely unknown, because there is no analysis of the potential
magnitude of residual bias, and hence no idea of the degree of error in
unanchored MAIC estimates. Moreover, the inclusion of single-arm studies in
an analysis is subject to the additional assumptions and biases incurred by
these study designs (Deeks et al. 2003).
3.1.1.2Availability of multiple studies
In half of the published analyses, issues arose with multiple IPD or aggregate
populations for the same treatments. In both cases wheremultiple populations
with IPD were available, the populations were simply pooled and treated as
one large population. There was seemingly no attempt to account for the
clustering of individuals within the component trials, which has been seen to
incur bias and reduce power in the closely related context of IPDmeta-analysis
(Abo-Zaid et al. 2013). A better option in this scenario, in the absence of MAIC
methodology which accounts for clustering, is to perform identical MAICs
based on each IPD population, and then pool the relative effect estimates (on
the linear predictor scale) with standard (network) meta-analysis methods
(e.g. Ades 2003; Dias et al. 2011c; Hasselblad 1998; Higgins and Whitehead
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1996; Lu and Ades 2004).
Multiple aggregate populations were pooled in two out of three cases, and
analysed separately in one other. When aggregate populations are pooled,
this should always be done with relative effects on the linear predictor scale to
avoid complications such as conflicts of scale (see Section 2.3.3). There are two
equivalent ways in which such an analysis may be done: (i) perform identical
MAICs into each aggregate population, and then pool the d̂BC relative effect
estimates; or (ii) pool the aggregate populations and the d̂AC relative effect
estimates, and then perform a single MAIC into the pooled population. In
either case, the pooling of relative effect estimates should take place on the
linear predictor scale using standard methods (Ades 2003; Dias et al. 2011c;
Hasselblad 1998; Higgins and Whitehead 1996; Lu and Ades 2004), and the
resulting target population will be the (appropriately weighted) combination
of the aggregate populations—which may or may not match the true target
population for the decision. If separate analyses are performed for each
aggregate population, it should be noted that the resulting estimates are each
valid for a different target population (i.e. for each aggregate population) and
are not comparable unless the target populations have balanced distributions
of effect modifiers.
3.1.1.3 Larger treatment networks
Two papers presented analyses involving more than three treatments. One by
Signorovitch et al. (2011b) had four treatments arranged in a square network
(Figure 3.1a), essentially giving two possible common comparators (placebo
and another active treatment) between the treatments of interest B and C. The
other by Kirson et al. (2013) had four treatments in a star network (Figure 3.1b),
in this case having two competitor treatments C and D to make indirect
comparisons with B.
Signorovitch et al. (2011b) had access to IPD on the AB and BD studies,
with aggregate data on the AC and CD studies; therefore two possible MAIC
analyses could be performed, one via treatment A, and another via treatment D.
The two resulting indirect comparison estimates are valid for different target
populations—one for AC and one for CD—which were then pooled. The
target population of the MAIC in this case is therefore a weighted combination
of the AC and CD populations, which is unlikely to match the true target
population for the decision.
Kirson et al. (2013) faced a similar scenario, where there were two competi-
tor treatments C and D with aggregate AC and AD trial data with which to
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form an indirect comparison. Again, two MAICs were performed, this time
giving an estimate of dBC(AC) and of dBD(AD). These relative effect estimates
are not comparable as they are both valid for different target populations
(AC and AD respectively), unless the two target populations have balanced
distributions of effect modifiers. There is no way with current MAIC methods
to achieve a coherent comparison of all four treatments in this case when the


















Figure 3.1 (a) Signorovitch et al. (2011b) perform two MAICs via alternate
common comparators; (b) Kirson et al. (2013) perform two MAICs for two
different competitor treatments. Thick edges indicate availability of IPD, thin
edges indicate only AgD being available.
3.1.1.4Eective sample size and weight distributions
Only 40% of the publishedMAIC analysesmade anymention of either effective
sample size or the distribution of weights: three included an ESS, and one
other included a summary of the distribution of weights. The reporting
of at least one of these is fundamental to understanding and diagnosing
poor overlap between the IPD and aggregate populations. When the ESS is
markedly reduced, or equivalently the weights are highly variable, estimates
become unstable and inferences depend heavily on just a small number of
individuals. The three papers reporting ESS saw an 80% average reduction
from the original sample size (range: 57–98%). Absolute values for ESS ranged
from 14 to 591.
3.1.1.5Choice of matching variables
The number of matching variables used in the published MAIC analyses
varied between 2 and 17. Most analyses balanced the standard deviations
of covariates as well as means or other summary statistics between the
populations, but only one (Sikirica et al. 2013) included any interactions
or higher order terms in the weighting model. The majority of published
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MAIC analyses therefore are subject to the additional assumptions set out in
Section 2.3.4 due to the use of marginal covariate distributions instead of the
joint distribution; in particular, an assumption must be made either regarding
the balance of covariate correlations between populations, or regarding the
lack of interaction terms in the implicit outcome model induced on the scale
of the indirect comparison.
In no anchored analysis was there any attempt to justify the effect modifier
status of the variables included in the weighting model, either with clinical
expertise or with prior empirical evidence. The NICE Methods Guide (NICE
2013) is explicit that effect modifier status should be justified prior to analysis.
For unanchored comparisons, every prognostic variable as well as effect modi-
fier should be included; only three analyses justified the included variables as
being prognostic or effect modifying in any manner.
In general, published anchored MAIC analyses reported comparative
estimates before and after the weighting adjustment, and noted any difference.
However, the observation of a difference in relative effects after an analysis
has been done should not be used to justify that an anchored MAIC should
be preferred over a standard indirect comparison; such arguments amount
to post hoc reasoning, whereas in the context of NICE technology appraisals
all analyses should be clearly pre-specified (NICE 2013). No attempts were
made prior to any analysis to assess the magnitude of impact of effect modifier
imbalance on the indirect comparison.
In some cases where common placebo arms were present, placebo tests
were performed as an attempt to justify the validity of the MAIC. However,
such tests can only detect imbalance in observed or unobserved prognostic
variables, and are completely unable to detect imbalances in observed or
unobserved effect modifiers. It is arguable whether placebo tests in this
context add any value at all: anchored indirect comparisons by design account
for differences in prognostic variables between the two populations, so any
imbalanced prognostic variableswill not lead to bias in the indirect comparison
but will cause a placebo test to “fail”; placebo tests should not be used to
“justify” unanchored indirect comparisons due to their low power.
3.1.1.6 Choice of scale
The choice of scale for an indirect comparison is important, as assumptions
are implied on the indirect comparison scale regarding additivity of effects,
definition of prognostic and effect modifying variables, and distributional
properties (Section 2.3.3). Almost all published MAICs carried out the indirect
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comparison on the natural outcome scale. In many cases this led to indirect
comparisons being made on scales not commonly used for meta-analyses,
such as probability differences rather than log odds ratios. As in meta-analysis,
the appropriate scale should be considered on a case-by-case basis, in light of
the biological and clinical knowledge, with the default scale determined by
existing literature.
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Table 3.1 Applications of MAIC in the literature.
Paper Trials and
treatments


























































































































































































































































































































































































For C1: 35 (29)
For C2: 35 (15)
For C3: 57 (14)
For C4: 35 (26)
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3.1.2 Applications of STC in the literature
Our literature search returned only one published application of STC to date.
Nixon et al. (2014) present an analysis of oral therapies for the treatment
of relapsing-remitting multiple sclerosis. A network diagram is shown in
Figure 3.2. The AB population consisted of 1556 patients randomised to either
fingolimod (B) or placebo (A) across two original trials with IPD. Unlike any
MAIC analyses using pooled IPD, Nixon et al. correctly accounted for the
clustering of the IPD by including a study-level baseline risk term in the
outcome model (i.e. a separate intercept for each AB study). There were three
trials with aggregate data: two comparing dimethyl fumarate (C) to placebo in
a total of 2301 patients, and another comparing teriflunomide (D) to placebo in
1088 patients. Risk ratios and covariate distributions of the two AC trials were
pooled simply using inverse variance weighting (essentially a fixed-effect meta-
analysis of the two trials). Differences in covariate and outcome definitions
between the AC and AD studies led Nixon et al. to produce two STC models,
one using the AC definitions for prediction into the AC population, and the








Figure 3.2 Network diagram for the STC analyses performed by Nixon et al.
(2014). Thick edges indicate availability of IPD, thin edges indicate only AgD
being available.
Of all published applications across MAIC and STC, Nixon et al. (2014) are
the only authors to attempt to justify effect modifier status of any variables;
both expert clinical opinion and the results of previous subgroup analyseswere
used in evidence. There was no analysis of the imbalance in any covariates
between the three populations beyond simple numerical differences, however
the use of an AIC-based backwards selection algorithm to choose the final
model suggests that the remaining covariates were significantly predictive
of outcome. The outcome model itself was a linear probability model, using
an identity link function to regress the probability of response against the
covariates. As noted earlier this is an uncommon modelling choice, not least
because such models can lead to predicted probabilities that lie outside the
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range 0 to 1. Similarly, this choice of model scale in this case also leads
to problems with the anchored indirect comparison, which is constructed
naturally on the (log) relative risk scale. It therefore breaks the “anchoring”
which is taken advantage of by the anchored indirect comparison. In the
outcome regression, prognostic variables (and effect modifiers) are defined
with respect to the linear probability scale, however the use of the log RR for
the anchored indirect comparison means that prognostic variables will not
cancel (see Section 2.2.2).
3.2Applications of population adjustment in NICE Technology
Appraisals
The use of population adjustment methodology is becoming increasingly
widespread in technology appraisals, in which it is typical for only limited
IPD to be available. A company submitting to a regulatory or reimbursement
agency will have IPD available for their own trials, but likely only published
AgD from their competitors’. In this section, we undertake a review of TAs
published by NICE (NICE 2018d), aiming to characterise the use of population
adjustment methods. As well as investigating the uptake of population
adjustment in different clinical areas, we are interested in the ways in which
these methods are used and whether the key assumptions are likely to hold,
to assess the adequacy of current practice for decision making. We discuss
how these methods have been received by appraisal committees and how they
have impacted decision making.
3.2.1Review outline
We reviewed all NICE TAs published between 1st January 2010 and 20th April
2018 for the use of population adjustment methods. We excluded appraisals
that had access to IPD from all included studies, and focused on those with
only partial availability of IPD. From those appraisals using one or more
forms of population adjustment, we extracted the following information from
company submissions:
• Population adjustment method used;
• Whether the comparison was anchored or unanchored;
• Outcome type;
• Clinical area;
• Number of covariates adjusted for;
• How the covariates were chosen;
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• For appraisals using MAIC, effective sample sizes after weighting;
• Whether a larger network structure was present (e.g. multiple compara-
tors and/or aggregate studies), and how this was dealt with.
3.2.2 Results
A total of 268 technology appraisals have been published by NICE since
2010—when MAIC and STC were first suggested in the literature (Caro and
Ishak 2010; Signorovitch et al. 2010)—up until 20th April 2018. Of these,
21 appraisals used a form of population adjustment; three of these had IPD
available from all included studies, so we focus on the remaining 18 appraisals
with only partial IPD. Figure 3.3 shows the selection process. The included
appraisals are tabulated in Table 3.2.














Figure 3.3 Flow chart showing the process of selecting technology appraisals,
and the numbers excluded and remaining at each stage.
The first use of population adjustment in a TA was TA311 in 2014. Since
then, the use of population adjustment in TAs has increased rapidly, in terms
of both the absolute number and the relative proportion of appraisals using
population adjustment methods Figure 3.4. In 2017, a total of nine appraisals
used population adjustment, accounting for 14.5% of all appraisals that year.
3.2.2.1 Usage by clinical area
Since 2010, almost half of all published TAs have been in oncology (127 of 268,
47.4%). Of these, 15 (11.8%) used population adjustment, accounting for over
80 percent of all applications of population adjustment in appraisals to date.
Only two other clinical areas saw any applications of population adjustment:
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Figure 3.4 The number and percentage of NICE technology appraisals using
population adjustment methodology has increased greatly since the introduc-
tion of these methods in the literature in 2010.
* Two TAs used population adjustment out of 25 up to 20th April 2018.
two out of 12 (16.7%) appraisals in hepatology (both for hepatitis C), and
one out of 28 (3.6%) appraisals in rheumatology. The usage of population
adjustment methods in oncology TAs has increased since 2010, both in terms
of the number and proportion of TAs using these methods. In 2017, a total of 9
appraisals in oncology (25.7%) used population adjustment methods, up from
one appraisal (9.1%) in 2014 (Figure 3.5). The increasing use of population
adjustment in oncology appraisals, which themselves make up the largest
proportion of all appraisals, is the main driver behind the overall results in
Figure 3.4.
3.2.2.2Outcome types
Unsurprisingly, due to the majority of applications of population adjustment
being in oncology appraisals, survival outcomes (e.g. progression-free survival,
overall survival) were the most common outcome type used in population
adjustment—13 of 18 appraisals (72.2%) included a population-adjusted
survival outcome. Rate outcomes such as response rates were used in 5
appraisals, and duration and change from baseline outcomes in one appraisal
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Figure 3.5 For technology appraisals in oncology, the number and percentage
using population adjustment methods has increased greatly since the intro-
duction of these methods in the literature in 2010.
* Two TAs used population adjustment out of 12 up to 20th April 2018.
each. Two appraisals (TA462, TA451) used population adjustment for more
than one type of outcome (survival and response rate, and response rate and
duration respectively).
3.2.2.3 Population adjustmentmethod
The large majority of appraisals using some form of population adjustment
used MAIC (16 out of 18, 88.9%). STC was less popular, used in only 3
appraisals (16.7%). Two appraisals used both MAIC and STC and compared
the results, which were reported to be similar in each case (TA383, TA492).
One appraisal (TA410) used neither MAIC nor STC. In this appraisal, a
published prediction model (developed for a previous appraisal (NICE 2014b))
was used to adjust the survival curves from the AgD trials to the population
of the IPD trial.
Of the 16 appraisals performingMAIC, only 9 (56.3%) reported an effective
sample size (ESS) (see equation (2.21) in Section 2.2.1). Of these, the median
effective sample size was 80.0 (range: 4.0 to 335.5, IQR: 15.4 to 52.0), with a
median reduction in effective sample size from the original sample size of
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74.2% (range: 7.9% to 94.1%, IQR: 48.0% to 84.6%). Such large reductions in
ESS indicate that in many cases there may be poor overlap between the IPD
and AgD studies. A substantial proportion of TAs reported small absolute ESS,
and the resulting comparisons are therefore dependent on a small number of
individuals in the IPD study and may be unstable.
3.2.2.4Anchored and unanchored comparisons
Only 2/18 appraisals (11.1%) formed anchored comparisons (TA383, TA449).
The remaining 16 appraisals (88.9%) instead formed unanchored comparisons
without a common comparator, relying on strong assumptions that are very
difficult to justify and are thus subject to unknown amounts of residual bias.
No appraisals attempted to quantify residual bias, although this is challenging
to achieve (Phillippo et al. 2016). Appraisal committees and review groups
treated estimates from unanchored comparisons with strong caution.
3.2.2.5Covariates adjusted for
For appraisals reporting unanchored comparisons, the median number of
covariates adjusted for was 6, and ranged from 1 to 13 covariates. Only
one of the two appraisals reporting anchored comparisons presented any
information on the choice of covariates; in this appraisal (TA383) 10 covariates
were adjusted for.
Common covariates adjusted for in oncology appraisals were age, Eastern
Cooperative Oncology Group (ECOG) performance status, gender, and the
number and/or type of previous therapies. Many appraisals also adjusted for
other clinical factors such as biomarker levels or disease subtypes.
Both hepatitis C appraisals (TA364, TA331) adjusted for age, body mass
index (BMI), gender, fibrosis staging, and viral load. One appraisal (TA364)
further adjusted for race, genotype, and several biomarker levels in two MAIC
analyses for different genotypes and comparator treatments, but in a third
MAIC analysis only had sufficient sample size to adjust for viral load.
The single rheumatology appraisal (TA383) adjusted for 10 covariates
including age, gender, race, concomitant treatments, two biomarkers and three
functional/activity scores.
The most common justification for covariate selection amongst appraisals
reporting unanchored comparisons was simply to adjust for all baseline
characteristics reported in both studies. This was also true for appraisal TA383
which used an anchored comparison, despite the fact that adjustment is only
required for covariates which were effect modifiers in anchored comparisons.
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(The other appraisal with an anchored comparison, TA449, did not report any
information on variable selection.) Unnecessary adjustment will not introduce
bias but may increase uncertainty, particularly with MAIC (see Section 2.3.1
and Phillippo et al. (2016), although we note that TA38 took place before the
advice in Phillippo et al. (2016) was published). Two appraisals (TA429, TA457)
justified the selection of covariates using expert clinical opinion. One appraisal
using MAIC (TA510) asked experts to rank covariates by importance, then
added covariates into the model one-by-one in decreasing order of importance;
the finalmodel choicewas determined by consideration of effective sample size.
Unanchored MAICs in particular have to make trade-offs between effective
sample size and the number of adjustment variables, since the number of
potential prognostic factors is likely to be large. However, unless all prognostic
factors and effect modifiers are included in the adjustment, the estimates will
remain biased (see Section 2.3.2, and Phillippo et al. 2016). Moreover, the
covariates for which the effective sample size reduction is greatest are those
which are most imbalanced between populations, and are therefore more
important to adjust for amongst the covariates with similar prognostic or effect
modifying strength. Two appraisals using STC used statistical techniques to
choose covariates. One (TA333) selected covariates that were “significant” in
the regression model, which is again likely to incur residual bias—particularly
in small samples (Steyerberg et al. 1999). Another (TA492) selected covariates to
maximise cross-validated predictive performance, which is more appropriate
than selection based on “significance” given that STC relies on accurate
predictions into the aggregate population, but is still subject to the limitations
of in-sample validation (Phillippo et al. 2016).
3.2.2.6 Larger networks
As originally proposed, MAIC and STC cannot be extended to larger network
structures with multiple comparators of interest and/or multiple aggregate
studies. However, these scenarios frequently arise in practice: a total of 10 out
of 18 TAs (55.6%) involved larger networks of treatments and studies.
In five of these (71.4%; TA331, TA383, TA429, TA500, TA510), multiple
population adjusted indirect comparisons were performed and then simply
left as stand-alone estimates. Each of these estimates will be valid for different
target populations, and so cannot be interpreted together coherently unless
additional assumptions are met—namely that all the target populations are in
fact identical (in terms of effect modifiers for anchored comparisons, and also
in terms of prognostic variables for unanchored comparisons).
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One appraisal (TA492) used STC (and MAIC as a sensitivity analysis) to
predict active treatment arms for each single-arm study in an unconnected
network, and then analysed this newly-connected network using network
meta-analysis (NMA). This results in a coherent set of relative effect estimates.
However, aside from the very strong assumptions required for the unanchored
comparisons, this analysis must also assume that there are no imbalances in
effect modifiers between the single-arm studies included in the NMA. Another
serious concern is the repeated use of the predicted active treatment arms,
which are all based on the same data set and so are not independent.
Two appraisals (TA311, TA380) had wider networks of treatments and
studies including the two treatments of primary interest, but that were not
fully connected. These networks were analysed using NMA (without any
population adjustment) using an equivalency assumption for two treatments
(TA311) andamatchedpairs analysis (TA380) to connect thenetworks. Separate
unanchoredMAICswere then used to create population-adjusted comparisons
as sensitivity analyses.
One appraisal (TA427) had additional single-arm IPD sources which were
used to provide additional stand-alone comparisons (in this case using Cox
regression for survival outcomes). Guidance on single-arm comparisons with
full IPD in NICE TAs has previously been published by Faria et al. (2015).
Lastly, the method of analysis was unclear for one appraisal (TA364) which
had multiple comparators of interest, some with several AgD studies available.
However, given that unanchoredMAICwas used, this analysis is susceptible to
the same sets of pitfalls described above depending on whether the estimates
were left as stand-alone estimates or synthesised as a network.
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Table 3.2 Applications of population adjustment in NICE Technology Ap-
praisals. Superscripts in the covariates column indicate the subset of covariates
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3.3 Discussion
In these two reviews, we have seen that population adjustment methods
are becoming ever more prevalent in the published literature and in NICE
Technology Appraisals. Different practices may be found in submissions
to other reimbursement agencies, who may also receive and interpret such
analyses differently. Both reviews span a limited time period since these
methods were first published and practice is likely to continue to evolve, for
example as methodological guidance is published. A further limitation of
these reviews is that the data extraction was carried out by a single reviewer
only. Since its publication in late 2016, the NICE Decision Support Unit
Technical Support Document 18 (Phillippo et al. 2016) has been cited in every
following TA that used population adjustment methods, with committees and
review groups using TSD 18 to inform and justify their conclusions regarding
population-adjusted analyses.
In NICE TAs, decisions are not based solely on clinical effectiveness; cost
considerations are also taken into account in a cost-effectiveness analysis.
The impact of population adjustment methods on appraisals is therefore
understood within this context. Through discussions with colleagues at NICE
(Phillippo et al. 2019a), it has become apparent that committees often had
concerns regarding the quality of evidence produced by such methods: the
data used in the analyses were often weak (for example, immature follow-up
data or small single-arm studies), and there was additional uncertainty over
the covariates that were adjusted for (which covariates were selected and
how, and whether and to what extent any unobserved covariates introduced
bias). As a result, committees typically looked for greater cost-effectiveness
before making a positive recommendation to offset the perceived risks from
lower-quality, uncertain evidence. Appraisal committees were typically more
likely to use the results of population-adjusted analyses for decision-making
when they were presented alongside an additional confirmatory analysis, and
when the uncertainty in the method was acknowledged and explored (for
example using sensitivity analyses).
In both the published literature and in NICE TAs, a large number of
analyses were unanchored with no common comparator, and hence rely on
very strong assumptions as outlined in Section 2.3.2. The proliferation of
unanchored analyses is likely to escalate, in large part due to the rise of
single-arm studies for accelerated or conditional approval with regulators
such as the US Food and Drug Administration or the European Medicines
Agency (Hatswell et al. 2016). However, the evidential requirements for
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demonstrating clinical efficacy (to obtain licensing) can be less stringent than
those for demonstrating cost effectiveness (to obtain reimbursement). NICE
appraisal committees and evidence review groups have been justifiably wary
of the use of unanchored population adjustment methods to bridge this
evidence gap, with many commenting that the results should be interpreted
with caution andmay contain an unknown amount of bias. Increased dialogue
between regulators and reimbursement agencies may help bridge this gap in
evidence requirements.
All current population adjustment methods assume that there are no
unmeasured effect modifiers when making anchored comparisons. For unan-
chored comparisons, it is further assumed that there are no unmeasured
prognostic factors. This latter assumption is particularly strong and difficult
to justify. Quantifying residual bias due to unmeasured confounding is an
area for future work, which we discuss in Section 9.2.8.
Several applications in the literature and in technology appraisals had
multiple comparators and/or AgD study populations for which comparisons
were required (see Sections 3.1.1.3, 3.1.2 and 3.2.2.6). Current MAIC and
STC methodology cannot handle larger network structures: multiple analyses
were performed in each case, and then either left as stand-alone comparisons
or themselves synthesised using network meta-analysis, requiring further
assumptions in the process. Furthermore, current MAIC and STC methods
produce estimates which are valid only for the aggregate study population
(typically that of a competitor) without additional assumptions, which may
not match the target population for the decision (Phillippo et al. 2016). This
fact has been largely overlooked in appraisals and in the published literature
to date, although one appraisal (TA451) did note that the MAIC analysis that
was performed took the results of an IPD trial deemed to be relevant to the
decision population and adjusted them into a non-representative aggregate
trial population. Clearly if effect modification is present then it is not enough to
simply produce “unbiased” estimates: the estimates producedmust be specific
to the decision population, otherwise they are of little use to decision-makers.
This motivates the development of new methods which can extend naturally
to larger networks of treatments and can produce estimates for a given target
decision population, in the following chapter. Furthermore, if all trials are
a subset of the decision target population with respect to one or more effect
modifiers, then any adjustment must rely on extrapolation; if these effect
modifiers are discrete, adjustment may be impossible.
The large majority of published analyses and technology appraisals used
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MAIC to obtain population-adjusted indirect comparisons. Effective sample
sizes were typically small and often substantially reduced compared to the
original sample sizes, indicating potential lack of overlap between the IPD and
AgD populations. Lack of overlap is of particular concern with re-weighting
methods such as MAIC since they cannot extrapolate to account for covariate
values beyond those observed in the IPD, and thus may produce estimates that
remain biased even when all necessary covariates are included in the model.
This motivates the need for simulation studies to explore the robustness of
MAIC (and other population adjustment methods) in scenarios where there is
a lack of overlap between populations (see Section 8.2.5).
Three appraisals were excluded from our review of TAs, as IPD were avail-
able from all included studies (NICE 2016a, 2017g, 2018a). These appraisals
were all unanchored comparisons of survival outcomes in oncology, and used
a selection of propensity score, covariate matching, and regression methods.
Having IPD available from all studies is the gold-standard and is preferable if
at all possible. This is because IPD allows for analyses that havemore statistical
power and may rely on less stringent assumptions, and allows assumptions to
be tested. Methodological guidance is available for analyses with full IPD in
NICE TAs (Faria et al. 2015).
For population-adjusted analyses to have the desired impact on decision
making, including in technology appraisals, several key improvements are
needed to current practice (Phillippo et al. 2016). Firstly, a target population
relevant to decisionmakers should be defined, and estimatesmust be produced
for this population in order to be relevant. Current population adjustment
methods can only produce estimates valid for the population represented by
the aggregate study unless further assumptions are made, which may not
represent the decision at hand; this has been largely overlooked in appraisals
and applications in the literature to date (although note that several of the TAs
and all of the applications in the literature thatwe identified pre-date published
guidance). For anchored comparisons there should be clear prior justification
for effect modification, based on empirical evidence from previous studies
and/or clinical expertise. To date, only one published application of anchored
population adjustment made any attempt to justify effect modification (Nixon
et al. 2014, see Section 3.1.2); no technology appraisals or any other applications
in the literature that reported anchored population-adjusted analyses provided
any such justification. Unanchored comparisons require reliable predictions
of absolute effects via adjustment for both prognostic and effect modifying
covariates, and are highly susceptible to unobserved confounding due to a
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lack of randomisation. Simply adjusting for all available covariates, as is
currently common practice, is not sufficient. For unanchored comparisons
to be impactful, covariates should be selected with predictive performance
in mind and estimates of the potential range of residual bias are required;
otherwise, the amount of bias in the estimates is unknown and may even
be larger than for an unadjusted comparison. This is not easy to achieve
(some suggestions are made in the discussion, see Section 9.2.8), but without
such reassurance decision makers are likely to remain justifiably wary of
unanchored analyses. Many of the above issues can be mitigated—at least in
part—by the availability of IPD from all studies in an analysis, and thus the




A new approach: Multilevel
Network Meta-Regression
Currentmethods for population-adjusted indirect comparisons combining IPD
and AgD include MAIC and STC, and network meta-regression (Section 2.2).
MAIC and STC (Caro and Ishak 2010; Ishak et al. 2015; Signorovitch et al.
2010) are based on reweighting and regression adjustment ideas seen in
the standardisation literature, and represent a departure from the standard
framework for indirect comparisons and network meta-analysis (Sections 2.2.1
and 2.2.2). MAIC and STC are designed with a simple two-study scenario
in mind where there is IPD available from an AB study and only published
AgD from an AC study, and are not readily generalisable to larger treatment
networks. Moreover, they are also limited to providing a comparison adjusted
to the population of the AgD trial without further assumptions, which may
not match the relevant target population for decision makers—rendering
estimates irrelevant (Section 2.5). Current networkmeta-regression approaches
(Section 2.2.3) are consistent with the standard NMA framework, can be
applied to networks of all sizes, and can produce estimates for relevant
target populations. These methods combine available IPD with AgD in a
NMA framework and estimate treatment-covariate interaction terms for effect
modifiers (Donegan et al. 2013; Jansen 2012; Saramago et al. 2012; Sutton
et al. 2008; Thom et al. 2015). Typically, the same model is applied at both
the individual and aggregate level, which leads to aggregation bias (a form
of ecological bias) when the model is non-linear (Rothman et al. 2008). Two
approaches have been proposed to account for this. The first is to split the
interaction effect into between-study (or aggregate-level) and within-study
(or individual-level) effects (Donegan et al. 2013; Saramago et al. 2012; Sutton
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et al. 2008; Thom et al. 2015). However, in the two-study scenario there is
insufficient data to identify the additional between-study parameter alongside
the treatment effect; this approach is therefore not applicable in this scenario.
The second approach is to define the aggregate-level model by integrating the
individual-level model over the study population, avoiding aggregation bias
by properly relating the two levels. So far, this approach has only been derived
for the simple case of discrete covariates, where the integration reduces to
summation (Jansen 2012), limiting its usefulness. There is therefore a clear
need for new methods which address these issues.
As we found in our review of the literature, there have been promising
attempts to combine information from several levels in an ecological context,
where data are available in aggregate form on, say, geographical areas, but only
limited individual survey data are available (Jackson et al. 2006, 2008; see Sec-
tion 2.2.3). These methods motivated the approach of Jansen (2012) mentioned
above to network meta-regression combining IPD and AgD. In this chapter
we build on the ideas of Jansen (2012) and the ecological inference literature,
further generalising thesemethods to incorporate both continuous and discrete
covariates for use in population-adjusted indirect comparisons and network
meta-regression combining IPD and AgD. We call this approach Multilevel
Network Meta-Regression (ML-NMR). ML-NMR extends the standard NMA
framework to synthesise evidence from both IPD and AgD simultaneously
whilst avoiding aggregation bias, and is highly flexible. When IPD are available
on all studies, ML-NMR reduces to IPD network meta-regression—the “gold
standard” approach.
We begin by outlining the general framework for ML-NMR, based on
that set out by Jackson et al. (2006, 2008) but contextualised for indirect
comparisons in a simple two-study scenario (Section 4.1). Derivation of the
model depends upon two things: i) the likelihood for the individual-level data,
and ii) the link function used for the individual-level linear predictor. Firstly,
we consider deriving the correct form of the aggregate-level likelihood from
the individual-level likelihood (Section 4.2). We then describe the derivation of
ML-NMRmodels when all covariates are discrete (Section 4.3.1), as considered
by Jansen (2012). ML-NMR models are then derived for continuous covariates
(Section 4.3.2), however analytic approaches are not always tractable. This
motivates discussion of general numerical methods in Section 4.3.3, which are
widely applicable and easily implementable. In Section 4.3.4, we demonstrate
how models combining discrete and continuous covariates may be obtained
from the previous results. We discuss some practical considerations in
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Section 4.5, including identifiability and data availability. In Section 4.6, we
show the natural extension of ML-NMR to larger treatment networks. Finally,
we conclude with a discussion (Section 4.7).
4.1General framework for ML-NMR
To develop the general framework for ML-NMR, we consider an individual-
level regression model, which we can fit directly to the IPD in the AB study.
The individual-level model also underlies the AgD AC study, however we do
not have the IPD to fit this directly. Instead, we integrate the individual-level
model over the AC study population to form an aggregate-level model with
which to fit to the summary outcomes. Mathematically, we write
Individual:
yik(AB) ∼ πInd(θik(AB)) (4.1a)
g(θik(AB))  µ(AB) + xTik(AB)(β1 + β2,k) + γk (4.1b)
Aggregate:






µ(AC) + xT(β1 + β2,k) + γk
)
fk(AC)(x) dx (4.1d)
The individual- and aggregate-level data are given appropriate likelihood
distributionsπInd(·) andπAgg(·), where the choice of individual-level likelihood
will determine the corresponding aggregate-level likelihood (see Section 4.2).
θik(AB) is the conditional mean outcome for an individual i on treatment k
in the AB trial with covariates xik(AB). θ•k(AC) is the marginal mean outcome
on treatment k in the AC trial, and fk(AC)(x) is the distribution of x in those
assigned to treatment k the AC trial. g(·) is a suitable link function, and X
denotes the support of x. The coefficients µ are study-specific baselines, β1
are coefficients for prognostic variables, and β2,k are coefficients for effect
modifiers specific to each treatment k. The effect of the k-th treatment (at
the individual level), γk , is defined with respect to the reference treatment A,
and we set γA  0 and β2,A  0. Some coefficients of β1 or β2,k may be set
to zero, if it is known that a particular covariate is not prognostic or effect
modifying respectively. In a Bayesian analysis, prior distributions are placed
over each of the parameters µ(AB), µ(AC), β1, β2,B , β2,C , γB , γC . For brevity, we
will frequently refer to the individual-level linear predictor for individuals on
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treatment k in a population P with covariates x using the notation
ηk(P)(x)  µ(P) + xT(β1 + β2,k) + γk ,














We must address some key issues before the ML-NMR model (4.1) can be
implemented. Firstly, we must derive an aggregate level likelihood (4.1c) from
the individual level likelihood (4.1a), ensuring that the relationship between
levels is maintained. For several individual level likelihoods the corresponding
aggregate likelihood is intuitive, but this is not always the case. We discuss
the proper derivation of aggregate level likelihoods in Section 4.2. Secondly,
the integral in the aggregate level model (4.1d) must be evaluated; the manner
of this evaluation depends on the type of covariates (discrete, continuous,
or a mixture of both) and the link function g(·). Algebraic approaches are
developed in Section 4.3.2, and numerical integration examined in Section 4.3.3.
4.2 From individual to aggregate likelihoods
The choice of an individual level likelihood distribution is natural, how-
ever care must be taken in subsequently defining the appropriate aggregate
level likelihood distribution as a summary (e.g. a mean or summation) over
individual likelihoods.
For example, if a continuous outcome is of interestwith aNormal individual
likelihood, summarised in the AgD by mean outcome, then the respective
aggregate likelihood—the mean of the (independent) individual likelihoods—
will also be Normal:
















4.2. FROM INDIVIDUAL TO AGGREGATE LIKELIHOODS
where yik(AB) is the outcome for an individual i on treatment k in the AB trial,
and ȳk(AC) is the mean outcome on treatment k in the AC trial. The variance
parameters σ2k(AB) would be given prior distributions and estimated from the
data in a Bayesian analysis, and the standard errors of the means sk(AC) would
be given as data.
If the data are in the formof counts or numbers of events, then an individual
Poisson likelihood may be used, the sum over which gives a Poisson aggregate
likelihood:













where yik(AB) is the number of events occurring in exposure time Eik(AB) for
an individual i on treatment k in the AB trial, and E•k(AC) is the total exposure
time on treatment k in the AC trial. Note that the aggregate summary for
the Poisson model is the total number of events y•k(AC), as opposed to the
mean outcome in the Normal model above. The parameters λik(AB) and λ̄k(AC)
are conditional and marginal event rates. These are modelled by θik(AB) and
θ•k(AC) respectively, typically with a log link function (see Section 4.3.2.2).
However, the situation is not so straightforward when binary data are
observed. With a Bernoulli individual likelihood the respective aggregate
likelihood is not Binomial, as in general each individual has a different event
probability due to differences in prognostic factors. In this case the true
aggregate likelihood, the sum of independent (but not identically distributed)
Bernoulli likelihoods, is Poisson Binomial:













where yik(AB) is a binary event indicator for individual i on treatment k in
the AB study, and y•k(AC) is the total number of events on treatment k in
the AC study. Here, pik(AB) is the probability of an event for an individual
i on treatment k in the AB study, which is modelled by θik(AB), typically
using a logit link function. The parameter vector of the Poisson Binomial
pk(AC) 
(
p1k(AC) , . . . , pNk(AC)(AC)
)
is a vector of event probabilities for the Nk(AC)
individuals on treatment k in the AC study.
Aside from the lack of IPD in the AC trial to estimate the vector pk(AC), there
is a further issuewhich prevents us fromusing (4.4b) directly: evaluation of the
Poisson Binomial likelihood is not straightforward. Exact evaluation involves
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a recursive summation of factorially many terms, which is very slow and can
be numerically unstable; the individual event probabilities are also required,
which are not available due to the lack of IPD. More efficient approaches using
the Discrete Fourier Transform have been proposed (Fernandez and Williams
2010; Hong 2013) which are fast and avoid numerical instabilities; however
these still rely upon the availability of individual event probabilities. To
circumvent these issues, we can use an approximation of the Poisson Binomial
likelihood, which will not only lead to efficient computation, but will be
tractable when only aggregate data are available.
4.2.1 Binomial approximations to the Poisson Binomial likelihood
Themost common approximation (also used in standard aggregate data NMA)
is to consider the number of events y•k(AC) to be Binomially distributed with
average probability p̄k(AC),
y•k(AC) ∼ Bin(Nk(AC) , p̄k(AC)). (4.5)
In this case, the average probability is modelled using θ•k(AC), typically with a
logit link function (see Section 4.3.2.4).
This approximationonlyworkswellwhen the individual event probabilities
pik(AC) are all approximately equal for a given treatment k (Ehm 1991). When
this is not the case, the Binomial and Poisson Binomial share the same mean:
Binomial mean  Nk(AC) p̄k(AC)











pik(AC)  Nk(AC) p̄k(AC) ,
but differ in their variance:
Binomial variance  Nk(AC) p̄k(AC)(1 − p̄k(AC))




and it can be shown that∑
i
pik(AC)(1 − pik(AC)) ≤ Nk(AC) p̄k(AC)(1 − p̄k(AC)),
with equality if and only if pik(AC)  p̄k(AC) ∀i.
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Le Cam (1960) considered an alternative Binomial approximation, whereby
both Nk(AC) and p̄k(AC) are adjusted in order to match both the variance and
the mean of the Poisson Binomial:






















i p2ik(AC). The mean probability parameter p̄k(AC) is
again modelled with θ•k(AC) and a logit link. The second parameter p̄2k(AC)
(which is related to the variance of the individual probabilities) is modelled
in a similar manner, where the integration in (4.1d) is over the squared linear
predictor. We discuss this in detail in Section 4.3.2.4.
Peköz et al. (2009) derive a shifted-Binomial approximation, which further
matches the skewness of the Poisson Binomial by adjusting three parameters
(the third being the shift parameter); however Peköz et al. (2010) find that in
practice the largest improvements arise from the use of the two-parameter
approximation over the simple approximation, with the three-parameter
approximation giving little additional improvement at the expense of greater
complexity and computational cost. We therefore do not explore any higher-
order approximations beyond the two-parameter Binomial approximation.
4.3Deriving the aggregate level model by integration
Implementing ML-NMR involves an integration step in the aggregate-level
model (4.1d). In a Bayesian framework, ML-NMR is likely to be implemented
using Markov Chain Monte Carlo (MCMC), for example in WinBUGS, JAGS,
or Stan. At each iteration of the MCMC algorithm, we must evaluate the
integral (4.1d) at a given set of values for the parameters (µ(AC) , β1 , β2,k , γk).
There are two possible approaches: (i) analytical, where the exact form of
the aggregate-level model is derived and can be explicitly written into the
MCMC algorithm; or (ii) numerical, where a numerical integration method is
enlisted. Analytical approaches are fast and offer insight into the nature of
multilevel models and aggregation bias; however, different approaches are
required for different link functions and covariate distributions, meaning that
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a general implementation is not possible, and the resulting expressions for
the aggregate-level model can grow increasingly complex, or may even be
intractable. This motivates the exploration of numerical approaches, which
sacrifice some speed and mathematical insight but may be broadly applied to
fit ML-NMR models in myriad scenarios.
4.3.1 ML-NMRwith discrete covariates
If the covariates x are all discrete, then the integration in the aggregate level









where now X is the set of discrete levels of x, and fk(AC)(x) is the proportion
of individuals in each level in the AC trial. Jansen (2012) describes how a
network meta-analysis combining IPD and AgD may be performed using
(4.7) in a logistic regression scenario with only discrete covariates, and using
the simple one-parameter Binomial approximation to the Poisson Binomial
likelihood (4.5).
4.3.2 ML-NMRwith continuous covariates: analytic approaches
When all covariates are continuous, the manner in which the aggregate level
model is evaluated depends on the choice of link function g(·).
4.3.2.1 Integration with an identity link
When g(y)  y, the identity link, the integration is trivially the expectation






With any other non-linear link function, simply “plugging in” the mean
covariate values in this manner will lead to aggregation bias since (g(X)) ,
g((X)).
4.3.2.2 Integration with a log link
When g(·) is the log link function, for example with a continuous outcome
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In this case, the integrationmay be performed explicitly by noting the definition
of the moment generating function (MGF) for a (multivariate) random variable x








exp(sTx) fk(AC)(x) dx. (4.9)
Therefore, we rewrite the aggregate level model in terms of the joint MGF























 exp(µ(AC) + γk)Mx(AC)(β1 + β2,k). (4.10)
Table 4.1 lists theMGFs for some commondistributions likely to be encountered
in practice.
Table 4.1 Moment generating functions for common distributions.
Distribution Moment generating function Sufficient statistics
required
Normal
x ∼ N(m , σ2)




Mx(AC)(s)  exp(sTm + 12 sTΣs) Mean vector m
Covariance matrix Σ
Gamma
x ∼ Gam(a , b)




Mx(AC)(s)  1 − p + p exp(s) Proportion p
If the aggregate data are instead given as relative effect estimates—the
difference in transformed mean outcomes on each treatment—we can simply
derive the aggregate level model for relative effects data from (4.10):
dAC(AC)  log(θ•C(AC)) − log(θ•A(AC))






The joint MGF Mx(AC)(·) could be derived empirically if IPD were avail-
able on the covariates in the AC study using the estimator M̂x(AC)(s) 
N−1(AC)
∑N(AC)
i1 exp(sTxi). However, such level of detail is unlikely to be provided
in published reports. Instead, if a specific covariate distribution is either
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known or may be assumed, sufficient statistics can be used to construct the
MGF. One practical consideration must be noted with this approach: not every
distribution has a MGF, including most notably the log-Normal distribution.
For skew covariates defined to be positive, which might otherwise be assumed
to follow a log-Normal distribution, the Gamma distribution could be used
instead (later in Section 8.2.6, simulations suggest that the assumed form of
the covariate distribution may not greatly impact the results).
For example, with multivariate Normal covariates x ∼ MVN(m ,Σ) with








2 (β1 + β2,k)




In this case, the aggregate levelmodel for relative effects data (4.11) becomes
dAC(AC)  log(θ•C(AC)) − log(θ•A(AC))



















Σβ2,C︸                   ︷︷                   ︸
(b)
. (4.13)
The multivariate Normal scenario offers some insight into the relationship
between ML-NMR and the naïve approach of “plugging in” mean covariate
values. Both (4.12) and (4.13) can be viewed as an adjustment to the naïve
model (4.12a, 4.13a), with the adjustment terms (4.12b, 4.13b) involving
the covariate covariance matrix Σ accounting for the integration over the
population. Examining the adjustment term (4.13b), we notice that this
depends upon
• The covariance of prognostic variables and effect modifiers, and the
strength of each, through βT1Σβ2,C . This is large when highly prognostic
variables are correlated with strong effect modifiers, or when strong
effect modifiers which are also highly prognostic take a wide range of
values in the AC population (the population variance is large).
• The covariance of effectmodifiers and their strength, through 12βT2,CΣβ2,C .
This is large when strong effect modifiers are highly correlated, or
when strong effect modifiers take on a wide range of values in the AC
population (the population variance is large).
112
4.3. DERIVING THE AGGREGATE LEVEL MODEL BY INTEGRATION
This lends theoretical justification to intuitive thinking for when effect mod-
ification may lead to aggregation bias. In particular, aggregation bias is
expected to be small if either effect modifiers are weak, or the within-study
variance of effect modifiers is small. (The covariance inequality, a form of the
Cauchy-Schwarz inequality, bounds the covariance between two variables ascov(X1 ,X2) ≤ √var(X1)var(X2). Small within-study variance in the effect
modifiers is therefore sufficient to also limit the aggregation bias due to
correlations.)
4.3.2.3Integration with a probit link
Suppose that a binary outcome is of interest, and the probit link function
g(p)  Φ−1(p) (the standard Normal inverse cumulative distribution function)
is used. We saw in Section 4.2.1 that, for a Bernoulli individual-level likelihood,
the corresponding aggregate-level likelihood is Poisson Binomial, to which
we make either a one- or two-parameter Binomial approximation.
One-parameter Binomial approximation To recap, the one-parameter ap-
proximation (4.5) is to consider the number of events y•k(AC) to be Binomially






The mean probability p̄k(AC) is modelled by θ•k(AC), and using the probit link









This integral does not always have a closed form solution; however, we
can obtain a solution if the covariates are multivariate-Normal, xk(AC) ∼
MVN(mk(AC) ,Σk(AC)). Using the following result for the expectation of the








and noting that the linear predictor ηk(AC)(xk(AC)) is a linear transformation of
Normal random variables, so is itself Normally distributed:
η(xk(AC))  µ(AC) + xTk(AC)(β1 + β2,k) + γk
∼ N
(
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1 + (β1 + β2,k)TΣk(AC)(β1 + β2,k)
)−12 ) . (4.17)
As in Section 4.3.2.2, the ML-NMR aggregate-level model can be viewed as
an adjustment to the naïve approach of “plugging in” mean covariate values
to θ•k(AC)  Φ(ηk(AC)(mk(AC))), and the adjustment factor again involves the
strength of the prognostic and effect modifying covariates and their covariance
matrix through (β1 + β2,k)TΣk(AC)(β1 + β2,k).
Two-parameter Binomial approximation As noted in Section 4.2.1, the one-
parameter Binomial approximation to the Poisson Binomial likelihood only
works well when the individual event probabilities are approximately equal.
























To derive theAgDmodel using the two-parameter Binomial approximation,




i p2ik(AC). We model
p̄k(AC) by θ•k(AC) as in the one-parameter case using (4.14), and we model







)2 fk(AC)(x) dx. (4.18)
Again, the necessary integrals are not generally analytically tractable, but we
canobtain analytic results in the special case that xk(AC) ∼MVN(mk(AC) ,Σk(AC)).
We use the same result for θ•k(AC) obtained in (4.17). For θ2•k(AC), we again
note the Normal distribution of ηk(AC)(xk(AC)) (4.16), and use the result of
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1 + (β1 + β2,k)TΣ(AC)(β1 + β2,k)
)− 12 ,
(
1 + 2(β1 + β2,k)TΣ(AC)(β1 + β2,k)
)− 12 )
(4.20)
Owen’s T may be evaluated using fast numerical methods: an efficient hybrid
approach that selects between six alternate evaluation methods is given by
Patefield and Tandy (2000), and an adapted version of this algorithm is
implemented in the Stan function owens_t.
4.3.2.4Integration with a logit link
Suppose again that a binary outcome is of interest, but that this time the
logit link function is used. The corresponding aggregate-level likelihood is
Poisson Binomial, to which we make either a one- or two-parameter Binomial
approximation (Section 4.2.1).
One-parameter Binomial approximation The one-parameter approximation
(4.5) is to consider the number of events y•k(AC) to be Binomially distributed






The mean probability p̄k(AC) is modelled by θ•k(AC), and using the logit link









Unfortunately, this integral has no closed form solution.
Previous authors have suggested approximating the logit link by a probit
(Demidenko 2004; Salway and Wakefield 2005), for example















The two-probit approximation is particularly robust, and still results in a
proper likelihood distribution as the coefficients sum to one. Higher order
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approximations are possible and can be even more accurate, but do not
necessarily result in proper likelihood distributions.
Continuing with the one-probit approximation first, the average event












If the covariates are multivariate-Normal, xk(AC) ∼ MVN(mk(AC) ,Σk(AC))
then, following the same approach as Section 4.3.2.3 by noting the Normal











(β1 + β2,k)TΣ(AC)(β1 + β2,k)
)− 12 ª®¬.
(4.22)
This result is given by Salway and Wakefield (2005) for bivariate Normal
covariates. Simlarly to Section 4.3.2.2 and Section 4.3.2.3, this aggregate-level
model can be viewed as an adjustment to the naïve approach of “plugging in”
mean covariate values to θ•k(AC)  logit−1(ηk(AC)(mk(AC))), and the adjustment
factor again involves the strength of the prognostic and effect modifying
covariates and their covariance matrix through (β1 + β2,k)TΣk(AC)(β1 + β2,k).
With the two-probit approximation and multivariate-Normal xk(AC), again
noting the Normal distribution of ηk(AC)(xk(AC)) and using the result (4.15), we
obtain












1 + 1.3017−2(β1 + β2,k)TΣk(AC)(β1 + β2,k)
)−12 )
(4.23)
For skew covariates, as for models with a log link or probit link (see
Section 4.3.2.2 and Section 4.3.2.3), evaluation of the marginalisation integral is
troublesome: analytic integration for both log-Normal and Gamma distributed
covariates is not straightforward. In an ecological context, Salway and Wake-
field (2005) noted that estimates remained biased when skew covariates were
treated as Normal (although less so than the naïve approach), and uncertainty
was underestimated. For discrete covariates, the aggregation integral is simply
a sum over the levels of the covariates, and no approximation is required (see
Section 4.3.4).
Two-parameter Binomial approximation As noted previously (Section 4.2.1),
the one-parameter Binomial approximation to the Poisson Binomial likelihood
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only works well when the individual event probabilities are approximately
























To derive theAgDmodel using the two-parameter Binomial approximation,




i p2ik(AC). We model
p̄k(AC) by θ•k(AC) as in the one-parameter case using (4.21), and we model







)2 fk(AC)(x) dx. (4.24)
Again, the necessary integrals are not generally analytically tractable, but we
canobtain analytic results in the special case that xk(AC) ∼MVN(mk(AC) ,Σk(AC))
using the one-probit approximation to the logit. We use the same result for
θ•k(AC) obtained in (4.22). For θ2•k(AC), we again note the Normal distribution























































(β1 + β2,k)TΣ(AC)(β1 + β2,k)
)−12 )
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(β1 + β2,k)TΣ(AC)(β1 + β2,k)
)− 12 )
(4.25)
Derivation of the aggregate-level model for multivariate-Normal covari-
ates using both the two-probit and two-parameter Binomial approximations
together is not straightforward: the integral for θ•k(AC) may be evaluated in
a similar fashion to the one-probit approximation described here, but the
integral for the average squared probabilities modelled by θ2•k(AC) becomes
intractable.
4.3.3 ML-NMRwith continuous covariates: generalised numerical
approaches
Thus far we have considered analytic approaches to performing the marginali-
sation integral (4.1d). The resulting analytic forms of the aggregate level model
enable efficient computation, and lead to greater insight into the mathematical
nature of the multilevel model—specifically that the ML-NMR aggregate level
model may be viewed as an adjustment to the naïve aggregate level model.
However, such approaches are context-specific, requiring a different approach
for each link function, and are of little use when the marginalisation integral
becomes intractable (most notably when covariates are skewed). There is,
therefore, the need for a general numerical approach which is both flexible
and robust enough to be widely applicable.
Practically, the ML-NMR model will be implemented using Markov Chain
Monte Carlo (MCMC) for flexibility and simplicity (such as WinBUGS, JAGS,
or Stan). The role of numerical integration is therefore to evaluate themarginal-
isation integral (4.1d) for a given value of the parameters (µ(AC) , β1 , β2,k , γk)
at each iteration of the MCMC chain. We discuss several possible numerical
approaches, along with their merits and disadvantages, below.
4.3.3.1 Quadrature
One potential approach is to use a quadrature rule. For example, if the
covariate distribution is Normal, Gauss-Hermite quadrature may be used to
efficiently and accurately evaluate θ•k(AC) for a given set of parameter values
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at each MCMC iteration. Alternatively, more general quadrature methods
such as the trapezium rule, Simpson’s rule, or Romberg integration (see Press
et al. 2007, Chapter 4, for an overview), may be utilised. Whilst these methods
are fast and accurate, they cannot handle higher dimensional integrals (i.e.
with larger numbers of covariates) well: the number of quadrature points
required increases to the power of the number of dimensions. The appropriate
quadrature rule to use will also depend on the specific form of fk(AC)(·) or g(·).
4.3.3.2Monte Carlo integration
In contrast to quadrature rules which are deterministic algorithms, we might
instead consider forms of stochastic numerical integration, which involve
random sampling from the joint covariate distribution fk(AC)(·). Here, we
consider Monte Carlo integration. A large number Ñ of integration points
x̃k(AC) are simulated from fk(AC)(·) before the MCMC run, and treated as
additional data for the MCMC algorithm. At each MCMC iteration, the









For standard Monte Carlo integration, x̃k(AC) are sampled (pseudo-)
randomly from the covariate distribution fk(AC)(·); however, this can require
large numbers of integration points to obtain sufficiently accurate estimates.
The approximation can be made more efficient by using a quasi-random
sample of points (Quasi Monte Carlo, QMC), which are chosen sequentially
to cover the covariate space X more uniformly than pseudo-random samples,
resulting in fewer integration points needed to achieve the same accuracy.
QMC integration commonly achieves integration error rates of the order Ñ−1,
compared to standard Monte Carlo which only achieves Ñ− 12 (Caflisch 1998;
Niederreiter 1978). In other words, when using 10,000 integration points
drawn from a quasi-random sequence we would expect accuracy down to
around 4 decimal places, compared with an accuracy of 2 decimal places using
standard Monte Carlo integration.
A numerical integration approach based onQMC ismorewidely applicable
than one basedonquadrature (Section 4.3.3.1), since it can be applied regardless
of the number of covariates or their distributions, the type of link function,
or the complexity of the model. Moreover, QMC integration accounts for
correlations between covariates by design since x̃k(AC) are drawn from the
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joint covariate distribution; accounting for correlations between covariates
is not straightforward when using quadrature. We discuss the practical
implementation of QMC integration in greater detail later in section Section 5.1.
4.3.4 Combining discrete and continuous covariates
In Section 4.3.1, we saw that if all covariates are discrete, the integration
in the aggregate level model (4.1d) becomes a straightforward summation.
Sections 4.3.2 and 4.3.3 presented methods for deriving the aggregate level
model when all covariates are continuous, using either analytic or numerical
approaches.
When both continuous and discrete covariates are to be included in the
model, we may write the aggregate level model as an expansion over the levels
of the discrete covariates using the Laws of Total Probability and Expectation.
Dichotomising for a moment the covariates into discrete z and continuous x,

































The inner integration of (4.27) is then performed in the manner described in
the preceding sections.
Alternatively, when using QMC integration the discrete and continuous
covariates may be jointly simulated from fk(AC)(·). (This is made possible by
the copula approach described in Section 4.3.3.2, and later in greater detail in
Section 5.1.) The numerical integration (4.26) is then a summation over both
the continuous and discrete covariates. Although this has the potential to
increase the number of integration points required, particularly when there are
high correlations between covariates and many discrete covariates, in practice
we have not observed this to be an issue. Furthermore, implementation in code
is greatly simplified and made more general, since only a single summation
rather than the full expansion (4.27) is performed.
4.4 Producing estimates for a specific target population
Once the ML-NMR model has been specified and fitted to the data, we can
produce estimates of different quantities of interest. Typically in a technology
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appraisal context the quantities of interest are population-level quantities such
as average relative treatment effects (contrasts) or the predicted proportion
of individuals with a binary outcome, rather than individual-level treatment
effects and interactions. To be relevant for decision making, population-
adjusted estimates must be produced for the relevant target population. ML-
NMR can produce population-adjusted estimates for any target population
for which covariate information is available.
To produce estimates of population-average relative effects dab(P) between
any two treatments a and b in a population P, we can simply “plug in” the










 x̄T(P)(β2,b − β2,a) + γb − γa .
(4.28)
In a Bayesian framework using MCMC, we evaluate this formula at each of the
posterior samples of the parameters β2,a , β2,b , γa , and γb to produce posterior
samples for dab(P).
In general, we consider estimating the average h̄(P) of a quantity h(x , ξ)
in a target population P, which is some function of the covariates x and
a set ξ of the parameters µ(P), β1, β2,k , γk . Unless h(x , ξ) is linear in x,
like the population-average relative effects dab(P) in (4.28) above, we cannot
simply “plug in” mean covariate values to produce estimates. Doing so incurs









Instead, given the joint covariate distribution f(P)(·) in the target population,
h̄(P) is obtained by integrating over the joint covariate distribution (as a




h(x , ξ) f(P)(x) dx. (4.29)
Alternatively, if the target population is represented by a study or registry
with individual covariate information available, h̄(P)may be obtained by taking






h(xi(P) , ξ), (4.30)
where NP is the number of individuals in the sample, each with covariate
information xi(P). Another option in this case is to estimate f(P)(·) using the
individual covariate information, and use this in (4.29). This may be a more
robust approach, particularly if the sample size in the target population is
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small; comparing these approaches, perhaps through a simulation study, is an
area for further research.
In a Bayesian framework usingMCMC, equation (4.29) or (4.30) is evaluated
at each posterior sample to produce posterior samples for h̄(P).
For example, to calculate the average absolute response on each treatment
k on the natural outcome scale (or the predicted proportion of events for a
binary outcome), we use










The baseline response µ(P) in population P may be equal to µ(AB) or µ(AC) if P
is represented by the AB or AC study respectively, or may be estimated from
external data on population P.
Equation (4.28) for calculating the population-average relative effects dab(P)
between any two treatments b and a is obtained using
h(x , β2,a , β2,b , γa , γb)  xT(β2,b − β2,a) + γb − γa . (4.32)
In this case, since h(x , ξ) is linear in x, using (4.32) in either (4.29) or (4.30)
reduces to (4.28), which is simply h(x̄(P) , ξ).
4.5 Practical considerations
4.5.1 Using publishedmarginal covariate information
When using ML-NMR in practice, we typically only have access to limited
covariate information from the AgD study. This is often in the form of
published marginal covariate summaries, and we have no information on
the correlation structure between the covariates or on the true distributional
form of the marginal distributions. Where the true marginal distributions
of the covariates in the AgD study are unknown, we can instead choose
distributional forms for these covariates based on their theoretical properties
and/or to approximately match the observed distributional forms in the IPD.
For example, a covariate may be well-known to be approximately log-Normal
and/or observed as such in the IPD study, and we can then assume a marginal
distribution for this covariate in the AgD study to match the published
summary statistics. To account for the missing correlation structure, rather
than assuming that all correlations are zero (which may be unreasonable),
we can utilise the correlation structure observed amongst the covariates in
the IPD study and assume that this holds for the covariates in the AgD study.
122
4.5. PRACTICAL CONSIDERATIONS
It seems reasonable to assume that, whilst the marginal summaries for each
covariate may change from study to study (e.g. proportion of males, or mean
and standard deviation of weight), the relationships between covariates are
likely to remain similar (e.g. duration of disease is positively correlated with
the number of previous lines of treatment).
We have specified a model where the covariate distribution fk(AC) in the
AgD AC study may be different in each arm. Whilst randomisation ensures
that covariates are balanced across arms within a study on average, there are
likely to be chance imbalances in the covariate distributions between arms.
Allowing for distinct covariate distributions fk(AC) in each arm of the AC trial
therefore allows us to account for these chance imbalances. Reporting baseline
covariate distributions by arm is not uncommon for published trials—indeed,
it has been an explicit requirement of the CONSORT statement since its
first revision in 2001 (Moher et al. 2001; Schulz et al. 2010); however, if only
the overall baseline covariate distribution f(AC) is reported this may be used
instead, possibly at the expense of some bias.
The Monte Carlo integration approach outlined in Section 4.3.3.2 allows
the correlation structure for the AC study to be specified in a straightforward
manner. When producing the integration points x̃k(AC), we can impose the
assumed joint covariate distribution by using a Gaussian copula (Nelsen 2006),
so that the correlation matrix of the covariates in the AC study matches that
of the IPD AB study, whilst retaining the given marginal distributions. We
describe QMC integration with copulæ in detail in Section 5.1.
4.5.2Identifiability in small networks
In the small two-study scenario with an AB and an AC trial, model (4.1) is
not identifiable due to the lack of data: it is not possible to estimate both β2,C
and γC from a single data point (the C arm of the AC trial, as we do not have
IPD for the AC trial). There are several possible solutions, which we discuss
briefly.
Firstly, the shared effect modifier assumption (Section 2.5) may be used if
justifiable (typically on biological/clinical grounds, for example if B and C are
from the same class of treatments), so that β2,B  β2,C.
Alternatively, if the shared EM assumption is not justifiable, the mean
outcomes on treatments A and B may be predicted in the AC trial and
compared directly with the observed A and C outcomes without constructing
an aggregate level model for the AC trial as follows:
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Individual model in AB trial:
yik(AB) ∼ πInd(θik(AB))
g(θik(AB))  ηk(AB)(xik(AB)) (4.33a)
Predicted relative effect in AC trial:
d̂AB(AC)  x̄T(AC)(β̂2,B − β̂2,A) + γ̂B − γ̂A (4.33b)
Targeted comparison in AC trial:
d̂BC(AC)  d̂AC(AC) − d̂AB(AC) (4.33c)
where (4.33b) is a result of equation (4.28), and d̂AC(AC) is estimated by the AC
trial. This is conceptually similar to STC (except undertaken in a Bayesian
framework andwith aggregation bias explicitly accounted for rather than using
simulation), and should be considered as a “targeted comparison” rather than
a true evidence synthesis, as information from the AC trial is not propagated
through to the parameter estimates (although in practice this is unlikely to
make any meaningful difference, as the aggregate summaries from a single
trial do not contain much information about the individual level parameters).
The main disadvantage of this approach is that the indirect comparison must
be made in the AC population, which is unlikely to match the decision target
population.
Other approaches are possible if more data are available. For example, if
external data are available on the strength of effect modification, it may be
possible to construct an informative prior distribution for β2,C; however note
that the prior information is unlikely to be updated—the posterior distribution
for β2,C will be the same as the prior distribution—due to a lack of information
in the data. In larger treatment networks, greater flexibility in estimation is
possible (see Section 4.6).
4.6 Extension to larger treatment networks
Thus far we have described ML-NMR in a simple two study setting, motivated
by comparison with methods such as MAIC and STC. However, application
to larger networks of treatments is straightforward, and is simply a matter of
notation. Where we have used subscript parentheses to denote studies and
populations, we now refer to studies indexed numerically with index j. We
write the model using the reference treatment parameterisation (Section 1.2.2),
so that individual-level treatment effects γ1k and effect modifier coefficients
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β2,1k refer to the relative effect of treatment k against treatment 1, and by
convention we drop the subscript 1 for brevity: γk  γ1k and β2,k  β2,1k . This
generalises (4.1) as follows:
Individual:
yi jk ∼ πInd(θi jk) (4.34a)
g(θi jk)  η jk(xi jk)  µ j + xTi jk(β1 + β2,k) + γk (4.34b)
Aggregate:








f jk(x) dx (4.34d)
Again we set γ1  0, β2,1  0.
Here we have written a fixed effect (FE) model with no heterogeneity
in treatment effects γk between studies, due to the conditional constancy of
relative effects assumption which supposes that there are no unobserved
effect modifiers. We consider a random effects model in Section 4.6.2. Using
this notation allows ML-NMR to be applied to networks of any number
of trials and treatments. This notation also highlights how ML-NMR is a
generalisation of standard network meta-analysis models. When all studies
have IPD available, equations (4.34a) and (4.34b) describe a typical FE IPD
NMR. When no covariates are included, ML-NMR reduces to a standard FE
AgD NMA: (4.34d) becomes θ• jk  g−1
(
µ j + γk
)
, and the model is fitted to
the summary outcomes from each trial:
y• jk ∼ πAgg(θ• jk)
g(θ• jk)  µ j + γk
(4.35)
and γk are equal to dk , the aggregate-level relative effects.
The AgD NMA framework defines the consistency equations dab  db − da
for any two treatments a and b (see Section 1.2.7; Higgins andWhitehead 1996;
Lu and Ades 2006). These relate the (population-level) relative effects between
each pair of treatments in the network, and ensure that the resulting set of
relative effect estimates is consistent. However, in theML-NMR framework the
population-level relative effects are not assumed constant between populations
as the constancy of relative effects assumption is relaxed. Instead, ML-NMR
defines consistency equations at the individual level on the individual-level
treatment effects and effect modifier coefficients:
γab  γb − γa
β2,ab  β2,b − β2,a
(4.36)
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Notably, this implies consistency of the population-average relative effects
within each population, dab(P)  db(P) − da(P):
dab(P)  x̄T(P)β2,ab + γab
 x̄T(P)(β2,b − β2,a) + γb − γa
 (x̄T(P)β2,b + γb) − (x̄
T
(P)β2,a + γa)
 db(P) − da(P) (4.37)
following the same reasoning in Section 4.4, where integration over the
covariate distribution in population P reduces to plugging in mean covariate
values x̄(P) when working on the linear predictor scale. These consistency
relationships do not in general hold across populations. Standard AgD NMA
is a special case where it is assumed that there is no effect modification (or that
effect modifiers are balanced between all studies), so the population-average
relative effects are identical between studies and the usual NMA consistency
equations dab  db − da are recovered.
Larger networks also offer the opportunity to assess and, if necessary, relax
modelling assumptions given sufficient data. In the two study scenario we
are forced to make the shared effect modifier assumption in order to identify
the model, or otherwise we are limited to a targeted comparison in the AgD
population (see Section 4.5.2). With a larger network it may be possible to
relax the shared effect modifier assumption (Section 4.6.1), or to assess residual
heterogeneity or inconsistency (Sections 4.6.2 and 4.6.3).
4.6.1 Relaxing the shared eect modifier assumption
Within the ML-NMR framework, the shared effect modifier assumption
(Section 2.5) asserts that the regression coefficients β2,k for a set of treatments
k ∈ T are all equal. As discussed in Section 4.5.2, this assumption is necessary
to identify the model in the two study scenario (one IPD AB study and one
AgD AC study), where we assume that {B, C}  T .
In a larger treatment network, the data requirements for estimating a
treatment effect and independent EM interaction terms for a given treatment k
are either i) IPD from one or more trials including treatment k, or ii) sufficiently
many AgD studies including treatment k, with enough variation in covariate
values (equivalent to the requirements of a standard AgDmeta-regression). In
the case that neither of these requirements can be met, either informative prior
distributions or additional assumptions are required to estimate the model.
As in the two study scenario, the shared EM assumption can make the
model estimable by assuming that the effect modifier coefficients β2,k are
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identical amongst a set or class of treatments T . The data requirements
described above then apply to the set T as a whole, rather than to each
individual treatment.
To relax the shared EM assumption for a set of treatments T , we can
instead assume that the EM interactions are exchangeable. A hierarchical
model is placed on the EM interaction coefficients
β2,k;l ∼ N
(





for k ∈ T and each coefficient β2,k;l in the vector β2,k , where l indexes the
different covariates. The hyperparameters mβ2 ,l and σ2β2 ,l are themselves given
prior distributions in a Bayesian framework.
Theremay bemultiple (mutually exclusive) treatment setsT1 ,T2 , . . . within
the treatment network, and some of these may only contain a single treatment
on its own. Different assumptionsmay bemadewithin each set if required. For
example, the shared EM assumption may be made in some sets, exchangeable
EM interactionsmaybe estimated in others (with separate variance components
σ2
β2 ,l ,T1 , σ
2
β2 ,l ,T2 , etc. in each set), and other treatments and their EM interactions
may be estimated independently.
In practice, the data requirements for estimating exchangeable EM interac-
tions (4.38) may also be beyond the data available. In particular, the estimation
of the variance components σ2β2 is challenging, and only improves with increas-
ing numbers of treatments in T and/or informative prior distributions. If
there are multiple treatment sets within the network for which the shared EM
assumption is made, then the variance components could be assumed equal
between the treatment sets to further aid estimation, σ2
β2 ,l ,T1  σ
2
β2 ,l ,T2  σ
2
β2 ,l
for each covariate l. Another simplifying assumption which may aid estima-
tion is to assume that the variance components are equal between covariates,
σ2
β2 ,l
 σ2β2 . However, this latter assumption is much harder to justify, and
additionally relies on covariates being suitably scaled relative to each other
so that the magnitude of their effect modification is similar. Estimation of
the treatment-specific interactions β2,k also requires either IPD or a sufficient
number of AgD studies on each treatment in T , particularly when σ2β2 is large
or imprecisely estimated and little information is shared between treatments
in T .
4.6.2Assessing residual heterogeneity
The key assumption of population adjustment methods is that relative effects
are constant given the effect modifiers adjusted for (conditional constancy
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of relative effects). Within the ML-NMR framework (4.34), this assumption
corresponds to the individual-level relative effects γk being constant across
populations—in other words, we fit a fixed effect model. In the two study
scenario this is an untestable assumption. However, with a larger network
of studies and treatments it is possible to assess the conditional constancy of
relative effects assumption by fitting a random effects model. This is achieved
by modifying the linear predictor η jk(x) in equation (4.34) as follows:
Fixed Effect:
η jk(x)  µ j + xT(β1 + β2,k) + δ jk , δ jk  γk (4.39)
Random Effects:
η jk(x)  µ j + xT(β1 + β2,k) + δ jk (4.40a)
δ jk ∼ N(γk , τ2) (4.40b)
cor(δ ja , δ jb)  0.5 (4.40c)
where δ j1  0. Using the reference treatment parameterisation (Section 1.2.2),
the random effects are multivariate Normal with marginal distributions given
by (4.40b) and correlations equal to 0.5 (4.40c), under the assumption of
common heterogeneity variance τ2 (Higgins and Whitehead 1996). (Given
sufficient data, separate τ2k for each treatment and correlations cor(δ ja , δ jb) 
ψ(1)ab may be fitted with an appropriate prior distribution on the covariance
structure (Lu and Ades 2009), though this is less common in practice.) For two-
arm studies against treatment 1, there is a single univariate Normal random
effect on the non-treatment 1 arm, with distribution given by (4.40b). The
appropriateness of the conditional constancy of relative effects assumption can
then be assessed by comparing model fit (e.g. using the Deviance Information
Criterion) between the fixed and random effects models and by examining the
posterior distribution of the residual heterogeneity variance τ2.
The presence of residual heterogeneity has several potential causes. For
example, theremay be effectmodifiers that have not been included in themodel
or other model misspecification, the assumed joint covariate distributions
used to adjust the results from aggregate studies may be incorrect, or the
shared effect modifier assumption (if it was used) may be invalid. Attempts
may be made to rectify these issues in a revised model—if data permits—and
the residual heterogeneity of the revised model may then be checked.
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The random effects model (4.40) is likely to be more widely applicable
in practice than the exchangeable interactions model (4.38) as a relaxation of
the standard ML-NMR model (4.34b), since the data requirements are lesser.
The random effects model only requires the total number of studies to be
large enough to estimate the common heterogeneity variance τ2, whereas
the exchangeable interactions model requires the number of studies and
treatments in T to be large enough to estimate β2,k , mβ2 , and σ2β2 .
When producing estimates for a specific target population under the
random effects model, we again follow the approach described in Section 4.4.
However, estimates can be produced in two different ways, depending on
whether the additional uncertainty due to residual heterogeneity is accounted
for. For clarity, let us consider producing estimates of population-average
treatment effects, as given by (4.28):
dab(P)  x̄T(P)(β2,b − β2,a) + γb − γa .
Under the random effects model, the parameters γk are interpreted as mean
individual-level treatment effects, and so using these γk in (4.28) estimates the
mean of the population-average treatment effects one would expect to see in
studies representative of population P (super-population average treatment
effects, see Section 2.3.6). However, these estimates do not account for
the additional uncertainty due to residual heterogeneity: in any one study
performed in population P, the observed individual-level treatment effects
differ from the mean treatment effect due to residual heterogeneity described
by the random effects distribution N(γk , τ2). This additional uncertainty
can be accounted for by using the posterior predictive distribution for the
individual-level treatment effects (Dias et al. 2011a; Higgins et al. 2009; Smith
et al. 1995), which is multivariate Normal with marginal distributions and
correlations given by
δk;new ∼ N(γk , τ2)
cor(δa;new , δb;new)  0.5
(4.41)
and δ1;new  0. The δk;new describe the predicted individual-level treatment
effects one would expect to see in a new study in population P, and are then
substituted for γk in (4.28) to estimate the population-average treatment effects
in a new study in population P:
dab(P);new  x̄T(P)(β2,b − β2,a) + δb;new − δa;new. (4.42)
The posterior distribution of dab(P);new will display more uncertainty than that
of dab(P) (e.g. credible intervals will be wider), reflecting the amount of residual
heterogeneity present.
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As with the fixed effect model, the ML-NMR model with random effects
reduces to IPD RE network meta-regression with full IPD from every study:
yi jk ∼ πInd(θi jk) (4.43a)
g(θi jk)  η jk(xi jk)  µ j + xTi jk(β1 + β2,k) + δ jk (4.43b)
δ jk ∼ N(γk , τ2) (4.43c)
cor(δ ja , δ jb)  0.5 (4.43d)
Similarly, the REML-NMRmodel reduces to AgD RE NMAwhen there are no
covariates included in the model: (4.34d) becomes θ• jk  g−1
(
µ j + δ jk
)
, and
the model is fitted to the summary outcomes from each trial:
y• jk ∼ πAgg(θ• jk) (4.44a)
g(θ• jk)  µ j + δ jk (4.44b)
δ jk ∼ N(γk , τ2) (4.44c)
cor(δ ja , δ jb)  0.5 (4.44d)
and in this case γk are equal to dk , the aggregate-level relative effects.
4.6.3 Assessing inconsistency
ML-NMR, like standard IPD and AgD NMA, makes an assumption of consis-
tency that is enforced through a set of consistency equations (Section 1.2.7).
For ML-NMR, these apply to both the individual-level treatment effects and
the effect modifier interactions, following the equations in (4.36). The causes
of inconsistency in ML-NMR are the same as the causes of heterogeneity de-
scribed previously in Section 4.6.2. For example, there may be effect modifiers
that have not been included in the model or other model misspecification, the
assumed joint covariate distributions used to adjust the results from aggregate
studies may be incorrect, or the shared effect modifier assumption (if it was
used) may be invalid. Attempts may be made to rectify these issues in a
revised model—if data permits—and the revised model may then be assessed
for inconsistency. To assess inconsistency, we can use the same approaches
described in Section 1.2.7—in particular the unrelated mean effects model,
and node-splitting models.
4.6.3.1 Unrelatedmean eects
As originally described for NMA, the unrelated mean effects (UME) model
(Dias et al. 2011d) treats all contrasts—both basic (i.e. against treatment 1)
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and functional—as independent parameters, without imposing consistency
Section 1.2.7.1. The UME model needs to be written with the study-specific
baselines referring to a reference arm in each trial (as in the baseline shift
parameterisation, Section 1.2.1), rather than the reference treatment 1, since
the reference treatment parameterisation imposes consistency implicitly. For
random effects ML-NMR (4.40), we must also consider the EM interaction
terms, and whether or not we allow these to be inconsistent too. The linear
predictor and random effects structure of the UME model for RE ML-NMR
are written as
η jk(x)  µ(t1)j + x
T(β1 + β2,t1k) + δ jt1k (4.45a)
δ jt1k ∼ N(γt1k , τ2) (4.45b)
cor(δ jt1a , δ jt1b)  0.5 (4.45c)
for a study j with treatment t1 in arm 1, where µ(t1)j is the study-specific
baseline with respect to t1.
If we apply the consistency equations to the EM interactions, β2,ab 
β2,b − β2,a , then (4.45) only relaxes consistency in the treatment effects. There
can also be inconsistency in the EM interactions (Donegan et al. 2017); to assess
this as well, we instead place independent prior distributions on β2,ab , such as
N(0, σ2β2) for a suitable prior variance σ
2
β2
. However, this requires sufficient
data on each contrast to estimate independent interactions. This may not be
possible, for example if there are contrasts which are only informed by a small
number of AgD studies.
An intermediate approach is possible when the shared EM assumption
(Section 2.5) is used to fit theML-NMRmodel, so that the regression coefficients
β2,k for a set of treatments k ∈ T are all equal. In this case, we can use the
shared EM assumption—which implies that certain interactions are zero or
equal to each other—and allow the remaining interactions to be inconsistent.
To achieve this, consider (without loss of generality) that every treatment is
assigned to a mutually exclusive set T1 ,T2 , . . . (some treatments may be in a
set by themselves). Then, using the shared EM assumption, EM interactions
for contrasts between any two treatments within a given set T are equal to
zero, β2,ab  0 for any two treatments a , b ∈ T . EM interactions for contrasts
between treatments in any two different sets T1 ,T2 are equal, β2,a1a2  β2,b1b2
for any treatments a1 , b1 ∈ T1 and a2 , b2 ∈ T2, and are assigned a prior
distribution such as N(0, σ2β2). This allows us to assess inconsistency of the
shared EM interactions, and such a model should always be identifiable when
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the corresponding standard (consistency) ML-NMR model with shared EM
interactions is identifiable.
In any case, evidence for inconsistency is then based on comparing the
model fit (e.g. using residual deviance and DIC) between the ML-NMR
model assuming consistency and the UME model without consistency (see
Section 1.2.7.1).
4.6.3.2 Node-splitting
The node-splitting approach for network meta-regression models (Donegan
et al. 2017) described in Section 1.2.7.3 is naturally applicable to ML-NMR in
the same manner as IPD network meta-regression. For a given contrast b′ vs.
a′, the node-splitting model splits the estimation of the relative effect γa′b′ and
effect modifier interactions β2,a′b′ into parameters estimated by direct evidence
only, γDa′b′ and β
D
2,a′b′ , and parameters estimated by the indirect evidence from
the rest of the network, γIa′b′ and β
I
2,a′b′. To achieve this, the random effects
ML-NMR model (4.40) remains the same for studies not including both a′ and
b′ treatment arms. For studies including both a′ and b′ treatment arms, we
choose to re-parameterise the model with a′ as the reference treatment within
these studies. Mathematically, we write out the linear predictor and random
effects for this node-splitting model as
For studies without both a′ and b′ treatment arms:
η jk(x)  µ(1)j + x
T(β1 + β2,k) + δ jk (4.46a)
δ jk ∼ N(γk , τ2) (4.46b)
cor(δ ja , δ jb)  0.5 (4.46c)
For studies with both a′ and b′ treatment arms:




η jb′(x)  µ(a
′)
j + x
T(β1 + βD2,a′b′) + δ ja′b′ (4.46e)
η jk(x)  µ(a
′)
j + x
T(β1 + β2,k − β2,a′) + δ ja′k for k , a′, b′ (4.46f)
δ ja′b′ ∼ N(γDa′b′ , τ
2) (4.46g)
δ ja′k ∼ N(γk − γa′ , τ2) for k , a′, b′ (4.46h)
cor(δ ja′a , δ ja′b)  0.5 for a , b , a′, b′ (4.46i)
cor(δ ja′k , δ ja′b′)  0 for k , a′, b′ (4.46j)
where the re-parameterised study-specific baselines with respect to treatment
a′ are denoted by µ(a
′)
j , and we write the study-specific baselines with respect
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to treatment 1 as µ(1)j  µ j for additional clarity. As usual we set γ1  δ j1  0
and β2,1  0. If there are multi-arm studies with both a′ and b′ treatment
arms, then the other random effects δ ja′k with k , b′ are uncorrelated with
δ ja′b′, but are still correlated between themselves with cor(δ ja′a , δ ja′b)  0.5
for a , b , a′, b′ (assuming homogeneous τ2). The indirect estimates γIa′b′ and
βI2,a′b′ are obtained from the consistency equations
γIa′b′  γb′ − γa′ ,
βI2,a′b′  β2,b′ − β2,a′ .
(4.47)
The node-splitting model as written in (4.46) splits the EM interaction
terms for all covariates at once. Alternatively, a separate node-splitting model
could be fitted for each covariate in turn, where βD2,a′b′ is broken down into
a split interaction for one covariate, βD2,a′b′;l , and the consistency equations
are applied for the remaining covariates β2,a′b′;l  β2,b′;l − β2,a′;l . The latter
approach may be more tractable in scenarios with smaller amounts of data
on the b′ vs. a′ contrast and/or large numbers of effect modifying covariates,
since there are only 2 more parameters than the standard RE ML-NMR model
(γDa′b′ and β
D
2,a′b′;l), as opposed to L + 1 more when splitting all EM interactions
at once (γDa′b′ and β
D
2,a′b′), where L is the number of covariates.
Furthermore, there may be insufficient data on the b′ vs. a′ contrast even
to node-split the EM interaction terms one covariate at a time, for example if
the direct evidence consists of only a small number of AgD studies. In this
case, we may be able to assess inconsistency in the treatment contrast γa′b′ by
node-splitting into γDa′b′ and γ
I
a′b′, but not in the EM interactions, keeping the
consistency equations β2,a′b′  β2,b′ − β2,a′.
Section 1.2.7.2 describes how to interpret the results of node-splitting
models to assess inconsistency. As with the unrelated mean effects model
(Section 4.6.3.1), one check for inconsistency is to compare the model fit (e.g.
using residual deviance and DIC) between the ML-NMR model with and
without node-splitting. For each of the L covariates xl in the vector x, the






2,a′b′;l can be plotted
as functions of xl and compared, as can the posterior distribution of the







4.6.4Using publishedmarginal covariate information
To implement ML-NMR, we need to describe the joint covariate distribution
f jk(·) in each treatment arm of each AgD trial. In practice, joint covariate
information is unlikely to be available from the AgD studies, so instead
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we infer the forms of the marginal distributions and correlation structure
from other information such as clinical knowledge or from the IPD studies.
The approaches described and discussed in Section 4.5.1 for the two-study
scenario apply equally in larger networks, although there are some additional
considerations when multiple IPD studies are available from which to infer
information on the joint covariate distribution.
If multiple IPD studies are available, it is possible that the observed
marginal covariate distributions may differ in form between the IPD studies
(perhaps due to differences in inclusion criteria or other aspects of study
design). In this case, marginal distributions for each AgD study may be
inferred from the IPD study or studies deemed most representative.
Similarly, when inferring a correlation matrix for the AgD studies from
multiple IPD studies, one option is to choose the correlation matrix from an
IPD study deemed most representative for each AgD study. Another option
is to use a weighted average of the covariance matrices from the IPD studies
(or a suitable representative subset), for example by applying the approach
described by Hedges and Olkin (1985, Chapter 11) to each pairwise correlation.
The correlations ρ j;l1 l2 between covariates xl1 and xl2 in each study j are
z-transformed as




(1 + ρ j;l1 l2
1 − ρ j;l1 l2
)
, (4.48)
before taking a weighted average
ζ̄l1 l2 
∑
IPD j w jζ j;l1 l2∑
IPD j w j
, (4.49)
where the weights w j  N j − 3 are the inverse of the asymptotic variance of
ζ j;l1 l2 , and N j is the number of individuals in study j. The weighted average
correlations are then obtained by back-transformation of ζ̄l1 l2 using
ρ̄l1 l2 
exp(2ζ̄l1 l2) − 1
exp(2ζ̄l1 l2) + 1
. (4.50)
4.7 Discussion
In this chapter, we have proposed a new method for population-adjusted
indirect comparisons and network meta-regression. ML-NMR derives from a
method presented in the ecological inference literature, where the aggregate-
level model is obtained by integrating the individual-level model over the
covariate distribution (Jackson et al. 2006, 2008) (discussed in Section 2.2.3).
The methods in the ecological inference literature have been applied in the
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context of NMA previously, but were only derived for the simple case of
a binary outcome and binary covariates (Jansen 2012). There are several
key advantages to this approach, particularly in comparison with methods
such as MAIC (Ishak et al. 2015; Signorovitch et al. 2010) (see Section 2.2.1),
STC (Caro and Ishak 2010; Ishak et al. 2015) (see Section 2.2.2), or network
meta-regression based approaches (Donegan et al. 2013; Saramago et al. 2012;
Sutton et al. 2008; Thom et al. 2015) (see Section 2.2.3).
MAIC and STC are designedwith a simple two-study scenario inmind (one
IPD AB study, one AgD AC study). By comparison, ML-NMR is applicable to
treatment networks of any size, allowing use of all available information. Both
MAIC and STC can be considered as “targeted comparisons” rather than true
evidence syntheses, since information from the AC trial is not propagated
through to the parameter estimates. As we showed in Section 4.5.2, ML-NMR
can also be used in this manner, fitting a model in the IPD AB trial and
predicting outcomes on treatments A and B the AC trial population. However,
as with MAIC and STC, the results of this targeted comparison are then
limited in validity to the AC trial population, which may not reflect the target
population of interest.
We have considered an individual-level model where there is a single
treatment-covariate interaction term per effect modifying covariate. In the
context of IPD network meta-regression, Hua et al. (2016) suggest splitting the
EM interaction term into a within-study interaction β(w)2,k and a between-study
interaction β(b)2,k like so:




2,k + δ jk . (4.51)
Their reasoning is that combining information on interactions from within
and between studies can result in ecological bias due to unobserved effect
modifiers, and splitting the interaction term in this manner means that β(w)2,k
should be free from this bias. Hua et al. (2016) suggest drawing conclusions
from only the within-study interactions, and interpret differences between the
within- and between-study interaction estimates as evidence for ecological
bias. This same “split-interactions” model has been used by several authors
to incorporate AgD studies (Donegan et al. 2013; Riley et al. 2008; Riley and
Steyerberg 2010; Saramago et al. 2012) (others choose not to split interactions
(Sutton et al. 2008), see further discussion in Section 2.2.3). Using the notation
of ML-NMR, these models are written as
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Individual:
yi jk ∼ πInd(θi jk) (4.52a)




2,k + δ jk (4.52b)
Aggregate:
y• jk ∼ πAgg(θ• jk) (4.52c)
g(θ• jk)  µ j + x̄Tjβ
(b)
2,k + δ jk (4.52d)
where δ jk are either fixed or random effects as before. Notably, for the AgD
studies only the between-study interactions are used and the mean covariate
values x̄ j are “plugged in” to the linear predictor. As a result, differences
between the within- and between-study interactions are now due to two
possible sources of ecological bias: one from unobserved effect modifiers, and
an additional aggregation bias when the model is non-linear due to “plugging
in” means (see Greenland 1992, who refers to the latter as “pure specification”
bias). As well as population characteristics, effect modification may be due
to other study-level factors at such as differences in treatment intensity or
study setting; in practice, study-level factors may be difficult to determine
from the available data, and adjustment is more difficult than for population
characteristics since they do not vary between the individuals within each
study. Clearly, ML-NMR avoids the aggregation bias, since the individual
model is appropriately integrated over the covariate distribution in the AgD
studies. The other possible source of ecological bias—unobserved effect
modifiers—is assumed not to be present when fitting the standard ML-NMR
model due to the conditional constancy of relative effects assumption, which is
required to hold in order to produce unbiased estimates of population-adjusted
relative effects. As such, we have not split the interaction terms in theML-NMR
model. ML-NMR could bemodified to include split interaction terms, however
this results in a non-identifiable model in the two-study scenario, and likely
requires substantial amounts of data to estimate well. By comparison, the
RE ML-NMR model may be used to investigate residual heterogeneity due to
unobserved effect modifiers (or from other sources, such as an invalid shared
EM assumption), and is less data-intensive (Section 4.6.2). In practice, we thus
propose to use the RE ML-NMR model, although further research to compare
the different approaches is warranted (Section 9.2.2).
In Section 4.6, we conceptualised ML-NMR as an extension of the standard
NMA framework, which is an established and accepted method with a broad
literature. Standard IPD and AgD NMA are special cases of ML-NMR: ML-
NMR reduces to standard AgDNMAwhen there are no covariates included in
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the model, and to IPD network meta-regression when IPD are available from
every study (see Section 4.6). When implemented in a Bayesian framework
ML-NMR retains the flexibility and extensibility of Bayesian NMA, so that, for
example, prior information could be utilised, several data types with differing
likelihoods could be included, or the analysis embedded in a probabilistic
cost-effectiveness framework as widely used by decision makers (Claxton
et al. 2005; Critchfield and Willard 1986; Dias et al. 2013b; Doubilet et al.
1985). Inconsistency checks between the direct and indirect information are
frequently performed for NMA (Dias et al. 2010, 2013d; Higgins et al. 2012; Lu
and Ades 2006; see Section 1.2.7), and are equally applicable in a ML-NMR
analysis where a larger network of studies is available, as we described in
Section 4.6.3. ML-NMR aims to avoid heterogeneity and inconsistency by
adjusting for differences in effect modifying covariates, however it is important
to investigate whether there is any residual heterogeneity or inconsistency
after adjustment, and attempt to rectify this if data permits (Sections 4.6.2
and 4.6.3).
In Section 4.3.2, we presented algebraic derivations of the aggregate-level
model for the probit link function, logit link function (via approximation to the
probit), and log link function (via moment generating functions). However,
these algebraic approaches quickly become complex, are context-specific, and
are not always tractable (e.g. with skew covariates). Using QMC integration
instead provides a general numerical approach that is straightforward and
broadly applicable (Section 4.3.3.2), and, in practical terms, much quicker to
implement than an algebraic approach. The use of quasi-random sequences
for numerical integration improves upon the convergence rates of standard
pseudo-random Monte Carlo integration, and retains this performance in
high-dimensions. We describe the implementation of QMC integration in
detail in Section 5.1.
As is crucial for relevance in decision making, comparisons may be pro-
vided in any target population given sufficient information on the covariate
distribution (Section 4.4), without the need for additional assumptions re-
quired by methods such as MAIC or STC. However, extrapolation may be
necessary if the covariate distribution in the target population does not overlap
with the covariate distributions in the observed data. The target population
need not be a clinical trial, and could be taken from other data sources such as
registries.
All population adjustment methods rely on the availability of covariate
information in all included studies. In a connected network, adjustment is
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only required for effect modifiers (Phillippo et al. 2016; Phillippo et al. 2018a)
(Section 2.3.1) which, being of high clinical relevance, are more likely to be
widely reported in publications. Aside from unmeasured or unreported
covariates, other forms of missing information are also an issue.
Firstly, it is unlikely for publications to report the correlation structure
between covariates, although this may be available on request. Methods
such as MAIC ignore the correlations between covariates. However, as we
have shown algebraically for multivariate Normal covariates (Section 4.3.2),
correlations involving effect modifiers are implicated in aggregation bias along
withwithin-study variation. Assuming that correlation structures are the same
within the AgD and IPD, which may be more reasonable than assuming all
correlations are zero, we can impute the missing correlations when generating
the AgD integration points (Section 4.5.1). Correlation structures could differ
between the populations if, for example, different characteristics coexist, or
the sampling and randomisation methods differ between the trials. However,
later in the simulation study we show that varying the assumed correlation
structure of the AgD trial has negligible impact on the results (Section 8.2.6).
Furthermore, the true forms of the marginal distributions of the aggregate
covariates are likely unknown. Instead, we choose distributional forms for
the aggregate covariates based on theoretical properties and to approximately
match the observed distributional forms in the IPD (Section 4.5.1). However,
the true marginal distributions could differ between the populations if, for
example, the sampling and randomisation methods differ between the trials.
Later in the simulation study, we see that altering the assumed marginal
distributions for the AgD trial may have little impact on the results Section 8.2.6.
We propose a very flexible approach based on copulæ, allowing any set of
desired marginal distributions to be combined under a given joint correlation
structure (Section 4.3.3.2, and greater detail in Section 5.1). A limitation of this
approach is that uncertainty in selectingmarginal distributions and correlation
structures is not accounted for.
Missing values within the IPD are also likely to be encountered. One
solution is to simply remove those individuals with missing covariate values
from the analysis, which may be reasonable if the proportion of individuals
withmissing values is very small. However, in general this is not recommended,
as complete case analyses can incur bias and loss of precision. Multiple
imputation is a widely-used method of dealing with missing data (Kenward
and Carpenter 2007; Little and Rubin 2002). The Bayesian framework is
well-suited to implementing multiple imputation as covariates can be imputed
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at every iteration of the MCMC sampler, incorporating the uncertainty arising
from the missing values into the posterior distribution (Jackson et al. 2009;
Mason et al. 2012). Such approaches have previously been described for IPD
NMA (Quartagno and Carpenter 2016), and apply similarly to ML-NMR by
extension.
Derivation of the aggregate likelihood is not always straightforward (Sec-
tion 4.2), and may even be intractable. Most notably this is the case for survival
analysis—which represents the large majority of applications of population
adjustment methodology to date (Chapter 3)—where the aggregate likelihood
cannot be derived analytically. In Chapter 7 we extend ML-NMR to general
likelihoods, including for survival data, further increasing the applicability
of this new method. In Chapter 8, we perform an extensive simulation study
to assess the performance of ML-NMR in a wide variety of scenarios and its
robustness to failure in assumptions, in comparison with other methods. In
the following chapter we discuss computation of ML-NMR models, before





In this chapter, we discuss the computational aspects of implementing ML-
NMR. As we introduced in Section 4.1, one of the key ideas behind ML-NMR
is that the individual-level model θi jk  g−1(η jk(xi jk)) is integrated over the
covariate distribution f jk(·) in an AgD trial arm to obtain the appropriate




g−1(η jk(x)) f jk(x) dx. (5.1)
In Section 4.3.2, we considered the algebraic solutions to (5.1) in some special
cases; however, in general such algebraic solutions quickly become complex,
and may even be intractable. Instead, in Section 4.3.3 we proposed to use
numerical integration techniques to evaluate the integral. The most attractive
numerical approach for our purposes is Quasi-Monte Carlo integration (Sec-
tion 4.3.3.2), since it is more widely applicable than quadrature (Section 4.3.3.1)
and can be applied regardless of the number of covariates or the type or
complexity of the model.
Models involving IPD, includingML-NMR, can be large and slow to analyse
in both Bayesian and frequentist frameworks. It is therefore particularly
desirable to implemented such models in an efficient manner, saving both
time and computational effort. Efficiency may be dichotomised into two
concepts: computational efficiency, and statistical efficiency. In a Bayesian
MCMC framework, computational efficiency refers to minimising the amount
of time1 required in performing the calculations for a given sample iteration, for
example by “vectorising” code (removing for loops in favour of more efficient
1Other measures of computational effort may also be of interest, such as the number of
computation operations or the amount of memory required, but often we are simply concerned
with speeding up model run-times.
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vector/matrix statements). Statistical efficiency corresponds to obtaining the
greatest effective number of samples from the posterior distribution for a
given number of iterations, and is achieved by choosing a suitable model
parameterisation.
We begin by describing how Quasi-Monte Carlo integration is used to
evaluate the marginalisation integral (5.1), and suggest visual checks for the
magnitude of integration error. We then discuss the efficient implementation
of ML-NMR in Stan, focusing on issues of statistical efficiency (efficient
parameterisation) as opposed to computational efficiency. We also review
techniques for checking convergence and other sampler diagnostics in Stan.
Finally we explore assessment of model fit and model comparison in the
ML-NMR framework, before concluding with a discussion.
5.1 QMC integration with copulæ
In this section, we describe in greater detail the implementation of QMC
integration. We start by considering only continuous covariates; however, in
Section 5.1.1we describe a simple extension to incorporating discrete covariates
also.
To begin, we need to describe the joint covariate distribution f jk(·) in each
AgD study j on treatment k. Let us summarise f jk(·) by the L constituent
marginal distributions f jk;l(·), l  1, . . . , L, where L is the number of covariates,
and information on the relationship structure between covariates. Sklar’s
theorem shows that any joint distribution can be fully described in this manner,
by decomposition into marginal distributions and a relationship structure
(Sklar 1959, see also Nelsen 2006):
f jk(x)  C( f jk;1(x1), . . . , f jk;L(xL)). (5.2)
The function C( · · · ) is called a copula, and encodes the relationships between
the marginal distributions to “couple” them into the joint distribution. A
range of copula functions are available, each encoding different relationships
between covariates, whilst allowing arbitrary marginal distributions to be
specified (Nelsen 2006). We assume that the marginal distributions and
relationship structure are known—or at least may be inferred, since in practice
it is likely that only marginal covariate summaries (e.g. means and standard
deviations for continuous covariates, or proportions for discrete covariates)
will be reported from the AgD studies. As described in Section 4.5.1, when the
true marginal distributions in the AgD studies are unknown, we can choose
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distributional forms for these covariates based on their theoretical properties
and/or to approximately match the observed distributional forms in the
IPD, and then match these distributions to the reported summary statistics.
Similarly, we can utilise the relationship structure observed between covariates
in the IPD studies, and assume that this holds also in the AgD studies. Here
we will use a Gaussian copula, encoding the relationship structure between
covariateswith a correlationmatrixΩ jk ; however, the following process applies
in the same manner when other copulæ are chosen. Note that “Gaussian” here
refers only to the form of the copula: no restrictions are placed on the form of
the marginal distributions, which may take any arbitrary distribution (even
discrete marginal distributions are allowed, which we utilise in Section 5.1.1).
In practice, we find that this is a very flexible approach and can account for
a wide range of relationships between covariates. Using a Gaussian copula,
the necessary summaries from each AgD study are thus a description of the
marginal distributions f jk;l(·) (for example summarised bymeans and standard
deviations and a given distributional form) and the correlation matrix Ω jk .
The aim is to obtain a sample of integration points x̃i jk , i  1, . . . , Ñ from
the joint covariate distribution, with which we can evaluate the integral of any
given function over f jk(·). Rather than a (pseudo-)random sample from f jk(·),
which we could use for Monte Carlo integration over the covariate distribution,
we will instead seek a quasi-random sample of points that cover the covariate
space X more uniformly than a random sample, resulting in a Quasi-Monte
Carlo integration scheme. As outlined in Section 4.3.3.2, QMC integration can
achieve much faster convergence of integration errors than standard Monte
Carlo integration. StandardMonte Carlo integration has an expected error rate
of order Ñ− 12 , whereas QMC integration—whilst having a worst-case error
rate of the order Ñ−1(log Ñ)L—often achieves an error rate of the order Ñ−1,
even in high dimensions (Caflisch 1998; Niederreiter 1978). (See Section 5.1.2
for suggestions on checking the rate of convergence.)
We start with an L-dimensional sequence of quasi-random points ũi jk ,
i  1, . . . , Ñ in the unit hypercube [0, 1]L, where L  |X | is the dimension
of the covariate space X (i.e. the number of covariates). Several possible
quasi-random sequences have been proposed (see Caflisch 1998). Here, we use
a Sobol’ sequence (Sobol’ 1967) to generate ũi jk , using the function sobol from
the R package randtoolbox (Christophe and Petr 2018). Figure 5.1 shows a
sample of 2048 Sobol’ points in two dimensions, alongside the same number of
pseudo-random points (generated using the R function runif) for comparison.
We use a Gaussian copula (Nelsen 2006) to describe the relationship
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Figure 5.1 Samples of 2048 points ũ in two dimensions, generated pseudo-
randomly (left) and quasi-randomly using a two-dimensional Sobol’ sequence
(right).
structure between covariates, which imposes the correlation matrix Ω jk on
the Sobol’ points ũi jk . This is equivalent to applying the inverse cumulative
distribution function (CDF) Φ−1
Ω
(·) of the multivariate Normal with correlation
matrix Ω jk , and then the standard multivariate Normal CDF Φ(·),




to obtain correlated Sobol’ points ũ∗i jk . (In practice this is computed component-
wise as conditional univariateNormaldistributions; weuse the implementation
in the R package copula (Yan 2007).) Figure 5.2 shows this transformation
applied to the uncorrelated points from Figure 5.1, with a correlation of 0.4.
The inverse CDF method (also called the inverse transform method) is a
widely-used technique for generating samples from any distribution for which
the inverse CDF F−1(·) is known (see Devroye 1986, Chapter 2). The process
is simple: given a sample of uniformly distributed points u, the inverse CDF
is applied to obtain a sample x  F−1(u) from the desired target distribution.
We use this technique here to transform the correlated Sobol’ points ũ∗jk;l to
match the marginal covariate distributions reported in the AgD trials:
x̃ jk;l  F−1jk;l(ũ
∗
jk;l) for l  1, . . . , L, (5.4)
where F−1jk;l(·) is the inverseCDFof themarginal distribution of the l-th covariate
in study j on treatment k. The resulting integration points x̃i jk capture
the correlations between the covariates (e.g. longer duration of psoriasis
is correlated with having previous systemic treatment) whilst preserving
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Figure 5.2 The correlated points ũ∗ after applying a correlation of 0.4 to
the points ũ, for pseudo-random samples (left) and quasi-random (Sobol’)
samples (right).
the marginal distribution for each covariate. As an example, we consider
transforming the correlated Sobol’ points in two dimensions from Figure 5.2
to have marginal distributions with means 4 and 2, standard deviations 1.5
and 0.8, and distributed as Normal and Gamma distributions respectively.
Figure 5.3 shows marginal histograms of the integration points against the
true marginal distributions (solid line), and Figure 5.4 shows the integration
points jointly in two dimensions along with empirical density contours. Notice
how the marginal histograms for the quasi-random Sobol’ points follow the
true marginal densities much more closely for the same number of integration
points. Similarly, in two-dimensions the points cover the joint distribution
more uniformly and have smoother empirical density contours.
The integral (5.1) is then evaluated using the integration points x̃i jk as∫
X





g−1(η jk(x̃i jk)). (5.5)
Indeed, the integral of any general function h(x) of the covariates can be
evaluated using the integration points in this manner:∫
X






for example to produce estimates of population-average quantities in a given
target population, as described in Section 4.4.
145
5. COMPUTATION OF ML-NMR MODELS
(a) First marginal is Normally distributed with mean 4 and standard deviation 1.5.
(b) Second marginal is Gamma distributed with mean 2 and standard deviation 0.8.
Figure 5.3 Histograms of the integration points x̃ in each dimension, after
applying the inverse CDFs to ũ∗. The overlaid line shows the density of the
true marginal distribution from which the points are sampled. The same
transformation is applied to pseudo-random points (left) and quasi-random
(Sobol’) points (right).
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Figure 5.4 The integration points x̃ in two-dimensions, after applying the
inverse CDFs to ũ∗. Empirical contours of the integration points are overlaid.
The same transformation is applied to pseudo-random points (left) and
quasi-random (Sobol’) points (right).
5.1.1Incorporating discrete covariates
Earlier in Section 4.3.4, we suggested that one approach to integration over
discrete and continuous covariates simultaneously was to nest the integration
over continuous covariates in a summation over the levels of discrete covariates
(equation (4.27)). However, this quickly becomes an unwieldy approach as
the number of discrete covariates increases, and furthermore does not account
for correlations between discrete and continuous covariates unless summary
statistics are available within each discrete subgroup.
Instead, we propose to integrate over both discrete and continuous covari-
ates together using QMC integration. The process described previously is
unchanged by the inclusion of discrete covariates. If the correlation matrix
Ω jk is to be computed from the IPD and applied to the AgD studies, we use
Spearman’s rank correlation to allow for discrete covariates. This approach
allows correlations between discrete and continuous covariates to be accounted
for, and computation of the integral (5.1) via equation (5.5) is unchanged—
regardless of the number or type of covariates—avoiding unwieldy nested
summations. One possible drawback of this approach is that it has the poten-
tial to increase the number of integration points required, particularly when
there are large correlations and many discrete covariates; however, in practice
we have not observed this to be an issue.
5.1.2Checking integration error
The convergence of Monte Carlo integration schemes as Ñ →∞, evaluating
the integral (5.1) using (5.5), is guaranteed (under some mild regularity
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conditions which are unlikely to be of practical concern here) (Niederreiter
1978). However, in practice we would like to examine integration error for
finite Ñ, with the aim of determining a suitable value for Ñ. We propose
plotting empirical integration error against the number of integration points,
where empirical integration error is estimated by the relative difference from
the final estimate, at every posterior sample (since we are fitting ML-NMR
models using MCMC). Letting In ,s be the estimated value of the integral (5.5)
at posterior sample s using n integration points, mathematically the empirical
integration error at posterior sample s is written
In ,s − IÑ ,s , for n  1, . . . , Ñ − 1 and ∀s . (5.7)
For practical visualisation purposes, we suggest plotting the empirical inte-
gration error at suitable steps of n (e.g. in steps of 100), and summarising
the empirical integration error at each step of n over the entire posterior
distribution using a “violin” plot (a smooth density estimate) or box plot. An
example plot is shown in Figure 5.5; in this example we see that the integration
error over the entire posterior distribution decreases at the expected rate
of Ñ−1 (given by the dashed lines). Based on these plots, a judgement can
be made over suitable Ñ, weighing up decreasing integration error against
increasing computational cost. We use this technique in the applied examples
throughout this thesis, for example Figure 6.4 in Chapter 6.
Figure 5.5 An example plot of empirical integration error against the number
of (quasi-random Sobol’) integration points. Steps of 100 are used, at each of
which the empirical integration error is summarised over all posterior samples
using a violin plot. The dashed line is ±Ñ−1, showing that the integration
error is of this order.
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5.2Eicient implementation in Stan
We now consider several issues regarding the efficient implementation of
ML-NMR models in Stan. Here, we focus specifically on statistical efficiency
of ML-NMR models through efficient parameterisation, although our Stan
code (Appendix A) is written with computational efficiency in mind too.
Techniques for achieving both statistical and computational efficiency in Stan
are discussed in Section 23 of the Stan User’s Guide (Stan Development Team
2018).
In this section it will be helpful to consider the ML-NMR model written
in a general matrix form, with QMC integration (5.5) substituted in for the
aggregation integral (5.1), which also aligns with the implementation of the
model in Stan. Considering the fixed effect model for now (the random effects
model is discussed in Section 5.2.3), we write:
Individual:
yi jk ∼ πInd(θi jk) (5.8a)
g(θ)  Xξ (5.8b)
Aggregate:










where X is a design matrix with a row for each individual in the IPD, picking
out the appropriate components from parameter vector
ξ 
(
µ1 , . . . , µ J | βT1 | βT2,2 , . . . , βT2,K | γ2 , . . . , γK
)T
,
and θ is the corresponding vector of individual-level predictors θi jk . Vertical
bars emphasise the partitioning of ξ corresponding to study intercepts µ j ,
prognostic effects β1, EM interactions β2,k , and treatment effects γk . For
example, an individual in study 2 on treatment 4 with covariates xi24 would
have corresponding row of X equal to(
0, 1, 0 . . . , 0 | xTi24 | 0, 0, x
T
i24 , 0, . . . , 0 | 0, 0, x
T
i24 , 0, . . . , 0
)
.
At the aggregate level, X̃ jk is the “design matrix” of integration points for
study j treatment k, formed in the same way as the individual-level X but
with Ñ rows, one for each integration point. The summation in (5.8d) is
over the Ñ components of the vector g−1(X̃ jkξ), containing the values of the
back-transformed linear predictor evaluated at every integration point.
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5.2.1 Transforming covariates
Due to the way in which Stan works, sampling is most efficient if the posterior
distribution of the parameters is approximately uncorrelated and unit scaled
(standard deviation of 1). The following techniques aim to achieve this by
transforming the covariates in some manner.
5.2.1.1 Centring and scaling
The simplest change we can make to the model is to centre and scale the
(continuous) covariates. These are common practice in both Bayesian and
frequentist settings; the Stan User’s Guide covers these topics in Section 23.12
(Stan Development Team 2018).
Centring involves subtracting an overall mean value from each covari-
ate. This effectively unlinks the corresponding regression slopes from the
“intercepts” (here a generalised notion of an intercept, relating to any dis-
crete parameters), removing posterior correlation between these two sets of
parameters. In this context, the slopes are the components of β1 and β2,k
corresponding to continuous covariates, and the “intercepts” are the study
intercepts µ j , individual-level treatment effects γk , and components of β1 and
β2,k for any categorical covariates. The interpretation of the slope parameters
is unchanged by centring, but the interpretation of the “intercept” parameters
is now with respect to the mean values (instead of zero). (As a byproduct of
centring, these “intercept” parameters may become more interpretable: for
example, we are rarely interested in an individual with zero weight or age.)
Scaling involves dividing each of the covariates by a fixed value, either
chosen given observed covariate ranges or clinical knowledge, or set to the
observed standard deviation (in which case this is called standardising). For
ML-NMR, since we have only AgD available from some studies and an overall
standard deviation is not straightforward to calculate, the simplest approach
is the former. We are not concerned with choosing scaling values that result
in precisely unit-scaled parameters: a sensible approximate scaling is often
good enough.
Models fitted with and without centring and scaling of covariates are
equivalent: posterior estimates from a model fit with centred and scaled
covariates can be transformed to estimates from a model fit without these
transformations, simply by adding andmultiplying by the centring and scaling
values respectively. However, this equivalence only holds if the different
interpretation of the model parameters is accounted for when specifying prior
distributions (particularly when the prior distributions are informative).
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An additional advantage of using QMC integration is that it allows us to
simply transform the integrationpoints X̃ jk after theyhavebeenobtained, rather
than attempting to appropriately transform the AgD marginal distributions
and summary statistics before generating the integration points.
5.2.1.2QR decomposition
Centring and scaling covariates is enough to ensure efficient computation in
Stan when the covariates themselves are uncorrelated (or any correlations are
minimal). However, when covariates are correlated this induces correlations
between the regression parameters in the posterior distribution, which hinders
efficient sampling. Instead, we can reparameterise the model using a QR
decomposition of the design matrix, resulting in a transformed posterior
parameter space that is much more efficient to sample from (see Section 1.2 of
the Stan User’s Guide, Stan Development Team 2018).
The QR decomposition of a general r × c matrix X (with r ≥ c) is X  QR,
where Q is an r × c orthogonal matrix and R is a c × c upper-triangular
matrix (Golub and Van Loan 1996, Section 5.2).2 Since we are using QMC
integration to evaluate the integral for the aggregate-level model, we apply
the QR decomposition to the augmented design matrix X ∗ formed by joining
the numerical integration “design” matrices X̃ jk for the AgD below the IPD









The QR decomposition of this augmented design matrix is then
X ∗  QR,








 Q∗R∗ , (5.10)
where N∗ is the number of rows of X ∗. This ensures that the columns of Q∗
are unit scaled (have standard deviation 1). We partition Q∗ into sub-matrices
2This is the thin QR decomposition. There is a corresponding fat QR decomposition where
Qfat is r × r and Rfat is r × c. The two are related by Qfat  [Q ,Q2], with r − c additional





. The fat QR decomposition is not useful here.
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consisting of the corresponding rows from the IPD, and from the numerical









We then reparameterise the FE ML-NMR model (5.8) as
Individual:















where ξ∗  R∗ξ. The parameters on the original scale can be recovered by the
back-transformation ξ  (R∗)−1ξ∗.
The use of QMC integration allows us to easily implement a QR parameter-
isation, by considering the augmented design matrix X ∗ as a whole. However,
there are some caveats to the QR parameterisation. Firstly, since the QR
decomposition involves the numerical integration points X̃ jk , the decompo-
sition and resulting transformed parameter space may vary depending on
the number of numerical integration points Ñ used. Whilst this will not
introduce bias (the underlying model remains identical and can always be
recovered), this may mean that the resulting transformed parameter space is
not as optimal as possible. Centring and scaling the covariates before the QR
decomposition is applied may help mitigate this issue. Similarly, we should
specify prior distributions on the original parameters ξ rather than on the
transformed parameters ξ∗, since the interpretation of the latter is not only
unnatural but is liable to change with different choices of Ñ. Furthermore,
the QR parameterisation only works well when non- or weakly-informative
prior distributions are used; informative prior distributions can induce strong
correlations in the posterior distribution of the transformed parameters ξ∗,
hindering sampling, in which case the original parameterisation may perform
better.
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5.2.2Exchangeable eect modifier coeicients
The ML-NMR model with exchangeable effect modifier coefficients (Sec-
tion 4.6.1) specifies that, for a set of treatments k ∈ T , the effect modifier
interaction coefficients β2,k;l have a distribution
β2,k;l ∼ N(mβ2 ,l , σ2β2 ,l), (5.13)
for each covariate l. Fitting hierarchical structures such as these can be
problematic for MCMC sampling algorithms, leading to slow sampling and
biased posterior estimates, as the strong dependence between the hierarchical
mean and standard deviation induces a phenomenon known as Neal’s funnel
(afterNeal 2003). (In Stan, thismanifests as divergent transition errors clustered
around small values of the hierarchical standard deviation; see Section 5.2.5)
The parameterisation in (5.13) is commonly referred to as centred; an alternative
is the non-centred parameterisation, which instead samples over a parameter
β∗2,k;l with a standard Normal distribution and then back-transforms to the
required distribution (Betancourt and Girolami 2013; Papaspiliopoulos et al.
2007):
β∗2,k;l ∼ N(0, 1),







Neal’s funnel and its remedy through the non-centred parameterisation
are discussed in Section 21.7 of the Stan User’s Guide (Stan Development
Team 2018). The non-centred parameterisation can greatly improve sampling
efficiency, particularly when the number of treatments in the set T is small (as
is common); we use this parameterisation when coding the ML-NMR model
in Stan (Appendix A). However, using both the non-centred parameterisation
and QR decomposition (Section 5.2.1) together is not straightforward due
to the different transformations applied to the same set of EM interaction
parameters. In practice, we find that the non-centred parameterisation is often
necessary for well-behaved sampling (i.e. without divergent transition errors,
see Section 5.2.5): we therefore use the non-centred parameterisation and
simply centre and scale the covariates instead of using the QR decomposition
when fitting models with exchangeable EM interactions.
5.2.3Random eects
In Section 4.6.2, we modified the fixed effect ML-NMR model (given in matrix
form in equation (5.8)) to include random treatment effects accounting for any
residual heterogeneity. As shown in (4.40), the linear predictor η jk(x) becomes
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η jk(x)  µ j +xT(β1+β2,k)+δ jk , where the δ jk are study-specific random effects.
Using the reference-treatment notation (Section 1.2.2), we place a random
effect δ jk on every non-treatment 1 arm in each study (i.e. setting δ j1  0).
These have a multivariate Normal distribution, with marginal distributions
δ jk ∼ N(γk , τ2) and correlations cor(δ ja , δ jb)  0.5 between random effects on
non-treatment 1 arms in the same study (under the assumption of common
heterogeneity variance τ2) (Higgins and Whitehead 1996).
To write these random effects in a vector-matrix form for efficient im-
plementation, let δ j be the vector of random effects in study j (again, with
no random effect on k  1 arms), let D j be a design matrix selecting the
corresponding treatment effects from the vector γ  (γ2 , . . . , γK)T, and let Στ; j
be the covariance matrix between the random effects in study j, with τ2 on
the diagonal and τ2/2 off the diagonal. The random effects distribution for
each study is then written as δ j ∼ MVN(D jγ,Στ; j). Joining the vectors of
























This parameterisation of the random effects is a centred parameterisation, and
hence will suffer similar issues to those discussed in Section 5.2.2, particularly
when the number of studies is small. Instead, we implement a non-centred
parameterisation of (5.15), as discussed in Section 21.7 of the Stan User’s Guide
(Stan Development Team 2018). In Section 5.2.2, we described the non-centred
parameterisation of exchangeable EM interactions, where the hierarchical
distribution was univariate Normal (5.13); here, deriving the non-centred
parameterisation of the random effects follows a similar process, except now
the hierarchical distribution is multivariate Normal (5.15).
To derive the non-centred parameterisation, we need to find a suitable
linear transformation relating the desired random effects δ to independent
standard Normal parameters δ∗ (over which we can efficiently sample). One
way of achieving this is to use Cholesky decomposition (Golub and Van Loan
1996, Section 4.2). Firstly, we write the block-diagonal covariance matrix Στ in
terms of a block-diagonal correlation matrixΨ (where, under the assumption
of common heterogeneity variance, each block has 1s on the diagonal and 0.5s
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elsewhere) and the common heterogeneity variance τ2:
Στ  τ
2Ψ. (5.16)
We take the Cholesky decomposition L of the correlation matrix,
Ψ  LLT , (5.17)
and thus decompose the covariance matrix as
Στ  τLLTτ. (5.18)
Using (5.18), we then write the non-centred parameterisation as
δ∗ ∼MVN(0, I)
δ  Dγ + τLδ∗ ,
(5.19)
where 0 is a vector of zeros and I is the identity matrix.
Finally, we use this non-centred random effects parameterisation to write
the random effects ML-NMR model in matrix form. Notationally (and compu-
tationally), it is convenient to define a vector δ0 of zero mean random effects
augmented with fixed zeros for arms with k  1, where the elements of δ0 are
δ0; jk 
{
0 if k  1
τ [Lδ∗] jk if k > 1
(5.20)
and we have δ jk  γk + δ0; jk . The full RE ML-NMRmodel parameterised with
non-centred random effects is then
Individual:
yi jk ∼ πInd(θi jk) (5.21a)
g(θ)  Xξ + δ0;Ind (5.21b)
ξ 
(
µ1 , . . . , µ J , βT1 , β
T
2,2 , . . . , β
T




δ∗ ∼MVN(0, I) (5.21d)
δ0; jk 
{
0 if k  1
τ [Lδ∗] jk if k > 1
(5.21e)
Aggregate:











5. COMPUTATION OF ML-NMR MODELS
We set δ j1  γ1  0 and β2,1  0, and let δ0;Ind be the elements of δ0
corresponding to IPD study arms. The IPD design matrix X and the numerical
integration “design” matrices X jk are the same as in the FE model (5.8). Prior
distributions are specified for the parameters in ξ and for τ.
We also apply the covariate transformation techniques described in Sec-
tion 5.2.1 here, either centring and scaling the covariates or using the QR
decomposition. Unlike with the exchangeable EM interactions model (Sec-
tion 5.2.2), the QR decomposition is straightforward to apply here: the random
effects terms are separated out from the design matrix in equations (5.21b)

















5.2.4 Specifying initial values
MCMC algorithms require the user to specify initial values for the sampling
algorithm. Software packages such as WinBUGS offer to randomly generate
initial values; however, these are generated from the given prior distribution
and may be extreme (particularly with non-informative prior distributions)
which can cause numerical issues and/or slow convergence. By comparison,
Stan offers to generate initial valueswithin a given interval on an unconstrained
scale (e.g. the log scale for parameters constrained to be positive). This removes
the possibility of extreme values causing numerical issues, whilst hopefully
still providing initial values that are disparate enough across multiple chains
to detect issues such as multiple posterior modes. The interval in which
Stan generates initial values is set to [−2, 2] by default, but whether this is
appropriate depends on the scaling of outcomes and covariates.
When using the two-parameter Binomial approximation to the Poisson
Binomial aggregate likelihood (Section 4.2.1), we must ensure that Stan does
not choose invalid initial values—i.e. those that correspond to an adjusted
number of individuals N′jk less than the observed number of events y• jk . To
implement this restriction, we use a reject statement to reject the generated
initial values (and force Stan to try again) when N′jk < y• jk . In this way, we
can still rely on Stan’s inbuilt mechanism for generating initial values. This
condition should always be met once Stan is sampling from the posterior
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distribution: any rejections during sampling indicate serious conflict between
the model and the data, and any results should not be trusted in such case.
5.2.5Checking convergence and other diagnostics
The MCMC sampling algorithm used by Stan is different to that used by other
Bayesian software packages such as WinBUGS or JAGS. Stan implements a
form of Hamiltonian Monte Carlo (HMC), specifically the No U-Turn Sampler
(NUTS; Hoffman and Gelman 2011). Instead of producing samples in a
random walk, with acceptance probabilities determined by the ratio of the
posterior density at successive points, HMCproduces samples by simulating an
analogous physical system under Hamiltonian dynamics, where the sampler
has potential energy (determined by the posterior density) and momentum
(which is tuned for efficiency) as it moves through the sample space (for an
introduction, see Neal 2012). Whilst the computational cost for obtaining each
posterior sample is greater, the resulting samples themselves showmuch lower
autocorrelation than those fromWinBUGS or JAGS. Far fewer iterations are
therefore needed to obtain a suitable effective sample size (or corresponding
MonteCarlo error); typically only a few thousand iterations in Stan are required
to give the same effective sample size as tens or even hundreds of thousands
fromWinBUGS or JAGS. (It is even possible for Stan to produce anticorrelated
samples, in which case the effective sample size may be larger than the number
of iterations.)
General MCMC diagnostics are applicable when fitting Stan models. For
example, convergence may be assessed by running multiple parallel chains
from disparate initial values, and then calculating the value of R̂, also known
as the potential scale reduction factor or Gelman-Rubin statistic (Gelman
and Rubin 1992; Gelman et al. 2013a, pp. 284–285; see also Section 15.3 of
the Stan Language Reference Manual, Stan Development Team 2018). R̂
assesses convergence by comparing the between- and within-chain variances
to determinewhether the different chains are sampling from the same posterior
distribution. (R̂ can be interpreted as an estimate of the overdispersion of the
samples from the true posterior distribution, hence it is sometimes referred to
as the potential scale reduction factor.) We wish R̂ to be close to 1; typically
values greater than 1.1 are considered too large and indicate non-convergence,
and a larger number of iterations may be required (or there may be other
issues, such as chains sampling from different posterior modes).
Stan also provides a number of advanced diagnostics to help indicate
problems with sampling. One key diagnostic is the presence of divergent
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transitions; these mean that the NUTS algorithm used by Stan has detected that
it was not able to suitably sample from a region of the posterior distribution
(Betancourt and Girolami 2013; see also Section 14.5 of the Stan Language
Reference Manual, Stan Development Team 2018). For example, if random
effects are implemented using the centred parameterisation instead of the
non-centred parameterisation (see Section 5.2.3), then divergent transitions
are likely to occur at small values of τ (and the posterior estimate of τ will be
biased upward as a result). Stan will raise a warning if divergent transitions
occur, and their presence means that the posterior estimates may be biased.
It may be possible to remedy divergent transitions by reducing the step size
used in the NUTS algorithm, forcing the sampler to move more slowly;3
otherwise a more suitable model parameterisation may be required, such as
those discussed in the previous sections.
These diagnostics are all provided in the rstan R package which is used
to run Stan, and printed as part of the default output. Alternatively, the
shinystan package provides a graphical user interface for interactive conver-
gence checking and sampling diagnostics.
5.3 Model fit and comparison
As we described in Section 1.2.6 for standard NMA, in a Bayesian framework
model fit is often assessed using the residual deviance Dres, and different
models are often compared using the Deviance Information Criterion (DIC)
(Dias et al. 2011c; Spiegelhalter et al. 2002). We can follow this approach for
ML-NMRmodels also, as long as the form of the aggregate likelihood is known.
(We discuss model comparison for models with general likelihoods where the
aggregate likelihood may not have an explicit form later in Section 7.2.) The
form of the residual deviance (and thus pD and DIC) is dictated by the form
of the likelihood, and so we use one form for the IPD corresponding to the
individual-level likelihood, and one form for the AgD corresponding to the
aggregate-level likelihood.
The residual deviance for a data point is defined as the deviance (−2 times
the log likelihood) under the current model, minus the deviance under a
saturated model where every data point is perfectly predicted (McCullagh
and Nelder 1989). For the IPD, we denote the residual deviance contributions
by Dres;i jk , and for the AgD we denote the contributions by Dres;• jk . The total
3This is achieved by increasing target acceptance rate, which is set via the Stan control
argument adapt_delta. Increasing the target acceptance rate from its default value of 0.8, to a
higher value such as 0.95 or 0.99, results in a smaller step size.
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Dres;• jk . (5.23)
Table 5.1 lists residual deviance formulae for some common individual and
aggregate likelihoods.
For the purposes of checking absolute model fit, we are interested in the
posterior distribution of Dres, and of Dres;i jk and Dres;• jk for each data point
(individual or aggregate, respectively). The posterior mean of the residual
deviance, (Dres), can be compared to the number of independent data points
to check if model fit might be improved: the two will be approximately equal
under a well-fitting model assuming approximate Normality (which may not
hold in practice, e.g. for binary data in small samples orwith event probabilities
far from 0.5) (Spiegelhalter et al. 2002). The posterior distributions of the
residual deviance contributions Dres;i jk or Dres;• jk from each data point can
be plotted (e.g. posterior mean and 95% Credible Interval), to identify any
poorly-fitting observations (those with contributions much greater than 1). It
may be useful to check model fit for the IPD and AgD separately, as well as
overall: for example by splitting the total residual deviance (5.23) into totals
for the IPD and AgD, or by distinguishing between IPD and AgD in plots of
residual deviance contributions.
The DIC is calculated using equation (1.34) as
DIC   (Dres) + pD , (5.24)
penalising the residual deviance Dres by a measure of the effective number of
parameters, pD . Following Welton et al. (2012, p. 126), we calculate pD as the
difference between the posterior mean of Dres and the value of Dres calculated
at the posterior mean of the fitted values (i.e. replacing ŷi jk and ŷ• jk by ( ŷi jk)
and ( ŷ• jk) respectively in the formulae in Table 5.1):
pD   (Dres) − Dres

( ŷ). (5.25)
When comparing a set of candidate models, lower values of DIC are preferred;
typically differences of less than 3 are considered small, and differences of
more than 5 are considered substantial (Lunn et al. 2010, pp. 165–167; Dias
et al. 2018, p. 69). If differences in DIC are small we would typically prefer the












Table 5.1 Residual deviance contributions for some common individual and
aggregate-level likelihoods. For full details on each likelihood and its notation,
see the definitions in Section 4.2.
Likelihood Model prediction Residual deviance contribution
Normal individual, Normal aggregate *
yi jk ∼ N(θi jk , σ2jk) ŷi jk  θi jk Dres;i jk 
(yi jk− ŷi jk)2
σ2jk
y• jk ∼ N(θ• jk , s2jk) ŷ• jk  θ• jk Dres;• jk 
(y• jk− ŷ• jk)2
s2jk
Bernoulli individual, one-parameter Binomial aggregate
yi jk ∼ Bern(pi jk) ŷi jk  pi jk Dres;i jk  −2
(
yi jk log ŷi jk + (1 − yi jk) log(1 − ŷi jk)
)






+ (N jk − y• jk) log
( N jk−y• jk
N jk− ŷ• jk
))
Bernoulli individual, two-parameter Binomial aggregate †
yi jk ∼ Bern(pi jk) ŷi jk  pi jk Dres;i jk  −2
(
yi jk log ŷi jk + (1 − yi jk) log(1 − ŷi jk)
)
y• jk ∼ Bin(N′jk , p̄
′















Poisson individidual, Poisson aggregate
yi jk ∼ Pois(λi jkEi jk) ŷi jk  λi jkEi jk Dres;i jk  2
(




y• jk ∼ Pois(λ• jkE• jk) ŷ• jk  λ• jkE• jk Dres;• jk  2
(




* When calculating pD , set σ2jk to posterior median (see Section 5.3.1.1); s
2
jk assumed known.
† When calculating pD , set N′jk to posterior median (see Section 5.3.1.2).
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5.3.1Considerations for likelihoods withmore than one parameter
Calculation of the residual deviance, pD , and DIC is straightforward in most
cases when the aggregate likelihood has a known form. However, when the
likelihood has more than one unknown parameter the calculations become
more complicated. In this case, calculation of pD requires choosing suitable
plug-in values for each parameter, and if multiple parameters are modelled
the saturated deviance is also not uniquely defined. We now consider two
common cases where these issues arise.
5.3.1.1Considerations for a Normal likelihood with unknown variance
With a Normal individual-level likelihood, yi jk ∼ N(θi jk , σ2jk), a model is
placed on the mean parameter θi jk and the variance σ2jk is unknown. (At the
aggregate level we take s2jk as data, assumed known, so we do not have the
same issue.) When calculating pD , we evaluate the residual deviance at the
posterior mean of the fitted values; we therefore need to also plug in a suitable





( ŷi jk ),med(σ2jk )

(




In general, when calculating pD for a likelihood with both location and
scale parameters unknown, the location parameter (which is modelled) is
determined by the posterior mean of the fitted values, and the scale parameter
is fixed at a suitable value such as the posterior median.
5.3.1.2Considerations for the two-parameter Binomial likelihood
When fitting a model using the two-parameter Binomial approximation to
the aggregate Poisson Binomial likelihood (Section 4.2.1), there are two issues
that must be considered. Firstly, when calculating the residual deviance the
saturated model is not uniquely defined. This is because both likelihood
parameters p̄′jk and N
′
jk are modelled, and there are an infinite number of ways
in which p̄′jk and N
′
jk can be chosen together to perfectly predict the observed
number of events y• jk . Secondly, calculating pD requires choosing a suitable
plug-in value, in this case for N′jk .
To alleviate the first issue, one possibility is to avoid calculating the
saturated deviance altogether. The deviance may be used to calculate pD and
DIC by itself, without subtracting the saturated deviance (Spiegelhalter et al.
2002). This results in the same values for pD , since the saturated deviance
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cancels in equation (5.25), although suitable plug-in values will still need to
be chosen (i.e. the second issue still stands). Comparisons of deviance and
DIC between candidate models will also be unaffected, since the saturated
deviance is the same under all models and cancels out. However, the saturated
deviance acts as a standardising term, allowing the residual deviance to be
interpreted as an absolute measure of model fit (Spiegelhalter et al. 2002).
The need to calculate this standardising term is arguably more important in
ML-NMR models than in NMA with only IPD or AgD: since the individual-
level and aggregate-level likelihoods are different, the deviance contributions
require standardising in order to compare model fit between the IPD and AgD.
Therefore we now consider the calculation of the residual deviance for the
two-parameter Binomial model.
We choose to calculate the saturated deviance under a model where the
average event probability p̄′jk perfectly predicts the observed number of events,
for a given posterior sample of N′jk , since in our experience there is less
posterior variation in N′jk than p̄
′
jk . This is the formulation given in Table 5.1:







+ (N′jk − y• jk) log
(
N′jk − y• jk
N′jk − ŷ• jk
))
, (5.27)
where ŷ• jk  N′jk p̄
′
jk . An alternative choice would be to calculate the saturated
deviance under a model with N′jk fixed to equal the actual sample size N jk (i.e.
the one-parameter Binomial model), resulting in







+ (N jk − y• jk) log
(
N jk − y• jk
)
− (N′jk − y• jk) log
(




Under this formulation the additional flexibility of the two-parameter Binomial
is not reflected in the saturated deviance, but when comparing DIC between
candidate models the calculated saturated deviances are all the same so cancel
out. This cancellation is not guaranteed under (5.27): the calculated saturated
deviances are not necessarily the same for all candidate models, since N′jk may
be estimated differently under each fitted model.
Then, when calculating the effective number of parameters pD , we evaluate
the residual deviance at the posterior mean of the fitted values. In this case
the residual deviance also depends on N′jk , for which we also need to plug in a
suitable value. (This is also true of the deviance, so when calculating pD with
the deviance instead of the residual deviance the same choices apply.) We
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choose to use the posterior median of the adjusted sample size, med(N′jk), so
that (along with the formulation of residual deviance given in (5.27)), we have
Dres;• jk

( ŷ• jk ),med(N′jk )
 2
(





+ (med(N′jk) − y• jk) log
(
med(N′jk) − y• jk




Another choice would be the unadjusted sample size N jk , which gives
Dres;• jk

( ŷ• jk ),med(N′jk )
 2
(





+ (N jk − y• jk) log
(
N jk − y• jk




It remains to be seen which formulation of Dresdev, pD , and DIC is theoreti-
cally most desirable. However, these choices only relate to the aggregate part
of the model; since the values of Dresdev, pD , and DIC will be dominated by
the individual-level model and its fit to the IPD, the choice of formulation is
likely to make very little practical difference.
5.4Discussion
In this chapter, we have discussed several computational aspects of imple-
menting ML-NMRmodels in Stan. Obtaining the aggregate-level model using
QMC integration with copulæ is a flexible and widely applicable approach,
which can be used regardless of the number or form of covariates or the
complexity of the model. Using quasi-random sequences for numerical in-
tegration improves upon the convergence rates of standard pseudo-random
Monte Carlo integration, and retains this performance in high-dimensions.
We have used a Gaussian copula here to impart the given correlations on the
integration points (Section 5.1). This accounts for linear correlation in the
underlying relationships between covariates, but no restrictions are placed on
the form of the marginal distributions. In practice, we find that this is a very
flexible approach and can account for a wide range of observed relationships
between covariates; however, other copulæ could be used to assert covariance
structures under different assumptions (Nelsen 2006).
In Section 5.2, we discussed several techniques for improving statistical
efficiency, by transforming covariates (Section 5.2.1) and choosing an efficient
parameterisation of hierarchical structures (Sections 5.2.2 and 5.2.3). In the
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extreme case, we must choose a suitable model parameterisation to avoid
pathological sampling behaviour and biased posterior estimates. Whilst we
discussed these concepts in the context of implementing ML-NMR in Stan,
they are equally applicable to implementations of AgDNMA and IPD network
meta-regression, and also to implementations of this family of models in other
Bayesian software. A key advantage of Stan in this regard is that pathological
behaviour is automatically identified through divergent transitions, and the
user can take suitable remedial actions (see Section 5.2.5). In contrast, software
such as WinBUGS or JAGS in which these models are more traditionally
implemented will not explicitly warn of such pathological behaviour, instead
relying on more subtle signs such as high autocorrelation or “sticking” chains.
A significant advantage of Stan over other Bayesian software such as
WinBUGS or JAGS is that it is much more statistically efficient: much higher
effective sample sizes can be obtained for a set number of iterations, due to
the use of Hamiltonian Monte Carlo (Section 5.2.5). Not only can this lead
to substantial time savings, but there are further benefits for probabilistic
cost-effectiveness analysis where posterior samples are used to evaluate a
cost-effectiveness model (Claxton et al. 2005; Critchfield andWillard 1986; Dias
et al. 2011b; Doubilet et al. 1985), including avoiding the need for “thinning”
and reducing Monte Carlo error in the results.
Residual deviance and DIC are widely-used for checking model fit and for
model selection of NMA andmeta-regression models in a Bayesian framework
(Dias et al. 2011c; Hoaglin et al. 2011; Welton et al. 2012, Chapter 6; Dias
et al. 2018, Chapter 3). Other model comparison criteria besides DIC have
been proposed in the literature, each with different relative merits (for an
overview, see Gelman et al. 2013b), but have yet to be widely used in the NMA
literature. In Section 5.3, we extended the residual deviance and DIC ideas to
the ML-NMR framework by considering the contributions from the individual
and aggregate parts of the model. When the aggregate-level likelihood has a
known form this approach is straightforward, although there are complications
when the likelihood has more than one unknown parameter (such as the two-
parameter Binomial, or Normal with unknown variance). In such cases,
calculation of pD requires choosing suitable plug-in values for each parameter,
and if multiple parameters aremodelled the saturated deviance is not simple to
determine (see Section 5.3.1). We discuss alternative approaches for when the
aggregate-level likelihood has an unknown form later in Section 7.2—namely
the use of approximate leave-one-out (LOO) cross validation and the resulting
information criterion LOOIC (analogous to DIC), as proposed by (Vehtari
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et al. 2016). Calculating the LOOIC requires only posterior samples of the log
likelihood contribution for each data point (over the posterior distribution
of the model parameters)—which are always well-defined—and thus avoids
the need to specify the form of the likelihood. Indeed, LOOIC also avoids
the need to specify the saturated deviance or to plug in posterior estimates to
calculate pD , and so appears an attractive alternative to DIC when faced with
multi-parameter likelihoods. However, the approximations used in calculating
LOOIC break downwhen some data points are highly influential, or effectively
saturated in the model (i.e. a parameter informed by only a single data point).
Unfortunately, these scenarios are common in ML-NMR (and AgD NMA),
since often there are treatment comparisons in a network only informed by a
small number of studies or only one study. In such cases, these AgD studies
will be highly influential on the posterior distribution of the corresponding
treatment effect, and the approximate LOO approach breaks down. Some
solutions are discussed in Section 7.2, but these are non-trivial to implement.
For this reason we have continued to focus on DIC in this chapter, and we
use DIC for the examples in the following Chapter 6. However, the use of
approximate LOO and LOOIC for ML-NMR and AgD NMA is an interesting
area for further research.
Stan code implementing ML-NMR models in an efficient manner using
the techniques described in this chapter is given in Appendix A. Whilst the
provided Stan code is general for networks of any size and can be readily
adapted to other likelihoods, implementation still requires familiarity with
Stan. Future work is to develop an R package that provides a user-friendly
interface to fitting ML-NMR models (and, by extension, IPD and AgD NMA)
in Stan. This package would also simplify the generation of integration points
for QMC integration, produce plots of empirical integration error (as described
in Section 5.1.2), provide model fit and comparison statistics such as residual
deviance and DIC, and produce graphical and tabular summaries of results.
Such a package would streamline the process of implementing ML-NMR




Applied example of ML-NMR:
Plaque psoriasis
In this chapter, we apply Multilevel Network Meta-Regression to a real
example, and compare with current methods. Three treatments for moderate-
to-severe plaque psoriasis were compared with placebo over 12 weeks in
four phase 3 trials. In UNCOVER-1, patients were randomised to receive
placebo (PBO), ixekizumab every 2 weeks (IXE Q2W), or ixekizumab every
4 weeks (IXE Q4W) (Gordon et al. 2016). In UNCOVER-2 and UNCOVER-3,
patients were randomised to receive placebo, etanercept (ETN), ixekizumab
Q2W, or ixekizumab Q4W (Gordon et al. 2016; Griffiths et al. 2015). In
FIXTURE, patients were randomised to receive placebo, secukinumab 150 mg
(SEC 150), secukinumab 300 mg (SEC 300), or etanercept (Langley et al. 2014).
Figure 6.1 displays the resulting treatment network formed by the four studies.
IPD were available for the three UNCOVER trials. Outcomes of interest
include success/failure to achieve 75%, 90%, and 100% improvement on the
Psoriasis Area and Severity Index (PASI) scale (denoted PASI 75, PASI 90, and
PASI 100 respectively) at twelve weeks. Information on five clinically-relevant
covariates thought to be potential effect modifiers is available on individuals
in the UNCOVER trials, and summary statistics on the same covariates were
extracted from the FIXTURE trial (Langley et al. 2014). Table 6.1 summarises
the distribution of these at baseline in each trial.
We begin by performing a simple “targeted comparison” (see Section 4.5.2)
between ixekizumab Q2W and secukinumab 300 mg (the licensed dosages) via
the etanercept commoncomparator, comparing the resultswith a reanalysis of a
previously publishedMAIC (Strober et al. 2016). However, this analysis ignores
information from multiple other treatment arms and common comparators.
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Figure 6.1 The UNCOVER (Gordon et al. 2016; Griffiths et al. 2015) and
FIXTURE (Langley et al. 2014) trials form a network of six treatments. Shad-
ing indicates comparisons made in: (a) UNCOVER-2 and UNCOVER-3;
(b) UNCOVER-1; (c) FIXTURE. The thick and thin lines represent availability
of IPD and AgD on a comparison respectively. PBO = placebo, IXE = ixek-
izumab, SEC = secukinumab, ETN = etanercept. IXE and SEC were each
investigated with two different dosing regimens.
Using ML-NMR, we then extend the analysis to incorporate evidence from
all trial arms. Finally, we extend the analysis using the additional IPD and
AgD studies, allowing us to assess the shared EM assumption and investigate
residual heterogeneity. All analyses were performed using R (R Core Team
2018) and Stan (Carpenter et al. 2017).
Table 6.1 Baseline covariate summaries from the UNCOVER and FIXTURE
trials, over all trial arms. Reported sample size for UNCOVER-2 and 3 after
removing two individuals from each study with missing weight. Statistics are
mean (SD) unless otherwise specified.
UNCOVER-1 UNCOVER-2 UNCOVER-3 FIXTURE
(N = 1296) (N = 1219) (N = 1339) (N = 1306)
Age, years 45.7 (12.9) 45.0 (13.0) 45.7 (13.1) 44.5 (12.9)
* Body surface area, per cent 27.7 (17.3) 26.0 (16.5) 28.3 (17.1) 34.4 (18.9)
* Duration of psoriasis, years 19.6 (11.9) 18.7 (12.5) 18.2 (12.2) 16.5 (12.0)
Baseline PASI score 20.1 (8.0) 19.6 (7.2) 20.9 (8.2) 23.7 (10.2)
* Previous systemic treatment (%) 71.3 64.2 57.1 64.0
* Psoriatic arthritis (%) 26.3 23.6 20.5 14.7
Male (%) 68.1 67.0 68.2 71.1
* Weight, kg 92.2 (23.8) 91.6 (22.2) 91.2 (23.5) 83.3 (20.8)
* Covariate considered a potential effect modifier, to be included in population adjustment.
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6.1A simple population-adjusted indirect comparison
A previous MAIC sought to create a population-adjusted indirect comparison
between ixekizumab Q2W and secukinumab 300 mg via etanercept, adjusting
for the baseline covariates in Table 6.1, using the data from UNCOVER-2 and 3
and FIXTURE (Strober et al. 2016). Data from UNCOVER-1 could not be used,
as this study did not include an etanercept arm. We recreate theMAIC analysis
of Strober et al., and compare with a “targeted comparison” performed using
ML-NMR (as in Section 4.5.2). Figure 6.2 shows this comparison in the context
of the full network formed by the UNCOVER and FIXTURE trials (which was
shown in Figure 6.1). We focus on the PASI 75 outcome for the analyses in this
chapter, since the more demanding PASI 90 and PASI 100 outcomes present
difficulties for estimation with small numbers of observed events. (This issue
is resolved later in Chapter 7 using a joint multinomial model for the three
PASI outcomes.) In this section, we will refer to etanercept as treatment A,










Figure 6.2 The comparison between ixekizumab Q2W and secukinumab
300 mg targeted by a previous MAIC, using etanercept as a common compara-
tor, highlighted as a subset of the full network formed by the UNCOVER and
FIXTURE trials (Figure 6.1). The thick and thin lines represent availability
of IPD and AgD on a comparison respectively. IXE = ixekizumab, SEC =
secukinumab, ETN = etanercept.
6.1.1Methods
A population-adjusted indirect comparison in the FIXTURE study population
is given by dBC(AC)  dAC(AC) − dAB(AC), where the relative effects are defined
as standardised mean differences (SMD) on the PASI scale. The relative effect
dAC(AC) of secukinumab 300 mg vs. etanercept is estimated by the FIXTURE
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study. We will use MAIC and ML-NMR to estimate dAB(AC), the relative effect
of ixekizumab Q2W vs. etanercept in the FIXTURE study population.
6.1.1.1 MAIC
TheMAIC analysis (Section 2.2.1) matches the mean and standard deviation of
the continuous covariates (duration of psoriasis, weight, and body surface area)
and the proportion of binary covariates (previous systemic treatment, psoriatic
arthritis) in the IPD studies UNCOVER-2 and 3 to the AgD study FIXTURE.
Since there is more than one IPD study available, we calculate weights for
each study separately to respect randomisation. Following Section 2.2.1, we
obtain the weights for UNCOVER-2 and UNCOVER-3 in turn by minimising











where N jk is the number of individuals in study j on treatment k, and x∗i jk
is a vector of covariate moments for individual i in study j on treatment k,
centred around the covariate moments in the FIXTURE trial. That is, for a
continuous covariate with mean m and standard deviation s in the FIXTURE
trial, we include both xi jk −m and x2i jk −m
2 − s2 in the vector x∗i jk ; for a binary
covariate with proportion m in FIXTURE, we include xi jk − m. The weights
are then given by






We then estimate dAB(AC), the relative effect of ixekizumab Q2W vs. etan-
ercept in the FIXTURE study population, using the weights. Following
Section 3.1.1.2 (also Phillippo et al. 2016), we do this using a weighted one-
stage IPD meta-analysis over the UNCOVER trials. This is implemented as a
weighted Binomial GLM with a probit link function, fitted using the weights
wi jk , with a model including only a treatment indicator and study-specific
intercept to account for clustering:
(yi jk)  Φ
(
µ j + dAB(AC)(k  B)
)
. (6.3)
The standard error of the estimate d̂AB(AC) is calculated using bootstrapping.
The MAIC population-adjusted indirect comparison in the FIXTURE
population is then d̂BC(AC)  d̂AC(AC) − d̂AB(AC), where d̂AC(AC) is the relative
effect estimate from the FIXTURE trial.
In the interests of a fair comparison, the MAIC implemented here differs
slightly from the original analysis of Strober et al. (2016): in the original
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analysis the indirect comparison was effected on the risk difference scale, and
it was unclear whether randomisation was fully respected in the weighting
process. However, the results of our updated analysis are very similar to those
reported originally (Strober et al. 2016).
6.1.1.2ML-NMR
A simple population-adjusted indirect comparison using ML-NMR is concep-
tually very similar to STC (which is also a regression adjustment approach,
see Section 2.2.2). The main differences are that we perform ML-NMR in a
Bayesian framework and use numerical integration to produce estimates on
transformed scales rather than simulation. To perform a targeted comparison
(see Section 4.5.2), we fit a probit regression in the IPD UNCOVER trials and
then make predictions into the AgD FIXTURE population. The same set
of potentially effect modifying covariates from Table 6.1 are included in the
model, each with a main (prognostic) effect and an interaction effect with
treatment. (Note that baseline PASI score and body surface area are highly
correlated since the PASI score is based on cutpoints of body surface area, so
we only include body surface area in the adjustment in line with the previous
MAIC.) For each individual in the UNCOVER studies, the binary outcome
of success/failure to achieve PASI 75 follows a Bernoulli distribution, with
some individual success probability pi jk which is modelled with a probit link
function, and the “targeted comparison” (4.33) is written as:
Individual model in UNCOVER trials:
yi jk ∼ Bern(pi jk) (6.4a)
Φ−1(pi jk)  η jk(xi jk)  µ j + xTi jk(β1 + β2,k) + γk (6.4b)
Predicted relative effect in FIXTURE trial:
d̂AB(AC)  x̄T(AC)(β̂2,B − β̂2,A) + γ̂B − γ̂A (6.4c)
Targeted comparison in FIXTURE trial:
d̂BC(AC)  d̂AC(AC) − d̂AB(AC) (6.4d)
where Φ(·) is the standard Normal cumulative distribution function (CDF),
and d̂AC(AC) is the relative effect estimate from the FIXTURE trial. η jk(xi jk) is
the linear predictor for an individual on treatment k in trial j with covariate
vector xi jk . The coefficients µ j are study-specific baselines, β1 are coefficients
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for prognostic variables, and β2,k are coefficients for effect modifiers specific
to each treatment k. The effect of the k-th treatment (at the individual level),
γk , is defined with respect to the reference treatment A, and we set γA  0
and β2,A  0. We implement this model in Stan using the stan_glm function
from the rstanarm R package, placing weakly-informative N(0, 102) prior
distributions on the QR-transformed parameters (see Section 5.2.1.2). We
assess convergence using R̂ for each parameter, and check that there are no
divergent transitions (see Section 5.2.5).
6.1.2 Results
The results of the MAIC and ML-NMR analyses are very similar (Table 6.2).
TheMAIC estimate of the relative effect of secukinumab 300mg vs. ixekizumab
Q2W in the FIXTURE population is −0.28 SMD (95% Confidence Interval:
−0.56, −0.00). The ML-NMR estimate is −0.26 SMD (95% Credible Interval:
−0.53, 0.01), and is slightly more precise than the MAIC estimate. MAIC
effective sample sizes were 418 (59.1% of the original 707) and 558 (72.8% of
the original 766) in UNCOVER-2 and 3 respectively.
Table 6.2 Results of the MAIC and ML-NMR population-adjusted indirect
comparisons in the FIXTURE study population. The uncertainty intervals are
95% Credible Intervals for ML-NMR, and 95% Confidence Intervals for MAIC
and the FIXTURE study estimate.
Method
Contrast ML-NMR MAIC FIXTURE study
IXE Q2W vs. ETN 1.15 1.18
d̂AB(AC) (0.99, 1.33) (0.99, 1.37)
SEC 300 vs. ETN 0.89
d̂AC(AC) (0.69, 1.10)
SEC 300 vs. IXE Q2W −0.26 −0.28
d̂BC(AC) (−0.53 0.01) (−0.56, −0.00)
6.1.3 Limitations
This analysis has several important limitations. Firstly, etanercept was chosen
as the common comparator by Strober et al., but there is also a common placebo
comparator in the network (Figure 6.1). Etanercept was likely chosen over
placebo to increase precision of the indirect comparison, as there are few events
in the placebo arms. However, the placebo arms still contain information that
we can incorporate in our analysis. This is particularly desirable since excluding
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the placebo arms results in ignoring the IPD from an entire trial (UNCOVER-1).
Secondly, the network contains other doses of ixekizumab and secukinumab,
and we may be interested in comparisons between all treatments at all doses
for clinical or regulatory purposes. However, performing multiple population-
adjusted indirect comparisons between each pair of treatments does not result
in a consistent set of relative effect estimates—in exactly the same way that
multiple pairwise meta-analyses do not provide a consistent set of estimates
(Caldwell et al. 2005). Finally, the results of these population-adjusted indirect
comparisons are valid only for the FIXTURE study population, which may
not represent the decision target population (and hence leads the sponsor
of the UNCOVER trials to arguing that their competitor’s FIXTURE trial is
more representative). The results may be generalised to any target population
if the shared effect modifier assumption is made for ixekizumab Q2W and
secukinumab 300 mg (Section 2.5). However, this assumption is untestable
with the data available for this analysis.
6.2Incorporating evidence from all trial arms
Using ML-NMR it is straightforward to synthesise all of the available data on
all treatments from each of the studies (Figure 6.1), and to produce population-
adjusted indirect comparisons between any pair of treatments in any chosen
target population. We illustrate this by producing estimates for both the
FIXTURE and UNCOVER study populations.
6.2.1Methods
The full ML-NMRmodel (4.34) in this scenario is as follows. At the individual
level, the binary outcome of success/failure to achieve PASI 75 follows a
Bernoulli distribution, with some individual success probability pi jk that is
modelled with a probit link function in the same manner as the targeted
comparison (equation 6.4):
yi jk ∼ Bern(pi jk) (6.5a)
Φ−1(pi jk)  Φ−1(θi jk)  η jk(xi jk)  µ j + xTi jk(β1 + β2,k) + γk (6.5b)
where Φ(·) is the standard Normal cumulative distribution function (CDF).
θi jk and η jk(xi jk) are the conditional mean outcome and linear predictor for an
individual on treatment k in trial j with covariate vector xi jk . The coefficients
µ j are study-specific baselines, β1 are coefficients for prognostic variables, and
β2,k are coefficients for effect modifiers specific to each treatment k. The effect
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of the k-th treatment (at the individual level), γk , is defined with respect to
the reference treatment 1 (here chosen to be placebo), and we set γ1  0 and
β2,1  0. The individual-level model (equations 6.5a and 6.5b) is identical to
that used in the targeted comparison in the previous section (equations 6.4a
and 6.4b). We use the two-parameter Binomial approximation (4.6) to define
the aggregate likelihood



















with parameters p̄ jk and p̄2 jk modelled by integrating the individual-level
model over the covariate distribution f jk(·):














)2 f jk(x) dx , (6.5g)
where θ• jk is the marginal mean outcome on treatment k in trial j, and X
denotes the support of x.
To implement the aggregate-level model, we use the QMC integration
approach described in Section 4.3.3.2 to integrate the individual-level model
over the covariate distribution in the FIXTURE trial (Table 6.1). First, 10,000
points are taken from a five-dimensional Sobol’ sequence, one dimension for
each covariate: body surface area, duration of psoriasis, previous systemic
treatment, psoriatic arthritis, and weight. Marginal distributions for each
covariate in the FIXTURE trial are chosen to match the reported summary
statistics, with specific form based on theoretical properties and the observed
distributions in the UNCOVER trials: weight and duration are given a Gamma
distribution to account for skewness, and body surface area as a percentage is
given a scaled logit-Normal distribution (see Figure 6.3). Previous systemic
treatment and psoriatic arthritis are binary covariates. Since no information
on the correlations between covariates is available in FIXTURE, these are
assumed to match those observed in the UNCOVER trials. To account for this,
we compute a correlation matrix from the IPD UNCOVER trials (as described
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in Section 4.6.4)
1 0.19 0.05 −0.00 0.08
0.19 1 0.04 −0.05 0.14
0.05 0.04 1 0.04 0.05
−0.00 −0.05 0.04 1 −0.00








and impose this upon the Sobol’ points using a Gaussian copula, before
transforming to the required marginal distributions using the inverse CDF
method (see Section 5.1). The resulting integration points capture the corre-
lations between the covariates (e.g. longer duration of psoriasis is correlated
with having previous systemic treatment) whilst preserving the marginal
distribution for each covariate. Figures 6.4 and 6.5 demonstrate that empirical
integration error rates of the order Ñ−1 are indeed achieved over the entire
posterior distribution of the parameters, for both p̄ and p̄2 in each arm of the
FIXTURE study.
The ML-NMR model (6.5) is fitted to the PASI 75 outcomes, including
interaction terms for the five potential effect modifiers in Table 6.1. We take
a Bayesian approach implemented in Stan (Carpenter et al. 2017), placing a
non-informative N(0, 1002) prior distribution on each parameter. We assess
convergence using R̂ for each parameter, and check that there are no divergent
transitions (see Section 5.2.5). With only twoAgD secukinumab treatment arms
available, it is not possible to identify a model with five distinct effect modifier
interactions and a treatment effect for each secukinumab dose. However,
since secukinumab and ixekizumab share modes of action as interleukin-
17A blockers, we assume that the effect modifier interaction parameters are
common between these treatments across all doses (the shared effect modifier
assumption) to identify the model (Section 2.5).
Finally, we produce estimates of contrasts between each pair of treatments,
and of the proportion of individuals achieving PASI 75, in both the UNCOVER
and FIXTUREpopulations. The SMD contrasts between each pair of treatments
are produced by “plugging in” mean covariate values from the population
of interest into equation (4.28), as described in Section 4.4. To calculate the
predicted proportion of individuals achieving PASI 75 response on treatment
k in population P, we define
h(x , µP , β1 , β2,k , γk)  Φ(µP + xT(β1 + β2,k) + γk), (6.7)
where µP is the individual-level reference effect in population P, which may
be equal to µ j if P is study j in the analysis, or may be estimated from external
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Figure 6.3 The forms of the marginal distributions for the covariates in
the FIXTURE study are assumed to match those in the UNCOVER studies.
Histograms show the observed marginal distributions in the UNCOVER
studies, which are overlaid with the assumed distribution. The assumed
marginal distributions are shown for the FIXTURE study. Body surface area is
assumed a scaled logit-Normal distribution; weight and duration of psoriasis
are assumed a Gamma distribution.
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Figure 6.4 Empirical integration error for p̄ over the entire posterior distri-
bution of the model parameters, estimated as a relative difference from the
final estimate with 10,000 integration points (at each posterior sample). The
dashed line is ±Ñ−1, showing that the integration error rate is of this order.
data on P. We then produce estimates as described in Section 4.4. To obtain
the predicted proportion achieving PASI 75 in the IPDUNCOVER populations,
(6.7) is summarised over every individual using equation (4.30). For the
FIXTURE population, the predicted proportion is produced by integrating
(6.7) over the joint covariate distribution using numerical integration as in
equation (4.29).
6.2.2Results
The resulting contrast estimates are shown in Table 6.3 and Figure 6.6. There are
small differences in the estimated average treatment effects in each population,
for example, etanercept appears slightly more effective relative to placebo in
the FIXTURE study population than in the UNCOVER study populations.
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Figure 6.5 Empirical integration error for p̄2 over the entire posterior distri-
bution of the model parameters, estimated as a relative difference from the
final estimate with 10,000 integration points (at each posterior sample). The
dashed line is ±Ñ−1, showing that the integration error rate is of this order.
Examining the estimated effect modifier interactions in Table 6.4 alongside
the covariate summaries in Table 6.1, we see that this is to be expected: the
differences in mean covariate values between study populations are small
when combined with the size of the interaction terms. Furthermore, a random
effects (RE) NMA of the studies estimates the between-study heterogeneity
standard deviation to be 0.17 (0.02, 0.46), which is moderate compared to the
size of the average treatment effects. Using MAIC, the comparison between
ixekizumab Q2W and secukinumab 300 mg in the FIXTURE population is
estimated as a SMD of 0.28 (0.00, 0.56) in favour of ixekizumab Q2W; with
ML-NMR, we estimate 0.34 (0.10, 0.58). (A standard indirect comparison
estimates 0.37 (0.12, 0.63).) The point estimates are similar between the two
population adjustment approaches, as we would expect, but ML-NMR has
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reduced uncertainty compared to MAIC due to incorporating all available
information. The RE NMA estimate for this contrast is 0.45 (−0.02, 0.92),
which assumes that any imbalance in effect modifiers is random (Section 2.1.6).
Since the differences in effect modifiers between trials are small, the possible
bias in the RE NMA estimates are likely to also be small, and indeed all of
the ML-NMR estimates are close to the corresponding RE NMA estimates
(Figure 6.6); however, ML-NMR increases the precision of the estimates by
explaining the within-trial variation due to effect modification.
Figure 6.7 and Table 6.5 show the estimated proportion of individuals
achieving PASI 75 in each population, using MAIC and ML-NMR. Again, ML-
NMR has reduced uncertainty compared to MAIC, and we are able to produce
estimates for any target population—not just the FIXTURE trial population.
Every active treatment is effective compared to placebo, with the class of
interleukin-17A blockersmore effective than anti-TNFα treatment. Ixekizumab
Q2W displays the highest estimated proportion of individuals achieving
PASI 75, with posterior mean estimates ranging from 85.9% to 90.3% across the
UNCOVER and FIXTURE studies. The 95% Credible Intervals for comparisons
of ixekizumab Q2W against every other treatment exclude zero (on the probit
SMD scale), in all study populations assessed. In a decision making context,
estimates could be produced for the decision target population with a defined
covariate distribution, which neednotmatch any of the FIXTUREorUNCOVER
studies.
The total residual deviance was 3146.26 on 3858 data points, of which the
contribution from 3854 individual data points was 3141.81, and 4.45 from
4 aggregate data points, demonstrating that the model is a good fit to both
the IPD and AgD. Standard fixed and random effects NMA models have
total residual deviance of 3216.01 and 3210.44 respectively. Comparing the
deviance information criterion (DIC) (Spiegelhalter et al. 2002) between the
different approaches, ML-NMR has a lower DIC (3170) than either fixed (3225)
or random effects (3223) NMA. Comparing the FE and RENMAmodels shows
little evidence of between-study heterogeneity, although there are only four
studies in this analysis. Despite this, the ML-NMR model achieves better fit
than both the FE and RE NMAs and is more interpretable and informative, as
both between- and within-study variation is explained rather than averaged
over.
This analysis relies upon the shared effect modifier assumption to identify
the model parameters due to the small number of trials and treatments in
the network (Figure 6.1). We also assume that there are no unobserved effect
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Table 6.3 Estimated SMD contrasts and 95% Credible Intervals for each pair
of treatments in each study population (for ML-NMR) and from a random
effects NMA. Note that the ML-NMR contrast estimates between ixekizumab
and secukinumab treatments are the same in every population due to the
shared effect modifier assumption for these treatments.
ML-NMR study population RE NMA
Contrast FIXTURE UNCOVER-1 UNCOVER-2 UNCOVER-3 Weighted overall
IXE Q2W vs. PBO 2.94 2.98 2.95 2.93 2.91
(2.74, 3.14) (2.80, 3.17) (2.77, 3.13) (2.76, 3.11) (2.64, 3.19)
IXE Q4W vs. PBO 2.65 2.69 2.66 2.64 2.61
(2.45, 2.84) (2.51, 2.89) (2.47, 2.84) (2.46, 2.82) (2.32, 2.88)
ETN vs. PBO 1.74 1.65 1.64 1.65 1.61
(1.55, 1.93) (1.47, 1.83) (1.46, 1.81) (1.47, 1.81) (1.34, 1.91)
SEC 150 vs. PBO 2.29 2.33 2.30 2.28 2.16
(2.07, 2.53) (2.10, 2.58) (2.07, 2.54) (2.05, 2.52) (1.71, 2.61)
SEC 300 vs. PBO 2.60 2.64 2.61 2.59 2.46
(2.36, 2.83) (2.40, 2.90) (2.36, 2.86) (2.35, 2.83) (2.02, 2.89)
IXE Q4W vs. IXE Q2W −0.30 −0.30 −0.30 −0.30 −0.31
(−0.42, −0.17) (−0.42, −0.17) (−0.42, −0.17) (−0.42, −0.17) (−0.57, −0.05)
ETN vs. IXE Q2W −1.20∗ −1.33 −1.31 −1.29 −1.30
(−1.35, −1.06) (−1.47, −1.19) (−1.45, −1.18) (−1.42, −1.15) (−1.58, −1.01)
SEC 150 vs. IXE Q2W −0.65 −0.65 −0.65 −0.65 −0.75
(−0.89, −0.42) (−0.89, −0.42) (−0.89, −0.42) (−0.89, −0.42) (−1.24, −0.25)
SEC 300 vs. IXE Q2W −0.34† −0.34 −0.34 −0.34 −0.45
(−0.58, −0.10) (−0.58, −0.10) (−0.58, −0.10) (−0.58, −0.10) (−0.92, 0.02)
ETN vs. IXE Q4W −0.91 −1.04 −1.02 −0.99 −0.99
(−1.05, −0.75) (−1.17, −0.90) (−1.15, −0.89) (−1.12, −0.85) (−1.27, −0.68)
SEC 150 vs. IXE Q4W −0.36 −0.36 −0.36 −0.36 −0.45
(−0.59, −0.12) (−0.59, −0.12) (−0.59, −0.12) (−0.59, −0.12) (−0.93, 0.03)
SEC 300 vs. IXE Q4W −0.05 −0.05 −0.05 −0.05 −0.14
(−0.27, 0.19) (−0.27, 0.19) (−0.27, 0.19) (−0.27, 0.19) (−0.62, 0.31)
SEC 150 vs. ETN 0.55 0.68 0.66 0.63 0.54
(0.36, 0.74) (0.48, 0.88) (0.46, 0.87) (0.43, 0.84) (0.11, 0.97)
SEC 300 vs. ETN 0.86 0.99 0.97 0.94 0.85
(0.65, 1.06) (0.77, 1.20) (0.75, 1.18) (0.72, 1.14) (0.41, 1.26)
SEC 300 vs. SEC 150 0.31 0.31 0.31 0.31 0.31
(0.11, 0.53) (0.11, 0.53) (0.11, 0.53) (0.11, 0.53) (−0.16, 0.77)
* MAIC estimate is −1.18 (−1.37, −0.99). Standard indirect comparison uses the pooled study
estimate −1.27 (−1.42, −1.12) from UNCOVER-2 and 3.
†MAIC estimate is −0.28 (−0.56, −0.00). Standard indirect comparison estimate is −0.37
(−0.63, 0.12).
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Figure 6.6 Estimated contrasts at the population level, for each pair of treat-
ments in each study population. Note that the interval for MAIC is a 95%
Confidence Interval, as MAIC is a frequentist method.
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Figure 6.7 Estimated proportion of individuals achieving PASI 75 on each
treatment, in each study population. Note that theMAIC estimate is produced
in the FIXTURE study population, and the corresponding interval is a 95%
Confidence Interval as MAIC is a frequentist method.
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Table 6.4 Estimated interactions for each treatment class and potential effect
modifier, and estimated individual-level treatment effects. All estimates are




Previous systemic use −0.00 (−0.38, 0.35) 0.12 (−0.21, 0.46)
Duration of psoriasis, per 10 years 0.14 (−0.03, 0.30) 0.17 (0.02, 0.33)
Body surface area, per 10% 0.06 (−0.05, 0.17) 0.02 (−0.09, 0.13)
Weight, per 10 kg −0.10 (−0.18, −0.02) −0.04 (−0.11, 0.04)
Psoriatic arthritis 0.01 (−0.43, 0.48) 0.25 (−0.17, 0.71)
Reference individual treatment effect
IXE Q2W 2.82 (2.56, 3.10)
IXE Q4W 2.52 (2.25, 2.80)
ETN 1.67 (1.38, 1.96)
SEC 150 2.16 (1.86, 2.49)
SEC 300 2.47 (2.17, 2.79)
modifiers so that the conditional constancy of relative effects assumption holds.
In a larger network with more data available, we can attempt to relax and







Table 6.5 Estimated proportion of individuals achieving PASI 75 on each treatment in each study population, along with 95%
Credible Intervals, for each method. The observed proportions are accompanied by 95% Confidence Intervals, calculated on the
probit scale.
Treatment
Study population Method Placebo Ixekizumab Q2W Ixekizumab Q4W Etanercept Secukinumab 150 mg Secukinumab 300 mg
FIXTURE Observed 4.94 - - 43.96 66.97 77.09
(2.85, 7.90) (38.47, 49.56) (61.59, 72.05) (72.11, 81.56)
ML-NMR 3.83 85.93∗ 78.46 46.10 66.96 77.07
(2.58, 5.38) (81.58, 89.64) (72.84, 83.27) (40.93, 51.11) (61.82, 71.72) (72.72, 81.34)
UNCOVER-1 Observed 3.94 89.15 82.64 - - -
(2.31, 6.24) (85.83, 91.91) (78.73, 86.09)
ML-NMR 4.76 88.72 82.19 46.57 71.59 80.79
(3.37, 6.47) (86.48, 90.79) (79.10, 85.11) (40.92, 52.22) (63.69, 78.78) (73.72, 86.93)
UNCOVER-2 Observed 2.41 90.00 77.46 41.74 - -
(0.66, 6.05) (86.37, 92.94) (72.68, 81.75) (36.57, 47.04)
ML-NMR 4.06 86.59 79.31 43.05 67.92 77.83
(2.80, 5.66) (84.20, 88.88) (76.35, 82.11) (39.23, 46.97) (60.01, 75.19) (70.69, 84.00)
UNCOVER-3 Observed 7.29 87.50 85.30 53.40 - -
(4.04, 11.93) (83.77, 90.64) (81.34, 88.70) (48.26, 58.49)
ML-NMR 6.23 90.33 84.41 51.69 74.52 83.13
(4.48, 8.35) (88.35, 92.20) (81.74, 86.94) (47.55, 55.94) (67.41, 80.93) (76.49, 88.31)
* MAIC estimate is 84.74 (78.54, 89.62).
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6.3Extending the network further
The ML-NMR analysis described in Section 6.2 makes full use of the data
available in theUNCOVERandFIXTURE trials (Figure 6.1). However, IPD from
an additional study IXORA-S is also available, comparing ixekizumab with
another treatment of interest, ustekinumab (UST). Furthermore, a literature
search carried out by our industry collaborators found an additional three
AgD studies which compare secukinumab doses with placebo (ERASURE,
FEATURE, and JUNCTURE) and one which compares secukinumab with





















Figure 6.8 The full plaque psoriasis treatment network. The thick and thin
lines represent availability of IPD and AgD on a comparison respectively. The
number next to each line shows the number of studiesmaking this comparison.
PBO = placebo, IXE = ixekizumab, SEC = secukinumab, ETN = etanercept,
UST = ustekinumab. IXE and SEC were each investigated with two different
dosing regimens.
6.3.1Methods
We implement the same ML-NMR model (6.5) described in Section 6.2—
a Bernoulli individual likelihood with probit link function, and the two-
parameter Binomial approximation for the aggregate likelihood. We again
use a five-dimensional Sobol’ sequence for the QMC integration over the
five covariates, except now we have a set of integration points for five AgD
populations not just one. We halve the number of integration points to 5,000
for the full network analysis, since the convergence plots Figures 6.4 and 6.5







Table 6.6 Treatment comparisons made by studies in the full plaque psoriasis
treatment network; • indicates that the study included this treatment arm.
Study Placebo Ixekizumab Q2W Ixekizumab Q4W Etanercept Secukinumab 150 mg Secukinumab 300 mg Ustekinumab
IPD studies
UNCOVER-1 • • • - - - -
UNCOVER-2 • • • • - - -
UNCOVER-3 • • • • - - -
IXORA-S - • - - - - •
AgD studies
CLEAR - - - - - • •
ERASURE • - - - • • -
FEATURE • - - - • • -
FIXTURE • - - • • • -
JUNCTURE • - - - • • -
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the entire posterior distribution. We again place a non-informative N(0, 1002)
prior distribution on each parameter. We assess convergence using R̂ for each
parameter, and check that there are no divergent transitions (see Section 5.2.5).
The larger network also presents opportunities to explore the shared EM
assumption and any residual heterogeneity or inconsistency, using the models
described in Section 4.6.1, Section 4.6.2, and Section 4.6.3 respectively.
6.3.2Results
The resulting contrast estimates are shown in Table 6.7 for each study popula-
tion. Again, the differences in estimated average treatment effects between
each study population are small since the differences in covariate distributions
between each population are small when compared with the size of the esti-
mated EM interaction terms (Table 6.8). The point estimates for each contrast
are very similar to those in the smaller network (compare with Table 6.3).
However, as we would expect, the contrasts are more precisely estimated in
this analysis which draws upon more information than before: this is most
apparent for the etanercept and secukinumab treatments, where the additional
AgD studies provide the greatest amount of additional information. The gain
in precision over the RE NMA is smaller in this analysis compared to the
smaller network. The estimate of the heterogeneity standard deviation from
the RE NMA is 0.10 (0.01, 0.26), which is both smaller and more precise than
before. Indeed, the DIC of fixed and random effects NMA are nearly identical
(3497.0 and 3497.6 respectively), so we would choose the more parsimonious
FE model based on DIC alone. Fitting an unrelated mean effects (UME) NMA
(as described in Section 1.2.7.1) gives a DIC of 3498.8 and residual deviance of
3478.6, which are not substantially different to either the FE or RE NMAs (with
residual deviance of 3482.4 and 3478.4, respectively). There is also no change
in the heterogeneity standard deviation under the UME NMA model, which
is estimated as 0.10 (0.01, 0.28). Figure 6.9 compares the residual deviance
contributions under each NMA model (FE, RE, and UME). The points lie
largely on the line of equality, indicating little difference in fit between the
models. There is some suggestion that two IPD study arms (ixekizumab Q2W
arms in UNCOVER-2 and 3) fit better under the RE NMAmodel than the FE
NMA model (lying below the line of equality in Figure 6.9a), although the
95% Credible Intervals are very wide and include the line of equality. Overall,
there is little evidence for substantial heterogeneity or inconsistency in the
NMA, yet the ML-NMR model has a much lower DIC of 3451.4 (and residual
deviance of 3415.8). The ML-NMR model allows us to explain both between
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and within study variation, resulting in better fit.
The estimated proportion of individuals achieving the PASI 75 outcome
in each study population are given in Table 6.9 and Figure 6.10. As for the
contrast estimates, the estimated proportions have changed little from the
smaller network analysis (Table 6.5), but there is an increase in precision—
particularly for the etanercept and secukinumab treatments.
As before, for decision making purposes estimates could be provided in a
decision target population with a defined covariate distribution, which need
not match any of the included studies. For absolute estimates of the proportion
of individuals achieving the PASI 75 outcome (which may be required for
economic modelling and cost-effectiveness analysis, for example), an estimate
of the reference probability of achieving PASI 75 on placebo is also required.
This could be taken from the literature, or estimated from a registry or other
study in the target population.
The model presented above again makes the shared EM assumption
between the interleukin-17A blockers secukinumab and ixekizumab. In the
smaller network (Section 6.2), this assumption was required for identifiability.
With the addition of three further AgD trials involving secukinumab, we
hoped to be able to relax this assumption, either by using the exchangeable
interactions model (see Section 4.6.1) or by fitting independent interactions.
However this proved difficult with the amount of data available. Firstly, we
attempted to fit exchangeable interactions within the class of interleukin-17A
blockers for all five effectmodifiers at once. To do this, wemodify theML-NMR
model given in (6.5) to include a hierarchical structure on the respective EM
interaction parameters. Letting T  {IXE Q2W, IXE Q4W, SEC 150, SEC 300},
we write this as
β2,k;l ∼ N
(




∀k ∈ T and l ∈ {1, . . . , 5}, (6.8)
and the other β2,k corresponding to etanercept and ustekinumab are given
independent prior distributions. Even with strong prior distributions on
the hierarchical means mβ2 ,l and standard deviations σβ2 ,l , this model was
too weakly-identified by the available data to achieve a reliable fit. We then
attempted to fit exchangeable interactions for each effect modifier in turn,
keeping the shared EM assumption for the other four effect modifiers. For
each effect modifying covariate l∗ ∈ {1, . . . , 5} in turn, we write this model as
β2,k;l∗ ∼ N
(





β2,a;l  β2,b;l ∀a , b ∈ T and l ∈ {1, . . . , 5} \ l∗ ,
(6.9)
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and the other β2,k corresponding to etanercept and ustekinumab again given
independent prior distributions. Thesemodels were also tooweakly-identified.
There was also not enough data to fit a model with independent EM inter-
actions for all treatments (every β2,k;l given an independent prior), or to fit
models where the EM interactions are only shared between the two doses of
secukinumab (i.e. with T  {SEC 150, SEC 300} in (6.8)).
Whilst there were insufficient data to explicitly relax the shared EM
assumption using themodels described above (see Section 4.6.1 for a discussion
of these models and their data requirements), there are enough data to assess
whether there is residual heterogeneity with a random effects model (see
Section 4.6.2). If residual heterogeneity is present, this could either be due to
unobserved EMs or an inappropriate shared EM assumption (see Section 4.6.2).
Thus we can still assess the shared EM assumption in this network, even
though we cannot explicitly relax it. We also fit an unrelated mean effects
ML-NMR model, as described in Section 4.6.3.1, to check for inconsistency.
There are insufficient data to fully relax consistency of the EM interactions (i.e.
with no shared EM assumption), so we keep the shared EM assumption for the
class of interleukin-17A blockers and instead check inconsistency of the EM
interactions at the treatment class level. The results of the RE ML-NMRmodel
are very similar to the standard fixed effect (FE) model. The posterior median
of the heterogeneity standard deviation is estimated as 0.09 (0.01, 0.25), which
is small compared to the magnitude of the relative effects (Table 6.8). This
is only slightly smaller than the heterogeneity estimate from the RE NMA,
suggesting that the improved fit of ML-NMR is largely due to explaining
within-study variation rather than any between-study heterogeneity. Indeed,
the DIC of the RE ML-NMR model is 3449.2 (residual deviance 3412.2), which
does not suggest any substantial improvement over the FE model with DIC
3451.4 (residual deviance 3415.8). The UME ML-NMR model has DIC 3448.8
and residual deviance 3410.7, which again does not suggest any substantial
improvement over either the FE or RE ML-NMR models with consistency
(Table 6.10). The estimated heterogeneity standard deviation is also unchanged
between the REML-NMR and UMEML-NMR. Table 6.10 shows that the slight
reductions in residual deviance against the FEML-NMRmodel (to be expected,
since the RE and UME models are more flexible) are balanced against the
increased number of effective parameters (the FE consistency model is more
parsimonious). When examining Figure 6.9 which compares the residual
deviance contributions under each ML-NMR model (FE, RE, and UME), we
see that the points lie on the line of equality, indicating little difference in fit
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between themodels. There is some suggestion that one AgD point (the placebo
arm of the FIXTURE trial) fits better under the RE ML-NMR model than the
FEML-NMRmodel (lying below the line of equality in Figure 6.11a), although
the 95% Credible Intervals are very wide and include the line of equality.
Overall, there is therefore little evidence for substantial residual heterogeneity,
and no evidence for inconsistency in this analysis: we have not detected any
failings in either the conditional constancy of relative effects assumption, the
shared effect modifier assumption, or the consistency assumption.
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Table 6.7 Estimated basic SMD contrasts and 95% Credible Intervals for each treatment compared to placebo, plus the comparison
targeted by the previous MAIC, in each study population using the ML-NMR model and for the RE NMA.
ML-NMR study population RE NMA
Contrast CLEAR ERASURE FEATURE FIXTURE IXORA JUNCTURE UNCOVER-1 UNCOVER-2 UNCOVER-3 Weighted overall
IXE Q2W vs. PBO 2.96 2.96 2.97 2.94 2.97 2.99 2.99 2.96 2.94 2.92
(2.78, 3.15) (2.78, 3.14) (2.79, 3.16) (2.75, 3.14) (2.77, 3.19) (2.80, 3.17) (2.81, 3.18) (2.79, 3.14) (2.77, 3.12) (2.71, 3.13)
IXE Q4W vs. PBO 2.67 2.67 2.68 2.65 2.69 2.70 2.71 2.67 2.65 2.62
(2.50, 2.85) (2.50, 2.84) (2.52, 2.87) (2.48, 2.84) (2.49, 2.90) (2.53, 2.88) (2.53, 2.89) (2.51, 2.84) (2.49, 2.82) (2.42, 2.83)
ETN vs. PBO 1.74 1.72 1.72 1.77 1.72 1.70 1.69 1.67 1.68 1.65
(1.58, 1.90) (1.56, 1.88) (1.55, 1.89) (1.60, 1.95) (1.52, 1.93) (1.53, 1.88) (1.51, 1.87) (1.50, 1.84) (1.52, 1.84) (1.46, 1.85)
SEC 150 vs. PBO 2.38 2.37 2.39 2.36 2.39 2.40 2.41 2.38 2.36 2.28
(2.19, 2.58) (2.19, 2.57) (2.19, 2.60) (2.16, 2.55) (2.17, 2.62) (2.20, 2.61) (2.21, 2.62) (2.18, 2.58) (2.17, 2.55) (2.06, 2.54)
SEC 300 vs. PBO 2.71 2.71 2.72 2.69 2.72 2.73 2.74 2.71 2.69 2.61
(2.53, 2.90) (2.52, 2.90) (2.53, 2.93) (2.50, 2.88) (2.51, 2.95) (2.54, 2.95) (2.55, 2.95) (2.52, 2.91) (2.51, 2.89) (2.39, 2.86)
UST vs. PBO 2.26 2.27 2.27 2.26 2.23 2.30 2.28 2.27 2.26 2.12
(1.98, 2.58) (1.97, 2.60) (1.98, 2.59) (1.96, 2.59) (1.92, 2.54) (1.95, 2.71) (1.98, 2.60) (1.96, 2.62) (1.94, 2.64) (1.80, 2.46)
SEC 300 vs. IXE Q2W −0.25 −0.25 −0.25 −0.25∗ −0.25 −0.25 −0.25 −0.25 −0.25 −0.31
(−0.45, −0.06) (−0.45, −0.06) (−0.45, −0.06) (−0.45, −0.06) (−0.45, −0.06) (−0.45, −0.06) (−0.45, −0.06) (−0.45, −0.06) (−0.45, −0.06) (−0.55, −0.04)






Table 6.8 Estimated interactions for each treatment class and potential effect modifier, and estimated individual-level treatment
effects, for the ML-NMR model in the full network. All estimates are standardised mean differences versus placebo, with 95%
Credible Intervals.
Treatment class
Anti-TNFα IL-12 and IL-23 blocker IL-17A blocker
Effect modifier interaction
Previous systemic use 0.00 (−0.39, 0.39) −0.11 (−1.17, 0.81) 0.11 (−0.25, 0.47)
Duration of psoriasis, per 10 years 0.14 (−0.01, 0.31) 0.15 (−0.08, 0.37) 0.18 (0.03, 0.33)
Body surface area, per 10% 0.06 (−0.05, 0.17) 0.01 (−0.14, 0.18) 0.02 (−0.08, 0.13)
Weight, per 10 kg −0.10 (−0.18, −0.02) −0.04 (−0.16, 0.08) −0.03 (−0.10, 0.05)
Psoriatic arthritis −0.01 (−0.46, 0.49) 0.21 (−0.53, 0.98) 0.26 (−0.15, 0.71)
Reference individual treatment effect
IXE Q2W 2.83 (2.56, 3.14)
IXE Q4W 2.54 (2.26, 2.84)
ETN 1.71 (1.43, 2.00)
SEC 150 2.25 (1.97, 2.55)
SEC 300 2.58 (2.31, 2.88)
UST 2.29 (1.55, 3.19)
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(a)
(b)
Figure 6.9 Residual deviance contributions (posterior mean and 95%Credible
Interval) under (a) RE vs. FE NMAmodels, and (b) UME vs. RE NMAmodels.
193
6. PLAQUE PSORIASIS EXAMPLE
Figure 6.10 Estimated proportion of individuals achieving PASI 75 on each








Table 6.9 Estimated proportion of individuals achieving PASI 75 on each treatment in each study population, along with 95%
Credible Intervals, using ML-NMR.
Treatment
Study population Placebo Ixekizumab Q2W Ixekizumab Q4W Etanercept Secukinumab 150 mg Secukinumab 300 mg Ustekinumab
CLEAR 9.42 93.92 89.71 63.30 83.62 90.45 79.52
(5.96, 13.72) (90.71, 96.46) (84.89, 93.63) (55.04, 71.32) (77.95, 88.56) (87.24, 93.23) (75.05, 83.53)
ERASURE 4.37 87.31 80.46 47.32 71.65 81.55 66.88
(2.98, 6.05) (82.64, 91.16) (74.41, 85.61) (40.47, 53.88) (67.17, 76.11) (77.70, 85.02) (57.20, 75.69)
FEATURE 2.87 82.80 74.71 39.70 64.82 75.95 59.57
(1.42, 4.95) (74.95, 89.25) (65.12, 83.02) (30.19, 49.77) (56.10, 73.38) (68.34, 82.95) (47.10, 71.04)
FIXTURE 3.42 84.67∗ 76.99 45.20 67.37 78.15 62.98
(2.35, 4.70) (80.58, 88.40) (71.89, 81.81) (40.67, 49.89) (63.24, 71.33) (74.54, 81.56) (53.46, 71.71)
IXORA 5.30 89.53 83.43 51.16 75.30 84.35 69.40
(2.73, 8.92) (84.64, 93.51) (76.36, 89.35) (41.22, 61.62) (66.18, 83.33) (77.74, 90.02) (62.64, 75.99)
JUNCTURE 4.84 88.40 81.98 48.19 73.61 83.01 69.01
(2.59, 7.91) (82.07, 93.28) (74.01, 88.60) (38.09, 58.59) (65.54, 80.81) (76.26, 88.61) (55.82, 80.42)
UNCOVER-1 4.67 88.73 82.35 47.36 73.83 83.23 68.29
(3.37, 6.19) (86.39, 90.92) (79.47, 85.11) (41.92, 52.84) (67.06, 79.93) (78.05, 87.84) (58.93, 77.15)
UNCOVER-2 3.91 86.39 79.21 43.48 69.96 80.20 65.04
(2.72, 5.29) (83.68, 88.93) (76.07, 82.21) (39.63, 47.36) (63.52, 76.08) (74.68, 85.08) (54.54, 74.95)
UNCOVER-3 6.01 90.19 84.34 52.15 76.36 85.16 72.05
(4.38, 7.89) (88.12, 92.12) (81.57, 86.96) (48.08, 56.13) (70.42, 81.91) (80.51, 89.13) (61.81, 81.05)






PLETable6.10 Model fit statistics for the RE andUMEML-NMRmodels compared
with the standard FE model. pD is a measure of the effective number of
parameters. We also present estimates and 95% Credible Intervals for the
heterogeneity standard deviation τ, for the RE and UME models.
NMA ML-NMR
FE RE UME FE RE UME
Residual deviance 3482.4 3478.4 3478.6 3415.8 3412.2 3410.7
pD 14.6 19.3 20.2 35.6 37.1 38.0
DIC 3497.0 3497.6 3498.8 3451.4 3449.2 3448.8
τ - 0.10 (0.01, 0.26) 0.10 (0.01, 0.28) - 0.09 (0.01, 0.25) 0.09 (0.00, 0.27)
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(a)
(b)
Figure6.11 Residual deviance contributions (posteriormean and 95%Credible
Interval) under (a) RE vs. FE ML-NMRmodels, and (b) UME vs. RE ML-NMR
models.
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6.4 Discussion
In this chapter, we began by comparing a targeted comparison performed using
ML-NMR to a previousMAIC analysis. We then used the full ML-NMRmodel
to incorporate information from all the available treatment arms and studies
in the network formed by the UNCOVER and FIXTURE studies. Using all the
available information in the analysis resulted in more precise estimates than
the MAIC and targeted comparison, and the ML-NMR model out-performed
standard fixed and random effects NMA (in terms of DIC) as between- and
within-study heterogeneity was explained rather than averaged over. Finally,
we extended the network further, and attempted to assess the shared EM
and conditional constancy of relative effects assumptions. Whilst the random
effects ML-NMRmodels found no evidence of either assumption being broken,
we could not fit exchangeable EM interaction models to assess or relax the
shared EM assumption explicitly. ML-NMR models with exchangeable EM
interactions are likely to be data-intensive, and without informative prior
distributions for the hierarchical variance components they may be just as
data-intensive as a fully independent EM interaction model. Future work
could use simulation studies to determine the data requirements for such
models.
All of the studies in the extended network reported (at least) three PASI
endpoints: 75, 90, and 100% improvement from baseline. We focused on the
PASI 75 outcome in this chapter for computational reasons, since the small
numbers of observed events on the more demanding PASI 90 and PASI 100
outcomes posed difficulties for estimation. However, the higher PASI outcomes
are also of interest for decision-making: from a patient perspective the higher
outcomes are more desirable, and the different outcomes are likely to have
different utilities in a cost-effectiveness analysis for a reimbursement decision.
This motivates consideration of a joint model, where all PASI outcomes are
simultaneously modelled, aiming to alleviate the issues with estimating the
higher PASI outcomes separately. In the following chapter we extend the ML-
NMR framework to handle general likelihoods, and subsequently fit a model
to all three PASI outcomes simultaneously using a multinomial likelihood.
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Chapter 7
Extension to general likelihoods
Previously in Chapter 4, we presented the general ML-NMRmodel in equation
(4.34). Importantly, derivation of the aggregate-level model is split into two
steps: i) deriving the aggregate likelihood from the individual likelihood, and
ii) integrating the individual-level model over the covariate distribution in the
aggregate population to form the aggregate-level model. As we described in
Section 4.3.3.1, the integration step can be performed numerically using Quasi
Monte Carlo (QMC) integration, regardless of the number or distribution
of covariates, or the form of the link function. However, derivation of the
aggregate likelihood is not always straightforward (Section 4.2), and may
even be intractable. Most notably this is the case for the analysis of survival
outcomes—which represent the large majority of applications of population
adjustment methodology to date (Chapter 3)—where the aggregate likelihood
cannot be derived analytically. This is also the case for the plaque psoriasis
example in the previous chapter (Chapter 6) if we wish to jointly analyse
the ordered categorical outcomes (PASI 75, 90, and 100 cutpoints), and the
appropriate likelihood for the aggregate summary outcomes is not readily
apparent.
In this chapter, we begin by setting out the ML-NMR framework in a more
general form, based directly on the likelihood contributions from different
sources of data (Section 7.1). Likelihood contributions may be either individual
or aggregate, depending on whether they refer to an individual in a study or
an aggregate summary, respectively. Individual likelihood contributions may
also be either conditional or marginal, depending on whether they depend on
given covariate values or are averaged over the covariate distribution in a
population, respectively. When we specify an individual-level model (with
a likelihood, link function, and linear predictor), we are also specifying an
199
7. EXTENSION TO GENERAL LIKELIHOODS
individual conditional likelihood function. We can directly integrate the
individual conditional likelihood function over the joint covariate distribution
in a study to obtain an individual marginal likelihood function, describing the
likelihood where individual outcomes are known but individual covariates
are not. For example, this is the case when analysing survival outcomes
using time-to-event data reconstructed from published Kaplan-Meier curves
but with only published summary covariate information at baseline. Using
this approach, we describe the application of ML-NMR to censored survival
outcomes with general survival and hazard functions in Section 7.1.1. We can
perform the necessary integration numerically using the same approaches
described in Section 4.3.3 (here, we use QMC integration). We also consider
obtaining an aggregate marginal likelihood function by multiplying together
the individual marginal likelihood functions, which gives simple results when
outcomes are discrete. We apply this approach to obtain analytic results
for binary outcomes (which we compare with Section 4.2.1) and ordered
categorical outcomes in Sections 7.1.2 and 7.1.3, respectively. In Section 7.2, we
then consider the issue of model comparison under the generalised framework,
where the lack of an explicit aggregate likelihood complicates evaluation of
the usual quantities of interest (e.g. residual deviance, DIC). Finally we apply
these ideas to two examples, one of simulated survival data (Section 7.3) and
the other continuing with the plaque psoriasis example from Chapter 6 to
jointly model the outcomes (Section 7.4).
7.1 Deriving the aggregate likelihood using integration
We begin with the same individual-level model as before in equations (4.34a)
and (4.34b):
yi jk ∼ πInd(θi jk)
g(θi jk)  η jk(xi jk)  µ j + xTi jk(β1 + β2,k) + γk
with IPD outcomes yi jk for individuals i in study j receiving treatment k
given the likelihood distribution πInd(θi jk). The link function g(·) links the
conditionalmean outcomes θi jk to the linear predictor η jk(xi jk), with covariates
xi jk . The parameters µ j are study-specific intercepts, β1 and β2,k are regression
coefficients for prognostic and effect modifying covariates respectively, and γk
are individual-level treatment effects. We set β2,1  γ1  0 for the reference
treatment 1.
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Rather than proceeding to determine the appropriate aggregate likelihood
(for example using known statistical properties, such as the Normality of the
sum of Normally distributed outcomes), and then using numerical integration
to evaluate the marginal mean outcome in each aggregate population, we
instead consider the likelihood contributions from each level of the model. Let
ξ denote the set of all model parameters {µ j , β1 , β2,k , γk : ∀ j, k}, and denote
the individual conditional likelihood contributions (conditional on the covari-
ates) by Li jk |x(ξ; yi jk , xi jk). The form of the individual conditional likelihood
function follows from the chosen individual-level model, in particular the
individual-level likelihood πInd(·), link function g(·), and linear predictor η jk(·).
(To be strictly precise, we refer to the likelihood contribution as the value of the
likelihood function evaluated at a given ξ, yi jk , and xi jk .) We then integrate
the individual conditional likelihood function over the covariate distribution
f jk(·) on treatment k in study j to obtain the individual marginal likelihood
contributions
Li jk(ξ; yi jk) 
∫
X
Li jk |x(ξ; yi jk , x) f jk(x) dx , (7.1)
which no longer depend on x. In other words, for an individual on treatment
k in study j with outcome yi jk , if we do not know their individual covariate
vector xi jk but only the distribution f jk(·), their likelihood contribution is
given by (7.1). This integration may be performed using the QMC numerical
integration technique described previously (Section 4.3.3.2), or by hand if
analytically tractable. If we have summary outcomes y• jk on a given treatment
k in study j, we can attempt to derive a corresponding aggregate marginal
likelihood contribution as the product of the individual marginal likelihood
contributions (7.1), up to a normalising constant:
L• jk(ξ; y• jk) ∝
N jk∏
i1
Li jk(ξ; yi jk). (7.2)
If the result can be rearranged in terms of y• jk , we can then use L• jk(ξ; y• jk) to
evaluate the aggregate marginal likelihood contributions. This is straightfor-
ward when outcomes are discrete (as we see in Sections 7.1.2 and 7.1.3), but
may not be in general.
By working directly with the likelihood contributions from each level of
the model, we avoid having to explicitly derive the form of the aggregate
likelihood. The full ML-NMR model for general likelihoods may be written
using (7.1) and (7.2) as
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Individual:
Li jk |x(ξ; yi jk , xi jk)  πInd(yi jk |θi jk) (7.3a)
g(θi jk)  η jk(xi jk)  µ j + xTi jk(β1 + β2,k) + γk (7.3b)
Aggregate:
Li jk(ξ; yi jk) 
∫
X
Li jk |x(ξ; yi jk , x) f jk(x) dx (7.3c)
L• jk(ξ; y• jk) ∝
N jk∏
i1
Li jk(ξ; yi jk) (7.3d)
where in a Bayesian analysis, prior distributions are placed over each of
the parameters µ j , β1, β2,k , γk . Once the ML-NMR model has been fitted,
estimates may be produced for a specific target population following exactly
the approach in Section 4.4.
Computationally, we can fit these models in WinBUGS/OpenBUGS/JAGS
using the “zeros trick” to provide the correct (log) likelihood contributions via
a Poisson distribution with dummy zero observations (see Lunn et al. 2010,
Section 9.5.1, for further information). In Stan, we can directly code the (log)
likelihood contributions using a target += statement.
To clarify ideas, let us apply these ideas to derive ML-NMR models for
three examples.
7.1.1 Survival outcome data
The large majority of applications of population adjustment methodology to
date have been for survival analysis (Chapter 3). We are therefore interested
in extending the ML-NMR framework to handle time-to-event outcomes such
as survival, as this will greatly increase the applicability of the method.
We consider a scenario where every study provides outcome times ti jk for
each individual i in study j receiving treatment k, along with an indicator yi jk
of whether ti jk is an event (yi jk  1) or censoring (yi jk  0) time. For the AgD
studies, this data could be obtained by digitising published Kaplan-Meier
curves and reconstructing the event and censoring times using an algorithm
such as that described by Guyot et al. (2012). Individual covariate information
xi jk is available for every individual in the IPD studies, but for the AgD
studies only the joint distribution of the covariates at baseline f jk(·) is available.
Indeed, it is likely that only marginal covariate summaries are available from
the AgD studies, but we can reconstruct the full joint distribution under the
assumption that the form of the marginal covariate distributions and the
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pairwise correlations are the same as those observed in the IPD studies (see
Section 4.5.1).
In general, the individual-level conditional likelihood is defined by two
quantities: a survival function giving the probability of surviving to time t on
treatment k in study j given covariates x:
S jk(t |x)  (T ≥ t |x , j, k), (7.4)
and a hazard function describing the instantaneous hazard rate at time t:
λ jk(t |x)  lim
dt→0
(t ≤ T < t + dt |T ≥ t , x , j, k)
dt
. (7.5)
The individual conditional likelihood contributions from each time ti jk in the
IPD are given by
Li jk |x(ξ; ti jk , yi jk , xi jk)  S jk(ti jk |xi jk)λ jk(ti jk |xi jk)yi jk , (7.6)
so that both observed and censored events get a contribution for surviving
up until time ti jk , but only observed events get the additional contribution
from the instantaneous hazard rate at time ti jk . The forms of the survival and
hazard functions depend on the specific model chosen, but the framework
described here may be applied in any case, as long as both the survival and
hazard functions are specified. This includes parametric proportional hazards
models (Exponential, Weibull, Gompertz, etc.) (see Cox 1984, Chapter 2;
Collett 2003, Chapter 5), parametric accelerated failure time models (Weibull,
log-Logistic, Gamma, log-Normal, etc.) (see Collett 2003, Chapter 6), and
flexible parametric baseline hazard models (using splines as in the Royston-
Parmar model (Freeman and Carpenter 2017; Royston and Parmar 2002), or
fractional polynomials (Jansen 2011), etc.). Table 7.1 gives the survival and
hazard functions for some of these commonly-used survival models.
Using equation (7.1), the individual marginal likelihood contributions are
Li jk(ξ; ti jk , yi jk) 
∫
X




S jk(ti jk |x)λ jk(ti jk |x)yi jk f jk(x) dx. (7.8)
Since we have the (reconstructed) outcome times for each individual in the
AgD studies, we use the individual marginal likelihood contributions directly
(rather than taking their product to obtain the aggregate likelihood contribution
for a single summary outcome). Unlike the previous examples, this integral
cannot be simplified analytically; instead, we employ the QMC integration
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Table 7.1 Survival and hazard functions for some commonparametric survival
models.
Survival model Parameters Survival and hazard functions
Proportional hazards




Weibull Hazard rate θjk , modelled with
exp(η jk(x)); shape ν j
S(t)  exp(−θtν)
λ(t)  νθtν−1
Gompertz Hazard rate θjk , modelled with







λ(t)  θ exp(tν)
Accelerated failure time
Weibull Acceleration factor θjk , modelled
with exp(−η jk(x)); shape ν j
S(t)  exp(−θν tν)
λ(t)  νθν tν−1
log-Normal Acceleration factor θjk , modelled
with exp(−η jk(x)); variance σ2j ;
denote the Normal probability
density function φ(·) and cumu-
lative density function Φ(·)
















log-Logistic Acceleration factor θjk , modelled






Royston-Parmar (splines) Spline function ζ j(log(t)), with
derivative dζ j(log(t)) with re-
spect to log(t); hazard rate θjk
modelled with exp(η jk(x)))
S(t)  exp(− exp(ζ(log(t)))θ)
λ(t)  dζ(log(t)) exp(ζ(log(t)))θ
approach detailed in Section 4.3.3.2 to evaluate the integral. With a set of Ñ
integration points x̃ jk drawn from f jk(·), the individual marginal likelihood
contributions are evaluated as
Li jk(ξ; ti jk , yi jk)  Ñ−1
∑̃
x
S jk(ti jk |x̃)λ jk(ti jk |x̃)yi jk (7.9)
We apply this model later in Section 7.3 to an example of simulated survival
outcomes.
7.1.2 Binary outcome data
Suppose that we have binary outcomes yi jk ∼ Bern(pi jk). In this case, the
individual conditional likelihood contributions are
Li jk |x(ξ; yi jk , xi jk)  p
yi jk
i jk (1 − pi jk)
(1−yi jk ) ,
where the individual event probabilities pi jk are modelled using θi jk 
g−1(η jk(xi jk)) with a suitable link function g(·) (e.g. a logit or probit link
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function). Using equation (7.1), the individual marginal likelihood contribu-
tions are
Li jk(ξ; yi jk) 
∫
X






1 − g−1(η jk(x))
) (1−yi jk ) f jk(x) dx
 p̄
yi jk
jk (1 − p̄ jk)
(1−yi jk )
where p̄ jk 
∫
X
g−1(η jk(x)) f jk(x) dx is the mean event probability on treatment
k in study j (as in Sections 4.3.2.3 and 4.3.2.4), since yi jk ∈ {0, 1}. The aggregate
likelihood contribution for y• jk events out of N jk individuals on treatment k in
study j is then proportional to the product of y• jk many Li jk(ξ; 1) terms and
N jk − y• jk many Li jk(ξ; 0) terms:
L• jk(ξ; y• jk) ∝ Li jk(ξ; 1)y• jk Li jk(ξ; 0)(N jk−y• jk )
 p̄
y• jk
jk (1 − p̄ jk)
(N jk−y• jk )
which we recognise as a Bin(N jk , p̄ jk) likelihood. In other words, we recover
the one-parameter Binomial likelihood described in Section 4.2.1.
In Section 4.2.1, we improved upon the one-parameter Binomial likelihood
with a two-parameter Binomial likelihood in which both p̄ jk and N jk were
adjusted, aiming to obtain a likelihood closer to the “true” Poisson Binomial
aggregate likelihood. The Poisson Binomial likelihood describes the total
number of events given a vector of individual probabilities, where the exact
individuals experiencing an event are unknown; however, we cannot use
this likelihood directly as the parameter vector is not identifiable given the
aggregate data. Instead, the one-parameter Binomial likelihood assigns the
same event probability p̄ jk to each individual on treament k in study j; however,
this is not the most efficient model since we know that the individual event
probabilities differ. The two-parameter Binomial likelihood acknowledges this,
and as a result has a smaller variance (matching that of the Poisson Binomial).
Given full IPD, the individual-level Bernoulli likelihood would additionally
make use of the information on preciselywhich individuals experienced events.
Intuitively then, the two-parameter Binomial likelihood lies in between the
one-parameter Binomial likelihood and the full IPD individual-level Bernoulli
likelihood in terms of efficiency. The marginal likelihood approach is not
“wrong” here, it is just not the most efficient. In this case, we can improve
on the one-parameter Binomial likelihood obtained through the marginal
likelihood approach since we know the “true” form of the aggregate likelihood,
although in practice we find that this makes little difference to the results.
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However, this will not be possible in general, as we cannot always derive (or
even approximate) the appropriate likelihood distribution for the aggregate
data.
7.1.3 Ordered categorical outcome data
In the plaque psoriasis example introduced in Chapter 6, the outcomes of
interest are success/failure to achieve 75%, 90%, and 100% improvement in
PASI score from baseline, denoted PASI 75, 90, and 100 respectively. These
are ordered categorical outcomes, where obtaining an outcome (e.g. PASI 90)
necessarily means that the preceding outcomes have also been obtained
(e.g. PASI 75). Synthesis of such outcomes using aggregate data NMA
has been described previously (Dias et al. 2011c; Woolacott et al. 2006),
using a multinomial likelihood with ordered latent cutoffs on the underlying
transformed scale (e.g. with a probit link function).
In general, let us consider outcomes yi jk ∈ {1, . . . ,M} in M ordered
categories. At the individual level, these have a categorical likelihood
Li jk |x(ξ; yi jk , xi jk) 

pi jk;1 if yi jk  1
...
...




pi jk ,m  1 ∀i , j, k
(7.10)
The individual category probabilities pi jk;m are modelled by
pi jk ,m  g−1(η jk(xi jk) − cm−1) − g−1(η jk(xi jk) − cm), (7.11)
with a suitable link function g(·), such as a probit or logit link function. The
latent cutpoints cm are subject to the ordering constraints
c0 < c1 < · · · < cM−1 < cM ,
with c0  −∞ and cM  +∞ so that
pi jk ,1  1 − g−1(η jk(xi jk) − c1)
pi jk ,M  g−1(η jk(xi jk) − cM−1)
We further set c1  0, since c1 is equivalent to a global intercept and cannot
be identified at the same time as the study-specific intercepts µ j . This model
reduces to that for binary data with a Bernoulli likelihood when M  2. As
such, we proceed with the derivations in a very similar manner to before
(Section 7.1.2).
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Using equation (7.1), the individual marginal likelihood contributions are
Li jk(ξ; yi jk) 
∫
X





g−1(η jk(x) − cm−1) − g−1(η jk(x) − cm)
)
f jk(x) dx if yi jk  m


p̄ jk ,1 if yi jk  1
...
...
p̄ jk ,M if yi jk  M
where




g−1(η jk(x) − cm−1) − g−1(η jk(x) − cm)
)
f jk(x) dx (7.12)
is the mean event probability for outcome m on treatment k in study j.
The aggregate data are now vectors of (mutually exclusive) outcome
counts y• jk  (y• jk ,1 , . . . , y• jk ,M)T, where
∑M
m1 y• jk ,m  N jk . The model is
parameterised so that the count data are mutually exclusive: individuals are
each assigned to one of M mutually exclusive intervals defined by the M
categories (so for example, an individual achieving the PASI 90 outcome is
only counted in the PASI 90 category, and not counted for PASI 75 also). The
aggregate likelihood contributions from each y• jk are thus proportional to the
product of y• jk ,1 many Li jk(ξ; 1) terms, y• jk ,2 many Li jk(ξ; 2) terms, and so on,
up to y• jk ,M many Li jk(ξ; M) terms:
L• jk(ξ; y• jk) ∝
M∏
m1








where proportionality is up to a normalising constant. We recognise this as a
multinomial distributionMulti(p̄ jk ,1 , . . . , p̄ jk ,M), with average event probability
p̄ jk ,m in each category m. Notice that the characterisation as a multinomial
distribution is well-defined, since we have for each j and k that
M∑
m1
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1 · f jk(x) dx
 1.
Fitting the aggregate part of the model using the aggregate marginal
likelihood contributions in (7.13) requires the calculation of the average event
probabilities p̄ jk ,m at every iteration. In practice, we perform the necessary
integration in equation (7.12) numerically (Section 4.3.3), which carries a
non-trivial computational cost. To reduce the computational cost, we can
avoid unnecessary repeated calculations by rewriting (7.12) as










g−1(η jk(x) − cm−1) f jk(x) dx −
∫
X
g−1(η jk(x) − cm) f jk(x) dx
 q̄ jk ,m−1 − q̄ jk ,m ,
where
q̄ jk ,m 
∫
X
g−1(η jk(x) − cm) f jk(x) dx , (7.14)
with q̄ jk ,0  1 and q̄ jk ,M  0. We compute each q̄ jk ,m only once, and re-use the
necessary values when calculating p̄ jk ,m . Further cost savings can be made by
computing η jk(x) only once, and using the stored value in the calculation of
each q̄ jk ,m .
We apply this model later in Section 7.4 to the plaque psoriasis example.
7.2 Model comparison
There are three broad scenarios in the general framework given by equation
(7.3) depending on how the aggregate likelihood is evaluated, which each
entail different approaches to model comparison:
1. The integrand in (7.3c) may be simplified, so that the aggregate-level
likelihood is available in closed form (as in (4.34));
2. There is no closed-form aggregate likelihood and individual-level out-
comes are available, so the aggregate-level model is fitted using the
individual marginal likelihood contributions Li jk(ξ , yi jk);
3. There is no closed-form aggregate likelihood and only aggregate-level
outcomes are available, so the aggregate-level model is fitted using the
aggregate marginal likelihood contributions L• jk(ξ , y• jk).
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(In all scenarios, there is only aggregate covariate information available from
the AgD studies.) Scenario 1 is exactly that discussed in Chapter 4; the form of
the aggregate likelihood is known and we can calculate the residual deviance
Dres and the effective number of parameters pD , and hence the DIC, for model
comparison purposes (see Section 5.3).
For scenarios 2 and 3 the aggregate likelihood has no closed form, which
complicates calculation of the DIC. Instead, we propose to use approximate
leave-one-out (LOO) cross validation for model comparison.
Cross validation is a widely-used method for assessing the predictive
ability of regression models (Picard and Cook 1984). Performance in a future
data set is approximated by repeatedly re-fitting the model in question to
the sample data set, each time leaving out a different “hold-out” point (a
single point for LOO cross validation, or a partition of points for k-fold cross
validation) against which the predictive performance is evaluated. A general
measure of predictive performance for a given data point is the log predictive
density, which is equal to the expectation of the log likelihood of the data point
over the posterior distribution of the model parameters (Gelman et al. 2013b).
Cross validation then provides an approximation to the expected log predictive
density (ELPD) in a new data set. The ELPD is a measure of the expected
predictive performance of the model, and given a set of candidate models
we would choose the model with the greatest ELPD. Vehtari et al. (2016) also
define a LOO information criterion (LOOIC) as −2 ·ELPD, transforming ELPD
onto the deviance scale to be used in an analogous manner to DIC (i.e. lower
values are better). The DIC (Section 1.2.6) can also be seen as an approximation
to the ELPD, up to the scaling by −2, where plug-in posterior values are used
for the log predictive density rather than an expectation over the full posterior
distribution (see Gelman et al. 2013b).
Exact LOO cross validation is computationally expensive: for each data
point in turn, the model must be re-fit without that data point, and the log
predictive density of the hold-out point evaluated. Instead, it is possible
to estimate the ELPD using an importance sampling approach, where the
posterior samples of the log predictive density (i.e. the log likelihood for each
data point at each posterior sample of the model parameters) are weighted to
approximate the LOO cross validation ELPD (Gelfand et al. 1992). However,
the importance weights are often very unstable. Vehtari et al. (2016) propose
an improved approximate LOO approach, called Pareto-smoothed importance
sampling LOO (PSIS-LOO), where the importance weights are stabilised
(smoothed) by fitting a Pareto distribution to the upper tail of the distribution
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of importance weights. The R package loo implements PSIS-LOO, and
provides diagnostics for determining the adequacy of the PSIS approximation.
Vehtari et al. (2016) also describe how to calculate an estimate pLOO of the
effective number of parameters, and standard errors for ELPD, LOOIC, and
pLOO. Standard errors facilitate the judgement of substantial differences in
these quantities when comparing models. By comparison, when using DIC
the common approach is to compare differences with a χ2 distribution, which
is theoretically justified for Normal linear models or asymptotically but may
not always be appropriate in practice (Lunn et al. 2010, pp. 165–167; Dias et al.
2018, p. 69). Importantly, PSIS-LOO does not require the model to be re-run,
and the required inputs are simply the posterior samples of the log likelihood
contribution for each data point.
Survival analysis, as discussed in Section 7.1.1, falls under scenario 2:
there is no closed-form aggregate likelihood, and it is assumed that we
have event/censoring times for every individual (e.g. reconstructed from
Kaplan-Meier curves). In this scenario in general, to calculate the ELPD using
PSIS-LOO we use the posterior samples of the individual conditional log
likelihood contributions log Li jk |x(ξ; yi jk , xi jk) for the individuals in the IPD
studies (equation (7.3a)), and the posterior samples of the individual marginal
log likelihood contributions log Li jk(ξ; yi jk) for the individuals in the AgD
studies (equation (7.3c)).
In scenario 3, we have only aggregate outcomes in theAgD trials. This poses
problems for model comparison with PSIS-LOO, as the PSIS approximation
breaks down for highly influential data points. If we only have a small
number of AgD studies on a given treatment k, then each of these is influential
in the estimation of the the treatment effect γk (the remaining regression
coefficients for the prognostic and effect modifying variables will be almost
entirely informed by the IPD). In the extreme case there is only a single AgD
study informing a given treatment k, and LOO cross validation for this data
point is undefined—there is no way to predict this data point from the other
studies.
To avoid these issues, we must modify the PSIS-LOO approach described
above. The simplest option is to perform model comparison based on the
IPD only, ignoring the AgD studies. This may be a justifiable strategy when
the number of AgD studies is small, given that the AgD will be contributing
very little to the estimation of the regression model. With only a single AgD
study informing a treatment k, the model is essentially saturated for that
treatment—the treatment k arm informs exactly one parameter, γk , which
210
7.3. EXAMPLE: SURVIVAL ANALYSIS
provides perfect fit to that data point regardless of the model—and this AgD
study arm can be ignored for the purpose of model comparison. A more
rigorous solution, at the expense of increased computational effort, is to use
the approach referred to by Vehtari et al. (2016) as “PSIS-LOO+”. PSIS-LOO is
used as a first pass, followed by exact LOO cross validation for the problematic
data points where the approximation is inadequate, re-fitting the model with
these data points omitted one by one and computing their ELPD contributions
directly. Again, any treatments where the model is saturated (only a single
AgD study arm providing information) can be safely ignored.
7.3Example: survival analysis
In this section we consider an artificial example of survival (time-to-event)
outcomes. Since the data are simulated, we can compare the results and
performance of ML-NMR using only partial IPD to that of a full IPD NMA,
and to the known true values.
7.3.1Artificial scenario
The artificial scenario involves two studies, one comparing treatments A and
B, and the other comparing treatments A and C. The AB study randomised
500 individuals 1:1 to each treatment, and the AC study randomised 400
individuals 1:1. For each individual, we generate three covariates according to












, X2(AC) ∼ Gam(6, 2), X3(AC) ∼ Bern(0.7)
Outcomes are simulated from a Weibull model in each study, with scales
α(AB)  6.2, α(AC)  5.8 and shapes ν(AB)  0.8, ν(AC)  1.2. Under a
proportional hazards model, the hazard function at time t for an individual i
on treatment k in study j is then given by
λ jk(t |xi jk)  λ j;0(t) exp
(
xTi jk(β1 + β2,k) + γk
)
,
where xi jk  (xi jk;1 , xi jk;2 , xi jk;3)T is a vector of simulated covariates, λ j;0(t) is
a baseline hazard function for trial j, β1 are prognostic coefficients, β2,k are
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effect modifying coefficients, and γk are individual-level treatment effects. For
this simulation we set these coefficients equal to
β1  (0.1, 0.05,−0.25)T
β2,A  0, β2,B  β2,C  (−0.2,−0.2,−0.1)T
γA  0, γB  −1.2, γC  −0.5
Notice that all covariates are both prognostic and effect modifying, and we
have β2,B  β2,C so that the shared EM assumption holds. For the Weibull
model, the baseline hazard function is
λ j;0(t)  ν jα j tν j−1.
Survival times are simulated using the Cumulative Distribution Function
inversion method described by Bender et al. (2005), implemented in the R
package simsurv (Brilleman 2018). We censor all surviving individuals at
time t  1 for both studies, and further uniformly censor 10% of individuals
within each study. The resulting Kaplan-Meier survival curves are shown in
Figure 7.1. For the ML-NMR analysis, we provide only summary covariate
information for the AC trial (means and standard deviations for the continuous
covariates, and a proportion for the discrete covariate).
7.3.2 Methods
We implement the ML-NMR model for general likelihoods in equation (7.3),
described for survival outcomes in Section 7.1.1. We will fit Exponential,
Weibull, and Gompertz proportional hazards models, and use the LOOIC
(Section 7.2) to select the most appropriate model.
For each model, the linear predictor is
η jk(xi jk)  β0, j + xTi jk(β1 + β2,k) + γk , (7.15)
and we set β2,A  0, γA  0. Note that the study-specific intercept β0, j is the
log scale parameter for each study, so that α j  exp(β0, j). We also define
θjk(x)  exp(η jk(x)), which are interpreted as hazard rates modelled with a
log link function.
The Weibull model1 is specified by the survival and hazard functions





λ jk(t |x)  ν jθjk(x)tν j−1. (7.16b)
1Note that Stan uses an alternative Weibull parameterisation, based on a scale (inverse
rate) parameter instead of a hazard rate. Model (7.16) is equivalent to a model on the scale
parameters using exp
(
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Figure 7.1 Simulated Kaplan-Meier survival curves for each treatment in each
study. Censored events are marked with a cross (+).
The Exponential model is a special case of the Weibull model where ν j  1 ∀ j,
so the survival and hazard functions are





λ jk(t |x)  θjk(x). (7.17b)
Finally, the Gompertz model has survival and hazard functions






exp(tν j) − 1
) )
(7.18a)
λ jk(t |x)  θjk(x) exp(tν j). (7.18b)
For an individual in the IPD AB study with event/censoring time ti jk
and covariates xi jk , their (individual conditional) likelihood contribution is
given by substituting in S jk(ti jk |xi jk) and λ jk(ti jk |xi jk) from (7.16), (7.17), or
(7.18) into equation (7.6). For each event/censoring time in the AgD AC
study, the (individual marginal) likelihood contributions are given by equation
(7.7). To evaluate the integral, we employ the numerical integration approach
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described in Section 4.3.3.2, with Ñ  100 integration points x̃ jk drawn
from joint distribution f jk(·) of the covariates on each treatment k in study
j. The likelihood contributions are then given by substituting S jk(ti jk |x̃) and
λ jk(ti jk |x̃) into equation (7.9). The regression parameters β0, j , β1, β2,k , and γk
are all given vague N(0, 1002) prior distributions, and (for the Weibull and
Gompertz models) the shape parameters ν j are given improper uniform prior
distributions U(0,+∞). We assess convergence using R̂ for each parameter,
and check that there are no divergent transitions (see Section 5.2.5).
We also fit the Weibull, Exponential, and Gopmertz models (equations
(7.16), (7.17), and (7.18)) in an IPDNMAwith full IPD (i.e. individual outcomes
and covariates) available from both studies. The likelihood contributions for
every individual in both studies are given by (7.6). We also perform a standard
(unadjusted) indirect comparison: log hazard ratios are estimated in each study
separately using a Weibull model without adjustment for effect modifiers, dAB
for the AB study and dAC for the AC study, and then the indirect comparison
between B and C is formed as dBC  dAC − dAB.
7.3.3 Results
We begin by comparing the expected predictive performance of each model.
Table 7.2 shows the LOO model comparison statistics (see Section 7.2) for
each of the three models, fit using ML-NMR with only aggregate covariate
information in the AC study, and also fit using IPD NMA with full IPD. The
LOOIC is lowest (and, equivalently, ELPD highest) for the Weibull model,
for both ML-NMR and IPD NMA. The difference in ELPD, when compared
with the standard error of the difference, suggests that the Weibull model is
a substantially better fit than either the Exponential or Gompertz models, in
both the ML-NMR and IPD NMA scenarios. We therefore present the results
for the Weibull model in the remainder of this section, comparing between
ML-NMR, full IPD NMA, and the true values used for simulation. (Note
that, since LOOIC  −2 · ELPD, the standard errors for the differences in
LOOIC are simply double the standard errors for the differences in ELPD—
and we reach exactly the same conclusion on either scale.) Notably, the LOO
model comparison statistics are very similar when the same model is fit with
ML-NMR or with IPD NMA. Figure 7.2 compares the LOOIC contributions
from each individual event/censoring time between the Weibull model fit
using ML-NMR and using full IPD NMA. The LOOIC contributions follow
the straight line of equality well, showing that the same observations are
fitted similarly well whether the full IPD was used or aggregate AC data. The
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Table 7.2 Model comparison results, using full IPD NMA and ML-NMR. The
leave-one-out information criterion (LOOIC) is equal to −2 · ELPD, where
ELPD is the expected log pointwise predictive density, and lower LOOIC
values indicate better expected predictive performance. ploo is the effective
number of parameters. The ELPD differences are in comparison with the
respective Weibull models, with positive values favouring the Weibull model.
Standard errors for each statistic are given alongside in small brackets.
IPD NMA ML-NMR
Exponential Gompertz Weibull Exponential Gompertz Weibull
LOOIC −231.5 (63.5) −232.9 (63.4) −251.7 (64.5) −214.5 (63.8) −214.8 (63.7) −234.4 (64.6)
ELPD 115.8 (31.8) 116.4 (31.7) 125.9 (32.2) 107.3 (31.9) 107.4 (31.9) 117.2 (32.3)
pLOO 8.4 (0.6) 9.9 (0.7) 9.8 (0.7) 8.8 (0.9) 10.3 (1.0) 9.5 (0.8)
ELPD difference 10.1 (4.7) 9.4 (4.3) 9.9 (4.6) 9.8 (4.2)
only noticable exception to this is a horizontal cluster of LOOIC contributions
for a set of censoring times in the C treatment arm of the AgD AC trial,
which all have LOOIC contributions around 2.5 under the ML-NMR model.
These correspond to individuals all censored at the end of the trial (t  1),
which under the ML-NMR model are all given the same marginal likelihood
contribution.
The estimated population-average survival curves on each treatment in
each study population under the Weibull model fitted using ML-NMR are
shown in Figure 7.3, overlaid on the observed Kaplan-Meier curves. Visually,
the estimated survival curves are a good fit to the observed data. Table 7.3
presents the estimated log Hazard Ratios (HRs) for each pairwise comparison
in each population, along with the true values from the simulation. The
ML-NMR estimates agree well with both the IPD NMA and the true values,
and the B vs. A and C vs. A estimates within the AB and AC study populations
respectively are unchanged in point estimate or standard error. Standard
errors for comparisons not observed in the data are slightly increased (by
2–6%) using ML-NMR compared to full IPD NMA, which is expected due
to the reduced information available. The standard (unadjusted) indirect
comparison, also presented in Table 7.3, produces estimates that are clearly
biased in this scenario. The B vs. A and C vs. A log HRs are assumed to be
constant across both study populations, when in fact these are altered by effect
modifying covariates. The B vs. A estimate is therefore incorrectly applied to
the AC study population, resulting in an incorrect estimate of C vs. B in this
population; similarly, the C vs. A estimate is invalid in the AB study, and the
C vs. B estimate is invalid here too.
Examining the parameters from the ML-NMR and IPD NMAmodels in
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Figure 7.2 Contributions to the LOOIC from each event and censoring time
in the Weibull model, plotted for ML-NMR using only summary covariate
information in the AC study against an IPD NMA with full information from
every study.
Table 7.4, we see that these agree closely with each other and recover the true
parameter values well, with the true values lying within the majority of the
Credible Intervals.
7.3.4 Conclusions
In this artificial example, we have demonstrated how the ML-NMR framework
extended to general likelihoods (Section 7.1) can be used to fit survival models.
Whilst we focused on parametric proportional hazards models here (Weibull,
Exponetial, and Gompertz models), the derivations in Section 7.1.1 can be
applied in the same manner to fit survival models with any given hazard and
survival functions.
The results of the models fit withML-NMR (using only aggregate covariate
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Figure 7.3 ML-NMR estimated survival curves on each treatment in each
study population, under a Weibull model. Shaded bands indicate the 95%
Credible Intervals for the survival curves (thick lines), overlaid on the observed
Kaplan-Meier curves from the treatments in each study (thin lines).
information from the AC study) agree closely with the results from full
IPD NMA. Furthermore, the lack of IPD in the AC study did not greatly
reduce precision for ML-NMR compare to IPD NMA; the standard errors
of population-average log Hazard Ratios were the same for comparisons
observed within each study population, and only slightly increased for the
comparisons not observed. As described in Section 7.2, we used the LOOIC to
select the appropriate parametric model form. The conclusions of the model
selection process were identical for ML-NMR and IPD NMA, in both cases
correctly identifying the Weibull model as the most appropriate model from
those fitted.
For the QMC numerical integration, we used Ñ  100 integration points.
This number is much smaller than the 10,000 points used earlier in Chapter 6
for probit regression. The trade-off between the precision of the numerical
integration and the computation time is much more severe for survival models
(and indeed anyML-NMRmodels fit using the individualmarginal likelihood),
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Table 7.3 Table of estimated log Hazard Ratios and 95% Credible intervals
from the ML-NMR model, the full IPD NMA, and the standard indirect
comparison, alongside the true log Hazard Ratios, in the AB and AC study
populations.
Study Model B vs. A C vs. A C vs. B
AB Truth −1.62 −0.92 0.70
ML-NMR −1.63 −0.98 0.65
(−1.87, −1.41) (−1.49, −0.50) (0.12, 1.21)
IPD NMA −1.62 −0.87 0.75
(−1.85, −1.38) (−1.32, −0.40) (0.23, 1.29)
Standard IC −1.60 −1.37 0.23
(−1.84, −1.37) (−1.61, −1.14) (−0.24, 0.70)
AC Truth −2.07 −1.37 0.70
ML-NMR −2.00 −1.35 0.65
(−2.53, −1.47) (−1.60, −1.10) (0.12, 1.21)
IPD NMA −2.12 −1.36 0.75
(−2.61, −1.64) (−1.62, −1.11) (0.23, 1.29)
Standard IC −1.60 −1.37 0.23
(−1.84, −1.37) (−1.61, −1.14) (−0.24, 0.70)
since the numerical integration is performed for every individual in the
aggregate data, rather than only once per AgD treatment arm. Computation
time for the Weibull ML-NMR model with Ñ  100 took around 5 minutes on
a modern laptop (see Appendix C for details of the computing environment).
Visual inspection of the 400 cumulative numerical integration plots for the
individuals in the AC study confirmed that the expected convergence rate
of Ñ−1 was achieved, and the numerical integration was accurate down to
approximately 3 decimal places. Figure 7.4 shows an example of one of
these plots, for an individual on treatment C in the AC study. The empirical
integration error is estimated as a relativedifference from thefinal estimatewith
Ñ  100 integration points, for each posterior sample; these are summarised
using a smooth density estimate over the entire posterior distribution of the
model parameters, in increasing steps of 10 integration points. We see that
the empirical integration error decreases as Ñ−1 over the entire posterior
distribution, as the density estimates lie within the dashed line as Ñ increases.
Section 5.1.2 describes these plots, their construction, and interpretation in
greater detail. Whilst Ñ could be increased for more precise integration
(perhaps leveraging the computing power of a supercomputer), Ñ  100
seems to be adequate in this scenario. In other scenarios with greater numbers
of covariates and/or different hazard and survival functions a larger value of
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Table 7.4 Table of estimated model parameters and 95% Credible Intervals
from the ML-NMR model and the full IPD NMA, alongside the true values
used in the simulation.
Parameter Truth IPD NMA ML-NMR
Treatment Effect γB −1.20 −1.28 −1.08
(−1.61, −0.95) (−1.53, −0.62)
γC −0.50 −0.52 −0.43
(−1.12, 0.10) (−1.11, 0.26)
Prognostic Effect β1;1 0.10 0.17 0.12
(−0.05, 0.39) (−0.14, 0.37)
β1;2 0.05 0.02 0.14
(−0.07, 0.11) (−0.01, 0.28)
β1;3 −0.25 −0.32 −0.12
(−0.57, −0.08) (−0.45, 0.21)
EM Interaction β2;1 −0.20 −0.23 −0.20
(−0.54, 0.10) (−0.63, 0.20)
β2;2 −0.20 −0.15 −0.24
(−0.28, −0.03) (−0.44, −0.05)
β2;3 −0.10 −0.22 −0.41
(−0.59, 0.14) (−0.94, 0.10)
Shape νAB 0.80 0.86 0.86
(0.79, 0.93) (0.79, 0.94)
νAC 1.20 1.16 1.15
(1.06, 1.26) (1.05, 1.26)
Scale αAB 6.20 6.82 5.24
(5.28, 8.62) (3.72, 7.27)
αAC 5.80 5.17 3.07
(3.23, 7.68) (1.91, 4.89)
Ñ may be necessary, and the cumulative integration plots should always be
checked for convergence and suitable precision.
Whilst ML-NMR and IPD NMA were seen to perform very similarly in
this scenario, the additional IPD available to IPD NMA does offer additional
possibilities for analysis. For example, ML-NMR makes the shared EM
assumption (Section 2.5) in this scenario for identifiability. In the interests of a
fair comparison between ML-NMR and IPD NMA, both methods made use of
this assumption in this analysis—which is known to hold due to the simulation
setup. However, IPD NMA could relax this assumption and estimate separate
EM interaction coefficients β2,B and β2,C, rather than assuming equality. (In
this scenario, since we know that β2,B  β2,C, the standard errors for IPD
NMA would be inflated by the unnecessarily more flexible model.) In larger
treatment networks it is possible to relax the shared EM assumption for
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Figure 7.4 An example plot of empirical integration error using QMC inte-
gration to evaluate the marginal likelihood, for one individual on treatment
C in the AC trial. The integration error is estimated as a relative difference
from the final estimate (with Ñ  100 integration points), over the entire
posterior distribution of the model parameters (i.e. at each posterior sample).
The dashed line is ±Ñ−1, showing the the integration error is of this order;
for comparison, the solid line is ±Ñ− 12 , which is the expected error rate for
standard (pseudo-random) Monte Carlo integration.
ML-NMR, as described in Section 4.6.
Finally, although ML-NMR was seen to perform well in comparison to IPD
NMA and the known truth, this scenario is only a single instance. Further
simulations in a simulation study could validate the performance of ML-
NMR for survival analysis, and investigate the impact of invalid assumptions.
However, we expect the results and conclusions of the simulation study on
binary outcomes in Chapter 8 to apply broadly to ML-NMR models of general
forms—including for survival analysis.
7.4 Example: plaque psoriasis with ordered categorical PASI
outcomes
InChapter 6, we introduced an example comparingplaquepsoriasis treatments.
Every trial in the network reported three PASI outcomes at different cutoffs (75,
90, and 100% improvement in PASI score from baseline). The full treatment
network (Figure 6.8) was analysed using ML-NMR in Section 6.3, but the
analysis focused on only the PASI 75 outcome for computational reasons. The
numbers of observed events for the more demanding PASI 90 and PASI 100
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outcomes were small, and posed difficulties for estimation. However, from a
decision-making perspective the higher PASI outcomes are of greater interest.
In this section, we use the ML-NMR model developed in Section 7.1.3 to
synthesise all three PASI outcomes simultaneously. By sharing information
between the outcomes in a coherent model, we aim to avoid the computational
problems associated with modelling the higher PASI outcomes separately, and
obtain more precise estimates across all three outcomes.
7.4.1Methods
We implement theML-NMRmodel for ordered categorical outcomes described
in Section 7.1.3. There are M  4 categories, and we let yi jk ∈ {1, . . . , 4}
correspond to less than 75% reduction in PASI score (i.e. failure to achieve
PASI 75), ≥ 75% and < 90% reduction (achieving PASI 75 but not PASI 90),
≥ 90% and < 100% reduction (achieving PASI 90 but not PASI 100), and 100%
reduction (achieving PASI 100), respectively, for an individual i in study j
receiving treatment k. The individual categorical likelihood given in equation
(7.10) is
Li jk |x(ξ; yi jk , xi jk) 

pi jk;1 if yi jk  1
...
...




pi jk ,m  1 ∀i , j, k
and we use the probit link function Φ(·) in equation (7.11) to model the
individual category probabilities as
pi jk ,m  Φ(η jk(xi jk) − cm−1) − Φ(η jk(xi jk) − cm),
for m  1, . . . , 4, given individual covariate vectors xi jk and linear predictor
η jk(x)  µ j + xT(β1 + β2,k)+ γk as defined in Section 4.1, where we set β2,A  0
and γA  0. The latent cutpoints cm are subject to the ordering constraints
c0 < c1 < c2 < c3 < c4 , (7.19)
and, we set c0  −∞, c1  0, and c4  +∞. The latent cutpoint c1 corresponds
to achieving PASI 75, c2 corresponds to achieving PASI 90, and c3 corresponds
to achieving PASI 100.
Priors for the latent cutpoints are most straightforward to specify on the
differences between adjacent cutpoints, for example cm − cm−1 ∼ U(0, uc) for
m  2, 3 with an appropriate upper bound uc (as used by Dias et al. (2011c)
with uc  5), so that the ordering constraints (7.19) are satisfied. When
fitting the model in Stan, the ordering constraints (7.19) are guaranteed by
221
7. EXTENSION TO GENERAL LIKELIHOODS
declaring the cm to be an ordered vector, so prior distributions can be placed
directly on the cutpoints if desired. In this analysis, we place improper
uniform prior distributions U(−∞,+∞) on c2 and c3, which are automatically
truncated to satisfy the ordering constraints (7.19). We also place N(0, 102)
prior distributions on each of the parameters µ j , β1, and β2, j .
The aggregate-level likelihood for the summary outcome vector y• jk 
(y• jk ,1 , . . . , y• jk ,4)T from study j on treatment k is given by (7.13):






which is a Multinomial likelihood with average event probability p̄ jk ,m in each
category m  1, 2, 3, 4. The average event probabilities are calculated from the
intermediate quantities q̄ jk ,m as p̄ jk ,m  q̄ jk ,m−1 − q̄ jk ,m , where q̄ jk ,m is given in
equation (7.14):
q̄ jk ,m 
∫
X
Φ(η jk(x) − cm) f jk(x) dx ,
avoiding unnecessary repeated integration. We compute these integrals using
QMC integration, as described in Section 4.3.3.2, with Ñ  5000 integration
points x̃ jk drawn from joint distribution f jk(·) of the covariates on each
treatment k in study j, so that
q̄ jk ,m ' Ñ−1
∑
Φ(η jk(x̃ jk) − cm).
We calculate population-average treatment effects in each study population
following the approach in Section 4.4. On the SMD scale (the linear predictor
scale), these are equivalent to “plugging-in” mean covariate values from the
population of interest, so the population-average treatment effect between
treatments a and b in population P is estimated using
dab(P)  x̄T(P)(β2,b − β2,a) + γb − γa , (7.20)
where x̄(P) is the vector of mean covariate values in population P.
To estimate the proportion of individuals achieving each PASI endpoint




µ(P) + xT(β1 + β2,k) + γk − cm
)
, (7.21)
which represents theprobability of an individual inpopulationP with covariate
values x achieving the PASI endpoint corresponding to the latent cutpoint cm
(i.e. m  1 corresponds to PASI 75, m  2 to PASI 90, and m  3 to PASI 100).
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The population base rate µ(P) is required, which may be estimated from
external data on the population P; here, we produce estimates for each of the
observed study populations, and simply use the intercepts µ j estimated in the
model. Since equation (7.21) is non-linear in terms of the model parameters,
we must use (4.29) (in AgD studies) or (4.30) (in IPD studies) to evaluate the
population average of (7.21). We will use QMC integration to evaluate (4.29)






where xi(P) and N are either the N j covariate values of individuals in the IPD
study j, or the Ñ integration points x̃ ∼ f j(·) for AgD study j.
For comparison, we also fit standard AgD fixed and random effects NMA
models with no covariate adjustment, using a multinomial likelihood. For all
models, we assess convergence using R̂ for each parameter, and check that
there are no divergent transitions (see Section 5.2.5).
7.4.2Results
Figure 7.5 and Table 7.5 show the estimated population-average SMD contrasts
for each treatment compared to placebo in each study population, calculated
using (7.20). Also shown in Figure 7.5 are the contrasts calculated previously
in Section 6.3 (see Table 6.7), using only the PASI 75 data. The point estimates
from both models agree closely, however uncertainty is slightly reduced for
all contrasts when utilising data on all three PASI outcomes compared to just
PASI 75—aswewould expect. There is little variation in the population-average
treatment effects between populations; as before, this is due to the differences
in effect modifier distributions between study populations being small when
combined with the strength of the interaction. The estimated heterogeneity
standard deviation from the RE NMA without covariate adjustment was
0.09 (0.01, 0.26), which is small compared to the magnitude of the relative
effects (Table 7.5), and is unchanged from the RE NMA analysis of the PASI 75
outcome only (Section 6.3.2). The DIC values for the FE and RE NMA models
without covariate adjustment were 8958.4 and 8956.6 respectively; there is little
difference between thesemodels, andwewould choose themore parsimonious
fixed effect model based on DIC alone. However, despite a lack of evidence
for substantial between-study heterogeneity, the ML-NMR model has a much
lower DIC of 8815.1. The ML-NMR model allows us to explain both between
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and within study variation, resulting in better fit and reduced uncertainty in
contrast estimates across the study populations (Table 7.5).
Examining the individual-level treatment effect and EM interaction param-
eters in Table 7.6 and comparing with the same parameters in the model using
only PASI 75 data (Table 6.8), we see that that these are again very similar,
with some gains in precision due to using all PASI outcomes rather than only
PASI 75. The greatest gains in precision are seen for ustekinumab, which has
the least amount of data (both IPD and AgD) in the network amongst all the
treatments, and is the sole IL-12/23 blocker so is not sharing information on
EM interactions with any other treatments.
The estimatedproportion of individuals in each studypopulation achieving
each PASI outcome are shown in Figure 7.6, and listed in Tables 7.7 to 7.9.
For interpretability and comparability with the previous results from the
PASI 75 only model, these are non-exclusive probabilities (e.g. the probability
of achieving 75% reduction or greater in PASI score), as opposed to exclusive
category probabilities as used to parameterise the model (e.g. the probability
of achieving 75% or greater but less than 90% reduction in PASI score). For the
predicted proportion of individuals achieving PASI 75, the point estimates are
very similar to those based on only the PASI 75 data (Figure 6.10 and Table 6.9),




































































Figure 7.5 Estimated contrasts (standardised mean differences) at the popu-
lation level for each pair of treatments in each study population, from the
ML-NMR model combining information from all PASI endpoints and that
using only PASI 75.
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Table 7.5 Estimated basic SMD contrasts and 95% Credible Intervals for each
treatment compared to placebo, plus the comparison targeted by the previous
MAIC, in each study population using the ML-NMR model and for the RE
NMA.
ML-NMR study population RE NMA
Contrast CLEAR ERASURE FEATURE FIXTURE IXORA JUNCTURE UNCOVER-1 UNCOVER-2 UNCOVER-3 Weighted overall
IXE Q2W vs. PBO 2.95 2.94 2.95 2.93 2.97 2.96 2.98 2.95 2.92 2.87
(2.79, 3.11) (2.79, 3.10) (2.79, 3.12) (2.77, 3.11) (2.78, 3.17) (2.80, 3.14) (2.81, 3.15) (2.79, 3.11) (2.77, 3.08) (2.69, 3.07)
IXE Q4W vs. PBO 2.78 2.77 2.78 2.76 2.80 2.79 2.81 2.78 2.75 2.69
(2.62, 2.94) (2.62, 2.93) (2.61, 2.95) (2.60, 2.94) (2.61, 3.00) (2.63, 2.97) (2.64, 2.98) (2.62, 2.94) (2.60, 2.91) (2.49, 2.89)
ETN vs. PBO 1.70 1.68 1.69 1.73 1.71 1.68 1.67 1.65 1.65 1.61
(1.56, 1.87) (1.53, 1.84) (1.53, 1.86) (1.57, 1.89) (1.52, 1.92) (1.51, 1.85) (1.50, 1.85) (1.49, 1.82) (1.50, 1.81) (1.43, 1.81)
SEC 150 vs. PBO 2.31 2.31 2.31 2.30 2.33 2.33 2.34 2.31 2.29 2.19
(2.14, 2.50) (2.13, 2.49) (2.13, 2.51) (2.12, 2.48) (2.13, 2.56) (2.14, 2.53) (2.15, 2.54) (2.13, 2.51) (2.11, 2.48) (2.00, 2.42)
SEC 300 vs. PBO 2.72 2.72 2.73 2.71 2.74 2.74 2.75 2.72 2.70 2.60
(2.55, 2.90) (2.55, 2.89) (2.55, 2.91) (2.54, 2.88) (2.54, 2.96) (2.56, 2.94) (2.57, 2.95) (2.55, 2.91) (2.53, 2.88) (2.42, 2.82)
UST vs. PBO 2.28 2.28 2.28 2.28 2.25 2.29 2.28 2.26 2.26 2.16
(2.06, 2.49) (2.05, 2.51) (2.05, 2.50) (2.05, 2.50) (2.00, 2.51) (2.01, 2.56) (2.04, 2.52) (2.01, 2.50) (2.01, 2.51) (1.92, 2.44)
SEC 300 vs. IXE Q2W −0.22 −0.22 −0.22 −0.22∗ −0.22 −0.22 −0.22 −0.22 −0.22 −0.27
(−0.37, −0.06) (−0.37, −0.06) (−0.37, −0.06) (−0.37, −0.06) (−0.37, −0.06) (−0.37, −0.06) (−0.37, −0.06) (−0.37, −0.06) (−0.37, −0.06) (−0.49, −0.03)











Table 7.6 Estimated interactions for each treatment class and potential effect
modifier, and estimated individual-level treatment effects, for the ML-NMR
model combining information from all PASI endpoints. All estimates are
standardised mean differences versus placebo, with 95% Credible Intervals.
Treatment class
Anti-TNFα IL-12 and IL-23 blocker IL-17A blocker
Effect modifier interaction
Previous systemic use 0.10 (−0.28, 0.48) −0.01 (−0.69, 0.69) 0.13 (−0.22, 0.48)
Duration of psoriasis, per 10 years 0.17 (0.02, 0.32) 0.12 (−0.08, 0.32) 0.17 (0.03, 0.31)
Body surface area, per 10% 0.04 (−0.06, 0.15) 0.05 (−0.08, 0.20) 0.00 (−0.09, 0.11)
Weight, per 10 kg −0.09 (−0.17, −0.01) −0.04 (−0.14, 0.07) −0.05 (−0.12, 0.02)
Psoriatic arthritis 0.01 (−0.45, 0.47) 0.31 (−0.36, 1.00) 0.27 (−0.14, 0.70)
Reference individual treatment effect
IXE Q2W 2.81 (2.56, 3.07)
IXE Q4W 2.63 (2.38, 2.90)
ETN 1.61 (1.35, 1.88)
SEC 150 2.17 (1.91, 2.45)
SEC 300 2.58 (2.33, 2.85)
UST 2.21 (1.63, 2.75)
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Figure 7.6 Estimated proportion of individuals achieving each PASI endpoint












Table 7.7 Estimated proportion of individuals achieving PASI 75 on each
treatment in each study population, along with 95% Credible Intervals, using
ML-NMR combining information from all PASI endpoints.
Treatment
Study population Placebo Ixekizumab Q2W Ixekizumab Q4W Etanercept Secukinumab 150 mg Secukinumab 300 mg Ustekinumab
CLEAR 8.44 92.75 90.16 59.57 80.01 89.33 78.47
(5.99, 11.56) (90.13, 95.01) (86.74, 93.04) (53.35, 65.65) (75.56, 84.15) (87.12, 91.30) (74.79, 81.74)
ERASURE 4.32 86.37 82.42 45.26 68.61 81.16 67.23
(2.99, 5.83) (82.52, 89.65) (77.73, 86.52) (39.62, 51.09) (64.79, 72.38) (78.20, 84.02) (60.46, 73.59)
FEATURE 4.27 86.10 82.12 45.22 68.29 80.86 66.51
(2.54, 6.60) (80.56, 90.78) (75.53, 87.88) (36.77, 53.83) (60.99, 75.22) (75.10, 85.82) (57.10, 75.04)
FIXTURE 3.74 85.00 80.78 44.55 66.25 79.42 65.05
(2.64, 5.07) (81.46, 88.00) (76.49, 84.46) (40.39, 48.95) (62.58, 69.78) (76.70, 82.08) (58.44, 71.18)
IXORA 4.94 88.47 84.92 49.40 72.03 83.71 68.87
(2.86, 7.73) (85.04, 91.45) (80.38, 88.95) (41.94, 56.69) (64.87, 78.37) (78.70, 87.99) (63.23, 74.17)
JUNCTURE 4.30 86.28 82.36 44.51 68.66 81.11 66.56
(2.49, 6.65) (80.71, 90.95) (75.89, 87.90) (36.09, 53.13) (61.58, 75.17) (75.37, 85.93) (56.14, 75.99)
UNCOVER-1 4.71 87.91 84.25 46.46 71.04 82.97 68.49
(3.48, 6.15) (86.19, 89.55) (82.27, 86.22) (42.05, 50.99) (64.94, 76.73) (78.72, 86.79) (61.08, 75.36)
UNCOVER-2 4.41 86.80 82.91 44.34 69.10 81.56 66.66
(3.21, 5.79) (84.87, 88.60) (80.66, 84.96) (40.81, 47.82) (63.35, 74.52) (77.39, 85.41) (58.66, 73.91)
UNCOVER-3 5.90 89.25 85.87 50.07 73.37 84.67 71.65







Table 7.8 Estimated proportion of individuals achieving PASI 90 on each
treatment in each study population, along with 95% Credible Intervals, using
ML-NMR combining information from all PASI endpoints.
Treatment
Study population Placebo Ixekizumab Q2W Ixekizumab Q4W Etanercept Secukinumab 150 mg Secukinumab 300 mg Ustekinumab
CLEAR 2.11 78.50 73.33 34.12 56.85 71.71 55.34
(1.32, 3.19) (73.20, 83.38) (67.08, 79.08) (28.60, 40.19) (50.81, 62.89) (67.83, 75.41) (50.61, 59.79)
ERASURE 0.89 66.72 60.51 22.22 42.77 58.60 42.01
(0.55, 1.31) (60.64, 72.45) (53.88, 66.99) (18.18, 26.74) (38.60, 47.05) (54.48, 62.77) (34.97, 49.26)
FEATURE 0.88 66.40 60.21 22.28 42.54 58.30 41.32
(0.45, 1.53) (57.78, 74.49) (50.93, 69.11) (16.32, 28.95) (34.91, 50.45) (50.38, 65.69) (31.92, 51.13)
FIXTURE 0.74 64.31 57.93 21.44 40.06 55.97 39.53
(0.47, 1.10) (58.99, 69.32) (52.04, 63.42) (18.37, 24.74) (36.36, 43.83) (52.29, 59.67) (32.66, 46.44)
IXORA 1.05 70.30 64.31 25.32 46.69 62.43 43.40
(0.51, 1.86) (64.37, 75.83) (57.37, 71.01) (19.64, 31.43) (38.70, 54.50) (54.89, 69.26) (37.31, 49.61)
JUNCTURE 0.89 66.78 60.63 21.83 43.02 58.74 41.51
(0.44, 1.58) (58.04, 74.94) (51.47, 69.41) (15.86, 28.75) (35.51, 50.53) (50.96, 66.02) (31.15, 52.61)
UNCOVER-1 1.00 69.30 63.26 23.14 45.59 61.34 43.38
(0.67, 1.42) (66.40, 72.15) (60.19, 66.31) (19.82, 26.65) (38.83, 52.35) (55.22, 67.38) (35.59, 51.43)
UNCOVER-2 0.92 67.29 61.08 21.33 43.26 59.13 41.30
(0.59, 1.32) (64.17, 70.38) (57.81, 64.20) (18.76, 24.01) (37.15, 49.60) (53.40, 65.04) (33.18, 49.69)
UNCOVER-3 1.33 71.69 65.83 25.84 48.32 63.95 47.00












Table 7.9 Estimated proportion of individuals achieving PASI 100 on each
treatment in each study population, along with 95% Credible Intervals, using
ML-NMR combining information from all PASI endpoints.
Treatment
Study population Placebo Ixekizumab Q2W Ixekizumab Q4W Etanercept Secukinumab 150 mg Secukinumab 300 mg Ustekinumab
CLEAR 0.23 48.84 42.26 11.35 25.88 40.28 25.29
(0.12, 0.39) (42.01, 55.83) (35.25, 49.59) (8.53, 14.67) (21.01, 31.01) (35.97, 44.57) (21.51, 29.45)
ERASURE 0.08 35.11 29.19 5.97 15.88 27.45 16.02
(0.04, 0.13) (29.21, 41.27) (23.56, 35.32) (4.40, 7.86) (13.37, 18.62) (24.02, 31.07) (11.67, 21.21)
FEATURE 0.08 34.94 29.06 6.03 15.84 27.33 15.64
(0.03, 0.15) (26.68, 43.76) (21.40, 37.66) (3.75, 8.95) (11.43, 21.07) (20.95, 34.16) (10.20, 22.29)
FIXTURE 0.06 32.51 26.76 5.55 14.15 25.10 14.41
(0.03, 0.10) (27.44, 37.61) (22.15, 31.78) (4.37, 6.94) (12.02, 16.43) (22.13, 28.12) (10.26, 19.09)
IXORA 0.09 38.80 32.61 7.17 18.38 30.83 16.56
(0.04, 0.19) (32.60, 45.06) (26.23, 39.22) (4.84, 9.91) (13.35, 23.87) (24.41, 37.53) (12.80, 20.75)
JUNCTURE 0.08 35.40 29.50 5.89 16.17 27.76 15.85
(0.03, 0.16) (27.11, 44.34) (21.72, 38.08) (3.64, 8.85) (11.71, 21.22) (21.40, 34.48) (9.86, 23.66)
UNCOVER-1 0.09 37.75 31.62 6.33 17.71 29.91 16.87
(0.05, 0.14) (34.69, 40.93) (28.74, 34.56) (4.98, 7.85) (13.52, 22.57) (24.48, 35.71) (12.04, 22.43)
UNCOVER-2 0.08 35.50 29.51 5.53 16.15 27.84 15.51
(0.04, 0.13) (32.43, 38.73) (26.60, 32.49) (4.50, 6.63) (12.46, 20.35) (23.03, 33.23) (10.82, 21.16)
UNCOVER-3 0.13 40.38 34.10 7.39 19.52 32.31 19.27
(0.07, 0.20) (37.33, 43.51) (31.10, 37.10) (6.12, 8.79) (15.42, 24.04) (27.17, 38.00) (13.52, 26.11)
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7.4.3 Conclusions
In this section, we used the ML-NMR model derived in Section 7.1.3 to syn-
thesise ordered categorical outcomes, namely 75%, 90%, and 100% cutpoints
in PASI score improvements from baseline. Previously in Chapter 6, we
synthesised only the PASI 75 data: whilst the higher PASI outcomes are more
interesting from a decision-making perspective, the low numbers of observed
events posed difficulties for estimation in stand-alone analyses. By considering
the PASI 75, 90, and 100 outcomes together as an ordered categorical outcome,
we share information across the three cutpoints which alleviates the estimation
issues with the higher PASI outcomes and leads to more precise estimates. Es-
timated average treatment effects and the proportion of individuals achieving
each PASI endpoint are available in any of the included study populations
or in an external target population for decision-making (given a covariate
distribution and, for absolute proportions, a baseline event rate).
Synthesising the three PASI outcomes together in this manner does re-
quire additional assumptions: the outcomes are assumed to be defined by
cutpoints in some underlying continuous variable, which further implies
that the treatments and covariates affect each outcome via this underlying
continuous variable and that their effects are constant across cutpoints. These
assumptions are likely justified, given that the outcomes are indeed specified
as cutpoints in percent improvement in PASI score. Additionally, the probit
model assumes that the treatments and covariates act only on the location of
the distribution of the underlying continuous variable, and not on its scale
(i.e. the standard deviation used in standardising outcomes to SMDs is the
same across treatments and covariate values). Furthermore, in this analysis
we have used fixed latent cutpoints cm , which are assumed to be the same in
every trial. Variations in outcome definition between trials could affect this
assumption, and instead “random” cutpoints cm j which are exchangeable at
level m between trials j could be fitted (Dias et al. 2011c). However, we have
not attempted to fit a random cutpoint model here.
7.5 Discussion
In this chapter, we have extended the ML-NMR framework to handle general
likelihoods and expand the range of models which can be fitted. As in Chap-
ter 4, we began with a fully-specified individual-level model, and considered
how to aggregate this model to apply to summary data. In Chapter 4, we
proceeded by determining explicitly the form of the aggregate likelihood, rely-
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ing on well-known results such as the sum of Normally distributed outcomes
being Normally distributed. However, in Section 7.1 we instead proceeded by
considering the likelihood contributions from each level of the model. Individ-
uals in studies with IPD have individual conditional likelihood contributions
defined by the individual-level model, conditional on their covariate values.
Integrating the individual conditional likelihood function over the covariate
distribution in a study results in an individual marginal likelihood function,
which is then used in one of two ways, depending on the data available, with
different levels of generality.
Firstly, in settings where the aggregate data consist of individual outcomes
but only summary covariate information (such as survival data reconstructed
from Kaplan-Meier curves), the aggregate part of the model is fitted directly
using the individualmarginal likelihood contributions. In this case, themethod
is fully general: individual conditional likelihood functions of any form can be
integrated numerically to evaluate the individual marginal likelihood function
using one of the approaches described in Section 4.3.3.
Secondly, we have settings where the aggregate data consist of summary
outcomes and summary covariate information. In this case, the individual
marginal likelihood contributions are multiplied together to obtain the aggre-
gate marginal likelihood contributions for the summary outcomes. Evaluation
of the aggregate marginal likelihood contributions requires that these can be
expressed in terms of the summary outcomes, which is only straightforward
for discrete outcomes. This would appear to limit the generality of the ap-
proach for continuous outcomes; however, the aggregate-level likelihood has a
known closed form for many continuous individual-level likelihoods common
in practice (Section 4.2).
The survival analysis example in Section 7.3 focused on a scenario where
event/censoring times were available from each individual in the aggregate
studies, for example reconstructed from Kaplan-Meier plots (Guyot et al. 2012).
If individual event/censoring times are not available, but instead only log
hazard ratios are reported (or can be recovered, see Parmar et al. 1998), the
simplest solution is to synthesise the log HRs using a Normal likelihood, and if
the individual-level linear predictor η jk(·) is on the log HR scale no numerical
integration is needed and mean covariate values can simply be “plugged in”.




η jb(x̄ j) − η ja(x̄ j), s2jab
)
,
where s2jab is the variance of the log HR (given as data) and x̄ j is the vector
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of mean covariate values in study j. (Studies with three or more arms
would require the correlations between log HRs to be accounted for in the
likelihood, as in Section 1.2.8.) It may also be possible to instead synthesise
reported summary outcomes such as hazard ratios or median survival times
by considering the aggregate marginal likelihood contributions for these data
(Section 7.1). This remains an area for further research (see Section 9.2.3).
We have only considered adjusting for covariates measured at baseline:
time-varying covariates were not considered since it is likely that, in the
aggregate studies, summary covariate information is available only available
at baseline and not throughout follow-up. The inclusion of time-varying
covariates in a survival model is often an attempt to correct for observed
non-proportionality (e.g. failure of the proportional hazards assumption).
However, as noted by Therneau and Grambsch (2000, Section 6.6), such
problems may by symptomatic of other issues such as omitted covariates, an
incorrect functional form for a covariate, or using an inappropriate model
form (e.g. a proportional hazards model when an accelerated failure time
model would be more appropriate). Notably, the solutions for these issues
can be dealt with within the ML-NMR framework we have described, without
requiring further information on time-varying covariates.
Although our survival analysis example focused on parametric propor-
tional hazards models, it is straightforward to fit other survival models such as
accelerated failure timemodels, or more flexible models on the baseline hazard
function such as the Royston-Parmar model (Freeman and Carpenter 2017;
Royston and Parmar 2002) or fractional polynomials (Jansen 2011). Piecewise
exponential models with a Poisson likelihood have been shown to be equiva-
lent to the partial likelihood for a semi-parametric Cox model (Cox 1972) when
the number of intervals (within which the hazard is modelled as constant) is
equal to the number of events (Crowther et al. 2012). This formulation admits
a Bayesian approach to the semi-parametric Cox model, and it should be
possible to apply the marginal likelihood approach to fit piecewise exponential
models in the ML-NMR framework. However, implementation of the Cox
model in a Bayesian framework in this manner is often very computationally
intensive (Crowther et al. 2012), and the addition of numerical integration
will only exacerbate this. A wide range of other semi- and non-parametric
prior distributions for the baseline hazard function have been proposed (for
an overview, see Ibrahim et al. 2001, Chapter 3; Müller et al. 2015, Chapter 6),
which could also be investigated. The Stan code (see Appendix A.3.2) that we
have developed is modular, and all that is required to fit a range of alternative
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models in the ML-NMR framework is to specify the form of the survival and
hazard functions for the individual conditional likelihood (i.e. conditional on
the covariates). Once these have been specified, the numerical integration
step to obtain the individual marginal likelihood remains the same, and is
automatically implemented in the Stan code.
Fittingmodels where part of the model has no explicit closed form presents
new challenges, in particular for model comparison. Whilst the relative fit of
data points under a given model can always be investigated using the deviance
(−2 times the log likelihood), computation of standard model comparison
statistics such as the DIC (Spiegelhalter et al. 2002) is complicated when the
aggregate likelihood has no closed form. In Section 7.2, we proposed instead
to use approximate leave-one-out cross validation for model comparison, as
described by Vehtari et al. (2016). This approach requires only the posterior
samples of the log likelihood contributions, and so can be computed without
a closed form aggregate likelihood. We applied this approach successfully in





Despite their increasing popularity, population adjustment methods such
as MAIC and STC have yet to be subjected to extensive simulation studies.
In this chapter, we undertake a thorough simulation study designed to test
the performance of ML-NMR alongside MAIC and STC in a wide range of
scenarios, in particular under failure of assumptions. Section 8.1 sets out the
simulation study plan, and Section 8.2 presents and discusses the results.
8.1Simulation study plan
This simulation study plan follows the ADEMP framework (Morris et al. 2019),






The following sections are devoted to describing each of these elements in
turn.
8.1.1Aims
The simulation study aims to assess the performance of ML-NMR against
current population adjustment methods (MAIC and STC), in a range of ideal
and non-ideal scenarios under various failures of assumptions. The primary
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concerns are bias and efficiency of the estimators. We shall also consider other
frequentist properties such as coverage.
8.1.2 Data-generatingmechanisms
For this simulation study, we will consider a binary outcome, generated
under a logit (log odds ratio) model. The basic data structure involves three
treatments (A, B, C) investigated in two studies, AB and AC. We will simulate
two continuous covariates which modify the effect of treatments B and C.
Individual patient data (IPD) are available for the AB study as a binary
outcome and covariate information for each individual. Only aggregate data
(AgD) are available for the AC study, given as an overall event count and
summary covariate information. For the AC study, individual outcomes will
be simulated and then aggregated.
The underlying model is of the form
yi jk ∼ Bern(θi jk)
logit(θi jk)  µ j + q
(





xi jk ∼ φ j
where outcomes yi jk for individual i in study j receiving treatment k are
generated from a Bernoulli distribution with individual event probability
θi jk . A logit link function is used to define an outcome model on the linear
predictor scale, with study intercept µ j , covariate vector xi jk and coefficients
βk , and treatment effects γk . The covariates are generated following the joint
distribution φ j . The function q(·) defines a (potentially non-linear) relationship
between the covariates and outcome. Covariates are centred in the regression
model against the mean in each study m j , so that the model coefficients are
more easily interpreted as log odds and log odds ratios at the mean.
We set γA  0, γB  −2, γC  −1.5, µAB  1, µAC  1.5. The values of
βk will be set depending on the scenarios set out below, but always βA  0
because A is the reference treatment.
In the AB trial, the two covariates will be generatedwithmeans mX1(AB)  1
and mX2(AB)  0.5, and standard deviations σX1(AB)  0.5 and σX2(AB)  0.1 (as
either a Normal or Gamma covariate, see g and h below). The distributions
of the covariates in the AC trial are set to achieve the required overlap (see e
below).
We shall consider varying the following parameters (where the reference
levels for each parameter are bold and underlined below):
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a. Sample size N in AB and AC trials (100, 500, 1000). We will use 1:1
randomisation within each study.
b. Strength of effect modification. Modifying the treatment effect log odds
ratio by 0.1, 0.5 per AB covariate SD, i.e. βk  0.1σX(AB) or 0.5σX(AB).
This corresponds to roughly ±10% and ±50% modification of treatment
effects within ±2 SD of the mean covariate value mX(AB) in the AB study.
c. Shared effect modification. Effect modifier coefficients are shared (βB 
βC) or not between treatments B and C.
d. Strength of correlation between covariates in each study (ρ(AB)  ρ(AC) =
0, 0.25, 0.5).
e. Between-study overlap. Full overlap (AC contained entirely within AB),
and 50%, 100% of AC population outside of AB. Set using a proxy
parameter κ (see below).
f. Covariate-outcome relationship. Linear, non-linear beyond the range of
the AB study.
g. Distribution of covariates in AB. Consider Normal covariates and
Gamma covariates.
h. Distribution of covariates in AC. Consider Normal covariates and
Gamma covariates.
i. Correlation structures. Same in both studies (ρ(AB)  ρ(AC)), different
in each study (ρ(AB) , ρ(AC)).
For the purposes of computation time and reporting, we will not consider a
full factorial design of all possible data-generating mechanisms. Instead, each
parameter will be varied independently. However, we will consider a factorial
examination of scenarios e and f (investigating extrapolation when it is not
valid), and of g, h, and i (investigating assuming the same form of covariate
distribution and correlation structure between studies when not valid).
For scenario e, we wish to vary the overlap between the study populations,
which we define as the proportion of the AC joint density φ(AC) contained
within the 95% highest density region (HDR) of the AB joint density φ(AB).






φ(AC)(x) dx , (8.1)
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where the (1 − α)%HDR is the region R(AB),α  {x : φ(AB)(x) ≥ c(AB),α}, with
c(AB),α the largest constant satisfying (x ∈ R(AB),α) ≥ 1 − α. Clearly the exact
relationship between the parameters of the joint distribution in each study and
the true overlap is highly complex, and so instead we use a proxy parameter
κ. Approximately, κ  0 corresponds to no overlap, κ  0.5 to 50% overlap,
and κ  1 to full overlap. Using κ, we then define the mean and standard
deviation of each covariate in the AC population as
mX(AC) 
(




We later calculate the true overlap in several scenarios using numerical
integration to evaluate the integral (8.1). The HDR is calculated numerically
using the density quantilemethod, outlined byHyndman (1996); for numerical
integration over two dimensions we use the R package cubature (available
from https://cran.r-project.org/package=cubature).
For scenario f, the non-linear relationship will be specified with a sigmoid
function, parametrised so that y ≈ x within ±2 SD of the mean covariate value









Figure 8.1 The function q(·) is approximately linear within the range of the
AB study, but attenuates outside this range.
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8.1.3Estimands
The estimands of interest will be population-average relative effects dAB , dAC ,
dBC with target population:
1. Represented by the AC trial population,
2. Represented by the AB trial population.
8.1.4Methods




4. Standard indirect comparison.
For each of methods 1–3, we will consider models with a full set of effect
modifiers or missing one effect modifier. ML-NMR will be carried out using
Quasi-Monte Carlo numerical integration as described in Chapter 4, with a
Gaussian copula to account for the correlations between covariates. MAIC
and STC are described in Section 2.2.1 and Section 2.2.2 respectively. Standard
errors for MAIC will be estimating using bootstrapping. The standard indirect
comparison (without population adjustment) follows the Bucher method
(Bucher et al. 1997).
8.1.5Performancemeasures
The following performance measures will be computed:
• Bias  1Nsim
∑Nsim
i1 (d̂i − d),





i1 (d̂i − d̄)2,










d̂lower,i ≤ d ≤ d̂upper,i
)
.
where d̂i are Nsim repeated estimates of some truth d, with sample mean
d̄ 
∑Nsim
i1 d̂i , model estimated variance v̂ar(d̂i), and lower and upper con-
fidence/credible interval limits d̂lower,i and d̂upper,i . Bias is the difference
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between the expected value of an estimator and the truth, estimated as the
average difference between the repeated estimates and the truth. An unbiased
estimator (bias of zero) is desirable. The empirical standard error is the true
variability of the estimator, estimated as the observed standard error of the
repeated estimates. The model standard error is the average standard error
reported by a method over all repetitions (taken on the variance scale). We
thus desire both that the empirical standard error is small (the estimator is
precise) and that the empirical standard error is well-estimated by the model
standard error (so that uncertainty is appropriately quantified). The coverage
probability is the probability that the confidence or credible intervals contain
the true value, estimated as the proportion of repetitions with intervals that
include the true value, which we wish to be at the nominal level (here 95%).
Since the primary concerns are bias and efficiency, we will evaluate
sufficient sample size based on bias and empirical standard error. The Monte









We will begin by running Nsim  1000 simulations. At this point, we will
evaluate the Monte Carlo standard errors to determine whether these are
sufficiently low with respect to the magnitude of the treatment effects, and
consider running further simulations.
8.2 Simulation results
The simulation study was run on BlueCrystal Phase 3, the University of Bristol
supercomputer (see Appendix C for details of the computing environment).
The R package simsalaparwas utilised to simplify the mechanics of the study,
including parallelisation, error handling, and saving of results (Hofert and
Mächler 2016). Each scenario was replicated 2000 times to achieveMonte Carlo
standard errors (on the log odds ratio scale) below 0.035 for bias and 0.025
for empirical standard error, for all methods (other than a small number of
scenarios for whichMAICwas highly unstable). By running the simulations in
parallel, the total 4-core slave time of over 1800 hours (11 weeks) was reduced
to an actual run time of around 10 days.
Due to the size of simulation study, tabulated summaries of results can be
found in Appendix B.
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8.2.1Scenario a: sample size
In scenario a, the sample sizes of the two studies were varied between 100,
500, and 1000. Figure 8.2a shows the bias in the population-average contrast
estimates for each method, adjusting for all effect modifiers, along with 95%
Monte Carlo confidence intervals. To aid comparison between methods, the
points are coloured by contrast, with lighter shades for the AB population and
darker for the AC population. Figure 8.2b shows the corresponding empirical
and model standard errors. Coverage zip plots (Morris et al. 2019) for the
dBC(AC) contrast estimate are shown in Figure 8.3, centred around zero bias.
These display the 95% confidence or credible intervals for each repetition,
centile-ranked on the vertical axis by (d̂i − d)√v̂ar(d̂i)
 , (8.3)
and coloured according to whether the interval includes the truth (“coverers”,
in green, at the bottom) or not (“non-coverers”, in purple, at the top). The
location of the colour change on the vertical axis is thus the estimated coverage
(i.e. the proportion of coverers). If the intervals have nominal coverage, the
colour change will occur at the 95th centile (i.e. at the nominal level). The
horizontal dashed lines give the 95% Monte Carlo confidence interval for the
coverage. The zip plot will appear symmetrical around zero (with a Y or zip
shape) if the estimates are unbiased, otherwise the zip plot will be skewed to
one side. Table B.1 provides the results in tabular format.
We see that ML-NMR and STC are comparable in terms of both bias and
standard error, largely eliminating the bias that the Bucher method (standard
indirect comparison) incurs, with similar empirical standard errors that are
well-estimated by the model standard errors. For the smallest sample size
(100), the model standard errors slightly underestimate the empirical standard
errors. Some small bias remains in each of the estimates for ML-NMR and
STC, and is most pronounced at the smallest sample size; this is likely due
to the small sample bias inherent to logistic regression and the low average
number of events on treatment B (13.6 from 50 individuals) (Vittinghoff and
McCulloch 2007). As expected, ML-NMR produces more precise estimates
(i.e. with lower standard error) for contrasts between treatments where there
is direct evidence than those based on indirect evidence (dAB(AB) and dAC(AC)
are more precisely estimated than the remaining contrasts). ML-NMR and
STC also perform similarly in terms of coverage, achieving nominal coverage
for sample sizes 500 and 1000. Both methods display slight under-coverage
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at the smallest sample size (100), 90.6% (89.3, 91.8) for ML-NMR and 93.6%
(92.6, 94.7) for STC, perhaps due to increased small-sample bias. The standard
indirect comparison is always below nominal coverage, and coverage drops
off severely with increasing sample size as a biased estimator is more precisely
estimated (note the rightward skew to the zip, which agrees with Figure 8.2a).
MAIC does not perform as well as ML-NMR or STC in this scenario. The
reference level of between-study overlap is set at 50%, but this means that
any reweighting scheme such as MAIC cannot hope to eliminate the bias
since extrapolation is not possible. As a result, MAIC provides a lesser bias
reduction than ML-NMR and STC for sample sizes 500 and 100, and for the
smallest sample size actually substantially increases the bias compared to a
standard indirect comparison. Empirical standard errors for MAIC are larger
than for ML-NMR and STC, and the MAIC model standard error is only a
good estimate at the largest sample size. For sample size 500, the MAIC model
standard errors (derived through bootstrapping) are extremely unstable, as
the weights are highly dependent on a small number of individuals, and were
only successfully obtained 47% of the time. For sample size 100, estimation
failed entirely 23% of the time, and no attempts to obtain model standard
errors were successful. Coverage for sample size 500 is at the nominal value,
despite remaining bias and unstable standard errors. For sample size 1000,
coverage of 90.7% (89.4, 91.9) is below the nominal value, as the standard
errors have stabilised but the estimator remains biased.
Whenone of the two effectmodifiers is not adjusted for, none of themethods
are able to eliminate bias from the estimates (Figure 8.4a, also Table B.2). ML-
NMR and STC show slightly reduced standard errors compared to the models
with the full set of effect modifiers (Figure 8.4b). Again, the empirical standard
errors are well-estimated by the model standard errors for the larger sample
sizes, with a slight underestimation for the smallest sample size. MAIC has
markedly reduced standard errors compared to adjustment for both effect
modifiers, and the bootstrap model standard errors are now stable for the
larger sample sizes. This is because the overlap between studies is necessarily
lower as the number of covariates increases. However, MAIC is still unstable
for the smallest sample size. Coverage of all three population adjustment
methods begins to drop from the nominal level as sample size increases,
down to around 92% for sample size 1000 (Figure 8.5). This is due to the bias
remaining in the estimates, as further evidenced by the rightward skew to the
zip plots. However, coverage is still well above that of the standard indirect





Figure 8.2 Bias (a) and standard errors (b) for the population-average contrast
estimates for scenario a, along with 95% Monte Carlo confidence intervals.
Each method (other than Bucher) adjusts for the full set of effect modifiers.
Sample size is varied between 100, 500, and 1000. The points are coloured




Figure 8.3 Coverage zip plots for the dBC(AC) contrast estimate for scenario a.
Each method (other than Bucher) adjusts for the full set of effect modifiers.
Sample size is varied between 100, 500, and 1000. The 95% confidence/credible
intervals are coloured as coverers (green) or non-coverers (purple), and the
colour change should occur at the 95th centile (i.e. nominal coverage). The






Figure 8.4 Bias (a) and standard errors (b) for the population-average contrast
estimates for scenario a, along with 95% Monte Carlo confidence intervals.
One of the two effect modifiers was not adjusted for. Sample size is varied
between 100, 500, and 1000. The points are coloured by contrast, with lighter
shades for the AB population and darker for the AC population.
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Figure 8.5 Coverage zip plots for the dBC(AC) contrast estimate for scenario
a. One of the two effect modifiers was not adjusted for. Sample size is
varied between 100, 500, and 1000. The 95% confidence/credible intervals are
coloured as coverers (green) or non-coverers (purple), and the colour change
should occur at the 95th centile (i.e. nominal coverage). The horizontal dashed
lines are 95% Monte Carlo confidence intervals for the coverage.
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8.2.2Scenario b: strength of eect modification
In scenario b, the strength of effect modification was varied from weak (0.1
change in log odds ratio per covariate standard deviation in the AB study) to
strong (0.5 change in log odds ratio per covariate standard deviation in the
AB study), and was the same for both treament B and C (so the shared effect
modifier assumption holds). Figure 8.6a shows the bias in the population-
average contrast estimates for each method, adjusting for all effect modifiers,
along with 95% Monte Carlo confidence intervals. Figure 8.6b shows the
corresponding empirical and model standard errors. (See also Table B.3.) Both
ML-NMR and STC have successfully removed the bias from the standard
indirect comparison, and display very similar standard errors. The standard
errors are largely unaffected by the strength of the effectmodification, although
the model standard errors for ML-NMR and STC slightly underestimate the
empirical standard errors when the effect modification is strong. MAIC has
also removed most of the bias, though some remains due to lack of overlap
between the two studies, and appears to do better when the effect modification
is stronger. Empirical standard errors for MAIC are higher than for ML-NMR
and STC, and again the bootstrapmodel standard errors are extremely unstable.
Coverage for all three population adjustment methods is at the nominal level
(Figure 8.7), although there is a small drop for ML-NMR and STC to 93.0%
(91.9, 94.2) and 93.9% (92.9, 94.9) when the effect modification is stronger due
to the slight underestimation of the standard error. Coverage for the standard
indirect comparison drops to zero when the effect modification is strong, as
the incurred bias is so large.
When one of the two effect modifiers is not adjusted for, all population
adjustment methods fail to remove the bias (Figure 8.8a, also Table B.4).
As expected, the amount of bias remaining is larger when the missing effect
modifier is stronger. The standard errors of all population adjustmentmethods
are reduced compared to adjustment for all effect modifiers, and again do
not differ by the strength of effect modification (Figure 8.8b). The coverage
for all population adjustment methods drops further when the missing effect





Figure 8.6 Bias (a) and standard errors (b) for the population-average contrast
estimates for scenario b, along with 95% Monte Carlo confidence intervals.
Strength of effect modification is varied from weak (0.1 change in log odds
ratio per covariate standard deviation in the AB study) to strong (0.5 change
in log odds ratio per covariate standard deviation in the AB study). Each
method (other than Bucher) adjusts for the full set of effect modifiers. The
points are coloured by contrast, with lighter shades for the AB population
and darker for the AC population.
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Figure 8.7 Coverage zip plots for the dBC(AC) contrast estimate for scenario
b. Strength of effect modification is varied from weak (0.1 change in log
odds ratio per covariate standard deviation in the AB study) to strong (0.5
change in log odds ratio per covariate standard deviation in the AB study).
Each method (other than Bucher) adjusts for the full set of effect modifiers.
The 95% confidence/credible intervals are coloured as coverers (green) or
non-coverers (purple), and the colour change should occur at the 95th centile
(i.e. nominal coverage). The horizontal dashed lines are 95% Monte Carlo





Figure 8.8 Bias (a) and standard errors (b) for the population-average contrast
estimates for scenario b, along with 95% Monte Carlo confidence intervals.
Strength of effect modification is varied from weak (0.1 change in log odds
ratio per covariate standard deviation in the AB study) to strong (0.5 change
in log odds ratio per covariate standard deviation in the AB study). One of the
two effect modifiers was not adjusted for. The points are coloured by contrast,
with lighter shades for the AB population and darker for the AC population.
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Figure 8.9 Coverage zip plots for the dBC(AC) contrast estimate for scenario b.
Strength of effect modification is varied from weak (0.1 change in log odds
ratio per covariate standard deviation in the AB study) to strong (0.5 change
in log odds ratio per covariate standard deviation in the AB study). One of
the two effect modifiers was not adjusted for. The 95% confidence/credible
intervals are coloured as coverers (green) or non-coverers (purple), and the
colour change should occur at the 95th centile (i.e. nominal coverage). The




8.2.3 Scenario c: shared EM assumption
In scenario c the shared effect modifier assumption is broken, so that treatment
B is subject to weak effect modification whilst treatment C is subject to strong
effect modification and vice versa. We expect to see that all population
adjustment methods are capable of producing unbiased estimates in the AC
population, but that extrapolation into other populations is biased, and indeed
this is what occurs (Figure 8.10a). Standard errors (Figure 8.10b) and coverage
(Figure 8.11) are largely unchanged from scenario b (see also Table B.5). Again,
ML-NMR and STC show slight underestimation of the empirical standard
error when there is strong effect modification, leading to a small drop in
coverage down to around 93%.
The increase in bias for a standard indirect comparison when treatment
B is strongly modified compared to weakly modified (Figure 8.10a) is due to
the focus on the AC population. Since a standard indirect comparison does
not adjust for population differences, the estimates of dAB, dAC, and dBC are
the same regardless of population. However, when the target of inference is
a comparison in the AC population, the estimate of dAC(AC) is unbiased and
bias in the estimate of dAB(AC) (and thus dBC(AC)) is driven by the strength
of effect modification of treatment B. If the target of inference was instead
a comparison in the AB population, this pattern would be reversed (bias
now being driven by the strength of effect modification of treatment C). A
similar pattern, driven by the same mechanism, is observed in scenario b (see
Figure 8.2a).
When one of the two effect modifiers is not adjusted for, further bias is
introduced into the estimates, in all target populations (Figure 8.12a, see also
Table B.6). This bias is generally larger for estimates involving extrapolation of
treatment effects affected by strong unobserved effect modifiers, e.g. dAC(AB)
and dBC(AB) when C is strongly modified by a missing effect modifier. Again,
standard error is reduced when fewer effect modifiers are adjusted for (Fig-
ure 8.12b). Coverage for dBC(AC) is close to nominal level for all population
adjustment methods when the missing effect modifier for B is weak as the
incurred bias is small, but drops severely when the missing effect modifier for





Figure 8.10 Bias (a) and standard error (b) for the population-average contrast
estimates for scenario c, along with 95% Monte Carlo confidence intervals.
Each method (other than Bucher) adjusts for the full set of effect modifiers.
The shared effect modifier assumption is broken, so that treatment B is subject
to weak effect modification whilst treatment C is subject to strong effect
modification and vice versa. The points are coloured by contrast, with lighter
shades for the AB population and darker for the AC population.
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Figure 8.11 Coverage zip plots for the dBC(AC) contrast estimate for scenario c.
Each method (other than Bucher) adjusts for the full set of effect modifiers.
The shared effect modifier assumption is broken, so that treatment B is
subject to weak effect modification whilst treatment C is subject to strong
effect modification and vice versa. The 95% confidence/credible intervals are
coloured as coverers (green) or non-coverers (purple), and the colour change
should occur at the 95th centile (i.e. nominal coverage). The horizontal dashed





Figure8.12 Bias (a) and standard errors (b) for the population-average contrast
estimates for scenario c, along with 95% Monte Carlo confidence intervals.
One of the two effectmodifiers was not adjusted for. The shared effectmodifier
assumption is broken, so that treatment B is subject to weak effect modification
whilst treatment C is subject to strong effect modification and vice versa. The
points are coloured by contrast, with lighter shades for the AB population
and darker for the AC population.
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Figure 8.13 Coverage zip plots for the dBC(AC) contrast estimate for scenario
c. One of the two effect modifiers was not adjusted for. The shared effect
modifier assumption is broken, so that treatment B is subject to weak effect
modification whilst treatment C is subject to strong effect modification and
vice versa. The 95% confidence/credible intervals are coloured as coverers
(green) or non-coverers (purple), and the colour change should occur at the
95th centile (i.e. nominal coverage). The horizontal dashed lines are 95%
Monte Carlo confidence intervals for the coverage.
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8.2.4Scenario d: correlation between covariates
In scenario d, the correlation between covariates is varied between 0, 0.25, and
0.5, and the correlation is the same in both study populations. Figure 8.14a
shows that ML-NMR and STC are unaffected by the correlation between
covariates, achieving bias removal regardless of the correlation. Standard
errors are similarly unaffected (Figure 8.14b), and coverage is at the nominal
level (Figure 8.15). Table B.7 shows the results in tabular format. For MAIC,
both bias and standard error are reduced as the correlation between covariates
increases. This is because, as the correlation increases, the effective number
of covariates decreases and the overlap between study populations increases
(Figure 8.16). The simulation parameter κ is only a proxy for overlap and does
not account for correlation between covariates, so the true overlap changes
with the correlation despite holding κ constant at 0.5. Since MAIC cannot
eliminate the bias, coverage drops as the standard error decreases (as the
correlation increases), down to 93.4% (92.3, 94.6) when the correlation is 0.5.
When one of the two effect modifiers is not adjusted for, all population
adjustmentmethods produce biased estimates (Figure 8.17a, see also Table B.8).
However, as we expect, the amount of bias reduces as the correlation between
the observed and missing effect modifiers increases. If we were to continue
simulations with correlations tending closer to 1, the bias due to a missing
effect modifier would disappear entirely. Again, standard error is reduced
when fewer effect modifiers are adjusted for (Figure 8.17b). Coverage for all
population adjustment methods was slightly below the nominal level (around





Figure8.14 Bias (a) and standard errors (b) for the population-average contrast
estimates for scenario d, along with 95% Monte Carlo confidence intervals.
The correlation between covariates is varied between 0, 0.25, and 0.5. Each
method (other than Bucher) adjusts for the full set of effect modifiers. The
points are coloured by contrast, with lighter shades for the AB population
and darker for the AC population.
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Figure 8.15 Coverage zip plots for the dBC(AC) contrast estimate for scenario
d. The correlation between covariates is varied between 0, 0.25, and 0.5.
Each method (other than Bucher) adjusts for the full set of effect modifiers.
The 95% confidence/credible intervals are coloured as coverers (green) or
non-coverers (purple), and the colour change should occur at the 95th centile
(i.e. nominal coverage). The horizontal dashed lines are 95% Monte Carlo
confidence intervals for the coverage.
Figure 8.16 Joint covariate distributions in the AB and AC study, as the
correlation between covariates is varied. The true overlap is defined as the
proportion of the AC joint density contained within the 95% HDR of the AB





Figure8.17 Bias (a) and standard errors (b) for the population-average contrast
estimates for scenario d, along with 95% Monte Carlo confidence intervals.
The correlation between covariates is varied between 0, 0.25, and 0.5. One
of the two effect modifiers was not adjusted for. The points are coloured by




Figure 8.18 Coverage zip plots for the dBC(AC) contrast estimate for scenario d.
The correlation between covariates is varied between 0, 0.25, and 0.5. One of
the two effect modifiers was not adjusted for. The 95% confidence/credible
intervals are coloured as coverers (green) or non-coverers (purple), and the
colour change should occur at the 95th centile (i.e. nominal coverage). The




8.2.5 Scenarios e and f: between-study overlap and covariate-outcome
relationship
In scenarios e and f, the between-study overlap and covariate-outcome rela-
tionship are varied jointly. The between-study overlap is varied between 0 (no
overlap, all of AC population outside of the AB population), 0.5 (approximately
50% of AC outside of AB), and 1 (full overlap, all of AC within AB), and the
covariate-outcome relationship is either linear or non-linear (equation 8.2).
When the covariate-outcome relationship is linear, both ML-NMR and
STC produce unbiased estimates (Figure 8.19a, Table B.9). MAIC is unable to
produce any estimates when there is no overlap between study populations,
and remains biased when the overlap is 0.5. Only when the study populations
overlap completely does MAIC produce unbiased estimates.
When the covariate-outcome relationship is non-linear, ML-NMR and STC
(set to fit a linear relationship) are both biasedwhen there is no overlap between
the study populations. There is no discernible bias when the overlap is 0.5
or 1, as equation (8.2) behaves linearly within the range of the AB population.
However, prediction into another target population with a greater difference
in covariate values from the AB and AC populations would still result in bias.
Again, MAIC cannot produce estimates when there is no overlap between
study populations.
Standard errors for all population adjustment methods decrease as the
level of overlap increases (Figure 8.19b). Empirical standard errors are well-
estimated by model standard errors for ML-NMR and STC, however MAIC
only produced stable bootstrap model standard errors when the overlap was 1.
For the population adjustment methods, nominal coverage is achieved
when the covariate-outcome relationship is linear (Figure 8.20). With a non-
linear relationship, coverage drops slightly to 93.0% (91.9, 94.2) for ML-NMR
and to 93.4% (92.4, 94.5) when there is no overlap, but is unaffected at 0.5 and
full overlap as there is no discernable bias. MAIC achieves nominal coverage
for 0.5 and full overlap.
When one of the two effect modifiers is not adjusted for, all population
adjustment methods produce biased estimates (Figure 8.21a, Table B.10). As
expected, the bias due to the missing effect modifier reduces as the overlap
between studies increases, since the difference in the missing effect modifier
between the study populations becomes smaller. Due to this, coverage shows
the opposite relationship with overlap, dropping as the overlap decreases
(Figure 8.22). Again, standard error is reduced when fewer effect modifiers





Figure 8.19 Bias (a) and standard errors (b) the population-average contrast
estimates for scenarios e and f, along with 95% Monte Carlo confidence
intervals. Each method (other than Bucher) adjusts for the full set of effect
modifiers. The between-study overlap and covariate-outcome relationship
are varied jointly. The points are coloured by contrast, with lighter shades for
the AB population and darker for the AC population.
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Figure 8.20 Coverage zip plots for the dBC(AC) contrast estimate for scenarios
e and f. Each method (other than Bucher) adjusts for the full set of effect
modifiers. The between-study overlap and covariate-outcome relationship
are varied jointly. The 95% confidence/credible intervals are coloured as
coverers (green) or non-coverers (purple), and the colour change should occur
at the 95th centile (i.e. nominal coverage). The horizontal dashed lines are





Figure8.21 Bias (a) and standard errors (b) for the population-average contrast
estimates for scenarios e and f, along with 95% Monte Carlo confidence
intervals. One of the two effect modifiers was not adjusted for. The between-
study overlap and covariate-outcome relationship are varied jointly. The
points are coloured by contrast, with lighter shades for the AB population
and darker for the AC population.
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Figure 8.22 Coverage zip plots for the dBC(AC) contrast estimate for scenarios
e and f. One of the two effect modifiers was not adjusted for. The between-
study overlap and covariate-outcome relationship are varied jointly. The 95%
confidence/credible intervals are coloured as coverers (green) or non-coverers
(purple), and the colour change should occur at the 95th centile (i.e. nominal
coverage). The horizontal dashed lines are 95% Monte Carlo confidence
intervals for the coverage.
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8.2.6Scenarios g, h, and i: covariate distributions and correlation structures
In scenarios g, h, and i, the covariate distributions and correlation structures in
each study population are varied jointly. The covariate distributions are set to
either Normal or Gamma in each of the study populations, and the correlation
between covariates in the AC population was varied between 0, 0.25, and 0.5.
The correlation between covariates in the AB population was held constant at
0.25.
We are particularly interested in the performance of ML-NMR in this
scenario, since ML-NMR makes the assumption that distributional form and
correlation structure are the same in the AgD studies as in the IPD. Scenarios g,
h, and i break this assumption. Despite this, ML-NMR is not seen to incur any
bias when the distributional form and/or correlation structure are different
in each population (Figure 8.23). The empirical standard errors, and their
estimation by the model standard errors, are also unaffected (Figure 8.24). The
bias and standard error of MAIC are slightly smaller when the covariates in
the AB population are Gamma distributed compared to Normally distributed;
however, this is due to the skew of the Gamma distribution slightly increasing
the true overlap between the study populations (compare row 1 with 3, and
2 with 4, in Figure 8.26). Nominal coverage is achieved by all population
adjustment methods, regardless of the covariate distributions or correlation
structure (Figure 8.25). See Table B.11 for a table of these results.
Once again, when one of the two effect modifiers is not adjusted for, all
population adjustment methods produce biased estimates (Figure 8.27) but
standard error is reduced (Figure 8.28). Coverage is slightly reduced for
all population adjustment methods, to around 94%, as a result of the bias
(Figure 8.25). The results are tabulated in Table B.12.
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Figure 8.23 Bias in the population-average contrast estimates for scenarios
g, h, and i, along with 95% Monte Carlo confidence intervals. Each method
(other than Bucher) adjusts for the full set of effect modifiers. The covariate
distributions and correlation structures in each study population are varied
jointly. The points are coloured by contrast, with lighter shades for the AB
population and darker for the AC population.
270
8.2. SIMULATION RESULTS
Figure 8.24 Empirical and model standard errors for scenarios g, h, and i,
along with 95% Monte Carlo confidence intervals. Each method (other than
Bucher) adjusts for the full set of effect modifiers. The covariate distributions
and correlation structures in each study population are varied jointly. The
points are coloured by contrast, with lighter shades for the AB population
and darker for the AC population.
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Figure 8.25 Coverage zip plots for the dBC(AC) contrast estimate for scenarios
g, h, and i. Each method (other than Bucher) adjusts for the full set of effect
modifiers. The covariate distributions and correlation structures in each study
population are varied jointly. The 95% confidence/credible intervals are
coloured as coverers (green) or non-coverers (purple), and the colour change
should occur at the 95th centile (i.e. nominal coverage). The horizontal dashed
lines are 95% Monte Carlo confidence intervals for the coverage.
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Figure 8.26 Joint covariate distributions in the AB and AC study, as the
covariate distributions and correlation between covariates are varied. The true
overlap is defined as the proportion of the AC joint density contained within
the 95% HDR of the AB joint density, calculated using numerical integration.
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Figure 8.27 Bias in the population-average contrast estimates for scenarios
g, h, and i, along with 95% Monte Carlo confidence intervals. One of the
two effect modifiers was not adjusted for. The covariate distributions and
correlation structures in each study population are varied jointly. The points
are coloured by contrast, with lighter shades for the AB population and darker
for the AC population.
274
8.2. SIMULATION RESULTS
Figure 8.28 Empirical and model standard errors for scenarios g, h, and i,
along with 95% Monte Carlo confidence intervals. One of the two effect
modifiers was not adjusted for. The covariate distributions and correlation
structures in each study population are varied jointly. The points are coloured




Figure 8.29 Coverage zip plots for the dBC(AC) contrast estimate for scenarios
g, h, and i. One of the two effect modifiers was not adjusted for. The covariate
distributions and correlation structures in each study population are varied
jointly. The 95% confidence/credible intervals are coloured as coverers (green)
or non-coverers (purple), and the colour change should occur at the 95th
centile (i.e. nominal coverage). The horizontal dashed lines are 95% Monte




In this simulation study, we have investigated the performance of ML-NMR
in comparison with current population adjustment methods (MAIC and
STC), in a wide range of scenarios. ML-NMR and STC perform very similarly
throughout the simulation study. This is to be expected, as the twomethods are
both regression adjustment methods. ML-NMR offers additional advantages
over STC, including the ability to synthesise a larger network of treatments,
and to produce estimates in any target population. ML-NMR makes further
assumptions about the covariate distributions and correlation structure in
the aggregate population in order to derive the aggregate likelihood through
integration, namely that they are the same as in the IPD population. However,
the performance of ML-NMR was not found to be sensitive to this assumption
(see scenarios g, h, and i, Section 8.2.6).
Serious questions must be raised about the use of MAIC for population
adjustment. MAIC performed poorly in all simulation scenarios, and in some
cases even increased the bias compared to a standard indirect comparison.
Bootstrap error estimation was also extremely unstable, except for the largest
sample sizes. The issues with MAIC stem from the fact that it is a reweighting
method, and therefore cannot extrapolate. As such, bias can only be completely
removed when the population of the AgD study is entirely contained within
the population of the IPD study (see scenario e, Section 8.2.5). However, when
the two study populations overlap entirely there is unlikely to be much bias
as the imbalance in effect modifiers is necessarily small, and thus population
adjustment methods may not be needed. Furthermore, this means that MAIC
is only valid from at most one end of the indirect comparison—that with IPD
on the study with a broader distribution of covariates. MAIC analysis in the
other direction will result in estimates that are biased, possibly by more than a
standard indirect comparison (as well as being produced for a different target
population). If the two study populations do not overlap at all, then no MAIC
analyses are possible.
As regression methods, ML-NMR and STC are able to extrapolate beyond
the range of the IPD, producing estimates even when there is no overlap
between study populations. However, when extrapolation occurs, estimates
will only be unbiased if such extrapolation is valid. For example, in scenarios
e and f (Section 8.2.5), ML-NMR and STC produced biased estimates when
there was no overlap between populations and the true covariate-outcome
relationship was non-linear outside of the range of the IPD, but only a linear
relationship was accounted for.
277
8. SIMULATION STUDY
Notably, all population adjustment methods are susceptible to bias (and
as a result, under-coverage) when an effect modifier is missing from the
adjustment. This highlights the necessity of careful and considered selection
of potential effect modifiers prior to analysis (see Section 2.3.1; also Phillippo
et al. 2016; Phillippo et al. 2018a). When all effect modifiers have been
identified and included in the adjustment model, ML-NMR and STC are both
robust techniques for obtaining population-adjusted indirect comparisons.
The additional flexibility of ML-NMR makes this an attractive choice for




In this chapter, we begin by summarising the main contributions of this thesis
(Section 9.1). We then make suggestions for future research (Section 9.2),
before a final conclusion (Section 9.3).
9.1Summary and discussion of thesis
The contributions of this thesis can be split into five broad headings. Firstly,
we have reviewed the current literature on methods for population adjustment
and related problems, set out their properties and assumptions, and reviewed
applications in the published literature and in submissions to NICE.Motivated
by these reviews, we then proposed a new method for population-adjusted
indirect comparisons and network meta-regression combining IPD and AgD,
called Multilevel Network Meta-Regression, which aims to address the issues
with current approaches. We implemented ML-NMR using a general method
for numerical integration and efficient computational methods in Stan, before
applying ML-NMR to a real example of plaque psoriasis treatments with
binary outcomes. We then extended the ML-NMR framework to handle
general individual-level likelihoods, where the corresponding aggregate-level
likelihood may not have a known form, and applied this to an artificial
example of survival outcomes and to the plaque psoriasis example with
ordered categorical outcomes. Finally, we investigated the performance of
ML-NMR alongside current methods in a comprehensive simulation study.
9.1.1Review of population adjustmentmethods and surrounding literature
This thesis began with a review of the literature on methods for population
adjustment and closely related problems (Chapter 2). Population adjustment
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describes a general problem in which we wish to estimate the relative effects
of a set of treatments from a collection of studies, adjusting for differences in
baseline characteristics between studies, but where IPD are only available in a
subset of studies. In the simplest two-study scenario, outcomes from an IPD
AB trial are adjusted into the population of an AgD AC trial; a population-
adjusted indirect comparison is then formed between treatments B and C in
the AC trial population (Section 2.2). If there is a common comparator A arm
between the IPD and AgD studies, then an anchored indirect comparison is
formed using the relative effects. This is the same as the standard indirect
comparison described by Bucher et al. (1997), except that differences in effect
modifying covariates are adjusted for. If there is no common comparator arm,
then we are forced instead to form an unanchored indirect comparison using
the absolute effects on treatments B and C. In this case, all prognostic and
effect modifying covariates are required to be adjusted for in order to produce
an unbiased comparison—a very strong assumption, which is very hard to
verify.
The most widely used of the current methods, MAIC (Ishak et al. 2015;
Signorovitch et al. 2010) and STC (Caro and Ishak 2010; Ishak et al. 2015),
are based on ideas of reweighting and regression adjustment, respectively,
that date back several decades and have been applied to the closely related
problems of standardisation, generalisation, and calibration (Section 2.1). They
are both designed with the simple two-study scenario in mind, and are not
readily generalisable to larger networks of studies and treatments. They
are also limited to producing estimates in the AC trial population without
further assumptions, whichmay not match the target population for a decision.
Moreover, as a reweighting method MAIC cannot extrapolate, and requires
sufficient overlap between the IPD and AgD study populations. This severely
limits the range of scenarios in which MAIC can produce a valid comparison,
a fact borne out by the simulation study (Chapter 8).
Other approaches based on network meta-regression have also been
proposed (see Section 2.2.3; Donegan et al. 2013; Jackson et al. 2006, 2008;
Saramago et al. 2012; Sutton et al. 2008; Thom et al. 2015). These specify a
model at both the individual level, used to fit individuals in the IPD, and at
the aggregate level, used to fit the summary outcomes from the AgD. Several
of these approaches define the same model at the individual and aggregate
levels, and simply “plug in” mean covariate values from the AgD studies
(Donegan et al. 2013; Saramago et al. 2012; Sutton et al. 2008; Thom et al.
2015). However, this incurs aggregation bias when the link function is not
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the identity function (Berlin et al. 2002; Rothman et al. 2008). Several authors
propose splitting the estimation of EM interaction effects into between- and
within-study interactions (Donegan et al. 2013; Hua et al. 2016; Riley et al.
2008; Riley and Steyerberg 2010; Saramago et al. 2012; Thom et al. 2015) in
order to account for aggregation bias and investigate potential ecological bias,
but these models are not identifiable in small networks due to the additional
parameters. An alternative approach derives from the ecological inference
literature Jackson et al. (2006, 2008), where the aggregate-level model is an
integration of the individual-level model over the aggregate study population
(Jansen 2012). This avoids aggregation bias by correctly relating the individual
and aggregate levels of the model through integration, and the model scales
naturally to networks of all sizes. These models had previously only been
derived for the special case of binary covariates (Jansen 2012); however, we
later proceeded to generalise this approach and develop a general framework
for population-adjusted indirect comparisons and network meta-regression
combining IPD and AgD.
A key outcome of this reviewwas to set out the properties and assumptions
of these methods, in light of the surrounding literature. All methods for indi-
rect comparison and meta-analysis—population-adjusted or otherwise—rely
on some form of constancy assumption (Table 2.1). This assumption means
that either relative effects (for anchored indirect comparisons and connected
networks) or absolute effects (for unanchored indirect comparisons) are con-
stant across populations, with the latter being a much stronger assumption
and very hard to verify. Constancy may be conditional on a set of covari-
ates (for population-adjusted indirect comparisons and meta-regression) or
assumed to hold across all populations without adjustment (for standard
indirect comparisons and meta-analysis). Another key assumption, required
by MAIC and STC to produce estimates in target populations other than that
of the AgD trial, is the shared effect modifier assumption (Section 2.5). This
means that the relative effects of a given set of active treatments are modified
in the same way by the same set of effect modifying covariates. Prior to this
review, these assumptions had not been set out in this context, nor had the
theoretical properties of each of the respective methods been discussed in the
context of population adjustment. Moreover, there was no guidance on the
use of population adjustment methods in submissions to NICE, despite the
increasing use of such methods in submissions. This review was published
as NICE Decision Support Unit Technical Support Document 18 (Phillippo
et al. 2016; in abridged form as Phillippo et al. 2018a), alongside additional
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guidance on the use of population adjustment methods in submissions to
NICE. Since its publication, Technical Support Document 18 has been cited in
every technology appraisal in which population adjustment methods were
employed (Section 3.2).
In light of these assumptions and properties, we then reviewed the ap-
plications of MAIC and STC in the published literature (Section 3.1), and
applications of all forms of population adjustment in NICE Technology Ap-
praisal submissions (Section 3.2). These reviews revealed several deficiencies
in current practice, which have thus far limited the usefulness of population-
adjusted analyses for decision making. These include the prevalence of
unanchored analyses that rely on very strong assumptions that are very hard
to justify, the inability to produce estimates for the relevant decision target
population, and insufficient justification for variable selection or effect modifier
status.
These reviews also highlighted limitations of the current methods, moti-
vating the development of a new method, multilevel network meta-regression.
9.1.2 Development of multilevel networkmeta-regression
In Chapter 4, we proposed a new method for population-adjusted indirect
comparisons and network meta-regression combining IPD and AgD, which
we call multilevel network meta-regression. There are several key advantages
to ML-NMR, particularly in comparison with methods such as MAIC (Ishak
et al. 2015; Signorovitch et al. 2010), STC (Caro and Ishak 2010; Ishak et al.
2015), or other network meta-regression based approaches (Donegan et al.
2013; Jackson et al. 2006, 2008; Saramago et al. 2012; Sutton et al. 2008; Thom
et al. 2015).
Firstly, ML-NMR is applicable to treatment networks of any size, allowing
use of all available information. Unlike other meta-regression approaches,
the model remains identifiable in the two-study scenario, whilst avoiding
aggregation bias. The approach of Jackson et al. (2006, 2008) (on which
ML-NMR is based) also enjoys this property, however the model has only
been derived for binary covariates. Being an extension of IPD NMR, ML-
NMR scales naturally to larger networks, unlike MAIC or STC. Crucially for
decision making, comparisons may be provided in any target population
given sufficient information on the covariate distribution. MAIC and STC
require the shared EM assumption to produce estimates for populations other
than that represented by the AgD trial (Section 2.5). ML-NMR also uses this
assumption to identify the model in small networks (Section 4.5.2), but when
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larger networks of studies and treatments are available ML-NMR offers the
possibility of assessing and relaxing this assumption (Section 4.6.1).
All population adjustment methods rely on some form of constancy
assumption; ML-NMR (along with anchored MAIC and STC, and other meta-
regression based approaches) relies on conditional constancy of relative effects,
which means that all effect modifiers have been suitably adjusted for in the
model. The presence of residual heterogeneity or inconsistency indicates a
failure of conditional constancy of relative effects, since this means that there
are factors that affect the relative effects that have not been suitably accounted
for. Possible causes include unobserved effect modifiers or a misspecified
model (e.g. using an incorrect functional form of a covariate, or using the
shared EM assumption when it is invalid). It is therefore important to use
random effects models to assess heterogeneity and node splitting or unrelated
mean effects models to assess inconsistency.
9.1.3Eicient computation of ML-NMRmodels
In Chapter 5, we described several techniques for the efficient implementation
of ML-NMR in Stan, including transformation of covariates (Section 5.2.1) and
choosing an efficient parameterisation of hierarchical structures (Sections 5.2.2
and 5.2.3) such as random effects or exchangeable EM interactions. In the
extreme case, we must choose a suitable model parameterisation to avoid
pathological sampling behaviour and biased posterior estimates. These
concepts are equally applicable to implementations of AgD NMA and IPD
NMR in Stan, and also to implementations of this family of models in other
Bayesian software.
The use of QMC integration to obtain the aggregate-level model is a flexible
and widely applicable approach, which can be used regardless of the number
or form of covariates or the complexity of the model (Sections 4.3.3.2 and 5.1).
Using quasi-random sequences for numerical integration improves upon
the convergence rates of standard pseudo-randomMonte Carlo integration,
and retains this performance in high-dimensions. We have used a Gaussian
copula to impart a given correlation structure on the integration points,
whilst allowing free choice of the form of the marginal distributions; other
methods such as MAIC or STC ignore this correlation structure (Section 2.3.4).
Moreover, in Section 4.3.2 we showed (for multivariate Normal covariates) that
correlations between covariates are implicated in aggregation bias. Specifically,
when AgD are incorporated in a meta-regression with a non-identity link
function by “plugging in” mean covariate values, the amount of aggregation
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bias depends on the correlation between covariates, the strength of effect
modification, and the population variance of the effect modifying covariates.
Whilst we have found the use of a Gaussian copula to be very flexible in
accounting for observed relationships between covariates, other copulæ could
be used to assert relationship structures under different assumptions (Nelsen
2006). In comparison with MAIC and STC, this approach does require greater
effort in specifying the form of the marginal distributions and correlation
structure. Moreover, the marginal distributions and correlations may have
been specified incorrectly; however, ML-NMR was not seen to be sensitive
to this misspecification in the simulation study (Section 8.2.6). A limitation
of this approach is that uncertainty in specifying the form of the marginal
covariate distributions and the correlation structure is not accounted for.
9.1.4 Extension of ML-NMR to general likelihoods
The ML-NMR approach described in Chapter 4 relies on the form of the
aggregate-level likelihood being known (Section 4.2), however this may not
always be possible. Most notably, the form of the aggregate-level likelihood
is unknown when a survival or time-to-event outcome is of interest—as is
the case for the large majority of the applications of population adjustment
methods to date (Chapter 3). The extension of ML-NMR to handle general
likelihoods in Chapter 7 is thus well-motivated. As before, we begin by
fully specifying the individual-level model. However, the aggregate-level
model is then fitted by considering the likelihood contributions from the
AgD, which are obtained directly using numerical integration without the
need to specify the form of the aggregate-level likelihood. This approach
greatly expands the range of scenarios in which ML-NMR models can be
fitted. When the aggregate data consist of individual outcomes and summary
covariate information (such as survival data reconstructed from Kaplan-Meier
curves), the method is fully general: the individual-level model can take
any form, and the aggregate-level model can always be fitted via numerical
integration. However, when the aggregate data consist of summary outcomes
and summary covariate information, this approach is only applicable when the
aggregate marginal likelihood contributions can be expressed in terms of the
summary outcomes. This is only straightforward for discrete outcomes. This
would appear to limit the generality of the approach for continuous outcomes;
however, the aggregate-level likelihood has a known closed form for many
continuous individual-level likelihoods common in practice (Section 4.2).
Fittingmodels where part of the model has no explicit closed form presents
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new challenges, in particular for model comparison. Whilst the fit of data
points under a given model can always be investigated using the deviance (−2
times the log likelihood), computation of standard model comparison statistics
such as the DIC (Spiegelhalter et al. 2002) is complicated when the aggregate-
level likelihood has no closed form. In Section 7.2, we proposed instead to
use approximate leave-one-out cross validation for model comparison, as
described by Vehtari et al. (2016). This approach requires only the posterior
samples of the log likelihood contributions, and so can be computed without
a closed form aggregate-level likelihood.
9.1.5Comprehensive simulation study
In Chapter 8, we undertook a comprehensive simulation study to investigate
the performance of ML-NMR alongside MAIC, STC, and standard indirect
comparison in a wide range of scenarios, including varying sample sizes,
strength of effect modification, overlap between studies, and joint covariate
distributions. As well as validating the performance of the different methods
when assumptions were met, we were particularly interested in how the
methods fared when assumptions were broken: namely conditional constancy
of relative effects (i.e. no missing effect modifiers), the shared effect modifier
assumption, validity of extrapolation beyond the IPD study population, and
(for ML-NMR) correctly specifying the form of the marginal distributions
and correlations between covariates in the AgD study. The simulation study
focused on the two-study scenario for comparison with MAIC, STC, and
standard indirect comparison; however, we expect the conclusions regarding
ML-NMR to extend to larger networks also, since the underlying assumptions
remain the same.
ML-NMR was seen to perform well when the requisite assumptions were
met, largely eliminating the bias incurred by a standard indirect comparison
and estimating standard errors well. STC performed very similarly, being a
regression adjustment method also. ML-NMR additionally requires the joint
covariate distribution in the AgD studies to be correctly specified; in practice
this is likely to be achieved by inferring the forms of the marginal distributions
and the correlations between covariates from the IPD studies (Section 4.5.1).
However, the performance of ML-NMR was not found to be sensitive to this
assumption, and still performed well even when marginal distributions and
correlations were misspecified (Section 8.2.6).
In contrast to ML-NMR and STC, MAIC performed poorly in all simulation
scenarios, and in some cases even increased the bias compared to a standard
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indirect comparison. The issues with MAIC stem from the fact that it is a
reweighting method, and therefore cannot extrapolate. As such, bias can only
be completely removed when the population of the AgD study is entirely
contained within the population of the IPD study (see Section 8.2.5). However,
when the two study populations overlap entirely there is unlikely to be
much bias as the imbalance in effect modifiers is likely to be small, and thus
population adjustment methods may not be needed. Furthermore, this means
that MAIC is only valid from at most one company’s perspective of the indirect
comparison—that of the company whose study (for which they have IPD) has
a broader distribution of covariates. MAIC analysis from the other company’s
perspective (who has IPD on the other study, with a more restricted covariate
distribution) will result in estimates that are biased, possibly by more than a
standard indirect comparison (as well as being produced for a different target
population). If the two study populations do not overlap at all, then no MAIC
analyses are possible. The simulation study therefore raises serious questions
regarding whether MAIC is fit for purpose. Previous simulation studies
investigating MAIC have not observed this issue regarding overlap (Belger
et al. 2015a,b; Hatswell et al. 2018; Leahy 2019; Signorovitch et al. 2013a).
This is likely because they we not designed to vary the overlap of continuous
covariates between studies, instead basing simulations on scenarios with good
overlap where MAIC could work well, or because they focused on binary
covariates, where issues only arise when covariate proportions are close to
zero or one in the IPD study.
When an effect modifier was missing from the adjustment, and thus the
conditional constancy of relative effects assumption was broken, all population
adjustment methods were susceptible to bias (and as a result, under-coverage).
This highlights the necessity of careful and considered selection of potential
effect modifiers prior to analysis (Section 2.3.1). When all effect modifiers
have been identified and included in the adjustment model, ML-NMR and
STC are both robust techniques for obtaining population-adjusted indirect
comparisons. The additional flexibility of ML-NMR makes this an attractive
choice for population adjustment in a wide variety of scenarios.
9.2 Suggestions for future research
This thesis hasmotivated the need for newmethods for population adjustment,
described ML-NMR as a general and widely-applicable approach, and demon-
strated its performance in a wide range of simulated scenarios. However, open
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questions remain which warrant future research.
9.2.1Investigating data requirements
Whilst ML-NMR can in theory be applied to networks with any number
of treatments and any number of IPD and AgD studies, in practice there
must be sufficient data available to estimate the model. For example, we
may need to rely on the shared effect modifier assumption to identify EM
interaction coefficients for some treatments where IPD studies or a sufficient
number of AgD studies with a range of covariate distributions are not available
(Section 4.5.2), rather than fitting exchangeable or independent EM interaction
coefficients (Section 4.6.1). The simulation study showed that all population
adjustmentmethodswere sensitive to the validity of the shared EMassumption
(Section 8.2.3), and thus it is preferable not to rely on the shared EMassumption
unless supported by clinical or biological reasoning (Section 2.5). Even then,
it is desirable to assess and relax this assumption. Future simulation studies
could be undertaken to determine the data requirements for fittingmodelswith
exchangeable or independent EM interactions. Such simulation studies could
investigate the feasibility and performance of shared and independent EM
interaction models with different numbers of IPD and AgD studies, different
numbers of treatments in a class with exchangeable EM interactions, and
with varying ranges of covariate values between the studies. This would give
analysts using ML-NMR better intuition for the data requirements of such
models, which may help identify potential issues prior to analysis—perhaps
giving the opportunity to pursue greater availability of IPD, or identify more
informative prior distributions (here for the EM interaction coefficients and
the treatment effects) to supplement weaker data.
9.2.2Split between- and within-study interactions
The ML-NMR models that we have considered involve an individual-level
model where there is a single treatment-covariate interaction term β2,k , as in
equation (4.34b):
g(θi jk)  µ j + xTi jk(β1 + β2,k) + γk .
As we have described in Sections 2.2.3 and 4.7, several authors (Donegan et al.
2013; Hua et al. 2016; Riley et al. 2008; Riley and Steyerberg 2010; Saramago et al.
2012) have suggested to instead split the interaction term into a within-study
interaction β(w)2,k and a between-study interaction β
(b)
2,k , as in equation (4.51):




2,k + γk .
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The motivation is that combining information on interactions from within
and between studies can result in ecological bias due to unobserved effect
modifiers, and splitting the interaction term in this manner means that β(w)2,k
should be free from this bias (Hua et al. 2016). Several authors (Donegan et al.
2013; Riley et al. 2008; Riley and Steyerberg 2010; Saramago et al. 2012) use this
split interaction model to incorporate AgD studies, where the AgD studies
only contribute to the between-study interaction β(b)2,k and mean covariate
values are “plugged in”, as in equation (4.52):
g(θ• jk)  µ j + x̄Tjβ
(b)
2,k + γk .
In this case, when g(·) is not the identity function differences between β(w)2,k
and β(b)2,k are additionally due to aggregation bias (Greenland 1992).
ML-NMR avoids aggregation bias since the aggregate-level model is
appropriately related to the individual-level model through integration over
the covariate distribution in the AgD studies. However, unobserved EMs are
still a concern—whether these are individual-level covariates, or study-level
differences in treatment regimens or outcome definitions for example. We
have not split the interaction terms in the ML-NMR model: we assume that
there are no unobserved EMs so that the conditional constancy of relative
effects assumption holds, which is required in order to produce unbiased
estimates of population-adjusted relative effects.
The ML-NMR model could be modified to include split interaction terms
and assess the conditional constancy of relative effects assumption in this
manner, however this results in a non-identifiable model in the two-study
scenario, and likely requires substantial amounts of data to estimate well.
Instead, we have proposed assessing the conditional constancy of relative
effects assumption by investigating residual heterogeneity using a random
effects model (Section 4.6.2) and inconsistency using unrelated mean effects
or node-splitting models (Section 4.6.3), which have lesser data requirements
than splitting EM interactions. The presence of either residual heterogeneity or
inconsistency indicates a failure of the conditional constancy of relative effects
assumption, due to unobserved EMs or other model misspecification (such
as an invalid shared EM assumption). Future research could investigate the
relative performance of fitting ML-NMR models with split interaction terms
versus checking for residual heterogeneity or inconsistency as methods for
assessing the conditional constancy of relative effects assumption. For example,
it remains to be seen—given sufficient data for either approach—which would
be more powerful and better able to detect failings in this crucial assumption.
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9.2.3Including contrast-based aggregate data
The ML-NMR model that we have developed is based on aggregate data
being available in an arm-based format, for example event counts or mean
outcomes on each treatment arm in an AgD study. However, it is also common
for aggregate data to be available in a contrast-based format as a summary
relative effect measure between two treatment arms, such as log odds ratios or
a difference in means. In this format, studies with two treatment arms report
a single relative effect; studies with three treatment arms report two relative
effects (which are correlated, by virtue of a shared reference arm), and so on.
In this case, the usual approach (as described in Section 1.2.8 for AgD
NMA; Dias et al. 2011c; Salanti et al. 2007; Woods et al. 2010) is to use a
multivariate Normal likelihood, with marginal distributions and covariances
y• jab ∼ N(θ• jab , s2jab) (9.1a)
cov(y• jab , y• jac)  v(a)jbc , (9.1b)
where y• jab is the summary relative effect of treatment b vs. treatment a in
study j, with standard error s jab . For studies with three or more treatment
arms, the relative effects y• jab and y• jac for any two treatments b and c both
compared to a have covariance v(a)jbc . If the covariance v
(a)
jbc is not reported but
the standard error s jbc of the c vs. b relative effect y jbc is available, then the









In cases where the relative effects are simple differences between mean
outcomes on each treatment, the covariance v(a)jbc is equal to the variance of
the outcome in the reference treatment a arm (Dias et al. 2011c). When the
reference treatment arm variance is not reported, it may be possible to impute
from those reported in other trials (Dakin et al. 2011). When a study reports
only a single relative effect, the likelihood is univariate Normal given by
(9.1a). In the context of ML-NMR, the expected marginal relative effect θ• jab
is modelled with an identity link function; thus the usual integration of the
individual-level model over the covariate distribution reduces to “plugging in”
mean covariate values x̄ j like so
θ• jab  η jb(x̄ j) − η ja(x̄ j)
 x̄T(β2,b − β2,a) + γb − γa ,
(9.3)
where η jk(·) is the linear predictor described previously (Chapter 4):
η jk(x)  µ j + xT(β1 + β2,k) + γk . (9.4)
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This approach, whilst widely used in the general meta-analysis literature,
relies upon the assumption of (multivariate) Normality. This is typically justi-
fied asymptotically by the Central Limit Theorem, but may not be appropriate
in practice—particularly for the results of smaller studies. An alternative
approach, requiring further investigation, would be to follow the methods
described in Chapter 7 and attempt to derive the aggregate marginal likelihood
contributions for these data (Section 7.1). The ML-NMR model for general
likelihoods, written in terms of the likelihood contributions from the different
levels of the model, was given in equation (7.3). After specifying an individual-
level model, defining the individual conditional likelihood contributions given
the covariates, the individual marginal likelihood contributions were obtained
by integration over the covariate distribution. With summary relative effects
data, the aim would be to write the product of these individual marginal
likelihood contributions over the individuals in both treatment a and b arms
in terms of the summary relative effect y• jab . This would avoid the need for
a Normality assumption, and instead fit the summary relative effects using
their exact likelihood contributions. However, it remains to be seen whether
the required derivations are analytically tractable.
9.2.4 Including results from subgroup analyses and reported regression
coeicients
As discussed in Section 9.2.1, the most demanding data requirements for
ML-NMR often involve the estimation of EM interactions. To estimate these
parameters for a given treatment we require either: IPD studies involving
the treatment, multiple AgD studies involving the treatment with sufficiently
different covariate distributions, or an identifying assumption such as the
shared EM assumption. These requirements may be difficult to meet: the
acquisition of IPD is often non-trivial, there are only a certain number of
relevant trials reported in the literature, and the shared EM assumption may
not always be appropriate. Therefore, any additional sources of information on
EM interactions are valuable and likely to aid estimation of ML-NMR models.
Potential sources of information include the results of subgroup analyses, or
reported regression coefficients.
When results of subgroup analyses are available, the one possible solution
is to translate any difference in treatment effects between subgroups into an
informative prior for the corresponding EM interaction parameter. However,
this is not an exact approach, and may not be the most efficient use of such
information. Alternatively, the aggregate-level model can be modified to
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directly incorporate the subgroup outcomes; in other words, rather than the
usual aggregate-level model for a summary outcome y• jk , we would fit an
aggregate-level model to each summary outcome y• jk;z in a set of z  1, . . . , Z j
subgroups. The subgroup variables themselves may be discrete covariates, or
continuous covariates that have been split into categories.
If outcomes y• jk;z are reported in a factorial fashion for each distinct
combination of subgroup variables, then the aggregate-level model becomes








f jk(x) dx , (9.5b)
where Xz is now the support of the covariates in subgroup z. The Quasi
Monte-Carlo integration approach (Sections 4.3.3.2 and 5.1) can be modified to
fit this aggregate-level model. Firstly, Ñ integration points x̃ jk are generated
from the full covariate distribution f jk(·) (Section 5.1). Then these integration
points are split into each discrete subgroup, labelled as x̃ jk;z . Finally, the

















The practical properties of this approach require further investigation. For
example, it is likely that a greater number of integration points will be required
compared to an analysis without subgroups, since the integration points are
being split amongst Z j discrete subgroups. Furthermore, this approach may
run in to difficulties if certain subgroups are narrowly-defined or specified
at extreme covariate values, since the number of integration points in such
subgroups may become too small. Such issues become increasingly likely as
the number of subgroup variables increases.
If outcomes are not reported for each discrete combination of subgroup
variables, but are instead reported marginally by each subgroup variable, then
the above approach is not appropriate since the marginal subgroup outcomes
are correlated. It is not immediately apparent how such correlations can be
calculated, nor how the correlated subgroup outcomes should be modelled.
When reported estimates of regression coefficients are available, alongwith
their standard errors (and preferably their correlations), these may simply be
incorporated into informative prior distributions for the corresponding model
parameters. A further potential source of information on model parameters is
expert opinion, from which informative prior distributions may be elicited.
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An important consideration when including information from either
subgroup analyses or reported regression coefficients is the possibility of
reporting bias. It is more likely that ad hoc subgroup analyses are reported if
they are “significant” or demonstrate a large difference in treatment effects—
even if the observed effect modification is entirely chance—and thus any
reported ad hoc subgroup analyses are likely to be biased towards larger
estimates of effect modification (Brookes et al. 2004; Hahn et al. 2000). There
should therefore be a strong preference for using pre-specified subgroup
analyses to inform ML-NMR, in an attempt to avoid such bias.
9.2.5 Addressing limitations in included studies
Throughout this thesis, we have assumed that the studies included in the
analysis are internally valid; that is, they produce unbiased estimates of
relative treatment effects within their respective sample populations. Issues
with internal validity are commonly highlighted using a structured checklist,
such as the Cochrane Risk of Bias tool (Higgins et al. 2011, 2016).
When IPD are available, it may be possible to account for certain issues
of internal validity through an appropriate method of analysis. For example,
non-compliance issues are commonly dealt with using instrumental variable
methods to obtain complier average causal effects (DiazOrdaz et al. 2018;
Imbens andRubin 1997). Severalmethods to account for treatment switching in
the analysis of survival or time-to-event outcomes are available, including rank-
preserving structural failure time models (Robins and Tsiatis 1991), iterative
parameter estimation (Branson and Whitehead 2002), and inverse probability
of censoring weighting (Robins and Finkelstein 2000). Future research could
investigate incorporating such methods into ML-NMR analyses.
Missing covariate and outcome data are also likely to be encountered
within the IPD. Multiple imputation is a widely-used method of dealing
with missing data (Kenward and Carpenter 2007; Little and Rubin 2002), to
which the Bayesian framework is well-suited. Missing data can be imputed at
every iteration of the MCMC sampler, incorporating the uncertainty arising
from the missing values into the posterior distribution (Jackson et al. 2009;
Mason et al. 2012). Such approaches have previously been described for IPD
NMA (Quartagno and Carpenter 2016), and apply similarly to ML-NMR by
extension.
However, when such issues are present within the AgD studies there may
be little that can be done. If an adjustment was performed in the original
analysis of the study and subsequently published, then the adjusted summary
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relative effect estimates could instead be incorporated into themodel following
the approach described in Section 9.2.3. Otherwise, ML-NMR (as with AgD
NMA) can only note where biases may be present in the included AgD studies.
In a decision making context, threshold analysis is a form of sensitivity
analysis that aims to determine whether biases in the included evidence could
plausibly alter the treatment decision—without requiring the estimation of
or adjustment for any such biases—and may also be applied to the results of
ML-NMR analyses (Caldwell et al. 2016; Phillippo et al. 2018b, 2019b).
9.2.6Model fit andmodel comparison
When fitting NMAmodels in a Bayesian framework, model fit is often assessed
using the residual deviance and different models are often compared using the
DIC (Dias et al. 2011c; Spiegelhalter et al. 2002), as described in Section 1.2.6.
We can follow this approach for ML-NMR models also, as long as the form of
the aggregate likelihood is known (Section 5.3).
However, when using the two-parameter Binomial aggregate-level likeli-
hood to model summary count data, there are some additional complications.
These stem from the fact that the likelihood has more than one parameter—the
adjusted mean probability p̄′jk and the adjusted number of individuals N
′
jk—
and both are modelled parameters. Firstly, calculating the effective number of
parameters pD requires evaluating the residual deviance at the fitted values.
In likelihoods with more than one parameter such as the two-parameter
Binomial, the fitted values do not fully determine the values of the parameters.
In this case, we need to plug in a suitable value of N′jk ; we chose the posterior
median, but other choices could be made such as the unadjusted sample size
N jk . Secondly, when calculating the saturated deviance, the two modelled
likelihood parameters are not uniquely defined at a given fitted value ŷ• jk ;
any combination of N′jk and p̄
′
jk could be chosen to produce a given value of
ŷ• jk  N′jk p̄
′
jk . We chose to calculate the saturated deviance under a model
where p̄′jk perfectly predicts the observed number of events at each posterior
sample of N′jk , but other choices include fixing N
′
jk  N jk . This second issue
can be avoided by instead using the deviance (i.e. without subtracting the
saturated deviance to obtain the residual deviance) to calculate DIC and pD ;
however, whilst this does not affect comparisons between candidate models
this does inhibit checking absolute model fit, particularly between the IPD
and AgD contributions to the model since these will be scaled differently
(Section 5.3.1.2). It remains to be seen which approaches to calculating the
effective number of parameters and the residual deviance are theoretically or
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practically most desirable. However, these choices only relate to the aggregate
part of the model, and since the overall model fit and DIC will be dominated
by the individual-level model and its fit to the IPD, the choice is unlikely to
make much practical difference.
When the form of the aggregate-level likelihood is unknown, as is the
case when using the generalised approach in Chapter 7 that calculates the
likelihood contributions directly, we need to take an alternative approach
to assessing model fit and model comparison. In Section 7.2, we suggested
using approximate leave-one-out cross validation instead, following Vehtari
et al. (2016) to use Pareto-smoothed importance sampling to approximate
the expected log pointwise predictive density. PSIS-LOO requires only the
posterior samples of the log likelihood, and can thus be calculated without
explicit knowledge of the form of the likelihood. This approach works well
when the AgD are in the form of individual outcomes and summary covariate
distributions, as is the case for survival data reconstructed from Kaplan-Meier
curves, and we successfully used PSIS-LOO to perform model comparison
for the artificial survival example in Section 7.3. However, the approximation
used by PSIS-LOO breaks down when there are data points that are highly
influential; this is the case when the AgD are summary outcomes and there
are only a small number of AgD studies per treatment. In this case, each
aggregate data point is highly influential, and may even be “saturated” in the
model if it is the only data point informing a parameter (e.g. a treatment effect).
We suggested some solutions to this issue in Section 7.2, including basing
model comparison only on the IPD, or modifying the PSIS-LOO approach to
ignore data points that are saturated in the model (since these data points will
always be perfectly fit, under any model). The latter solution is preferable,
since the fit to AgD studies which are not saturated in the model is taken into
account. However, at present this requires manually selecting the data points
to ignore from the PSIS-LOO calculation, which is arduous—particularly in
larger networks. It should be possible to automatically determine the data
points that are saturated in the model and exclude these from the PSIS-LOO
calculation, making this approach more practically appealing; this is an area
for further research. Indeed, once this practical limitation has been addressed,
PSIS-LOO may be readily applied to standard AgD NMA, where the same
issue is frequently encountered, as well as IPD NMR or ML-NMR. This is
an attractive proposition, since PSIS-LOO has several benefits over DIC: it
is a better measure of future predictive performance; it is fully Bayesian,
accounting for the full posterior distribution rather than relying on plug-in
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posterior estimates; and standard errors facilitate judgement of differences
when comparing models (see Section 7.2; Gelman et al. 2013b; Vehtari et al.
2016).
9.2.7Incorporating data from single-arm or observational studies
The methods developed in this thesis are focused on scenarios where a
connected network of randomised controlled trials is present. However, as we
have identified in our review of the applied literature and submissions to NICE
(Chapter 3), the majority of applications of population adjustment methods
such as MAIC and STC to date have involved single-arm or observational
studies in disconnected networks. An important area for future research is
therefore the extension of ML-NMR to incorporate data from single-arm or
observational studies.
One possible approach is to place a random effect distribution on the
study-specific baselines µ j (Dias et al. 2013c; Li and Begg 1994; Thom et al.
2015). This is straightforward under the reference treatment parameterisation
(Section 1.2.2), since the baseline parameters all refer to the reference treatment
1. Data from single-arm studies are then incorporated by comparison with the
predicted absolute effects on the reference treatment, using the same individual-
or aggregate-level model as for the randomised studies in equation (4.34). The
assumption here is that absolute treatment effects can be predicted on average
given the covariates, and that any remaining differences in absolute outcomes
between studies are random. This is a very strong assumption, requiring
that there are no systematic differences in prognostic or effect modifying
covariates between study populations. Moreover, when this assumption does
not hold, biases can be introduced across the treatment network—including for
comparisons only informed by randomised studies (placing random effects on
the study-specific baselines interferes with randomisation, see Dias et al. 2013c;
Senn 2010). Unanchored MAIC or STC make an even stronger assumption
(conditional constancy of absolute effects, see Section 2.3.2), requiring that
absolute treatment effects can be predicted exactly given the covariates; this
would be equivalent to a single fixed baseline µ across studies.
If comparative observational data are available (i.e. includingmore than one
treatment, and thus informing relative rather than absolute effects) then other
approachesmay be taken (Schmitz et al. 2013). Observational datamay be used
to create informative prior distributions, potentially down-weighted using a
“power prior” to reflect additional uncertainty in the evidence (Prevost et al.
2000). Another approach is to assume that relative effects are exchangeable
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between different study types using a hierarchical model (Prevost et al. 2000;
Schmitz et al. 2013); relative effects can then be compared between different
study types, and it is also possible to incorporate bias adjustment and to allow
for additional uncertainty in observational evidence by down-weighting.
Importantly, including single-arm or observational data in unanchored
indirect comparisons or in larger networks requires very strong assumptions
(Section 2.3.2). Such analyses are susceptible to residual bias due to un-
measured confounding. It is therefore crucial to assess residual bias if such
analyses are to be useful for decision-making.
9.2.8 Quantifying residual bias due to unmeasured confounding in
unanchored indirect comparisons
Since they respect within-study randomisation, anchored indirect comparisons
are unaffected by differences in prognostic variables between studies, and
need only to account for differences in effect modifying variables. Conversely,
unanchored indirect comparisons do not rely on within-study randomisation,
and are therefore susceptible to large amounts of systematic error unless all
prognostic variables and effect modifiers are accounted for. If unanchored
indirect comparisons are to be used, it is therefore necessary to attempt to
quantify the possible extent of any residual systematic error resulting from
unobserved prognostic variables and effect modifiers.
The simplest way to quantify residual bias is by comparing observed and
predicted outcomes on the treatment of interest in a range of different studies
in the target population; however, this might not be a viable option if there
are no such studies available. It should be noted however that unobserved
covariates are only one source of heterogeneity between studies (and bias in
an ensuing indirect comparison); for example, differences in study design and
conduct will also introduce heterogeneity, but cannot be accounted for with
population adjustment methods. The way in which residual systematic error is
quantified is therefore an area that requires further research. We explore some
initial suggestions here (also published in Phillippo et al. 2016), focusing on
the two-study unanchored indirect comparison scenario, although the ideas
generalise to larger networks.
9.2.8.1 Out-of-samplemethods
One possible method for quantifying the possible extent of systematic bias
present in a unanchored indirect comparison, comparing a treatment B in
an IPD study with a treatment C in an AgD study, involves comparing the
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heterogeneity observed in a set of studies in the target population to the
heterogeneity in predictions from the model.
Firstly, a set of external studies in the target population with aggregate
data on the relevant outcome is identified; these need not all be on the
same treatment. A random-effects pooling across absolute outcomes on
study arms in the target population, controlling for treatment, is then carried
out. Predicted outcomes on treatment B in each of the study arms used in
the pooling can be obtained using a population adjustment method, and a
similar pooling performed. If all prognostic variables and effect modifiers are
accounted for, then the between-studies variation of the predicted outcomes,
say τ2∗ , will match that of the observed outcomes τ2 (that is, residual variation
will be minimised). Conversely, lower between-studies variation of predicted
outcomes would be expected if some prognostic variables and/or effect
modifiers remain unaccounted for. The ratio of the between-studies variance in
predicted to observed outcomes, τ2∗ /τ2, could be interpreted as the proportion
of systematic error “explained” by the included covariates. It is likely that, in
practice, limited study data will be available, and therefore the estimation of
between-study variance may be difficult.
Methods based on between-study variance should be underpinned by a
protocol-driven systematic review to prevent selection of an overly homoge-
neous sample of studies for inclusion. Likewise, a company’s own trials would
be expected to be more homogeneous than a wider selection of trials in the
target population.
9.2.8.2In-samplemethods
Other approaches for quantifying the systematic error in unanchored compar-
isons are possible. For example, if regression-based approaches such as STC
or ML-NMR are used, cross-validation methods (e.g. Picard and Cook 1984)
enable the estimation of the prediction error in the outcome model, which is
largely due to missing prognostic variables and/or effect modifiers. K-fold
cross-validation is a frequently used method, in which the IPD are split into
K equal-sized sets. Each of the K sets is omitted in turn at the model fitting
stage, and used as a validation set to check the model predictions. Prediction
error may then be averaged over the K sets. A value of K  10 is often used,
although the choice of K should be based on the situation at hand, particu-
larly with reference to the available sample size, as there is a bias-variance
trade-off. If regression-based approaches such as STC or ML-NMR are used,
R2 values may be used to assess the predictive performance of the model;
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R2 may be interpreted as the proportion of variance explained by the model,
similarly to the between-studies variance ratio described above (e.g. Xu 2003).
(A Bayesian approach to calculating R2 is described by Gelman et al. (2018),
whichwould be appropriate forML-NMR in a Bayesian framework.) A general
disadvantage in our context of cross-validation, R2, and other “in-sample”
methods for checking predictive accuracy (as opposed to the “out-of-sample”
methods above), is that the individuals in the IPD trial are likely to be more
homogeneous than those of the wider target population, thus leading to
overconfidence in the abilities of population adjustment methods to predict
outcomes in the target population. In-sample methods in general will most
likely underestimate the true amount of residual variation.
9.2.9 An R package for ML-NMR
Stan code for implementing ML-NMR is provided in Appendix A. The code
is modular and designed to be easily repurposed: it is straightforward to
substitute in different likelihoods and link functions to model other outcomes.
However, a working knowledge of Stan and R is still required. We therefore
plan to develop an R package that implements the ML-NMRmodels in a more
user-friendly manner. Since ML-NMR is an extension of the standard NMA
framework, with AgD NMA and IPD NMR as special cases (Section 4.6), such
an R package would also enable a broad range of network meta-analyses with
any level of AgD and IPD availability. The package would also simplify the
generation of numerical integration points (Section 5.1), support checking
of MCMC convergence and numerical integration error, calculate model fit
and model comparison statistics (Section 5.3), and facilitate the production of
estimates of quantities of interest in different target populations (Section 4.4).
Such a package would streamline the process of implementing ML-NMR
models, and make the methods accessible to a wider range of users.
9.3 Conclusion
In this thesis, we have reviewed the literature on population adjustment
methods and their applications; proposed ML-NMR as a new and general
method for population-adjusted indirect comparisons and network meta-
regression combining IPD andAgD; provided efficient computationalmethods
for implementing ML-NMR; and investigated the performance of ML-NMR
alongside current methods in a comprehensive simulation study. Whilst we
have been motivated by the context of population adjustment in network
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meta-analysis and indirect comparisons of randomised controlled trials, with
a particular focus on health technology assessment and appraisal, there is
potential for impact in the wider literature. The problem of synthesising
information reported at different levels of aggregation is common to many
areas, and the methods developed in this thesis are likely to be applicable
to this general problem in a variety of contexts. Of particular note is the
ecological inference literature, where integration of an individual-level model
over a population has thus far been pursued algebraically (Jackson et al. 2006,
2008; Salway and Wakefield 2005), and which inspired the first applications
to network meta-regression (Jansen 2012). As we have discussed in this
final chapter, several areas for future research still remain, which would
further support the practical implementation of ML-NMR and its extension to
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BMI Body mass index
CDF Cumulative distribution function
DIC Deviance information criterion
DR Doubly robust
ELPD Expected log predictive density
EM Effect modifier
ESS Effective sample size
ETN Etanercept
FDA Food and Drug Administration
FE Fixed effect
GLM Generalised linear model
HDR Highest density region
HMC Hamiltonian Monte Carlo
HR Hazard ratio
IPD Individual patient data





LOOIC Leave-one-out information criterion
MAIC Matching adjusted indirect comparison
MCMC Markov chain Monte Carlo
MCSE Monte Carlo standard error
MGF Moment generating function
ML-NMR Multilevel network meta-regression




PASI Psoriasis area and severity index




PSIS Pareto-smoothed importance sampling
QMC Quasi-Monte Carlo
RE Random effects
SATE Sample average treatment effect
SATT Sample average treatment effect on the treated
SD Standard deviation
SEC Secukinumab
SMD Standardised mean difference
SPATE Superpopulation average treatment effect




UME Unrelated mean effects
UST Ustekinumab




0 A vector of zeros
(·) Indicator function
α Parameters in a propensity score model
β1 Regression parameter for prognostic effects of covariates
β2,ab Regression parameter for interaction of effect modifying
covariates with the relative effect of treatment b vs. a; we
define β2,k  β2,1k
γab Individual-level (conditional) relative effect of treatment b vs.
a; we define γk  γ1k
δ jab Study-specific relative effect of treatment b vs. a in study j;
we define δ jk  δ j1k
η jk(x) Linear predictor at covariate values x, in study j on treatment
k
θ• jk Expected aggregate (marginal) outcome on treatment k in
study j; we write simply θjk when there is no ambiguity
θi jk Expected individual (conditional) outcome for individual i
in study j on treatment k
λ jk(t) Hazard function for treatment k in study j
µ(b)j Study-specific baseline (intercept) parameters, with respect
to treatment b, for study j; we write µ j for µ(1)j when there is
no ambiguity
ν j Shape parameter for survival distribution in study j
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ξ Parameter vector, consisting of µ j , β1, β2,k , and γk
π(·) A likelihood distribution; for ML-NMR we distinguish be-
tween πInd(·) and πAgg for individual- and aggregate-level
likelihoods, respectively
ρ j;l1 l2 Correlation between covariates xl1 and xl2 in study j
σ2jk Variance for individual-level Normal likelihood, on treatment
k in study j
σ2
β2;l
Variance of exchangeable effect modifier distribution for the
l-th covariate




Φ(·) Standard Normal cumulative distribution function
ψ(k)ab Correlation between random effects δ jka and δ jkb
Ω jk Correlationmatrix between covariates on treatment k in study
j
cm Latent cutpoints for an ordered categorical outcome model
C( · · · ) Copula function
dab(P) Population-average relative effect of treatment b vs. a in
population P, and we define dk(P)  d1k(P); when constancy
of relative effects is assumed (e.g. for an NMA), we drop the
subscript (P)
Dres;• jk Residual deviance contribution for the aggregate data on
treatment k in study j
Dres;i jk Residual deviance contribution for individual i on treatment
k in study j
Dres Total residual deviance
f jk(·) Joint covariate distribution on treatment k in study j, with
marginal distributions f jk;l(·)




h(·) A general function of the covariates and parameters
H(·) An objective function to be minimised; HMAIC(·) for MAIC,
HEB(·) for entropy balancing
J Number of studies
K Number of treatments
L Number of covariates
Li jk(ξ; yi jk , xi jk) Individual conditional likelihood function for an individual
i in study j on treatment k, conditional on covariates xi jk
Li jk(ξ; yi jk) Individual marginal likelihood function for an individual i
in study j on treatment k
L• jk(ξ; y• jk) Aggregate marginal likelihood function for aggregate data
on treatment k in study j
mβ2;l Mean of exchangeable effect modifier distribution for the l-th
covariate
Mx(P)(·) Moment generating function for covariate x in the population
P
M Number of categories, for a categorical outcome
N jk Number of individuals in study j on treatment k
Ñ Number of numerical integration points
pi jk Probability of an event for individual i in study j on treatment
k
p̄ jk Average probability of an event in study j on treatment k
pD Effective number of parameters, based on residual deviance
p(x) Propensity score, as a function of covariates
s jk Standard error of the mean outcome on treatment k in study
j
S jk(t) Survival function for treatment k in study j
ti jk Survival time for individual i in study j on treatment k
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T A set of treatments
ũ Uniform points in the unit hypercube, for numerical integra-
tion
ũ∗ Correlated points in the unit hypercube, for numerical inte-
gration
wik For MAIC, the weight assigned to individual i on treatment
k in the AB trial
x Vector of covariates, with xEM denoting the subvector of effect
modifiers
x̃ Vector of numerical integration points
x̄ jk Vector of mean covariate values on treatment k in study j
X Support of x
y• jk Summary outcome on treatment k in study j; we write simply
y jk when there is no ambiguity




This appendix provides Stan code for the NMA and ML-NMR models used
in this thesis. Code for binary outcomes, as used in Chapter 6, is given in
Section A.1. Code for ordered categorical outcomes, as used in Section 7.4,
is given in Section A.2. Code for survival outcomes, as used in Section 7.3,
is given in Section A.3. The Stan code is modular and designed to be easily
repurposed: different likelihoods and link functions may be substituted in to
model other outcomes. We outline how to run the ML-NMR models in Stan
from R in Section A.4.
A.1Binary outcomes
This section provides Stan code for the analysis of binary outcomes, as used in
Chapter 6.
A.1.1Networkmeta-analysis
Firstly, we provide Stan code for fixed effect (Section A.1.1.1) and random
effects (Section A.1.1.2) network meta-analysis using aggregate data (i.e. event
counts per arm). We also provide code for assessing consistency using an
unrelated mean effects model (Section A.1.1.3).
A.1.1.1Fixed eect
The following Stan code can be used to fit a fixed effect AgD NMA. Here we
consider a binary outcome reported as event counts per arm, synthesised using
a Binomial likelihood and probit link function. Other likelihoods (line 45) and
link functions (line 37) may be substituted in. In the generated quantities block,
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the variables resdev_alt and totresdev_alt provide the residual deviance
contributions and total residual deviance under the equivalent model where
some studies are fitted with IPD—i.e. here using a Bernoulli likelihood for




int<lower = 2> n_i; // Number of data points
5 // Data
int<lower = 0> y[n_i]; // Number of events
int<lower = 1> n[n_i]; // Number of individuals
int<lower = 1> trt[n_i]; // Treatment code
int<lower = 1> study[n_i]; // Study
10
// Priors
real<lower = 0> prior_sd_mu;
real<lower = 0> prior_sd_d;
15 // For equivalent IPD + AgD deviance calculation
int<lower = 0, upper = 1> has_ipd[n_i]; // IPD study indicator
}
transformed data {
int<lower = 2> n_t = max(trt); // Number of treatments
20 int<lower = 1> n_s = max(study); // Number of studies
}
parameters {
vector[n_s] mu; // Study baselines





30 // Linear predictor
for (i in 1:n_i) {
if (trt[i] > 1) eta[i] = mu[study[i]] + d[trt[i] - 1];








mu ~ normal(0, prior_sd_mu);
d ~ normal(0, prior_sd_d);
// Likelihood







50 vector[n_i] yhat = to_vector(n) .* theta;
real totresdev;




for (i in 1:n_i) {
// Log likelihood
log_lik[i] = binomial_lpmf(y[i] | n[i], theta[i]);
60
// Residual deviance
resdev[i] = 2 * (lmultiply(y[i], y[i] / (n[i] * theta[i])) +
lmultiply(n[i] - y[i],
(n[i] - y[i]) / (n[i] - n[i] * theta[i])));
65
// For equivalent IPD + AgD model
if (has_ipd[i] == 1){
resdev_alt[i] = -2 * (y[i] * log(theta[i]) +
(n[i] - y[i]) * log(1 - theta[i]));









The fixed effect model (Section A.1.1.1) can be modified to include random
effects. Here, we assume homogeneous heterogeneity standard deviation τ,
which is given a half-Normal prior distribution (line 126; note the constraint
on the parameter tau to have a lower bound of 0 on line 101). The functions
block defines functions to construct the random effects structure within the
Stan program; alternatively, this could be constructed externally (e.g. in R)
and passed as data. The non-centered RE parameterisation is used (see
Section 5.2.3), via the Cholesky decomposition of the RE correlation matrix
(line 90). Transformed random effects are sampled as independent standard
Normal (line 129), which are then back-transformed (line 109).
1 functions {
// Construct RE correlation matrix
matrix Rho(int[] trt, int[] study, int n_i, int n_s) {
int ddim[n_s];
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5 int s = 1;
int arms = 0;
for (i in 1:n_i) {
if (trt[i] > 1) arms += 1;





15 if (i == n_i) ddim[s] = arms;
}
{
int totdim = sum(ddim);
20 matrix[totdim, totdim] R;
int cumdim = 0;
int d = 1;
for(j in 1:totdim) {
25 for(i in 1:totdim) {
if (i == j) R[i, j] = 1;
else if (j > cumdim && j <= cumdim + ddim[d] &&
i > cumdim && i <= cumdim + ddim[d])
R[i, j] = 0.5;
30 else R[i, j] = 0;









// Index random effects deltas for each data point
int[] whichdelta(int[] trt, int n_i) {
int des[n_i];
45 int s = 1;
for (i in 1:n_i) {
if (trt[i] == 1) des[i] = 0;
else {
des[i] = s;






// Return the total number of random effects deltas
int ndelta(int[] trt, int n_i) {
int count = 0;








65 int<lower = 2> n_i; // Number of data points
// Data
int<lower = 0> y[n_i]; // Number of events
int<lower = 1> n[n_i]; // Number of individuals
70 int<lower = 1> trt[n_i]; // Treatment code
int<lower = 1> study[n_i]; // Study
// Priors
real<lower = 0> prior_sd_mu;
75 real<lower = 0> prior_sd_d;
real<lower = 0> prior_sd_tau;
// For equivalent IPD + AgD deviance calculation
int<lower = 0, upper = 1> has_ipd[n_i]; // IPD study indicator
80 }
transformed data {
int<lower = 2> n_t = max(trt); // Number of treatments
int<lower = 1> n_s = max(study); // Number of studies
int<lower = 0> delta_design[n_i];
85 int<lower = 1> n_delta = ndelta(trt, n_i);
// RE MVN mean and correlations
vector[n_delta] RE_mu = rep_vector(0, n_delta);
// Cholesky decomposition of RE MVN correlations
90 matrix[n_delta, n_delta] RE_L = cholesky_decompose(Rho(trt, study, n_i, n_s));
// Which arms have RE deltas? Since we are using the reference treatment
// parameterisation (rather than the baseline shift parameterisation), any arm
// not on treatment 1 has a random effect
95 delta_design = whichdelta(trt, n_i);
}
parameters {
vector[n_s] mu; // Study baselines
vector[n_t - 1] d; // Recoded basic treatment parameters (no d_1)
100 vector[n_delta] u_delta; // Non-centered random effects







f_delta = tau * RE_L * u_delta;
110
// Linear predictor
for (i in 1:n_i) {
if (delta_design[i]) // Note: implies not treatment 1 arm
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// Probit model




mu ~ normal(0, prior_sd_mu);
125 d ~ normal(0, prior_sd_d);
tau ~ normal(0, prior_sd_tau);
// Random effects
u_delta ~ normal(0, 1);
130
// Likelihood






vector[n_i] rhat = to_vector(n) .* theta;
real totresdev;
140 // For equivalent IPD + AgD model
vector[n_i] resdev_alt;
real totresdev_alt;
for (i in 1:n_i) {
145 // Log likelihood
log_lik[i] = binomial_lpmf(y[i] | n[i], theta[i]);
// Residual deviance
resdev[i] = 2 * (lmultiply(y[i], y[i] / (n[i] * theta[i])) +
150 lmultiply(n[i] - y[i],
(n[i] - y[i]) / (n[i] - n[i] * theta[i])));
// Shrunken estimate delta
delta[i] = delta_design[i] ? (d[trt[i] - 1] + f_delta[delta_design[i]]) : 0;
155
// For equivalent IPD + AgD model
if (has_ipd[i] == 1){
resdev_alt[i] = -2 * (y[i] * log(theta[i]) +
(n[i] - y[i]) * log(1 - theta[i]));











The unrelated mean effects model treats all contrasts as unrelated param-
eters with independent prior distributions, without imposing consistency
(Section 1.2.7.1). The UME model needs to be written with the study-specific
baselines referring to a reference arm in each trial (the baseline shift parameter-
isation, Section 1.2.1), rather than the reference treatment 1, since the reference
treatment parameterisation imposes consistency implicitly. This is reflected
in the random effects structure, as specified by the functions defined in the
functions block.
1 functions {
// Construct RE correlation matrix
matrix Rho(int[] trt, int[] study, int n_i, int n_s) {
int ddim[n_s];
5 int arms = 0;
int s = 1;
for (i in 2:n_i) {
if (study[i] == study[i - 1]) arms += 1;
if (i < n_i && study[i] != study[i+1]) {




if (i == n_i) ddim[s] = arms;
15 }
{
int totdim = sum(ddim);
matrix[totdim, totdim] R;
20 int cumdim = 0;
int d = 1;
for(j in 1:totdim) {
for(i in 1:totdim) {
25 if (i == j) R[i, j] = 1;
else if (j > cumdim && j <= cumdim + ddim[d] &&
i > cumdim && i <= cumdim + ddim[d])
R[i, j] = 0.5;
else R[i, j] = 0;
30










// Determine reference treatment for each study
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int[] ref_trt(int[] trt, int[] study, int n_i) {
int ref[n_i];
45 ref[1] = trt[1];
for (i in 2:n_i) {
if (study[i] == study[i - 1])
ref[i] = ref[i - 1];
else




55 // Index random effects deltas for each data point
int[] whichdelta(int[] study, int n_i) {
int des[n_i];
int s = 1;
des[1] = 0;
60 for (i in 2:n_i) {








70 // Return the total number of random effects deltas
int ndelta(int[] study, int n_i) {
int count = 0;






int<lower = 2> n_i; // Number of data points
80
// Data
int<lower = 0> y[n_i]; // Number of events
int<lower = 1> n[n_i]; // Number of individuals
int<lower = 1> trt[n_i]; // Treatment code
85 int<lower = 1> study[n_i]; // Study
// For equivalent IPD + AgD deviance calculation
int<lower = 0, upper = 1> has_ipd[n_i]; // IPD study indicator
90 // Priors
real<lower = 0> prior_sd_mu;
real<lower = 0> prior_sd_dd;
real<lower = 0> prior_sd_tau;
}
95 transformed data {
int<lower = 2> n_t = max(trt);
int<lower = 1> n_s = max(study);
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// Unrelated mean effects
100 int<lower = 1> n_dd = n_t * (n_t - 1) / 2;
// Above line gives integer division warning, but this is fine here
int<lower = 0> delta_design[n_i] = whichdelta(study, n_i);
int<lower = 1> n_delta = ndelta(study, n_i);
int<lower = 1> ref[n_i] = ref_trt(trt, study, n_i);
105 int<lower = 0> dd_ind[n_t - 1, n_t] = rep_array(0, n_t - 1, n_t);
// RE MVN mean and correlations
vector[n_delta] RE_mu = rep_vector(0, n_delta);
// Cholesky decomposition of RE MVN correlations
110 matrix[n_delta, n_delta] RE_L = cholesky_decompose(Rho(trt, study, n_i, n_s));
// Construct lookup matrix for dd index from d_ab
{
int i = 1;
115 for (a in 1:(n_t - 1)) {
for (b in (a + 1):n_t) {







vector[n_s] mu; // Study baselines
125 vector[n_dd] dd; // Unrelated mean treatment effects
vector[n_delta] u_delta; // Non-centered random effects







135 f_delta = tau * RE_L * u_delta;
// Linear predictor
for (i in 1:n_i) {
if (delta_design[i]) {
140 if (trt[i] > ref[i])
eta[i] = mu[study[i]] + dd[dd_ind[ref[i], trt[i]]] +
f_delta[delta_design[i]];
else if (trt[i] < ref[i])
eta[i] = mu[study[i]] - dd[dd_ind[trt[i], ref[i]]] +
145 f_delta[delta_design[i]];
else
eta[i] = mu[study[i]] + f_delta[delta_design[i]];
}
else
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model {
// Priors
mu ~ normal(0, prior_sd_mu);
dd ~ normal(0, prior_sd_dd);
160 tau ~ normal(0, prior_sd_tau);
// Random effects
u_delta ~ normal(0, 1);
165 // Likelihood






vector[n_i] rhat = to_vector(n) .* theta;
real totresdev;
// For equivalent IPD + AgD model
175 vector[n_i] resdev_alt;
real totresdev_alt;
for (i in 1:n_i) {
// Log likelihood
180 log_lik[i] = binomial_lpmf(y[i] | n[i], theta[i]);
// Residual deviance
resdev[i] = 2 * (lmultiply(y[i], y[i] / (n[i] * theta[i])) +
lmultiply(n[i] - y[i],
185 (n[i] - y[i]) / (n[i] - n[i] * theta[i])));
// Shrunken estimate delta
if (delta_design[i]) {
if (trt[i] > ref[i])
190 delta[i] = dd[dd_ind[ref[i], trt[i]]] + f_delta[delta_design[i]];
else if (trt[i] < ref[i])






// For equivalent IPD + AgD model
200 if (has_ipd[i] == 1){
resdev_alt[i] = -2 * (y[i] * log(theta[i]) +





// Total residual deviance
totresdev = sum(resdev);





We now provide Stan code for the ML-NMR model for binary outcomes, both
fixed effect (Sections A.1.2.1 and A.1.2.2) and random effects (Section A.1.2.3).
We also provide code for assessing consistency using an unrelatedmean effects
model (Section A.1.2.4). The derivation of numerical integration points is
performed externally in R (see Section A.4).
A.1.2.1Fixed eect, shared or independent eect modifiers
The following code implements the fixed effect ML-NMR model (Section 4.6).
We represent the linear predictor for both individual and aggregate levels
together using an augmented designmatrix X ∗, to whichwe then apply the QR
decomposition, as described in Section 5.2.1.2. From the QR decomposition,
the matrices Q∗ and (R∗)−1 are input as data (Q and R_inv, respectively). EM
interaction parameters may either be independent or shared between a set of
treatments: the Stan code does not change for these cases, only the (augmented)
design matrix and the resulting QR decomposition.
1 data {
// -- Constants --
int<lower=1> ns_ipd; // Number of IPD studies
int<lower=1> ns_agd; // Number of AgD studies
5 int<lower=1> ni_ipd; // Total number of IPD individuals
int<lower=2> ni_agd; // Total number of AgD data points
int<lower=1> nt; // Number of treatments
int<lower=1> nint; // Number of samples for numerical integration
int<lower=0> nPV; // Number of prognostic variables
10 int<lower=0> nEM; // Number of effect modifier *interactions*
// (NOT number of EM variables)
int<lower=1> int_thin; // Thinning factor for saved p_ii integration points
// -- IPD --
15 int<lower=0, upper=1> y[ni_ipd]; // Binary outcome
// -- AgD --
int<lower=0> ag_n[ni_agd]; // Outcome denominator
int<lower=0> ag_y[ni_agd]; // Outcome numerator
20
// The following are only needed if no PVs are included in the model (improves
// sampling efficiency by not doing numerical integration on AgD reference
// treatment 1 arms)
25 // int<lower=1> ag_trt[ni_agd]; // Treatment indicator
// int<lower=2> ag_study[ni_agd]; // Study indicator
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// -- Thin QR decomposition --
matrix[ni_ipd + nint * ni_agd, ns_ipd + ns_agd + nPV + nEM + (nt - 1)] Q;
30 matrix[ns_ipd + ns_agd + nPV + nEM + (nt - 1),
ns_ipd + ns_agd + nPV + nEM + (nt - 1)] R_inv;







40 // Total number of parameters and data points
int totnpar = ns_ipd + ns_agd + nPV + nEM + (nt - 1);
int totni = ni_ipd + nint * ni_agd;
// Split Q matrix into IPD and AgD rows
45 matrix[ni_ipd, totnpar] Q_ipd = Q[1:ni_ipd];
matrix[nint * ni_agd, totnpar] Q_agd = Q[(ni_ipd + 1):totni];
// nint/int_thin for numerical integration checks
// This will give a warning about integer division, which cannot be avoided
50 int n_int_thin = nint / int_thin;
}
parameters {




// -- Likelihood parameters needed later for log lik calculation --
vector[ni_ipd] eta; // IPD linear predictor
vector[ni_ipd] theta; // IPD predicted probability
60 vector[ni_agd] nprime; // AgD adjusted binomial denominator
vector[ni_agd] pprime; // AgD adjusted binomial probability
// -- Back-transformed parameters --
65 vector[totnpar] allbeta = R_inv * beta_tilde;
// Study baselines
vector[ns_ipd + ns_agd] mu = allbeta[1:(ns_ipd + ns_agd)];
// Treatment effects
vector[nt - 1] gamma = allbeta[(ns_ipd + ns_agd +1):
70 (ns_ipd + ns_agd + nt - 1)];
// Prognostic variables
vector[nPV] beta1 = allbeta[(ns_ipd + ns_agd + nt):
(ns_ipd + ns_agd + nt - 1 + nPV)];
// EM interactions
75 vector[nEM] beta2 = allbeta[(ns_ipd + ns_agd + nt + nPV):totnpar];
// -- AgD integration --
vector[nint * ni_agd] p_ii = Phi(Q_agd * beta_tilde);
vector[ni_agd] p_bar;
80 vector[ni_agd] p2_bar;
// -- IPD model --
// We define the IPD and AgD models here in the transformed parameters block,
// as the linear predictors are required to calculate the log likelihood later
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85 // on. This is slightly more inefficient than defining the models locally in
// the model block.
eta = Q_ipd * beta_tilde;
theta = Phi(eta);
90 // -- AgD model --
// Using the two-parameter Binomial approximation to the Poisson Binomial
for (i in 1:ni_agd) {
// Uncomment if no PVs are included in the model, don't do numerical
// integration on reference arms
95
// if (nPV == 0 && ag_trt[i] == 1) {
// p_bar[i] = Phi(mu[ag_study[i]]);
// p2_bar[i] = Phi(mu[ag_study[i]])^2;
// nprime[i] = ag_n[i];
100 // pprime[i] = p_bar[i];
// } else {
p_bar[i] = mean(p_ii[(1 + (i - 1)*nint):(i*nint)]);
p2_bar[i] = dot_self(p_ii[(1 + (i - 1)*nint):(i*nint)]) / nint;
105
// Calculate adjusted n and p
nprime[i] = ag_n[i] * p_bar[i]^2 / p2_bar[i];
pprime[i] = p2_bar[i] / p_bar[i];
110 // }
// Reject if nprime less than number of observed events - should only happen
// when generating initial values
if (nprime[i] < ag_y[i]) reject("nprime = ", nprime[i],




// -- Priors --
120 // These prior statements will cause Stan to raise warnings regarding
// transformed parameters possibly needing Jacobian adjustments. These should
// be ignored, as the transformation is entirely linear
mu ~ normal(0, prior_sd_mu);
beta1 ~ normal(0, prior_sd_beta1);
125 beta2 ~ normal(0, prior_sd_beta2);
gamma ~ normal(0, prior_sd_gamma);
// -- IPD likelihood --
y ~ bernoulli(theta);
130
// -- AgD likelihood --
// We have to hand code the log likelihood contribution for the adjusted
// binomial here, as N is not necessarily an integer (which Stan doesn't
// like). The following is exactly equivalent to:
135 // ag_y ~ binomial(nprime, pprime);
for (i in 1:ni_agd)
target += lchoose(nprime[i], ag_y[i]) +
lmultiply(ag_y[i], pprime[i]) +
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// -- Log likelihood and residual deviance calculation --
vector[ni_ipd + ni_agd] log_lik;
vector[ni_ipd + ni_agd] resdev;
145
// -- Estimate integration error --
vector[ni_agd * n_int_thin] p_bar_cum;
vector[ni_agd * n_int_thin] p2_bar_cum;
150 // -- Predicted probabilities and numbers of events --
vector[ni_ipd + ni_agd] p_hat;
vector[ni_ipd + ni_agd] y_hat;
for (i in 1:ni_ipd) {
155 p_hat[i] = theta[i];
y_hat[i] = theta[i];
log_lik[i] = bernoulli_lpmf(y[i] | theta[i]);
resdev[i] = -2 * log_lik[i];
}
160
for (i in 1:ni_agd) {
log_lik[ni_ipd + i] = lchoose(nprime[i], ag_y[i]) +
lmultiply(ag_y[i], pprime[i]) +
(nprime[i] - ag_y[i]) * log1m(pprime[i]);
165
y_hat[ni_ipd + i] = nprime[i] * pprime[i];
p_hat[ni_ipd + i] = y_hat[i] / ag_n[i];
// Approximate residual deviance for AgD, letting nprime be fixed
170 resdev[ni_ipd + i] = 2 * (lmultiply(ag_y[i],
ag_y[i] / (nprime[i] * pprime[i])) +
lmultiply(ag_n[i] - ag_y[i],
(ag_n[i] - ag_y[i]) /
(ag_n[i] - nprime[i] * pprime[i])));
175
for (j in 1:n_int_thin) {
p_bar_cum[(i - 1)*n_int_thin + j] =
mean(p_ii[(1 + (i - 1)*nint):((i - 1)*nint + j*int_thin)]);
p2_bar_cum[(i - 1)*n_int_thin + j] =





A.1.2.2 Fixed eect, exchangeable eect modifiers
We can attempt to relax the shared effect modifier assumption by fitting a
model with exchangeable effect modifier interactions (Section 4.6.1). As we
described in Section 5.2.2, we cannot use the QR decomposition with this
model; we therefore provide the (centred and scaled) augmented designmatrix
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X ∗ as data, instead of its QR decomposition.
1 data {
// -- Constants --
int<lower=1> ns_ipd; // Number of IPD studies
int<lower=1> ns_agd; // Number of AgD studies
5 int<lower=1> ni_ipd; // Total number of IPD individuals
int<lower=2> ni_agd; // Total number of AgD data points
int<lower=1> nt; // Number of treatments
int<lower=1> nint; // Number of samples for numerical integration
int<lower=0> nPV; // Number of prognostic variables
10 int<lower=0> nEM; // Number of effect modifier *interactions*
// (NOT number of EM variables)
int<lower=1> int_thin; // Thinning factor for saved p_ii integration points
// -- RE class EM interaction --
15 int<lower=0> reptclass[nEM]; // Class coding vector
// -- IPD --
int<lower=0, upper=1> y[ni_ipd]; // Binary outcome
20 // -- AgD --
int<lower=0> ag_n[ni_agd]; // Outcome denominator
int<lower=0> ag_y[ni_agd]; // Outcome numerator
// The following are only needed if no PVs are included in the model (improves
// sampling efficiency by not doing numerical integration on AgD reference
25 // treatment 1 arms)
// int<lower=1> ag_trt[ni_agd]; // Treatment indicator
// int<lower=2> ag_study[ni_agd]; // Study indicator
// -- Design matrix --
30 matrix[ni_ipd + nint * ni_agd, ns_ipd + ns_agd + nPV + nEM + (nt - 1)] X;








// -- Options --
int<lower=0,upper=1> share_class_sd; // Common class sd (1) or not (0)?
}
transformed data {
45 // Total number of parameters and data points
int totnpar = ns_ipd + ns_agd + nPV + nEM + (nt - 1);
int totni = ni_ipd + nint * ni_agd;
// Split X matrix into IPD and AgD rows
50 matrix[ni_ipd, totnpar] X_ipd = X[1:ni_ipd];
matrix[nint * ni_agd, totnpar] X_agd = X[(ni_ipd + 1):totni];
// nint/int_thin for numerical integration checks
// This will give a warning about integer division, which cannot be avoided
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55 int n_int_thin = nint / int_thin;
// Number of treatment classess, inferred from class coding vector




vector[ns_ipd + ns_agd] mu;
vector[nPV] beta1;
vector[nt - 1] gamma;
65
// Uncentered EM interactions
vector[nEM] u_beta2;
// RE class EM interaction means and SDs
70 vector[ntclass] classmean_beta2;
vector<lower=0>[share_class_sd == 1 ? 1 : ntclass] classsd_beta2;
}
transformed parameters {
// -- Likelihood parameters needed later for log lik calculation --
75 vector[ni_ipd] eta; // IPD linear predictor
vector[ni_ipd] theta; // IPD predicted probability
vector[ni_agd] nprime; // AgD adjusted binomial denominator
vector[ni_agd] pprime; // AgD adjusted binomial probability
80 // -- Parameters --
vector[totnpar] allbeta;
// -- AgD integration --
vector[nint * ni_agd] p_ii;
85 vector[ni_agd] p_bar;
vector[ni_agd] p2_bar;
// -- Uncentered EM random interaction effect --
vector[nEM] beta2;
90
// If tclass = 0, don't put class effect on that treatment interaction
for (k in 1:nEM) {
if (reptclass[k] == 0) {
beta2[k] = u_beta2[k] * prior_sd_beta2_nonexch;
95 // Equivalent to beta2[k] ~ normal(0, prior_sd_beta2_nonexch)
}
else {
if (share_class_sd == 0)
beta2[k] = classmean_beta2[reptclass[k]] +
100 u_beta2[k] * classsd_beta2[reptclass[k]];
// Equivalent to
// beta2[k] ~ normal(classmean_beta2[...], classsd_beta2[...])
else
beta2[k] = classmean_beta2[reptclass[k]] +
105 u_beta2[k] * classsd_beta2[1];
}
}
// -- All parameters in one vector --
110 // Study baselines




allbeta[(ns_ipd + ns_agd +1):(ns_ipd + ns_agd + nt - 1)] = gamma;
// Prognostic variables
115 allbeta[(ns_ipd + ns_agd + nt):(ns_ipd + ns_agd + nt - 1 + nPV)] = beta1;
// EM interactions
allbeta[(ns_ipd + ns_agd + nt + nPV):totnpar] = beta2;
// -- IPD model --
120 // We define the IPD and AgD models here in the transformed parameters block,
// as the linear predictors are required to calculate the log likelihood later
// on. This is slightly more inefficient than defining the models locally in
// the model block.
eta = X_ipd * allbeta;
125 theta = Phi(eta);
// -- AgD model --
p_ii = Phi(X_agd * allbeta);
// Using the two-parameter Binomial approximation to the Poisson Binomial.
130 for (i in 1:ni_agd) {
// Uncomment if no PVs are included in the model, don't do numerical
// integration on reference arms
// if (nPV == 0 && ag_trt[i] == 1) {
135 // p_bar[i] = inv_logit(mu[ag_study[i]]);
// p2_bar[i] = inv_logit(mu[ag_study[i]])^2;
// nprime[i] = ag_n[i];
// pprime[i] = p_bar[i];
// } else {
140
p_bar[i] = mean(p_ii[(1 + (i - 1)*nint):(i*nint)]);
p2_bar[i] = dot_self(p_ii[(1 + (i - 1)*nint):(i*nint)]) / nint;
// Calculate adjusted n and p
145 nprime[i] = ag_n[i] * p_bar[i]^2 / p2_bar[i];
pprime[i] = p2_bar[i] / p_bar[i];
// }
150 // Reject if nprime less than number of observed events - should only happen
// when generating initial values
if (nprime[i] < ag_y[i]) reject("nprime = ", nprime[i],





// -- Priors --
// These prior statements will cause Stan to raise warnings regarding
160 // transformed parameters possibly needing Jacobian adjustments. These should
// be ignored, as the transformation is entirely linear
mu ~ normal(0, prior_sd_mu);
beta1 ~ normal(0, prior_sd_beta1);
gamma ~ normal(0, prior_sd_gamma);
165
// -- Random class effects --
classmean_beta2 ~ normal(0, prior_sd_mean_beta2_exch);
classsd_beta2 ~ normal(0, prior_sd_beta2_exch);
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170 u_beta2 ~ normal(0, 1);
// -- IPD likelihood --
y ~ bernoulli(theta);
175 // -- AgD likelihood --
// We have to hand code the log likelihood contribution for the adjusted
// binomial here, as N is not necessarily an integer (which Stan doesn't
// like). The following is exactly equivalent to:
// ag_y ~ binomial(nprime, pprime);
180 for (i in 1:ni_agd)
target += lchoose(nprime[i], ag_y[i]) +
lmultiply(ag_y[i], pprime[i]) +
(nprime[i] - ag_y[i]) * log1m(pprime[i]);
}
185 generated quantities {
// -- Log likelihood and residual deviance calculation --
vector[ni_ipd + ni_agd] log_lik;
vector[ni_ipd + ni_agd] resdev;
190 // -- Estimate integration error --
// vector[ni_agd] p_bar_diff;
// vector[ni_agd] p2_bar_diff;
vector[ni_agd * n_int_thin] p_bar_cum;
vector[ni_agd * n_int_thin] p2_bar_cum;
195
// -- Predicted probabilities and numbers of events --
vector[ni_ipd + ni_agd] p_hat;
vector[ni_ipd + ni_agd] y_hat;
200 for (i in 1:ni_ipd) {
p_hat[i] = theta[i];
y_hat[i] = theta[i];
log_lik[i] = bernoulli_lpmf(y[i] | theta[i]);
resdev[i] = -2 * log_lik[i];
205 }
for (i in 1:ni_agd) {
log_lik[ni_ipd + i] = lchoose(nprime[i], ag_y[i]) +
lmultiply(ag_y[i], pprime[i]) +
210 (nprime[i] - ag_y[i]) * log1m(pprime[i]);
y_hat[ni_ipd + i] = nprime[i] * pprime[i];
p_hat[ni_ipd + i] = y_hat[i] / ag_n[i];
215 // Approximate residual deviance for AgD, letting nprime be fixed
resdev[ni_ipd + i] = 2 * (lmultiply(ag_y[i],
ag_y[i] / (nprime[i] * pprime[i])) +
lmultiply(ag_n[i] - ag_y[i],
(ag_n[i] - ag_y[i]) /
220 (ag_n[i] - nprime[i] * pprime[i])));
for (j in 1:n_int_thin) {
p_bar_cum[(i - 1)*n_int_thin + j] =
mean(p_ii[(1 + (i - 1)*nint):((i - 1)*nint + j*int_thin)]);
225 p2_bar_cum[(i - 1)*n_int_thin + j] =
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We can assess residual heterogeneity by fitting a model with random effects
(Section 4.6.2). As before for NMA (Section A.1.1), the fixed effect ML-NMR
model (Section A.1.2.1) can be modified to include random effects. Here, we
assume homogeneous heterogeneity standard deviation τ, which is given a
half-Normal prior distribution (line 231; note the constraint on the parameter
tau to have a lower bound of 0 on line 133). The functions block defines
functions to construct the random effects structure within the Stan program
(these functions are identical to those used for theNMAcode in SectionA.1.1.2);
alternatively, this could be constructed externally (e.g. in R) and passed as
data. The non-centered RE parameterisation is used (see Section 5.2.3), via the
Cholesky decomposition of the RE correlation matrix (line 125). Transformed
random effects are sampled as independent standard Normal (line 234), which
are then back-transformed (line 143).
1 functions {
// Construct RE correlation matrix
matrix Rho(int[] trt, int[] study, int n_i, int n_s) {
int ddim[n_s];
5 int s = 1;
int arms = 0;
for (i in 1:n_i) {
if (trt[i] > 1) arms = arms + 1;
10 if (i < n_i && study[i] != study[i+1]) {
ddim[s] = arms;
arms = 0;
s = s + 1;
}
15 if (i == n_i) ddim[s] = arms;
}
{
int totdim = sum(ddim);
20 matrix[totdim, totdim] R;
int cumdim = 0;
int d = 1;
for(j in 1:totdim) {
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25 for(i in 1:totdim) {
if (i == j) R[i, j] = 1;
else if (j > cumdim && j <= cumdim + ddim[d] &&
i > cumdim && i <= cumdim + ddim[d])
R[i, j] = 0.5;
30 else R[i, j] = 0;
if (i == totdim && j == cumdim + ddim[d]) {
cumdim = cumdim + ddim[d];







// Index random effects deltas for each data point
int[] whichdelta(int[] trt, int n_i) {
int des[n_i];
45 int s = 1;
for (i in 1:n_i) {
if (trt[i] == 1) des[i] = 0;
else {
des[i] = s;






// Return the total number of random effects deltas
int ndelta(int[] trt, int n_i) {
int count = 0;





// -- Constants --
65 int<lower=1> ns_ipd; // Number of IPD studies
int<lower=1> ns_agd; // Number of AgD studies
int<lower=1> ni_ipd; // Total number of IPD individuals
int<lower=2> ni_agd; // Total number of AgD data points
int<lower=1> nt; // Number of treatments
70 int<lower=1> nint; // Number of samples for numerical integration
int<lower=0> nPV; // Number of prognostic variables
int<lower=0> nEM; // Number of effect modifier *interactions*
// (NOT number of EM variables)
int<lower=1> int_thin; // Thinning factor for saved p_ii integration points
75
// -- IPD --
int<lower=0, upper=1> y[ni_ipd]; // Binary outcome
// -- AgD --
80 int<lower=0> ag_n[ni_agd]; // Outcome denominator
int<lower=0> ag_y[ni_agd]; // Outcome numerator
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// -- Treatment and study indicators to construct RE terms --
int<lower=1> narm_ipd; // Number of IPD arms
85 int<lower=1> ipd_arm[ni_ipd]; // IPD arm indicator
int<lower=1> trt[narm_ipd + ni_agd]; // Treatment indicator
int<lower=1> study[narm_ipd + ni_agd]; // Study indicator
// -- Thin QR decomposition --
90 matrix[ni_ipd + nint * ni_agd, ns_ipd + ns_agd + nPV + nEM + (nt - 1)] Q;
matrix[ns_ipd + ns_agd + nPV + nEM + (nt - 1),
ns_ipd + ns_agd + nPV + nEM + (nt - 1)] R_inv;








// Total number of parameters and data points
int totnpar = ns_ipd + ns_agd + nPV + nEM + (nt - 1);
int totni = ni_ipd + nint * ni_agd;
105
// Split Q matrix into IPD and AgD rows
matrix[ni_ipd, totnpar] Q_ipd = Q[1:ni_ipd];
matrix[nint * ni_agd, totnpar] Q_agd = Q[(ni_ipd + 1):totni];
110 // nint/int_thin for numerical integration checks
// This will give a warning about integer division, which cannot be avoided
int n_int_thin = nint / int_thin;
// Which arms have RE deltas? Since we are using the reference treatment
115 // parameterisation (rather than the baseline shift parameterisation), any arm
// not on treatment 1 has a random effect
int<lower = 0> delta_design[narm_ipd + ni_agd] =
whichdelta(trt, narm_ipd + ni_agd);
int<lower = 1> n_delta = ndelta(trt, narm_ipd + ni_agd);
120
// RE MVN mean and correlations
vector[n_delta] RE_mu = rep_vector(0, n_delta);
// Cholesky decomposition of RE MVN correlations
matrix[n_delta, n_delta] RE_L =
125 cholesky_decompose(Rho(trt, study, narm_ipd + ni_agd, ns_ipd + ns_agd));
}
parameters {
// Parameters on QR scale
vector[totnpar] beta_tilde;
130
// Non-centered random effects
vector[n_delta] u_delta;
real<lower = 0> tau;
}
135 transformed parameters {
// -- Likelihood parameters needed later for log lik calculation --
vector[ni_ipd] eta; // IPD linear predictor
vector[ni_ipd] theta; // IPD predicted probability
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vector[ni_agd] nprime; // AgD adjusted binomial denominator
140 vector[ni_agd] pprime; // AgD adjusted binomial probability
// -- RE deltas --
vector[n_delta] f_delta = tau * RE_L * u_delta;
145
// -- Back-transformed parameters --
vector[totnpar] allbeta = R_inv * beta_tilde;
// Study baselines
vector[ns_ipd + ns_agd] mu = allbeta[1:(ns_ipd + ns_agd)];
150 // Treatment effects
vector[nt - 1] gamma = allbeta[(ns_ipd + ns_agd +1):
(ns_ipd + ns_agd + nt - 1)];
// Prognostic variables
vector[nPV] beta1 = allbeta[(ns_ipd + ns_agd + nt):
155 (ns_ipd + ns_agd + nt - 1 + nPV)];
// EM interactions
vector[nEM] beta2 = allbeta[(ns_ipd + ns_agd + nt + nPV):totnpar];
// -- AgD integration --
160 vector[nint * ni_agd] p_ii;
vector[ni_agd] p_bar;
vector[ni_agd] p2_bar;
// -- IPD model --
165 // We define the IPD and AgD models here in the transformed parameters block,
// as the linear predictors are required to calculate the log likelihood later
// on. This is slightly more inefficient than defining the models locally in
// the model block.
170 {
vector[ni_ipd] eta_ipd_noRE = Q_ipd * beta_tilde;
for (i in 1:ni_ipd) {
if (delta_design[ipd_arm[i]])







// -- AgD model --
// Using the two-parameter Binomial approximation to the Poisson Binomial.
{
vector[nint * ni_agd] eta_agd_noRE = Q_agd * beta_tilde;
185
for (i in 1:ni_agd) {
if (delta_design[narm_ipd + i])
p_ii[(1 + (i-1)*nint):(i*nint)] =
Phi(eta_agd_noRE[(1 + (i-1)*nint):(i*nint)] +
190 f_delta[delta_design[narm_ipd + i]]);
else
p_ii[(1 + (i-1)*nint):(i*nint)] =
Phi(eta_agd_noRE[(1 + (i-1)*nint):(i*nint)]);
195 // Uncomment if no PVs are included in the model, don't do numerical
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// integration on reference arms
// if (nPV == 0 && trt[narm_ipd + i] == 1) {
// p_bar[i] = inv_logit(mu[study[narm_ipd + i]]);
200 // p2_bar[i] = inv_logit(mu[study[narm_ipd + i]])^2;
// nprime[i] = ag_n[i];
// pprime[i] = p_bar[i];
// } else {
205 p_bar[i] = mean(p_ii[(1 + (i-1)*nint):(i*nint)]);
p2_bar[i] = dot_self(p_ii[(1 + (i-1)*nint):(i*nint)]) / nint;
// Calculate adjusted n and p
nprime[i] = ag_n[i] * p_bar[i]^2 / p2_bar[i];
210 pprime[i] = p2_bar[i] / p_bar[i];
// }
// Reject if nprime less than number of observed events - should only
215 // happen when generating initial values
if (nprime[i] < ag_y[i]) reject("nprime = ", nprime[i],





// -- Priors --
// These prior statements will cause Stan to raise warnings regarding
// transformed parameters possibly needing Jacobian adjustments. These should
225 // be ignored, as the transformation is entirely linear
mu ~ normal(0, prior_sd_mu);
beta1 ~ normal(0, prior_sd_beta1);
beta2 ~ normal(0, prior_sd_beta2);
gamma ~ normal(0, prior_sd_gamma);
230
tau ~ normal(0, prior_sd_tau);
// -- Random effects --
u_delta ~ normal(0, 1);
235
// -- IPD likelihood --
y ~ bernoulli(theta);
// -- AgD likelihood --
240 // We have to hand code the log likelihood contribution for the adjusted
// binomial here, as N is not necessarily an integer (which Stan doesn't
// like). The following is exactly equivalent to:
// ag_y ~ binomial(nprime, pprime);
for (i in 1:ni_agd)
245 target += lchoose(nprime[i], ag_y[i]) +
lmultiply(ag_y[i], pprime[i]) +
(nprime[i] - ag_y[i]) * log1m(pprime[i]);
}
generated quantities {
250 // -- Log likelihood and residual deviance calculation --
vector[ni_ipd + ni_agd] log_lik;
vector[ni_ipd + ni_agd] resdev;
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// -- Estimate integration error --
255 vector[ni_agd * n_int_thin] p_bar_cum;
vector[ni_agd * n_int_thin] p2_bar_cum;
// -- RE shrunken estimate delta --
// Note: These are the individual-level trial-specific treatment effects
260 vector[narm_ipd + ni_agd] delta;
// -- Predicted probabilities and numbers of events --
vector[ni_ipd + ni_agd] p_hat;
vector[ni_ipd + ni_agd] y_hat;
265
// For the shrunken estimates, since treatment 1 is the reference and REs are
// treatment based rather than arm based, any treatment 1 arm has delta = 0
for (i in 1:(narm_ipd + ni_agd)) {
delta[i] = trt[i] == 1 ? 0 : gamma[trt[i] - 1] + f_delta[delta_design[i]];
270 }
for (i in 1:ni_ipd) {
p_hat[i] = theta[i];
y_hat[i] = theta[i];
275 log_lik[i] = bernoulli_lpmf(y[i] | theta[i]);
resdev[i] = -2 * log_lik[i];
}
for (i in 1:ni_agd) {
280 log_lik[ni_ipd + i] = lchoose(nprime[i], ag_y[i]) +
lmultiply(ag_y[i], pprime[i]) +
(nprime[i] - ag_y[i]) * log1m(pprime[i]);
y_hat[ni_ipd + i] = nprime[i] * pprime[i];
285 p_hat[ni_ipd + i] = y_hat[i] / ag_n[i];
// Approximate residual deviance for AgD, letting nprime be fixed
resdev[ni_ipd + i] = 2 * (lmultiply(ag_y[i],
ag_y[i] / (nprime[i] * pprime[i])) +
290 lmultiply(ag_n[i] - ag_y[i],
(ag_n[i] - ag_y[i]) /
(ag_n[i] - nprime[i] * pprime[i])));
for (j in 1:n_int_thin) {
295 p_bar_cum[(i-1)*n_int_thin + j] =
mean(p_ii[(1 + (i-1)*nint):((i-1)*nint + j*int_thin)]);
p2_bar_cum[(i-1)*n_int_thin + j] =








We can assess consistency by fitting an unrelated mean effects model (Sec-
tion 4.6.3.1). Since the ML-NMR Stan code takes the augmented design matrix
(or its QR decomposition) as its input, it is possible to implement an UME
model by re-specifying the design matrix in terms of the independent contrast
parameters, one for each contrast for which data are available. However, the
UME model needs to be written with a reference arm in each trial (i.e. the
baseline shift parameterisation), rather than an overall reference treatment.
The following code therefore implements a random effects ML-NMR using the
baseline-shift parameterisation, which allows either a standard (consistency)
model or an UME (inconsistency) model to be fitted using the same code,
simply by changing the design matrix.
1 functions {
// Construct RE correlation matrix, using baseline shift parameterisation
matrix Rho(int[] study, int n_i, int n_s) {
int ddim[n_s];
5 int arms = 0;
int s = 1;
for (i in 2:n_i) {
if (study[i] == study[i - 1]) arms += 1;
if (i < n_i && study[i] != study[i+1]) {




if (i == n_i) ddim[s] = arms;
15 }
{
int totdim = sum(ddim);
matrix[totdim, totdim] R;
20 int cumdim = 0;
int d = 1;
for(j in 1:totdim) {
for(i in 1:totdim) {
25 if (i == j) R[i, j] = 1;
else if (j > cumdim && j <= cumdim + ddim[d] &&
i > cumdim && i <= cumdim + ddim[d])
R[i, j] = 0.5;
else R[i, j] = 0;
30












// Index random effects deltas for each data point
int[] whichdelta(int[] study, int n_i) {
int des[n_i];
int s = 1;
45 des[1] = 0;
for (i in 2:n_i) {
if (study[i] != study[i - 1]) des[i] = 0;
else {
des[i] = s;






// Return the total number of random effects deltas
int ndelta(int[] study, int n_i) {
int count = 0;





// -- Constants --
65 int<lower=1> ns_ipd; // Number of IPD studies
int<lower=1> ns_agd; // Number of AgD studies
int<lower=1> ni_ipd; // Total number of IPD individuals
int<lower=2> ni_agd; // Total number of AgD data points
int<lower=1> nt; // Number of treatments
70 int<lower=1> nint; // Number of samples for numerical integration
int<lower=0> nPV; // Number of prognostic variables
int<lower=0> nEM; // Number of effect modifier *interactions*
// (NOT number of EM variables)
int<lower=1> int_thin; // Thinning factor for saved p_ii integration points
75
// -- IPD --
int<lower=0, upper=1> y[ni_ipd]; // Binary outcome
// -- AgD --
80 int<lower=0> ag_n[ni_agd]; // Outcome denominator
int<lower=0> ag_y[ni_agd]; // Outcome numerator
// -- Treatment and study indicators to construct RE terms --
int<lower=1> narm_ipd; // Number of IPD arms
85 int<lower=1> ipd_arm[ni_ipd]; // IPD arm indicator
int<lower=1> study[narm_ipd + ni_agd]; // Study indicator
// -- Thin QR decomposition --
matrix[ni_ipd + nint * ni_agd, ns_ipd + ns_agd + nPV + nEM + (nt - 1)] Q;
90 matrix[ns_ipd + ns_agd + nPV + nEM + (nt - 1),
ns_ipd + ns_agd + nPV + nEM + (nt - 1)] R_inv;









100 transformed data {
// Total number of parameters and data points
int totnpar = ns_ipd + ns_agd + nPV + nEM + (nt - 1);
int totni = ni_ipd + nint * ni_agd;
105 // Split Q matrix into IPD and AgD rows
matrix[ni_ipd, totnpar] Q_ipd = Q[1:ni_ipd];
matrix[nint * ni_agd, totnpar] Q_agd = Q[(ni_ipd + 1):totni];
// nint/int_thin for numerical integration checks
110 // This will give a warning about integer division, which cannot be avoided
int n_int_thin = nint / int_thin;
// Which arms have RE deltas? Using the baseline shift parameterisation
int<lower = 0> delta_design[narm_ipd + ni_agd] =
115 whichdelta(study, narm_ipd + ni_agd);
int<lower = 1> n_delta = ndelta(study, narm_ipd + ni_agd);
// RE MVN mean and correlations
vector[n_delta] RE_mu = rep_vector(0, n_delta);
120 // Cholesky decomposition of RE MVN correlations
matrix[n_delta, n_delta] RE_L =
cholesky_decompose(Rho(study, narm_ipd + ni_agd, ns_ipd + ns_agd));
}
parameters {
125 // Parameters on QR scale
vector[totnpar] beta_tilde;
// Non-centered random effects
vector[n_delta] u_delta;
130 real<lower = 0> tau;
}
transformed parameters {
// -- Likelihood parameters needed later for log lik calculation --
vector[ni_ipd] eta; // IPD linear predictor
135 vector[ni_ipd] theta; // IPD predicted probability
vector[ni_agd] nprime; // AgD adjusted binomial denominator
vector[ni_agd] pprime; // AgD adjusted binomial probability
// -- RE deltas --
140 vector[n_delta] f_delta = tau * RE_L * u_delta;
// -- Back-transformed parameters --
vector[totnpar] allbeta = R_inv * beta_tilde;
// Study baselines
145 vector[ns_ipd + ns_agd] mu = allbeta[1:(ns_ipd + ns_agd)];
// Treatment effects
vector[nt - 1] gamma = allbeta[(ns_ipd + ns_agd +1):
(ns_ipd + ns_agd + nt - 1)];
// Prognostic variables
150 vector[nPV] beta1 = allbeta[(ns_ipd + ns_agd + nt):
(ns_ipd + ns_agd + nt - 1 + nPV)];
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// EM interactions
vector[nEM] beta2 = allbeta[(ns_ipd + ns_agd + nt + nPV):totnpar];
155 // -- AgD integration --
// Can save these directly to check how the integration error decreases, or
// just p_bar_diff and p2_bar_diff in the generated quantities block below
vector[nint * ni_agd] p_ii;
vector[ni_agd] p_bar;
160 vector[ni_agd] p2_bar;
// -- IPD model --
// We define the IPD and AgD models here in the transformed parameters block,
// as the linear predictors are required to calculate the log likelihood later
165 // on. This is slightly more inefficient than defining the models locally in
// the model block.
{
vector[ni_ipd] eta_ipd_noRE = Q_ipd * beta_tilde;
170 for (i in 1:ni_ipd) {
if (delta_design[ipd_arm[i]])






// -- AgD model --
180 // Using the two-parameter Binomial approximation to the Poisson Binomial.
{
vector[nint * ni_agd] eta_agd_noRE = Q_agd * beta_tilde;
for (i in 1:ni_agd) {
185 if (delta_design[narm_ipd + i])
p_ii[(1 + (i-1)*nint):(i*nint)] =
Phi(eta_agd_noRE[(1 + (i-1)*nint):(i*nint)] +
f_delta[delta_design[narm_ipd + i]]);
else
190 p_ii[(1 + (i-1)*nint):(i*nint)] =
Phi(eta_agd_noRE[(1 + (i-1)*nint):(i*nint)]);
// Uncomment if no PVs are included in the model, don't do numerical
// integration on reference arms
195
// if (nPV == 0 && delta_design[narm_ipd + i] == 0) {
// p_bar[i] = inv_logit(mu[study[narm_ipd + i]]);
// p2_bar[i] = inv_logit(mu[study[narm_ipd + i]])^2;
// nprime[i] = ag_n[i];
200 // pprime[i] = p_bar[i];
// } else {
p_bar[i] = mean(p_ii[(1 + (i-1)*nint):(i*nint)]);
p2_bar[i] = dot_self(p_ii[(1 + (i-1)*nint):(i*nint)]) / nint;
205
// Calculate adjusted n and p
nprime[i] = ag_n[i] * p_bar[i]^2 / p2_bar[i];




// Reject if nprime less than number of observed events - should only
// happen when generating initial values
if (nprime[i] < ag_y[i]) reject("nprime = ", nprime[i],





220 // -- Priors --
// These prior statements will cause Stan to raise warnings regarding
// transformed parameters possibly needing Jacobian adjustments. These should
// be ignored, as the transformation is entirely linear
mu ~ normal(0, prior_sd_mu);
225 beta1 ~ normal(0, prior_sd_beta1);
beta2 ~ normal(0, prior_sd_beta2);
gamma ~ normal(0, prior_sd_gamma);
tau ~ normal(0, prior_sd_tau);
230
// -- Random effects --
u_delta ~ normal(0, 1);
// -- IPD likelihood --
235 y ~ bernoulli(theta);
// -- AgD likelihood --
// We have to hand code the log likelihood contribution for the adjusted
// binomial here, as N is not necessarily an integer (which Stan doesn't
240 // like). The following is exactly equivalent to:
// ag_y ~ binomial(nprime, pprime);
for (i in 1:ni_agd)
target += lchoose(nprime[i], ag_y[i]) +
lmultiply(ag_y[i], pprime[i]) +
245 (nprime[i] - ag_y[i]) * log1m(pprime[i]);
}
generated quantities {
// -- Log likelihood and residual deviance calculation --
vector[ni_ipd + ni_agd] log_lik;
250 vector[ni_ipd + ni_agd] resdev;
// -- Estimate integration error --
vector[ni_agd * n_int_thin] p_bar_cum;
vector[ni_agd * n_int_thin] p2_bar_cum;
255
// -- Predicted probabilities and numbers of events --
vector[ni_ipd + ni_agd] p_hat;
vector[ni_ipd + ni_agd] y_hat;
260 for (i in 1:ni_ipd) {
p_hat[i] = theta[i];
y_hat[i] = theta[i];
log_lik[i] = bernoulli_lpmf(y[i] | theta[i]);
resdev[i] = -2 * log_lik[i];
265 }
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for (i in 1:ni_agd) {
log_lik[ni_ipd + i] = lchoose(nprime[i], ag_y[i]) +
lmultiply(ag_y[i], pprime[i]) +
270 (nprime[i] - ag_y[i]) * log1m(pprime[i]);
y_hat[ni_ipd + i] = nprime[i] * pprime[i];
p_hat[ni_ipd + i] = y_hat[i] / ag_n[i];
275 // Approximate residual deviance for AgD, letting nprime be fixed
resdev[ni_ipd + i] = 2 * (lmultiply(ag_y[i],
ag_y[i] / (nprime[i] * pprime[i])) +
lmultiply(ag_n[i] - ag_y[i],
(ag_n[i] - ag_y[i]) /
280 (ag_n[i] - nprime[i] * pprime[i])));
for (j in 1:n_int_thin) {
p_bar_cum[(i-1)*n_int_thin + j] =
mean(p_ii[(1 + (i-1)*nint):((i-1)*nint + j*int_thin)]);
285 p2_bar_cum[(i-1)*n_int_thin + j] =





A.2 Ordered categorical outcomes
This sectionprovides Stan code for the analysis of ordered categorical outcomes,
as used in Section 7.4. The code is largely identical to that for binary outcomes
in Section A.1, except for the changes required for the ordered categorical (or
for AgD, multinomial) likelihood.
A.2.1 Networkmeta-analysis
Firstly, we provide Stan code for fixed effect (Section A.2.1.1) and random
effects (Section A.2.1.2) network meta-analysis using aggregate data (i.e. event
counts in each category per arm).
A.2.1.1 Fixed eect
The following Stan code can be used to fit a fixed effect AgD NMA, using a
multinomial likelihood and probit link function. Prior distributions on the
differences between latent cutoffs cm − cm−1 are specified as half-Normal with
standarddeviation prior_cc_sd (line 67), but if a negative value of prior_cc_sd
is passed to Stan an improper uniform prior distribution U(−∞,∞) is used in-
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stead. This is possible since Stan automatically truncates the prior distribution
to satisfy the ordering constraint on the latent cutoffs (line 29).
1 data {
// Constants
int<lower = 2> n_i; // Number of data points
int<lower=2> ncat; // Number of ordered outcome categories
5
// Data
int<lower=0> y[n_i, ncat]; // Outcome category counts
int<lower=1> trt[n_i]; // Treatment indicator
int<lower=1> study[n_i]; // Study indicator
10
// For equivalent IPD + AgD deviance calculation







20 int<lower = 2> n_t = max(trt); // Number of treatments
int<lower = 1> n_s = max(study); // Number of studies
}
parameters {
vector[n_s] mu; // Study baselines
25 vector[n_t -1] d; // Recoded basic treatment parameters (no d_1)
// Ordered cutoffs on underlying probit-PASI scale
// "Fixed effect" cutoffs, the same across trials





35 // Linear predictor
for (i in 1:n_i) {
if (trt[i] > 1) eta[i] = mu[study[i]] + d[trt[i] - 1];
else eta[i] = mu[study[i]];
}
40
// Probit model, cutoffs for each category
for (i in 1:n_i) {
vector[ncat - 1] phi_temp;
phi_temp[1] = Phi(eta[i]);
45 theta[i, 1] = 1 - phi_temp[1];
for (k in 2:(ncat - 1)) {
phi_temp[k] = Phi(eta[i] - cc[k - 1]);
theta[i, k] = phi_temp[k - 1] - phi_temp[k];
}
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model {
// -- Priors --
55 mu ~ normal(0, prior_sd_mu);
d ~ normal(0, prior_sd_d);
// Implied improper uniform prior on cutpoints if given negative prior_cc_sd:
// cc ~ uniform(-inf, inf)
60 // Even if we place priors on cc ourselves, Stan will impose the ordering
// constraint for us, so these are effectively half-normal priors on the
// differences
if (prior_cc_sd >= 0) {
vector[ncat - 2] diff_cc;
65 for (k in 1:(ncat - 2))
diff_cc[k] = cc[k + 1] - cc[k];
diff_cc ~ normal(0, prior_cc_sd);
}
70 // -- Likelihood --









80 // For equivalent IPD + AgD model
vector[n_i] resdev_alt;
real totresdev_alt;
85 for (i in 1:n_i) {
log_lik[i] = multinomial_lpmf(y[i] | theta[i]);
y_hat[i] = sum(y[i]) * theta[i];
// Multinomial residual deviance
90 {
vector[ncat] dv;
for (k in 1:ncat) {
dv[k] = y[i, k] == 0 ? 0 : y[i, k] * (log(y[i, k]) - log(y_hat[i, k]));
}
95 resdev[i] = 2 * sum(dv);
}
// For equivalent IPD + AgD model
if (has_ipd[i] == 1){
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A.2.1.2Random eects
The fixed effect model (Section A.2.1.1) can be modified to include random
effects, in exactly the same manner as for binary outcomes (Section A.1.2.3).
Here, we assume homogeneous heterogeneity standard deviation τ, which is
given a half-Normal prior distribution.
1 functions {
// Construct RE correlation matrix
matrix Rho(int[] trt, int[] study, int n_i, int n_s) {
int ddim[n_s];
5 int s = 1;
int arms = 0;
for (i in 1:n_i) {
if (trt[i] > 1) arms += 1;





15 if (i == n_i) ddim[s] = arms;
}
{
int totdim = sum(ddim);
20 matrix[totdim, totdim] R;
int cumdim = 0;
int d = 1;
for(j in 1:totdim) {
25 for(i in 1:totdim) {
if (i == j) R[i, j] = 1;
else if (j > cumdim && j <= cumdim + ddim[d] &&
i > cumdim && i <= cumdim + ddim[d])
R[i, j] = 0.5;
30 else R[i, j] = 0;









// Index random effects deltas for each data point
int[] whichdelta(int[] trt, int n_i) {
int des[n_i];
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45 int s = 1;
for (i in 1:n_i) {
if (trt[i] == 1) des[i] = 0;
else {
des[i] = s;






// Return the total number of random effects deltas
int ndelta(int[] trt, int n_i) {
int count = 0;






65 int<lower = 2> n_i; // Number of data points
int<lower=2> ncat; // Number of ordered outcome categories
// Data
int<lower=0> y[n_i, ncat]; // Outcome category counts
70 int<lower=1> trt[n_i]; // Treatment indicator






// For equivalent IPD + AgD deviance calculation
80 int<lower = 0, upper = 1> has_ipd[n_i]; // IPD study indicator
}
transformed data {
int<lower = 2> n_t = max(trt); // Number of treatments
int<lower = 1> n_s = max(study); // Number of studies
85
int<lower = 0> delta_design[n_i];
int<lower = 1> n_delta = ndelta(trt, n_i);
// RE MVN mean and correlations
90 vector[n_delta] RE_mu = rep_vector(0, n_delta);
// Cholesky decomposition of RE MVN correlations
matrix[n_delta, n_delta] RE_L = cholesky_decompose(Rho(trt, study, n_i, n_s));
// Which arms have RE deltas? Since we are using the reference treatment
95 // parameterisation (rather than the baseline shift parameterisation), any arm
// not on treatment 1 has a random effect
delta_design = whichdelta(trt, n_i);
}
parameters {
100 vector[n_s] mu; // Study baselines
vector[n_t -1] d; // Recoded basic treatment parameters (no d_1)
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vector[n_delta] u_delta; // Non-centered random effects
real<lower = 0> tau; // RE heterogeneity standard deviation
105 // Ordered cutoffs on underlying probit-PASI scale
// "Fixed effect" cutoffs, the same across trials







115 f_delta = tau * RE_L * u_delta;
// Linear predictor
for (i in 1:n_i) {
if (delta_design[i]) // Note: implies not treatment 1 arm




125 // Probit model, cutoffs for each category
for (i in 1:n_i) {
vector[ncat - 1] phi_temp;
phi_temp[1] = Phi(eta[i]);
theta[i, 1] = 1 - phi_temp[1];
130 for (k in 2:(ncat - 1)) {
phi_temp[k] = Phi(eta[i] - cc[k - 1]);
theta[i, k] = phi_temp[k - 1] - phi_temp[k];
}





mu ~ normal(0, prior_sd_mu);
140 d ~ normal(0, prior_sd_d);
tau ~ normal(0, prior_sd_tau);
// Implied improper uniform prior on cutpoints if given negative prior_cc_sd:
// cc ~ uniform(-inf, inf)
145 // Even if we place priors on cc ourselves, Stan will impose the ordering
// constraint for us, so these are effectively half-normal priors on the
// differences
if (prior_cc_sd >= 0) {
vector[ncat - 2] diff_cc;
150 for (k in 1:(ncat - 2))
diff_cc[k] = cc[k + 1] - cc[k];
diff_cc ~ normal(0, prior_cc_sd);
}
155 // Random effects
u_delta ~ normal(0, 1);
// Likelihood
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for (i in 1:n_i)
160 y[i] ~ multinomial(theta[i]);
}
generated quantities {









for (i in 1:n_i) {
175 log_lik[i] = multinomial_lpmf(y[i] | theta[i]);
y_hat[i] = sum(y[i]) * theta[i];
// Multinomial residual deviance
{
180 vector[ncat] dv;
for (k in 1:ncat) {
dv[k] = y[i, k] == 0 ? 0 : y[i, k] * (log(y[i, k]) - log(y_hat[i, k]));
}
resdev[i] = 2 * sum(dv);
185 }
// For equivalent IPD + AgD model
if (has_ipd[i] == 1){
resdev_alt[i] = -2 * to_row_vector(y[i]) * log(theta[i]);
190 } else {
resdev_alt[i] = resdev[i];
}
// Shrunken estimates delta
195 delta[i] = delta_design[i] ? d[trt[i] - 1] + f_delta[delta_design[i]] : 0;
}
// Total residual deviance
totresdev = sum(resdev);
200 totresdev_alt = sum(resdev_alt);
}
A.2.2 Multilevel networkmeta-regression
We now provide Stan code for the fixed effect ML-NMR model for ordered
categorical outcomes. Again, the derivation of numerical integration points is
performed externally in R (see Section A.4). The modifications of this code
to incorporate random effects or to fit an unrelated mean effects model are
identical to those for binary outcomes, given in Sections A.1.2.3 and A.1.2.4
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respectively.
1 data {
// -- Constants --
int<lower=1> ns_ipd; // Number of IPD studies
int<lower=1> ns_agd; // Number of AgD studies
5 int<lower=1> ni_ipd; // Total number of IPD individuals
int<lower=2> ni_agd; // Total number of AgD data points
int<lower=1> nt; // Number of treatments
int<lower=1> nint; // Number of samples for numerical integration
int<lower=0> nPV; // Number of prognostic variables
10 int<lower=0> nEM; // Number of effect modifier *interactions*
// (NOT number of EM variables)
int<lower=2> ncat; // Number of ordered outcome categories
int<lower=1> int_thin; // Thinning factor for saved p_ii integration points
15 // -- IPD --
int<lower=1, upper=ncat> y[ni_ipd]; // Multinomial outcome
// -- AgD --
int<lower=0> ag_y[ni_agd, ncat]; // Outcome category counts
20
// The following are only needed if no PVs are included in the model (improves
// sampling efficiency by not doing numerical integration on AgD reference
// treatment 1 arms)
25 // int<lower=1> ag_trt[ni_agd]; // Treatment indicator
// int<lower=2> ag_study[ni_agd]; // Study indicator
// -- Thin QR decomposition --
matrix[ni_ipd + nint * ni_agd, ns_ipd + ns_agd + nPV + nEM + (nt - 1)] Q;
30 matrix[ns_ipd + ns_agd + nPV + nEM + (nt - 1),
ns_ipd + ns_agd + nPV + nEM + (nt - 1)] R_inv;







40 transformed data {
// Total number of parameters and data points
int totnpar = ns_ipd + ns_agd + nPV + nEM + (nt - 1);
int totni = ni_ipd + nint * ni_agd;
45 // Split Q matrix into IPD and AgD rows
matrix[ni_ipd, totnpar] Q_ipd = Q[1:ni_ipd];
matrix[nint * ni_agd, totnpar] Q_agd = Q[(ni_ipd + 1):totni];
// nint/int_thin for numerical integration checks
50 // This will give a warning about integer division, which cannot be avoided
int n_int_thin = nint / int_thin;
}
parameters {
// Parameters on QR scale
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55 vector[totnpar] beta_tilde;
// Ordered cutoffs on underlying probit-PASI scale
// "Fixed effect" cutoffs, the same across trials
positive_ordered[ncat - 2] f_cc;
60 }
transformed parameters {
// -- Cut offs --
vector[ncat - 1] cc;
65 // -- Likelihood parameters needed later for log lik calculation --
vector[ni_ipd] eta; // IPD linear predictor
vector[ncat] theta[ni_ipd]; // IPD predicted probabilities
// -- Back-transformed parameters --
70 vector[totnpar] allbeta = R_inv * beta_tilde;
// Study baselines
vector[ns_ipd + ns_agd] mu = allbeta[1:(ns_ipd + ns_agd)];
// Treatment effects
vector[nt - 1] gamma = allbeta[(ns_ipd + ns_agd +1):
75 (ns_ipd + ns_agd + nt - 1)];
// Prognostic variables
vector[nPV] beta1 = allbeta[(ns_ipd + ns_agd + nt):
(ns_ipd + ns_agd + nt - 1 + nPV)];
// EM interactions
80 vector[nEM] beta2 = allbeta[(ns_ipd + ns_agd + nt + nPV):totnpar];
// -- AgD integration --
// Can save these directly to check how the integration error decreases




90 // -- IPD model --
// We define the IPD and AgD models here in the transformed parameters block,
// as the linear predictors are required to calculate the log likelihood later
// on. This is slightly more inefficient than defining the models locally in
// the model block.
95 eta = Q_ipd * beta_tilde;
for (i in 1:ni_ipd) {
vector[ncat - 1] phi_temp;
phi_temp[1] = Phi(eta[i] - cc[1]);
100 theta[i, 1] = 1 - phi_temp[1];
for (k in 2:(ncat - 1)) {
phi_temp[k] = Phi(eta[i] - cc[k]);
theta[i, k] = phi_temp[k - 1] - phi_temp[k];
}
105 theta[i, ncat] = phi_temp[ncat - 1];
}
// -- AgD model --
{
110 vector[nint * ni_agd] eta_ii = Q_agd * beta_tilde;
vector[ncat - 1] q_bar[ni_agd];
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// k == 1
for (i in 1:ni_agd) {
115 q_ii[(1 + (i - 1)*nint):(i*nint), 1] =
Phi(eta_ii[(1 + (i - 1)*nint):(i*nint)] - cc[1]);
q_bar[i, 1] = mean(q_ii[(1 + (i - 1)*nint):(i*nint), 1]);
p_bar[i, 1] = 1 - q_bar[i, 1];
}
120 for (k in 2:(ncat - 1)) {
for (i in 1:ni_agd) {
q_ii[(1 + (i - 1)*nint):(i*nint), k] =
Phi(eta_ii[(1 + (i - 1)*nint):(i*nint)] - cc[k]);
q_bar[i, k] = mean(q_ii[(1 + (i - 1)*nint):(i*nint), k]);
125 p_bar[i, k] = q_bar[i, k - 1] - q_bar[i, k];
}
}
// k == ncat




// -- Priors --
// These prior statements will cause Stan to raise warnings regarding
135 // transformed parameters possibly needing Jacobian adjustments. These should
// be ignored, as the transformation is entirely linear
mu ~ normal(0, prior_sd_mu);
beta1 ~ normal(0, prior_sd_beta1);
beta2 ~ normal(0, prior_sd_beta2);
140 gamma ~ normal(0, prior_sd_gamma);
// Implied improper uniform prior on cutpoints if given negative prior_cc_sd:
// cc ~ uniform(-inf, inf)
// Even if we place priors on cc ourselves, Stan will impose the ordering
145 // constraint for us, so these are effectively half-normal priors on the
// differences
if (prior_cc_sd >= 0) {
vector[ncat - 2] diff_cc;
for (k in 1:(ncat - 2))
150 diff_cc[k] = cc[k + 1] - cc[k];
diff_cc ~ normal(0, prior_cc_sd);
}
155 // -- IPD likelihood --
for (i in 1:ni_ipd)
y[i] ~ categorical(theta[i]);
// -- AgD likelihood --




// -- Log likelihood and residual deviance calculation --
165 vector[ni_ipd + ni_agd] log_lik;
vector[ni_ipd + ni_agd] resdev;
// -- Estimate integration error --
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matrix[ni_agd * n_int_thin, ncat - 1] q_bar_cum;
170
// -- Predicted probabilities and numbers of events --
row_vector[ncat] p_hat[ni_ipd + ni_agd];
row_vector[ncat] y_hat[ni_ipd + ni_agd];
175 for (i in 1:ni_ipd) {
log_lik[i] = categorical_lpmf(y[i] | theta[i]);
p_hat[i] = theta[i]';
y_hat[i] = theta[i]';
resdev[i] = -2 * log_lik[i];
180 }
for (i in 1:ni_agd) {
log_lik[ni_ipd + i] = multinomial_lpmf(ag_y[i] | p_bar[i]);
p_hat[ni_ipd + i] = p_bar[i]';
185 y_hat[ni_ipd + i] = sum(ag_y[i]) * p_hat[ni_ipd + i];
// Multinomial residual deviance
{
vector[ncat] dv;
190 for (k in 1:ncat) {
dv[k] = ag_y[i, k] == 0 ?
0 :
ag_y[i, k] * (log(ag_y[i, k]) - log(y_hat[ni_ipd + i, k]));
}
195 resdev[ni_ipd + i] = 2 * sum(dv);
}
// Cumulative integration - note this is of the q_ii intermediates, NOT p_ii
for (k in 1:(ncat - 1)) {
200 for (j in 1:n_int_thin) {
q_bar_cum[(i - 1)*n_int_thin + j, k] =






This section provides Stan code for the analysis of survival or time-to-event
outcomes, as used in Section 7.3.
A.3.1 IPD networkmeta-regression
Firstly, we consider an IPD network meta-regression. The following code
allows the user to select the survival distribution (Exponential, Weibull, and
Gompertz are implemented) by setting the value of dist. There is an implicit
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improper uniform prior distribution U(0,∞) on the shape parameters ν j , but
a proper prior distribution could be specified if desired.
1 data {
// -- Constants --
int<lower=1> ns; // Number of studies
int<lower=1> ni; // Total number of individuals
5 int<lower=1> nt; // Number of treatments
int<lower=0> nPV; // Number of prognostic variables
int<lower=0> nEM; // Number of effect modifier *interactions*
// (NOT number of EM variables)
10 // -- Survival data --
vector<lower=0>[ni] y; // Observation time
int<lower=0, upper=1> status[ni]; // Event status (0 = censored, 1 = event)
int<lower=1> study[ni]; // Study id
15 // -- Distribution flag --
int<lower=1, upper=3> dist; // 1 = Exponential, 2 = Weibull, 3 = Gompertz
// -- Thin QR decomposition --
matrix[ni, ns + nPV + nEM + (nt - 1)] Q;
20 matrix[ns + nPV + nEM + (nt - 1), ns + nPV + nEM + (nt - 1)] R_inv;





// NOTE: There is an implicit improper uniform prior on the shape parameter,
// but a proper prior distribution could be specified if desired
}
30 transformed data {
// Total number of parameters and data points
int totnpar = ns + nPV + nEM + (nt - 1);
int totni = ni;
35 // Exponential model indicator, ZERO when exponential
int<lower=0, upper=1> nonexp = dist == 1 ? 0 : 1;
}
parameters {
// Parameters on QR scale
40 vector[totnpar] beta_tilde;
// Shape for parametric model




vector[ni] eta; // log rates
vector[ni] theta; // Rates
vector[ni] itheta; // Scales
50
// -- Back-transformed parameters --
vector[totnpar] allbeta = R_inv * beta_tilde;
371
A. STAN CODE LISTINGS
// Study baselines (equivalent to log scales)
vector[ns] mu = allbeta[1:ns];
55 // Treatment effects
vector[nt - 1] gamma = allbeta[(ns + 1):(ns + nt - 1)];
// Prognostic variables
vector[nPV] beta1 = allbeta[(ns + nt):(ns + nt - 1 + nPV)];
// EM interactions
60 vector[nEM] beta2 = allbeta[(ns + nt + nPV):totnpar];
// -- Model on log rate --
if (dist == 1) { // Exponential
eta = Q * beta_tilde;
65 } else if (dist == 2) { // Weibull
eta = (Q * beta_tilde) ./ shape[study];
} else if (dist == 3) { // Gompertz
eta = Q * beta_tilde;
}




// -- Priors --
75 // These prior statements will cause Stan to raise warnings regarding
// transformed parameters possibly needing Jacobian adjustments. These should
// be ignored, as the transformation is entirely linear.
mu ~ normal(0, prior_sd_mu);
beta1 ~ normal(0, prior_sd_beta1);
80 beta2 ~ normal(0, prior_sd_beta2);
gamma ~ normal(0, prior_sd_gamma);
// NOTE: implied improper uniform prior U(0, inf) on shape
85 // -- Likelihood --
if (dist == 1) { // Exponential model




target += exponential_lccdf(y[i] | theta[i]);
}
} else if (dist == 2) { // Weibull model
for (i in 1:ni) {
95 if (status[i]==1)
y[i] ~ weibull(shape[study[i]], itheta[i]);
else
target += weibull_lccdf(y[i] | shape[study[i]], itheta[i]);
}
100 } else if (dist == 3) { // Gompertz model
// Stan does not have Gompertz distribution, instead code the log likelihood
// contributions directly
for (i in 1:ni) {
if (status[i]==1)
105 target += -theta[i]/shape[study[i]] * expm1(shape[study[i]] * y[i]) +
eta[i] + (shape[study[i]] * y[i]);
else







// Transform intercepts back to scales
vector[ns] scale = exp(mu);
115 // Log likelihood contributions
vector[ni] log_lik;
if (dist == 1) { // Exponential model
for (i in 1:ni) {
120 if (status[i]==1)
log_lik[i] = exponential_lpdf(y[i] | theta[i]);
else
log_lik[i] = exponential_lccdf(y[i] | theta[i]);
}
125 } else if (dist == 2) { // Weibull model
for (i in 1:ni) {
if (status[i]==1)
log_lik[i] = weibull_lpdf(y[i] | shape[study[i]], itheta[i]);
else
130 log_lik[i] = weibull_lccdf(y[i] | shape[study[i]], itheta[i]);
}
} else if (dist == 3) { // Gompertz model
for (i in 1:ni) {
if (status[i]==1)
135 log_lik[i] = -theta[i]/shape[study[i]] * expm1(shape[study[i]] * y[i]) +
eta[i] + (shape[study[i]] * y[i]);
else





We now provide Stan code for the fixed effect ML-NMR model for survival
outcomes. Again, the derivation of numerical integration points is performed
externally in R (see SectionA.4). As for the IPDNMRmodel (SectionA.3.1), the
code allows the user to select the survival distribution (Exponential, Weibull,
and Gompertz are implemented) by setting the value of dist. Alternative
survival and hazard functions could be specified by the user in the functions
block. There is an implicit improper uniform prior distribution U(0,∞) on
the shape parameters ν j , but a proper prior distribution could be specified if
desired.
1 functions {
// -- Exponential --
// Survival
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vector S_exp(real y, vector rate) {
5 return exp(-y * rate);
}
// Hazard
vector h_exp(vector rate) {
10 return rate;
}
// -- Weibull --
vector S_weib(real y, vector rate, real shape) {
15 vector[num_elements(rate)] S;
for (i in 1:num_elements(rate)) {





vector h_weib(real y, vector rate, real shape) {
vector[num_elements(rate)] h;
25 for (i in 1:num_elements(rate)) {





// -- Gompertz --
// Survival
vector S_gomp(real y, vector rate, real shape) {
vector[num_elements(rate)] S;
35 for (i in 1:num_elements(rate)) {






vector h_gomp(real y, vector rate, real shape) {




// -- Constants --
int<lower=1> ns_ipd; // Number of IPD studies
int<lower=1> ns_agd; // Number of AgD studies
50 int<lower=1> ni_ipd; // Total number of IPD individuals
int<lower=2> ni_agd; // Total number of AgD data points
int<lower=1> nt; // Number of treatments
int<lower=1> nint; // Number of samples for numerical integration
int<lower=0> nPV; // Number of prognostic variables
55 int<lower=0> nEM; // Number of effect modifier *interactions*
// (NOT number of EM variables)
int<lower=1> int_thin; // Thinning factor for saved integration points
// -- Survival data --
60 vector<lower=0>[ni_ipd + ni_agd] y; // Observation time
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int<lower=0, upper=1> status[ni_ipd + ni_agd]; // Event status
// (0 = censored, 1 = event)
int<lower=1> study[ni_ipd + ni_agd]; // Study id
65 // -- Integration point details --
int<lower=1> int_id[ni_agd]; // Integration id (i.e. for an arm or study) for
// each AgD individual event time
int<lower=1> int_study[max(int_id)]; // Study id for integration points
70 // -- Distribution flag --
int<lower=1, upper=3> dist; // 1 = Exponential, 2 = Weibull, 3 = Gompertz
// -- Thin QR decomposition --
matrix[ni_ipd + nint * max(int_id), ns_ipd + ns_agd + nPV + nEM + (nt - 1)] Q;
75 matrix[ns_ipd + ns_agd + nPV + nEM + (nt - 1),
ns_ipd + ns_agd + nPV + nEM + (nt - 1)] R_inv;





// NOTE: There is an implicit improper uniform prior on the shape parameter,
// but a proper prior distribution could be specified if desired
85 }
transformed data {
// Total number of studies
int ns = ns_ipd + ns_agd;
90 // Total number of parameters
int totnpar = ns + nPV + nEM + (nt - 1);
// For numerical integration checks
// This will give a warning about integer division, which cannot be avoided
95 int n_int_thin = nint / int_thin;
// Exponential model indicator, ZERO when exponential
int<lower=0, upper=1> nonexp = dist == 1 ? 0 : 1;
100 // Status to vector (from array)
vector<lower=0, upper=1>[ni_ipd + ni_agd] status_v = to_vector(status);
// Study design vector, with expanded AgD integration points
int study_long[ni_ipd + nint * max(int_id)];
105 study_long[1:ni_ipd] = study[1:ni_ipd];
for (i in 1:max(int_id)) {





// Parameters on QR scale
vector[totnpar] beta_tilde;
115 // Shape for parametric model
// Exponential model has shape = 1 so parameter is removed (zero dimension)
vector<lower=0>[ns*nonexp] shape;
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}
transformed parameters {
120 vector[ni_ipd + nint * max(int_id)] eta; // log rates
vector[ni_ipd + nint * max(int_id)] theta; // Rates
vector[ni_ipd + nint * max(int_id)] itheta; // Scales
// -- Back-transformed parameters --
125 vector[totnpar] allbeta = R_inv * beta_tilde;
// Study baselines (equivalent to log scales)
vector[ns] mu = allbeta[1:ns];
// Treatment effects
vector[nt - 1] gamma = allbeta[(ns + 1):(ns + nt - 1)];
130 // Prognostic variables
vector[nPV] beta1 = allbeta[(ns + nt):(ns + nt - 1 + nPV)];
// EM interactions
vector[nEM] beta2 = allbeta[(ns + nt + nPV):totnpar];
135 // -- AgD integration --
vector[nint * ni_agd] S_ii;
vector[nint * ni_agd] h_ii;
vector[ni_agd] P_bar;
140 // -- Model on log rate --
if (dist == 1) { // Exponential
eta = Q * beta_tilde;
} else if (dist == 2) { // Weibull
eta = (Q * beta_tilde) ./ shape[study_long];
145 } else if (dist == 3) { // Gompertz
eta = Q * beta_tilde;
}
theta = exp(eta); // Rates
itheta = exp(-eta); // Scales
150
// -- Perform AgD integration --
// NOTE: Integration of hazard only needed for observed (not censored) events
for (i in 1:ni_agd) {
if (dist == 1) { // Exponential
155 S_ii[((i-1)*nint + 1):i*nint]
= S_exp(y[ni_ipd + i],
theta[(ni_ipd + (int_id[i]-1)*nint + 1):
(ni_ipd + int_id[i]*nint)]);
// Exponential hazard is just the rate
160 // NOTE: equivalent to using function h_exp but probably more efficient
h_ii[((i-1)*nint + 1):i*nint]
= status[ni_ipd + i] == 1
? theta[(ni_ipd + (int_id[i]-1)*nint + 1):(ni_ipd + int_id[i]*nint)]
: rep_vector(0, nint);
165 } else if (dist == 2) { // Weibull
S_ii[((i-1)*nint + 1):i*nint]
= S_weib(y[ni_ipd + i],
theta[(ni_ipd + (int_id[i]-1)*nint + 1):
(ni_ipd + int_id[i]*nint)],
170 shape[study[ni_ipd + i]]);
h_ii[((i-1)*nint + 1):i*nint]
= status[ni_ipd + i] == 1
? h_weib(y[ni_ipd + i],
theta[(ni_ipd + (int_id[i]-1)*nint + 1):
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175 (ni_ipd + int_id[i]*nint)],
shape[study[ni_ipd + i]])
: rep_vector(0, nint);
} else if (dist == 3) { // Gompertz
S_ii[((i-1)*nint + 1):i*nint]
180 = S_gomp(y[ni_ipd + i],




185 = status[ni_ipd + i] == 1
? h_gomp(y[ni_ipd + i],
theta[(ni_ipd + (int_id[i]-1)*nint + 1):
(ni_ipd + int_id[i]*nint)],
shape[study[ni_ipd + i]])
190 : rep_vector(0, nint);
}
// Take average to calculate marginal survival and hazard
// Again, only take mean of h_ii if uncensored
195 // NOTE: Set h_bar to 1 if censored, so that log(h_bar) is 0 (i.e. no log
// likelihood contribution)
if (status[ni_ipd + i] == 1) {
P_bar[i] = mean(S_ii[((i-1)*nint + 1):i*nint] .*
h_ii[((i-1)*nint + 1):i*nint]);
200 } else {





// -- Priors --
// These prior statements will cause Stan to raise warnings regarding
// transformed parameters possibly needing Jacobian adjustments. These should
// be ignored, as the transformation is entirely linear.
210 mu ~ normal(0, prior_sd_mu);
beta1 ~ normal(0, prior_sd_beta1);
beta2 ~ normal(0, prior_sd_beta2);
gamma ~ normal(0, prior_sd_gamma);
215 // NOTE: implied improper uniform prior U(0, inf) on shape
// -- IPD likelihood --
if (dist == 1) { // Exponential model




target += exponential_lccdf(y[i] | theta[i]);
}
225 } else if (dist == 2) { // Weibull model
for (i in 1:ni_ipd) {
if (status[i]==1)
y[i] ~ weibull(shape[study[i]], itheta[i]);
else
230 target += weibull_lccdf(y[i] | shape[study[i]], itheta[i]);
}
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} else if (dist == 3) { // Gompertz model
// Stan does not have Gompertz distribution, instead code the log likelihood
// contributions directly
235 for (i in 1:ni_ipd) {
if (status[i]==1)
target += -theta[i]/shape[study[i]] * expm1(shape[study[i]] * y[i]) +
eta[i] + (shape[study[i]] * y[i]);
else
240 target += -theta[i]/shape[study[i]] * expm1(shape[study[i]] * y[i]);
}
}
// -- AgD likelihood --




// Transform intercepts back to scales
250 vector[ns] scale = exp(mu);
// Log likelihood contributions
vector[ni_ipd + ni_agd] log_lik;
// -- Estimate integration error --
255 matrix[ni_agd, n_int_thin] P_bar_cum;
// -- IPD log likelihood --
if (dist == 1) { // Exponential model
for (i in 1:ni_ipd) {
260 if (status[i]==1)
log_lik[i] = exponential_lpdf(y[i] | theta[i]);
else
log_lik[i] = exponential_lccdf(y[i] | theta[i]);
}
265 } else if (dist == 2) { // Weibull model
for (i in 1:ni_ipd) {
if (status[i]==1)
log_lik[i] = weibull_lpdf(y[i] | shape[study[i]], itheta[i]);
else
270 log_lik[i] = weibull_lccdf(y[i] | shape[study[i]], itheta[i]);
}
} else if (dist == 3) { // Gompertz model
for (i in 1:ni_ipd) {
if (status[i]==1)
275 log_lik[i] = -theta[i]/shape[study[i]] * expm1(shape[study[i]] * y[i]) +
eta[i] + (shape[study[i]] * y[i]);
else
log_lik[i] = -theta[i]/shape[study[i]] * expm1(shape[study[i]] * y[i]);
}
280 }
// -- AgD log likelihood --
log_lik[(ni_ipd + 1):] = log(P_bar);
285 // Estimate integration error
for (j in 1:n_int_thin) {
for (i in 1:ni_agd) {
if (status[ni_ipd + i] == 1) {
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P_bar_cum[i,j] =
290 mean(S_ii[((i-1)*nint + 1):((i-1)*nint + j*int_thin)] .*
h_ii[((i-1)*nint + 1):((i-1)*nint + j*int_thin)]);
} else {





A.4Running ML-NMR in R
Stan interfaces are available in a variety of computing environments, including
R, Stata, and Python.1 We use R for the analyses throughout this thesis, and
run Stan via the rstan package. In this section, we outline how to prepare and
run ML-NMR models from R.
A.4.1Generating QMC integration points
Firstly, we need to generate QMC integration points (following Section 5.1),
which will be passed to the ML-NMR model in Stan as data. We use the
sobol function from the randtoolbox package to generate points from a Sobol’
sequence. A Gaussian copula is implemented using the copula package
(which also includes functions for other copulæ), with which we apply the
correlations observed in the IPD to the Sobol’ points before transforming to
the required marginal distributions using the inverse CDF method. We load
the tidyverse suite of packages to simplify the process of data manipulation.
The following code assumes that all data from the IPD studies are contained
in a data frame called ip_dat, and the AgD study summaries are contained
in a data frame called ag_dat. We illustrate with covariates from the plaque
psoriasis example in Chapter 6: duration of psoriasis (durnpso), previous
systemic treatment (prevsys), body surface area (bsa), weight (weight), and
psoriatic arthritis (psa).





# Assume that IPD are contained in ip_dat, AgD in ag_dat
1For a current list of interfaces, see https://mc-stan.org/users/interfaces/.
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# Column studyn is a numeric study indicator
# Column trtn is a numeric treatment indicator
10 # Scenario setup
ns_ipd <- length(unique(ip_dat$studyn)) # Number of IPD studies
ns_agd <- length(unique(ag_dat$studyn)) # Number of AgD studies
ntrt <- length(unique(c(ip_dat$trtn, ag_dat$trtn))) # Number of treatments
15 # Names of covariates to include in analysis (column names in ip_dat)
X_names <- c("durnpso", "prevsys", "bsa", "weight", "psa")
# Set parameters for numerical integration
n_X <- length(X_names) # Number of covariates
20 n_int <- 5000 # Number of sample points for numerical integration
# Draw n_int Sobol points in n_X dimensions
sobol_points <- sobol(n_int, n_X)
25 # Compute the correlation matrix of the covariates in the IPD using a




30 do(w = nrow(.) - 3, r = cor(select(., !! X_names), method = "spearman")) %>%
mutate(wcor = list(w * log((1 + r) / (1 - r)) / 2)) %>%
unnest(w) %>%
ungroup()
35 ipd_cor <- {Reduce(+, ipd_cors$wcor) / sum(ipd_cors$w)} %>%
{(exp(2 * .) - 1) / (exp(2 * .) + 1)}
diag(ipd_cor) <- 1
40 # Create copula object
ipd_copula <- normalCopula(P2p(ipd_cor), dim = n_X, dispstr = "un")
# Apply copula to the Sobol points
sobol_points_cor <- as.tibble(cCopula(sobol_points, ipd_copula,
45 inverse = TRUE)) %>%
setNames(X_names)
# Redefine logitnorm::qlogitnorm, the inverse CDF of logit Normal distribution,
# to be parameterised using mean and standard deviation
50 .lndiff <- function(est, smean, ssd){
x <- logitnorm::momentsLogitnorm(est[1], est[2])
(x[1] - smean)^2 + (sqrt(x[2]) - ssd)^2
}
55 .lnopt <- function(sample_mean, sample_sd) {
opt <- optim(c(sample_mean, sample_sd), .lndiff,
smean = sample_mean, ssd = sample_sd)
if (opt$convergence != 0) {
60 warning("Optimisation did not converge, NAs produced.")
c("mu" = NA, "sigma" = NA)
} else {
c("mu" = opt$par[1], "sigma" = opt$par[2])
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}
65 }
pars_logitnorm <- function(sample_mean, sample_sd) {
if (length(sample_mean) != length(sample_sd))
stop("Parameters not same length.")
70 if (any(sample_mean > 1 | sample_mean < 0))
stop("Sample mean not in [0,1]. Have you rescaled?")
as.data.frame(do.call(rbind, mapply(.lnopt, sample_mean, sample_sd,
SIMPLIFY = FALSE)))
75 }
qlogitnorm <- function(p, mean, sd){
pars <- pars_logitnorm(mean, sd)
logitnorm::qlogitnorm(p, pars$mu, pars$sigma)
80 }
# Use inverse CDF method to transform points to required marginal distributions
ag_xpoints <- ag_dat %>%
rowwise() %>%
85 do(durnpso = qgamma(sobol_points_cor$durnpso,
(.$durnpso_mean / .$durnpso_sd)^2 ,
.$durnpso_mean / .$durnpso_sd^2),
prevsys = qbinom(sobol_points_cor$prevsys, 1, .$prevsys / 100),
bsa = qlogitnorm(sobol_points_cor$bsa,
90 .$bsa_mean / 100, .$bsa_sd / 100) * 100,
weight = qgamma(sobol_points_cor$weight,
(.$weight_mean / .$weight_sd)^2 ,
.$weight_mean / .$weight_sd^2),
psa = qbinom(sobol_points_cor$psa, 1, .$psa / 100)
95 ) %>%
unnest(.id = "ag_id") %>%
select(ag_id, everything(), -matches("^ag_id[0-9]+$"))
A.4.2Calling Stan
Now that we have the QMC integration points, we can run the ML-NMR
model in Stan. The following code illustrates the process of fitting a FE
ML-NMR model for the plaque psoriasis example in Chapter 6, where binary
PASI 75 outcomes are modelled using a probit link function, and shared EM
interactions are assumed for the class of interleukin-17A blockers (ixekizumab
and secukinumab). The code implements centring and QR decomposition, for
efficient computation (Section 5.2.1). The corresponding ML-NMR Stan code
is given in Section A.1.2.1.




A. STAN CODE LISTINGS
options(mc.cores = parallel::detectCores())
5
# Function to get overall weighted mean of a covariate from IPD and AgD
global_mean <- function(v, # Name of covariate
ss, # Sample size variable in AgD
ipd, # IPD data frame
10 agd, # AgD data frame




v_ipd <- pull(ipd, !! v)
if (na.rm & any(is.na(v_ipd))) {
num_na <- sum(is.na(v_ipd))
20 v_ipd <- v_ipd[!is.na(v_ipd)]
message("Removed ", num_na, " missing values in IPD.")
} else if (any(is.na(v_ipd))) {
warning("IPD has missing values, NA returned.", call. = FALSE)
return(NA)
25 }
v_agd <- pull(agd, !! paste0(quo_name(enquo(v)), "_mean"))
ss_agd <- pull(agd, !! ss)
30 drop((sum(v_ipd) + ss_agd %*% v_agd) / (length(v_ipd) + sum(ss_agd)))
}
# Calculate an overall mean value for each covariate, to use for centring
gmean_durnpso <- global_mean(durnpso, sample_size_w0,
35 ip_dat, ag_dat)
gmean_bsa <- global_mean(bsa, sample_size_w0,
ip_dat, ag_dat)
gmean_weight <- global_mean(weight, sample_size_w0,
ip_dat, ag_dat)
40
# Create a big data frame with the AgD integration points added on to the bottom
# of the IPD
stan_xdat <- ip_dat %>%
select(studyn, trtn,
45 prevsys, durnpso, bsa, weight, psa) %>%
bind_rows(
ag_dat %>% transmute(ag_id = 1:n(), studyn, trtn) %>%
full_join(ag_xpoints, by = "ag_id") %>%
select(studyn, trtn, prevsys, durnpso, bsa, weight, psa)
50 ) %>%
mutate(study = as.factor(studyn), trt = as.factor(trtn),
trtclass = recode_factor(trtn,
"1" = 1, # Placebo
"2" = 2, "3" = 2, "5" = 2, "6" = 2, # IL-17 blockers
55 "4" = 3, # TNFa blocker
"7" = 4), # IL-12,23 blocker
prevsys = prevsys,
durnpso = durnpso - gmean_durnpso,
bsa = bsa - gmean_bsa,
60 weight = weight - gmean_weight,
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psa = psa)
# Now we can simply use the model.matrix function to create the model matrix.
# To be compatible with the Stan code, the resulting model matrix columns should
65 # be in the order: study baselines, treatment parameters, PVs, EM interactions.
X_all <- model.matrix(~ -1 + study + trt +
prevsys + durnpso + bsa + weight + psa +
(prevsys + durnpso + bsa + weight + psa):trtclass,
data = stan_xdat)
70
# Then get the thin QR decomposition
X_all_qr <- qr(X_all)
X_all_Q <- qr.Q(X_all_qr) * sqrt(nrow(X_all) - 1)
X_all_R <- qr.R(X_all_qr)[, sort.list(X_all_qr$pivot)] / sqrt(nrow(X_all) - 1)
75 X_all_R_inv <- solve(X_all_R)
# Construct the data list for Stan
pasi75_shared_standat <- list(
# Constants





85 nint = n_int,
nPV = n_X,
nEM = 3 * n_X, # Shared EM model, so number of active trt classes * n_X
int_thin = 100,
# IPD














105 # Run Stan
# The ML-NMR model code is saved in file ML-NMR_probit_indep_twoparbin_qr.stan
pasi75_shared_stan <- stan("./ML-NMR_probit_indep_twoparbin_qr.stan",
data = pasi75_shared_standat,
pars = c("beta0", "beta1", "beta2", "gamma", "nprime", "pprime",
110 "p_bar_cum", "p2_bar_cum",
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get_sampler_params(pasi75_shared_stan, inc_warmup = FALSE) %>%
120 map_dfr(~ as_tibble(.) %>% summarise_at(1:4, mean))
# The shinystan package can also be used to assess convergence interactively
# library(shinystan)
# pasi75_shared_sso <- drop_parameters(as.shinystan(pasi75_shared_stan),
125 # pars = c("log_lik", "p_bar_cum", "p2_bar_cum", "resdev", "r_hat"))
# launch_shinystan(pasi75_shared_sso)
# Print parameter estimates
print(pasi75_shared_stan, pars = c("beta0", "beta1", "beta2", "gamma"))
384
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B. TABLES OF SIMULATION STUDY RESULTS
B.1 Scenario a
Table B.1 Simulation results for scenario a, adjusting for all effect modifiers.
Sample size N is varied between 100, 500, and 1000. Monte Carlo standard
errors for each statistic are shown in brackets.
Method Contrast Scenario Bias Empirical SE Model SE Coverage
ML-NMR dAB(AB) N  100 -0.356 (0.013) 0.603 (0.010) 0.528 (0.002) 87.5 (0.7)
N  500 -0.056 (0.005) 0.215 (0.003) 0.207 (<0.001) 93.8 (0.5)
N  1000 -0.032 (0.003) 0.148 (0.002) 0.145 (<0.001) 94.4 (0.5)
dAC(AB) N  100 -0.286 (0.032) 1.420 (0.022) 1.219 (0.004) 91.0 (0.6)
N  500 -0.038 (0.011) 0.487 (0.008) 0.471 (<0.001) 94.6 (0.5)
N  1000 -0.005 (0.008) 0.336 (0.005) 0.328 (<0.001) 94.1 (0.5)
dBC(AB) N  100 0.070 (0.034) 1.513 (0.024) 1.301 (0.003) 90.5 (0.7)
N  500 0.019 (0.012) 0.522 (0.008) 0.507 (<0.001) 94.1 (0.5)
N  1000 0.026 (0.008) 0.361 (0.006) 0.354 (<0.001) 95.0 (0.5)
dAB(AC) N  100 -0.258 (0.032) 1.416 (0.022) 1.204 (0.004) 90.2 (0.7)
N  500 -0.041 (0.011) 0.474 (0.007) 0.462 (<0.001) 94.7 (0.5)
N  1000 -0.040 (0.007) 0.323 (0.005) 0.322 (<0.001) 95.0 (0.5)
dAC(AC) N  100 -0.188 (0.012) 0.542 (0.009) 0.517 (0.001) 93.1 (0.6)
N  500 -0.023 (0.005) 0.216 (0.003) 0.210 (<0.001) 94.3 (0.5)
N  1000 -0.014 (0.003) 0.153 (0.002) 0.148 (<0.001) 94.1 (0.5)
dBC(AC) N  100 0.070 (0.034) 1.513 (0.024) 1.301 (0.003) 90.5 (0.7)
N  500 0.019 (0.012) 0.522 (0.008) 0.507 (<0.001) 94.1 (0.5)
N  1000 0.026 (0.008) 0.361 (0.006) 0.354 (<0.001) 95.0 (0.5)
STC dAB(AC) N  100 -0.124 (0.028) 1.232 (0.019) 1.123 (0.003) 94.0 (0.5)
N  500 -0.020 (0.010) 0.463 (0.007) 0.457 (<0.001) 95.3 (0.5)
N  1000 -0.029 (0.007) 0.319 (0.005) 0.320 (<0.001) 95.2 (0.5)
dBC(AC) N  100 0.092 (0.030) 1.326 (0.021) 1.220 (0.003) 93.7 (0.5)
N  500 0.021 (0.011) 0.510 (0.008) 0.502 (<0.001) 94.2 (0.5)
N  1000 0.027 (0.008) 0.357 (0.006) 0.352 (<0.001) 95.2 (0.5)
MAIC dAB(AC) N  100 -3.215 (0.228) 10.203 (0.161) - (-) 79.1 (0.9)
N  500 -0.199 (0.028) 1.249 (0.020) - (-) 88.3 (0.7)
N  1000 -0.101 (0.015) 0.683 (0.011) 0.666 (0.005) 89.5 (0.7)
dBC(AC) N  100 3.176 (0.228) 10.214 (0.162) - (-) - (-)
N  500 0.200 (0.028) 1.260 (0.020) - (-) 94.6 (0.5)
N  1000 0.099 (0.016) 0.699 (0.011) 0.682 (0.005) 90.7 (0.7)
Bucher dAB(AC) N  100 -0.359 (0.011) 0.475 (0.008) 0.461 (<0.001) 87.5 (0.7)
N  500 -0.316 (0.005) 0.207 (0.003) 0.202 (<0.001) 65.0 (1.1)
N  1000 -0.317 (0.003) 0.145 (0.002) 0.143 (<0.001) 39.7 (1.1)
dBC(AC) N  100 0.327 (0.015) 0.678 (0.011) 0.664 (<0.001) 92.0 (0.6)
N  500 0.318 (0.007) 0.295 (0.005) 0.290 (<0.001) 80.2 (0.9)
N  1000 0.315 (0.005) 0.210 (0.003) 0.205 (<0.001) 66.5 (1.1)
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Table B.2 Simulation results for scenario a, only adjusting for one of two effect
modifiers. Sample size N is varied between 100, 500, and 1000. Monte Carlo
standard errors for each statistic are shown in brackets.
Method Contrast Scenario Bias Empirical SE Model SE Coverage
ML-NMR dAB(AB) N  100 -0.223 (0.012) 0.544 (0.009) 0.498 (0.001) 92.2 (0.6)
N  500 -0.035 (0.005) 0.212 (0.003) 0.205 (<0.001) 94.3 (0.5)
N  1000 -0.020 (0.003) 0.146 (0.002) 0.144 (<0.001) 94.4 (0.5)
dAC(AB) N  100 -0.025 (0.022) 0.962 (0.015) 0.892 (0.002) 93.2 (0.6)
N  500 0.115 (0.008) 0.370 (0.006) 0.358 (<0.001) 92.5 (0.6)
N  1000 0.140 (0.006) 0.258 (0.004) 0.251 (<0.001) 90.8 (0.6)
dBC(AB) N  100 0.198 (0.025) 1.098 (0.017) 1.004 (0.002) 92.7 (0.6)
N  500 0.150 (0.009) 0.416 (0.007) 0.408 (<0.001) 93.3 (0.6)
N  1000 0.160 (0.007) 0.293 (0.005) 0.286 (<0.001) 91.3 (0.6)
dAB(AC) N  100 -0.329 (0.022) 0.982 (0.016) 0.877 (0.003) 91.7 (0.6)
N  500 -0.165 (0.008) 0.353 (0.006) 0.351 (<0.001) 93.0 (0.6)
N  1000 -0.170 (0.006) 0.247 (0.004) 0.245 (<0.001) 90.1 (0.7)
dAC(AC) N  100 -0.131 (0.012) 0.519 (0.008) 0.502 (0.001) 93.8 (0.5)
N  500 -0.015 (0.005) 0.215 (0.003) 0.209 (<0.001) 94.2 (0.5)
N  1000 -0.010 (0.003) 0.152 (0.002) 0.147 (<0.001) 93.9 (0.5)
dBC(AC) N  100 0.198 (0.025) 1.098 (0.017) 1.004 (0.002) 92.7 (0.6)
N  500 0.150 (0.009) 0.416 (0.007) 0.408 (<0.001) 93.3 (0.6)
N  1000 0.160 (0.007) 0.293 (0.005) 0.286 (<0.001) 91.3 (0.6)
STC dAB(AC) N  100 -0.235 (0.020) 0.885 (0.014) 0.833 (0.003) 94.9 (0.5)
N  500 -0.149 (0.008) 0.347 (0.005) 0.347 (<0.001) 94.3 (0.5)
N  1000 -0.162 (0.005) 0.245 (0.004) 0.244 (<0.001) 91.0 (0.6)
dBC(AC) N  100 0.203 (0.022) 1.002 (0.016) 0.960 (0.002) 94.8 (0.5)
N  500 0.151 (0.009) 0.409 (0.006) 0.405 (<0.001) 93.7 (0.5)
N  1000 0.160 (0.007) 0.291 (0.005) 0.285 (<0.001) 91.6 (0.6)
MAIC dAB(AC) N  100 -0.454 (0.032) 1.417 (0.022) - (-) 83.3 (0.8)
N  500 -0.169 (0.010) 0.439 (0.007) 0.444 (0.001) 91.0 (0.6)
N  1000 -0.178 (0.007) 0.311 (0.005) 0.303 (<0.001) 89.3 (0.7)
dBC(AC) N  100 0.422 (0.034) 1.498 (0.024) - (-) 94.9 (0.5)
N  500 0.171 (0.011) 0.490 (0.008) 0.490 (0.001) 92.7 (0.6)
N  1000 0.176 (0.008) 0.346 (0.005) 0.337 (<0.001) 91.5 (0.6)
Bucher dAB(AC) N  100 -0.359 (0.011) 0.475 (0.008) 0.461 (<0.001) 87.5 (0.7)
N  500 -0.316 (0.005) 0.207 (0.003) 0.202 (<0.001) 65.0 (1.1)
N  1000 -0.317 (0.003) 0.145 (0.002) 0.143 (<0.001) 39.7 (1.1)
dBC(AC) N  100 0.327 (0.015) 0.678 (0.011) 0.664 (<0.001) 92.0 (0.6)
N  500 0.318 (0.007) 0.295 (0.005) 0.290 (<0.001) 80.2 (0.9)
N  1000 0.315 (0.005) 0.210 (0.003) 0.205 (<0.001) 66.5 (1.1)
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B.2 Scenario b
Table B.3 Simulation results for scenario b, adjusting for all effect modifiers.
Strength of effect modification is varied from weak to strong. Monte Carlo
standard errors for each statistic are shown in brackets.
Method Contrast Scenario Bias Empirical SE Model SE Coverage
ML-NMR dAB(AB) βB  βC  0.1σX(AB) -0.056 (0.005) 0.215 (0.003) 0.207 (<0.001) 93.8 (0.5)
βB  βC  0.5σX(AB) -0.066 (0.005) 0.225 (0.004) 0.216 (<0.001) 93.2 (0.6)
dAC(AB) βB  βC  0.1σX(AB) -0.038 (0.011) 0.487 (0.008) 0.471 (<0.001) 94.6 (0.5)
βB  βC  0.5σX(AB) -0.137 (0.012) 0.545 (0.009) 0.503 (<0.001) 92.2 (0.6)
dBC(AB) βB  βC  0.1σX(AB) 0.019 (0.012) 0.522 (0.008) 0.507 (<0.001) 94.1 (0.5)
βB  βC  0.5σX(AB) -0.071 (0.012) 0.545 (0.009) 0.516 (<0.001) 93.0 (0.6)
dAB(AC) βB  βC  0.1σX(AB) -0.041 (0.011) 0.474 (0.007) 0.462 (<0.001) 94.7 (0.5)
βB  βC  0.5σX(AB) 0.037 (0.011) 0.501 (0.008) 0.470 (<0.001) 93.5 (0.5)
dAC(AC) βB  βC  0.1σX(AB) -0.023 (0.005) 0.216 (0.003) 0.210 (<0.001) 94.3 (0.5)
βB  βC  0.5σX(AB) -0.034 (0.005) 0.213 (0.003) 0.214 (<0.001) 94.8 (0.5)
dBC(AC) βB  βC  0.1σX(AB) 0.019 (0.012) 0.522 (0.008) 0.507 (<0.001) 94.1 (0.5)
βB  βC  0.5σX(AB) -0.071 (0.012) 0.545 (0.009) 0.516 (<0.001) 93.0 (0.6)
STC dAB(AC) βB  βC  0.1σX(AB) -0.020 (0.010) 0.463 (0.007) 0.457 (<0.001) 95.3 (0.5)
βB  βC  0.5σX(AB) 0.023 (0.011) 0.488 (0.008) 0.464 (<0.001) 94.2 (0.5)
dBC(AC) βB  βC  0.1σX(AB) 0.021 (0.011) 0.510 (0.008) 0.502 (<0.001) 94.2 (0.5)
βB  βC  0.5σX(AB) -0.033 (0.012) 0.529 (0.008) 0.509 (<0.001) 93.9 (0.5)
MAIC dAB(AC) βB  βC  0.1σX(AB) -0.199 (0.028) 1.249 (0.020) - (-) 88.3 (0.7)
βB  βC  0.5σX(AB) -0.128 (0.022) 0.968 (0.015) - (-) 92.4 (0.6)
dBC(AC) βB  βC  0.1σX(AB) 0.200 (0.028) 1.260 (0.020) - (-) 94.6 (0.5)
βB  βC  0.5σX(AB) 0.118 (0.022) 0.985 (0.016) - (-) 95.0 (0.5)
Bucher dAB(AC) βB  βC  0.1σX(AB) -0.316 (0.005) 0.207 (0.003) 0.202 (<0.001) 65.0 (1.1)
βB  βC  0.5σX(AB) -1.468 (0.004) 0.200 (0.003) 0.200 (<0.001) 0.0 (0.0)
dBC(AC) βB  βC  0.1σX(AB) 0.318 (0.007) 0.295 (0.005) 0.290 (<0.001) 80.2 (0.9)
βB  βC  0.5σX(AB) 1.458 (0.006) 0.283 (0.004) 0.289 (<0.001) <0.1 (<0.1)
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Table B.4 Simulation results for scenario b, only adjusting for one of two
effect modifiers. Strength of effect modification is varied from weak to strong.
Monte Carlo standard errors for each statistic are shown in brackets.
Method Contrast Scenario Bias Empirical SE Model SE Coverage
ML-NMR dAB(AB) βB  βC  0.1σX(AB) -0.035 (0.005) 0.212 (0.003) 0.205 (<0.001) 94.3 (0.5)
βB  βC  0.5σX(AB) 0.006 (0.005) 0.213 (0.003) 0.209 (<0.001) 94.7 (0.5)
dAC(AB) βB  βC  0.1σX(AB) 0.115 (0.008) 0.370 (0.006) 0.358 (<0.001) 92.5 (0.6)
βB  βC  0.5σX(AB) 0.670 (0.008) 0.377 (0.006) 0.370 (<0.001) 56.4 (1.1)
dBC(AB) βB  βC  0.1σX(AB) 0.150 (0.009) 0.416 (0.007) 0.408 (<0.001) 93.3 (0.6)
βB  βC  0.5σX(AB) 0.664 (0.009) 0.402 (0.006) 0.405 (<0.001) 61.9 (1.1)
dAB(AC) βB  βC  0.1σX(AB) -0.165 (0.008) 0.353 (0.006) 0.351 (<0.001) 93.0 (0.6)
βB  βC  0.5σX(AB) -0.690 (0.008) 0.346 (0.005) 0.346 (<0.001) 46.9 (1.1)
dAC(AC) βB  βC  0.1σX(AB) -0.015 (0.005) 0.215 (0.003) 0.209 (<0.001) 94.2 (0.5)
βB  βC  0.5σX(AB) -0.026 (0.005) 0.210 (0.003) 0.212 (<0.001) 95.2 (0.5)
dBC(AC) βB  βC  0.1σX(AB) 0.150 (0.009) 0.416 (0.007) 0.408 (<0.001) 93.3 (0.6)
βB  βC  0.5σX(AB) 0.664 (0.009) 0.402 (0.006) 0.405 (<0.001) 61.9 (1.1)
STC dAB(AC) βB  βC  0.1σX(AB) -0.149 (0.008) 0.347 (0.005) 0.347 (<0.001) 94.3 (0.5)
βB  βC  0.5σX(AB) -0.690 (0.008) 0.339 (0.005) 0.343 (<0.001) 46.7 (1.1)
dBC(AC) βB  βC  0.1σX(AB) 0.151 (0.009) 0.409 (0.006) 0.405 (<0.001) 93.7 (0.5)
βB  βC  0.5σX(AB) 0.679 (0.009) 0.393 (0.006) 0.401 (<0.001) 59.8 (1.1)
MAIC dAB(AC) βB  βC  0.1σX(AB) -0.169 (0.010) 0.439 (0.007) 0.444 (0.001) 91.0 (0.6)
βB  βC  0.5σX(AB) -0.708 (0.009) 0.417 (0.007) 0.426 (0.001) 56.7 (1.1)
dBC(AC) βB  βC  0.1σX(AB) 0.171 (0.011) 0.490 (0.008) 0.490 (0.001) 92.7 (0.6)
βB  βC  0.5σX(AB) 0.698 (0.010) 0.456 (0.007) 0.474 (0.001) 69.4 (1.0)
Bucher dAB(AC) βB  βC  0.1σX(AB) -0.316 (0.005) 0.207 (0.003) 0.202 (<0.001) 65.0 (1.1)
βB  βC  0.5σX(AB) -1.468 (0.004) 0.200 (0.003) 0.200 (<0.001) 0.0 (0.0)
dBC(AC) βB  βC  0.1σX(AB) 0.318 (0.007) 0.295 (0.005) 0.290 (<0.001) 80.2 (0.9)
βB  βC  0.5σX(AB) 1.458 (0.006) 0.283 (0.004) 0.289 (<0.001) <0.1 (<0.1)
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B.3 Scenario c
Table B.5 Simulation results for scenario c, adjusting for all effect modifiers.
The shared effect modifier assumption is broken. Monte Carlo standard errors
for each statistic are shown in brackets.
Method Contrast Scenario Bias Empirical SE Model SE Coverage
ML-NMR dAB(AB) βB  0.1σX(AB), βC  0.5σX(AB) -0.061 (0.005) 0.213 (0.003) 0.207 (<0.001) 93.2 (0.6)
βB  0.5σX(AB), βC  0.1σX(AB) -0.066 (0.005) 0.225 (0.004) 0.216 (<0.001) 93.1 (0.6)
dAC(AB) βB  0.1σX(AB), βC  0.5σX(AB) 1.192 (0.011) 0.502 (0.008) 0.472 (<0.001) 30.2 (1.0)
βB  0.5σX(AB), βC  0.1σX(AB) -1.397 (0.012) 0.549 (0.009) 0.503 (<0.001) 19.8 (0.9)
dBC(AB) βB  0.1σX(AB), βC  0.5σX(AB) 1.253 (0.012) 0.537 (0.008) 0.508 (<0.001) 30.9 (1.0)
βB  0.5σX(AB), βC  0.1σX(AB) -1.331 (0.012) 0.549 (0.009) 0.516 (<0.001) 27.2 (1.0)
dAB(AC) βB  0.1σX(AB), βC  0.5σX(AB) -0.028 (0.011) 0.494 (0.008) 0.463 (<0.001) 93.3 (0.6)
βB  0.5σX(AB), βC  0.1σX(AB) 0.037 (0.011) 0.501 (0.008) 0.470 (<0.001) 93.5 (0.5)
dAC(AC) βB  0.1σX(AB), βC  0.5σX(AB) -0.035 (0.005) 0.207 (0.003) 0.211 (<0.001) 94.8 (0.5)
βB  0.5σX(AB), βC  0.1σX(AB) -0.034 (0.005) 0.216 (0.003) 0.214 (<0.001) 95.0 (0.5)
dBC(AC) βB  0.1σX(AB), βC  0.5σX(AB) -0.007 (0.012) 0.537 (0.008) 0.508 (<0.001) 93.0 (0.6)
βB  0.5σX(AB), βC  0.1σX(AB) -0.071 (0.012) 0.549 (0.009) 0.516 (<0.001) 92.6 (0.6)
STC dAB(AC) βB  0.1σX(AB), βC  0.5σX(AB) -0.007 (0.011) 0.483 (0.008) 0.457 (<0.001) 93.5 (0.6)
βB  0.5σX(AB), βC  0.1σX(AB) 0.023 (0.011) 0.488 (0.008) 0.464 (<0.001) 94.2 (0.5)
dBC(AC) βB  0.1σX(AB), βC  0.5σX(AB) -0.003 (0.012) 0.525 (0.008) 0.502 (<0.001) 93.5 (0.6)
βB  0.5σX(AB), βC  0.1σX(AB) -0.033 (0.012) 0.531 (0.008) 0.509 (<0.001) 93.5 (0.6)
MAIC dAB(AC) βB  0.1σX(AB), βC  0.5σX(AB) -0.212 (0.023) 1.029 (0.016) - (-) 88.0 (0.7)
βB  0.5σX(AB), βC  0.1σX(AB) -0.128 (0.022) 0.968 (0.015) - (-) 92.4 (0.6)
dBC(AC) βB  0.1σX(AB), βC  0.5σX(AB) 0.202 (0.023) 1.047 (0.017) - (-) 95.2 (0.5)
βB  0.5σX(AB), βC  0.1σX(AB) 0.118 (0.022) 0.987 (0.016) - (-) 95.0 (0.5)
Bucher dAB(AC) βB  0.1σX(AB), βC  0.5σX(AB) -0.320 (0.005) 0.205 (0.003) 0.202 (<0.001) 66.1 (1.1)
βB  0.5σX(AB), βC  0.1σX(AB) -1.468 (0.004) 0.200 (0.003) 0.200 (<0.001) 0.0 (0.0)
dBC(AC) βB  0.1σX(AB), βC  0.5σX(AB) 0.309 (0.006) 0.286 (0.005) 0.290 (<0.001) 81.3 (0.9)
βB  0.5σX(AB), βC  0.1σX(AB) 1.459 (0.006) 0.283 (0.004) 0.289 (<0.001) 0.1 (<0.1)
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B.3. SCENARIO C
Table B.6 Simulation results for scenario c, only adjusting for one of two effect
modifiers. The shared effect modifier assumption is broken. Monte Carlo
standard errors for each statistic are shown in brackets.
Method Contrast Scenario Bias Empirical SE Model SE Coverage
ML-NMR dAB(AB) βB  0.1σX(AB), βC  0.5σX(AB) -0.038 (0.005) 0.209 (0.003) 0.205 (<0.001) 93.9 (0.5)
βB  0.5σX(AB), βC  0.1σX(AB) 0.006 (0.005) 0.213 (0.003) 0.209 (<0.001) 95.0 (0.5)
dAC(AB) βB  0.1σX(AB), βC  0.5σX(AB) 1.355 (0.008) 0.368 (0.006) 0.359 (<0.001) 4.3 (0.5)
βB  0.5σX(AB), βC  0.1σX(AB) -0.590 (0.009) 0.381 (0.006) 0.370 (<0.001) 64.4 (1.1)
dBC(AB) βB  0.1σX(AB), βC  0.5σX(AB) 1.394 (0.009) 0.414 (0.007) 0.409 (<0.001) 7.8 (0.6)
βB  0.5σX(AB), βC  0.1σX(AB) -0.596 (0.009) 0.405 (0.006) 0.405 (<0.001) 68.3 (1.0)
dAB(AC) βB  0.1σX(AB), βC  0.5σX(AB) -0.160 (0.008) 0.362 (0.006) 0.351 (<0.001) 92.0 (0.6)
βB  0.5σX(AB), βC  0.1σX(AB) -0.690 (0.008) 0.346 (0.005) 0.346 (<0.001) 46.9 (1.1)
dAC(AC) βB  0.1σX(AB), βC  0.5σX(AB) -0.026 (0.005) 0.206 (0.003) 0.210 (<0.001) 95.0 (0.5)
βB  0.5σX(AB), βC  0.1σX(AB) -0.026 (0.005) 0.211 (0.003) 0.212 (<0.001) 95.0 (0.5)
dBC(AC) βB  0.1σX(AB), βC  0.5σX(AB) 0.134 (0.009) 0.414 (0.007) 0.409 (<0.001) 93.9 (0.5)
βB  0.5σX(AB), βC  0.1σX(AB) 0.664 (0.009) 0.405 (0.006) 0.405 (<0.001) 62.0 (1.1)
STC dAB(AC) βB  0.1σX(AB), βC  0.5σX(AB) -0.145 (0.008) 0.355 (0.006) 0.348 (<0.001) 93.0 (0.6)
βB  0.5σX(AB), βC  0.1σX(AB) -0.690 (0.008) 0.339 (0.005) 0.343 (<0.001) 46.7 (1.1)
dBC(AC) βB  0.1σX(AB), βC  0.5σX(AB) 0.134 (0.009) 0.407 (0.006) 0.405 (<0.001) 94.5 (0.5)
βB  0.5σX(AB), βC  0.1σX(AB) 0.680 (0.009) 0.396 (0.006) 0.401 (<0.001) 60.1 (1.1)
MAIC dAB(AC) βB  0.1σX(AB), βC  0.5σX(AB) -0.163 (0.010) 0.441 (0.007) 0.445 (0.001) 91.1 (0.6)
βB  0.5σX(AB), βC  0.1σX(AB) -0.708 (0.009) 0.417 (0.007) 0.426 (0.001) 56.7 (1.1)
dBC(AC) βB  0.1σX(AB), βC  0.5σX(AB) 0.153 (0.011) 0.479 (0.008) 0.491 (0.001) 93.9 (0.5)
βB  0.5σX(AB), βC  0.1σX(AB) 0.698 (0.010) 0.459 (0.007) 0.474 (0.001) 69.0 (1.0)
Bucher dAB(AC) βB  0.1σX(AB), βC  0.5σX(AB) -0.320 (0.005) 0.205 (0.003) 0.202 (<0.001) 66.1 (1.1)
βB  0.5σX(AB), βC  0.1σX(AB) -1.468 (0.004) 0.200 (0.003) 0.200 (<0.001) 0.0 (0.0)
dBC(AC) βB  0.1σX(AB), βC  0.5σX(AB) 0.309 (0.006) 0.286 (0.005) 0.290 (<0.001) 81.3 (0.9)
βB  0.5σX(AB), βC  0.1σX(AB) 1.459 (0.006) 0.283 (0.004) 0.289 (<0.001) 0.1 (<0.1)
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B.4 Scenario d
Table B.7 Simulation results for scenario d, adjusting for all effect modifiers.
The correlation between covariates is varied between 0, 0.25, and 0.5. Monte
Carlo standard errors for each statistic are shown in brackets.
Method Contrast Scenario Bias Empirical SE Model SE Coverage
ML-NMR dAB(AB) ρ(AB)  ρ(AC)  0 -0.059 (0.005) 0.211 (0.003) 0.207 (<0.001) 93.7 (0.5)
ρ(AB)  ρ(AC)  0.25 -0.056 (0.005) 0.215 (0.003) 0.207 (<0.001) 93.8 (0.5)
ρ(AB)  ρ(AC)  0.5 -0.059 (0.005) 0.212 (0.003) 0.207 (<0.001) 93.6 (0.5)
dAC(AB) ρ(AB)  ρ(AC)  0 -0.051 (0.012) 0.530 (0.008) 0.514 (<0.001) 94.5 (0.5)
ρ(AB)  ρ(AC)  0.25 -0.038 (0.011) 0.487 (0.008) 0.471 (<0.001) 94.6 (0.5)
ρ(AB)  ρ(AC)  0.5 -0.051 (0.010) 0.455 (0.007) 0.442 (<0.001) 94.0 (0.5)
dBC(AB) ρ(AB)  ρ(AC)  0 0.008 (0.013) 0.571 (0.009) 0.548 (<0.001) 94.3 (0.5)
ρ(AB)  ρ(AC)  0.25 0.019 (0.012) 0.522 (0.008) 0.507 (<0.001) 94.1 (0.5)
ρ(AB)  ρ(AC)  0.5 0.008 (0.011) 0.503 (0.008) 0.481 (<0.001) 94.5 (0.5)
dAB(AC) ρ(AB)  ρ(AC)  0 -0.045 (0.012) 0.524 (0.008) 0.506 (<0.001) 94.4 (0.5)
ρ(AB)  ρ(AC)  0.25 -0.041 (0.011) 0.474 (0.007) 0.462 (<0.001) 94.7 (0.5)
ρ(AB)  ρ(AC)  0.5 -0.046 (0.010) 0.449 (0.007) 0.432 (<0.001) 94.4 (0.5)
dAC(AC) ρ(AB)  ρ(AC)  0 -0.037 (0.005) 0.211 (0.003) 0.211 (<0.001) 94.4 (0.5)
ρ(AB)  ρ(AC)  0.25 -0.023 (0.005) 0.216 (0.003) 0.210 (<0.001) 94.3 (0.5)
ρ(AB)  ρ(AC)  0.5 -0.038 (0.005) 0.211 (0.003) 0.211 (<0.001) 94.5 (0.5)
dBC(AC) ρ(AB)  ρ(AC)  0 0.008 (0.013) 0.571 (0.009) 0.548 (<0.001) 94.3 (0.5)
ρ(AB)  ρ(AC)  0.25 0.019 (0.012) 0.522 (0.008) 0.507 (<0.001) 94.1 (0.5)
ρ(AB)  ρ(AC)  0.5 0.008 (0.011) 0.503 (0.008) 0.481 (<0.001) 94.5 (0.5)
STC dAB(AC) ρ(AB)  ρ(AC)  0 -0.024 (0.011) 0.511 (0.008) 0.500 (<0.001) 95.2 (0.5)
ρ(AB)  ρ(AC)  0.25 -0.020 (0.010) 0.463 (0.007) 0.457 (<0.001) 95.3 (0.5)
ρ(AB)  ρ(AC)  0.5 -0.025 (0.010) 0.439 (0.007) 0.427 (<0.001) 95.2 (0.5)
dBC(AC) ρ(AB)  ρ(AC)  0 0.011 (0.012) 0.557 (0.009) 0.542 (<0.001) 94.8 (0.5)
ρ(AB)  ρ(AC)  0.25 0.021 (0.011) 0.510 (0.008) 0.502 (<0.001) 94.2 (0.5)
ρ(AB)  ρ(AC)  0.5 0.011 (0.011) 0.492 (0.008) 0.475 (<0.001) 94.8 (0.5)
MAIC dAB(AC) ρ(AB)  ρ(AC)  0 -0.621 (0.067) 2.975 (0.047) - (-) 87.6 (0.7)
ρ(AB)  ρ(AC)  0.25 -0.199 (0.028) 1.249 (0.020) - (-) 88.3 (0.7)
ρ(AB)  ρ(AC)  0.5 -0.139 (0.018) 0.792 (0.013) - (-) 90.8 (0.6)
dBC(AC) ρ(AB)  ρ(AC)  0 0.609 (0.067) 2.991 (0.047) - (-) 100.0 (0.0)
ρ(AB)  ρ(AC)  0.25 0.200 (0.028) 1.260 (0.020) - (-) 94.6 (0.5)
ρ(AB)  ρ(AC)  0.5 0.126 (0.019) 0.828 (0.013) - (-) 93.4 (0.6)
Bucher dAB(AC) ρ(AB)  ρ(AC)  0 -0.320 (0.005) 0.203 (0.003) 0.202 (<0.001) 65.5 (1.1)
ρ(AB)  ρ(AC)  0.25 -0.316 (0.005) 0.207 (0.003) 0.202 (<0.001) 65.0 (1.1)
ρ(AB)  ρ(AC)  0.5 -0.317 (0.005) 0.204 (0.003) 0.202 (<0.001) 65.8 (1.1)
dBC(AC) ρ(AB)  ρ(AC)  0 0.307 (0.007) 0.296 (0.005) 0.290 (<0.001) 81.0 (0.9)
ρ(AB)  ρ(AC)  0.25 0.318 (0.007) 0.295 (0.005) 0.290 (<0.001) 80.2 (0.9)
ρ(AB)  ρ(AC)  0.5 0.304 (0.007) 0.298 (0.005) 0.290 (<0.001) 81.2 (0.9)
392
B.4. SCENARIO D
Table B.8 Simulation results for scenario d, only adjusting for one of two
effect modifiers. The correlation between covariates is varied between 0, 0.25,
and 0.5. Monte Carlo standard errors for each statistic are shown in brackets.
Method Contrast Scenario Bias Empirical SE Model SE Coverage
ML-NMR dAB(AB) ρ(AB)  ρ(AC)  0 -0.037 (0.005) 0.208 (0.003) 0.205 (<0.001) 94.1 (0.5)
ρ(AB)  ρ(AC)  0.25 -0.035 (0.005) 0.212 (0.003) 0.205 (<0.001) 94.3 (0.5)
ρ(AB)  ρ(AC)  0.5 -0.037 (0.005) 0.208 (0.003) 0.205 (<0.001) 94.2 (0.5)
dAC(AB) ρ(AB)  ρ(AC)  0 0.145 (0.008) 0.366 (0.006) 0.359 (<0.001) 92.2 (0.6)
ρ(AB)  ρ(AC)  0.25 0.115 (0.008) 0.370 (0.006) 0.358 (<0.001) 92.5 (0.6)
ρ(AB)  ρ(AC)  0.5 0.071 (0.008) 0.365 (0.006) 0.359 (<0.001) 94.1 (0.5)
dBC(AB) ρ(AB)  ρ(AC)  0 0.182 (0.009) 0.422 (0.007) 0.410 (<0.001) 92.2 (0.6)
ρ(AB)  ρ(AC)  0.25 0.150 (0.009) 0.416 (0.007) 0.408 (<0.001) 93.3 (0.6)
ρ(AB)  ρ(AC)  0.5 0.107 (0.009) 0.421 (0.007) 0.408 (<0.001) 93.2 (0.6)
dAB(AC) ρ(AB)  ρ(AC)  0 -0.211 (0.008) 0.359 (0.006) 0.352 (<0.001) 90.3 (0.7)
ρ(AB)  ρ(AC)  0.25 -0.165 (0.008) 0.353 (0.006) 0.351 (<0.001) 93.0 (0.6)
ρ(AB)  ρ(AC)  0.5 -0.137 (0.008) 0.357 (0.006) 0.351 (<0.001) 92.8 (0.6)
dAC(AC) ρ(AB)  ρ(AC)  0 -0.029 (0.005) 0.209 (0.003) 0.210 (<0.001) 94.7 (0.5)
ρ(AB)  ρ(AC)  0.25 -0.015 (0.005) 0.215 (0.003) 0.209 (<0.001) 94.2 (0.5)
ρ(AB)  ρ(AC)  0.5 -0.030 (0.005) 0.210 (0.003) 0.210 (<0.001) 94.5 (0.5)
dBC(AC) ρ(AB)  ρ(AC)  0 0.182 (0.009) 0.422 (0.007) 0.410 (<0.001) 92.2 (0.6)
ρ(AB)  ρ(AC)  0.25 0.150 (0.009) 0.416 (0.007) 0.408 (<0.001) 93.3 (0.6)
ρ(AB)  ρ(AC)  0.5 0.107 (0.009) 0.421 (0.007) 0.408 (<0.001) 93.2 (0.6)
STC dAB(AC) ρ(AB)  ρ(AC)  0 -0.195 (0.008) 0.352 (0.006) 0.349 (<0.001) 91.4 (0.6)
ρ(AB)  ρ(AC)  0.25 -0.149 (0.008) 0.347 (0.005) 0.347 (<0.001) 94.3 (0.5)
ρ(AB)  ρ(AC)  0.5 -0.122 (0.008) 0.351 (0.006) 0.347 (<0.001) 93.7 (0.5)
dBC(AC) ρ(AB)  ρ(AC)  0 0.182 (0.009) 0.415 (0.007) 0.406 (<0.001) 92.4 (0.6)
ρ(AB)  ρ(AC)  0.25 0.151 (0.009) 0.409 (0.006) 0.405 (<0.001) 93.7 (0.5)
ρ(AB)  ρ(AC)  0.5 0.109 (0.009) 0.414 (0.007) 0.405 (<0.001) 93.4 (0.6)
MAIC dAB(AC) ρ(AB)  ρ(AC)  0 -0.222 (0.010) 0.449 (0.007) 0.446 (0.001) 88.3 (0.7)
ρ(AB)  ρ(AC)  0.25 -0.169 (0.010) 0.439 (0.007) 0.444 (0.001) 91.0 (0.6)
ρ(AB)  ρ(AC)  0.5 -0.147 (0.010) 0.444 (0.007) 0.444 (0.001) 91.1 (0.6)
dBC(AC) ρ(AB)  ρ(AC)  0 0.209 (0.011) 0.499 (0.008) 0.492 (0.001) 91.8 (0.6)
ρ(AB)  ρ(AC)  0.25 0.171 (0.011) 0.490 (0.008) 0.490 (0.001) 92.7 (0.6)
ρ(AB)  ρ(AC)  0.5 0.134 (0.011) 0.494 (0.008) 0.491 (0.001) 93.1 (0.6)
Bucher dAB(AC) ρ(AB)  ρ(AC)  0 -0.320 (0.005) 0.203 (0.003) 0.202 (<0.001) 65.5 (1.1)
ρ(AB)  ρ(AC)  0.25 -0.316 (0.005) 0.207 (0.003) 0.202 (<0.001) 65.0 (1.1)
ρ(AB)  ρ(AC)  0.5 -0.317 (0.005) 0.204 (0.003) 0.202 (<0.001) 65.8 (1.1)
dBC(AC) ρ(AB)  ρ(AC)  0 0.307 (0.007) 0.296 (0.005) 0.290 (<0.001) 81.0 (0.9)
ρ(AB)  ρ(AC)  0.25 0.318 (0.007) 0.295 (0.005) 0.290 (<0.001) 80.2 (0.9)
ρ(AB)  ρ(AC)  0.5 0.304 (0.007) 0.298 (0.005) 0.290 (<0.001) 81.2 (0.9)
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Table B.9 Simulation results for scenarios e and f, adjusting for all effect
modifiers. The between-study overlap and covariate-outcome relationship
are varied jointly. Monte Carlo standard errors for each statistic are shown in
brackets.
Method Contrast Scenario Bias Empirical SE Model SE Coverage
ML-NMR dAB(AB) κ  0 linear q(·) -0.050 (0.005) 0.212 (0.003) 0.207 (<0.001) 93.3 (0.6)
κ  0 non-linear q(·) -0.018 (0.004) 0.197 (0.003) 0.197 (<0.001) 94.7 (0.5)
κ  0.5 linear q(·) -0.050 (0.005) 0.212 (0.003) 0.207 (<0.001) 93.4 (0.6)
κ  0.5 non-linear q(·) -0.018 (0.004) 0.197 (0.003) 0.197 (<0.001) 94.5 (0.5)
κ  1 linear q(·) -0.050 (0.005) 0.212 (0.003) 0.207 (<0.001) 93.8 (0.5)
κ  1 non-linear q(·) -0.018 (0.004) 0.198 (0.003) 0.196 (<0.001) 94.5 (0.5)
dAC(AB) κ  0 linear q(·) -0.083 (0.031) 1.394 (0.022) 1.338 (0.001) 94.0 (0.5)
κ  0 non-linear q(·) -0.317 (0.029) 1.319 (0.021) 1.280 (0.001) 93.0 (0.6)
κ  0.5 linear q(·) -0.052 (0.011) 0.488 (0.008) 0.470 (<0.001) 93.7 (0.5)
κ  0.5 non-linear q(·) -0.029 (0.011) 0.476 (0.008) 0.464 (<0.001) 94.2 (0.5)
κ  1 linear q(·) -0.042 (0.006) 0.247 (0.004) 0.243 (<0.001) 94.5 (0.5)
κ  1 non-linear q(·) -0.011 (0.006) 0.264 (0.004) 0.260 (<0.001) 94.8 (0.5)
dBC(AB) κ  0 linear q(·) -0.033 (0.032) 1.409 (0.022) 1.346 (0.001) 94.1 (0.5)
κ  0 non-linear q(·) -0.299 (0.030) 1.338 (0.021) 1.297 (0.001) 93.0 (0.6)
κ  0.5 linear q(·) -0.002 (0.012) 0.532 (0.008) 0.507 (<0.001) 93.3 (0.6)
κ  0.5 non-linear q(·) -0.011 (0.012) 0.520 (0.008) 0.506 (<0.001) 94.5 (0.5)
κ  1 linear q(·) 0.008 (0.007) 0.326 (0.005) 0.316 (<0.001) 94.3 (0.5)
κ  1 non-linear q(·) 0.007 (0.007) 0.331 (0.005) 0.326 (<0.001) 94.4 (0.5)









Method Contrast Scenario Bias Empirical SE Model SE Coverage
κ  0 non-linear q(·) 0.315 (0.029) 1.313 (0.021) 1.276 (0.001) 92.8 (0.6)
κ  0.5 linear q(·) -0.036 (0.011) 0.485 (0.008) 0.462 (<0.001) 93.5 (0.5)
κ  0.5 non-linear q(·) 0.009 (0.010) 0.460 (0.007) 0.449 (<0.001) 94.0 (0.5)
κ  1 linear q(·) -0.046 (0.006) 0.246 (0.004) 0.236 (<0.001) 93.2 (0.6)
κ  1 non-linear q(·) -0.014 (0.005) 0.233 (0.004) 0.229 (<0.001) 94.6 (0.5)
dAC(AC) κ  0 linear q(·) -0.038 (0.005) 0.210 (0.003) 0.211 (<0.001) 95.0 (0.5)
κ  0 non-linear q(·) 0.016 (0.006) 0.266 (0.004) 0.265 (<0.001) 94.7 (0.5)
κ  0.5 linear q(·) -0.038 (0.005) 0.210 (0.003) 0.211 (<0.001) 94.7 (0.5)
κ  0.5 non-linear q(·) -0.002 (0.005) 0.245 (0.004) 0.244 (<0.001) 95.0 (0.5)
κ  1 linear q(·) -0.038 (0.005) 0.210 (0.003) 0.211 (<0.001) 95.0 (0.5)
κ  1 non-linear q(·) -0.007 (0.005) 0.237 (0.004) 0.236 (<0.001) 94.9 (0.5)
dBC(AC) κ  0 linear q(·) -0.033 (0.032) 1.409 (0.022) 1.346 (0.001) 94.1 (0.5)
κ  0 non-linear q(·) -0.299 (0.030) 1.338 (0.021) 1.297 (0.001) 93.0 (0.6)
κ  0.5 linear q(·) -0.002 (0.012) 0.532 (0.008) 0.507 (<0.001) 93.3 (0.6)
κ  0.5 non-linear q(·) -0.011 (0.012) 0.520 (0.008) 0.506 (<0.001) 94.5 (0.5)
κ  1 linear q(·) 0.008 (0.007) 0.326 (0.005) 0.316 (<0.001) 94.3 (0.5)
κ  1 non-linear q(·) 0.007 (0.007) 0.331 (0.005) 0.326 (<0.001) 94.4 (0.5)
STC dAB(AC) κ  0 linear q(·) -0.004 (0.030) 1.356 (0.021) 1.313 (0.001) 94.3 (0.5)
κ  0 non-linear q(·) 0.303 (0.029) 1.283 (0.020) 1.262 (0.001) 93.8 (0.5)
κ  0.5 linear q(·) -0.015 (0.011) 0.474 (0.007) 0.457 (<0.001) 94.1 (0.5)
κ  0.5 non-linear q(·) 0.012 (0.010) 0.451 (0.007) 0.444 (<0.001) 94.6 (0.5)








Method Contrast Scenario Bias Empirical SE Model SE Coverage
κ  1 non-linear q(·) -0.006 (0.005) 0.229 (0.004) 0.227 (<0.001) 95.0 (0.5)
dBC(AC) κ  0 linear q(·) -0.010 (0.031) 1.375 (0.022) 1.330 (0.001) 94.3 (0.5)
κ  0 non-linear q(·) -0.300 (0.029) 1.315 (0.021) 1.289 (0.001) 93.5 (0.6)
κ  0.5 linear q(·) 0.002 (0.012) 0.521 (0.008) 0.502 (<0.001) 93.8 (0.5)
κ  0.5 non-linear q(·) -0.019 (0.012) 0.515 (0.008) 0.505 (<0.001) 94.8 (0.5)
κ  1 linear q(·) 0.005 (0.007) 0.321 (0.005) 0.313 (<0.001) 94.8 (0.5)
κ  1 non-linear q(·) -0.002 (0.007) 0.329 (0.005) 0.325 (<0.001) 94.5 (0.5)
MAIC dAB(AC) κ  0.5 linear q(·) -0.184 (0.023) 1.046 (0.017) - (-) 88.2 (0.7)
κ  0.5 non-linear q(·) -0.028 (0.022) 0.998 (0.016) - (-) 92.6 (0.6)
κ  1 linear q(·) -0.005 (0.006) 0.254 (0.004) 0.253 (<0.001) 94.7 (0.5)
κ  1 non-linear q(·) -0.006 (0.005) 0.240 (0.004) 0.243 (<0.001) 95.5 (0.5)
dBC(AC) κ  0.5 linear q(·) 0.170 (0.024) 1.064 (0.017) - (-) 94.8 (0.5)
κ  0.5 non-linear q(·) 0.021 (0.023) 1.028 (0.016) - (-) 93.5 (0.6)
κ  1 linear q(·) -0.009 (0.007) 0.330 (0.005) 0.328 (<0.001) 95.4 (0.5)
κ  1 non-linear q(·) -0.002 (0.008) 0.337 (0.005) 0.337 (<0.001) 94.8 (0.5)
Bucher dAB(AC) κ  0 linear q(·) -0.984 (0.005) 0.204 (0.003) 0.202 (<0.001) 0.1 (<0.1)
κ  0 non-linear q(·) -0.670 (0.004) 0.191 (0.003) 0.193 (<0.001) 6.3 (0.5)
κ  0.5 linear q(·) -0.309 (0.005) 0.204 (0.003) 0.202 (<0.001) 67.9 (1.0)
κ  0.5 non-linear q(·) -0.295 (0.004) 0.191 (0.003) 0.193 (<0.001) 66.8 (1.1)
κ  1 linear q(·) -0.084 (0.005) 0.204 (0.003) 0.202 (<0.001) 93.0 (0.6)









Method Contrast Scenario Bias Empirical SE Model SE Coverage
dBC(AC) κ  0 linear q(·) 0.971 (0.007) 0.292 (0.005) 0.290 (<0.001) 8.7 (0.6)
κ  0 non-linear q(·) 0.673 (0.007) 0.326 (0.005) 0.325 (<0.001) 45.6 (1.1)
κ  0.5 linear q(·) 0.296 (0.007) 0.292 (0.005) 0.290 (<0.001) 81.9 (0.9)
κ  0.5 non-linear q(·) 0.288 (0.007) 0.310 (0.005) 0.309 (<0.001) 85.0 (0.8)
κ  1 linear q(·) 0.071 (0.007) 0.292 (0.005) 0.290 (<0.001) 94.5 (0.5)







Table B.10 Simulation results for scenarios e and f, only adjusting for one
of two effect modifiers. The between-study overlap and covariate-outcome
relationship are varied jointly. Monte Carlo standard errors for each statistic
are shown in brackets.
Method Contrast Scenario Bias Empirical SE Model SE Coverage
ML-NMR dAB(AB) κ  0 linear q(·) -0.027 (0.005) 0.209 (0.003) 0.205 (<0.001) 93.6 (0.5)
κ  0 non-linear q(·) -0.012 (0.004) 0.195 (0.003) 0.195 (<0.001) 95.1 (0.5)
κ  0.5 linear q(·) -0.027 (0.005) 0.209 (0.003) 0.205 (<0.001) 93.8 (0.5)
κ  0.5 non-linear q(·) -0.012 (0.004) 0.195 (0.003) 0.195 (<0.001) 94.7 (0.5)
κ  1 linear q(·) -0.028 (0.005) 0.209 (0.003) 0.205 (<0.001) 93.8 (0.5)
κ  1 non-linear q(·) -0.013 (0.004) 0.195 (0.003) 0.195 (<0.001) 94.7 (0.5)
dAC(AB) κ  0 linear q(·) 0.414 (0.022) 0.973 (0.015) 0.936 (<0.001) 91.7 (0.6)
κ  0 non-linear q(·) 0.157 (0.021) 0.919 (0.015) 0.904 (<0.001) 94.0 (0.5)
κ  0.5 linear q(·) 0.111 (0.008) 0.368 (0.006) 0.358 (<0.001) 92.9 (0.6)
κ  0.5 non-linear q(·) 0.121 (0.008) 0.369 (0.006) 0.365 (<0.001) 93.2 (0.6)
κ  1 linear q(·) 0.010 (0.005) 0.227 (0.004) 0.226 (<0.001) 94.8 (0.5)
κ  1 non-linear q(·) 0.032 (0.006) 0.248 (0.004) 0.247 (<0.001) 94.5 (0.5)
dBC(AB) κ  0 linear q(·) 0.441 (0.022) 0.997 (0.016) 0.953 (<0.001) 91.8 (0.6)
κ  0 non-linear q(·) 0.169 (0.021) 0.943 (0.015) 0.927 (<0.001) 94.6 (0.5)
κ  0.5 linear q(·) 0.139 (0.010) 0.425 (0.007) 0.408 (<0.001) 92.8 (0.6)
κ  0.5 non-linear q(·) 0.134 (0.009) 0.421 (0.007) 0.415 (<0.001) 93.4 (0.6)
κ  1 linear q(·) 0.038 (0.007) 0.310 (0.005) 0.303 (<0.001) 94.3 (0.5)
κ  1 non-linear q(·) 0.045 (0.007) 0.318 (0.005) 0.315 (<0.001) 94.2 (0.5)









Method Contrast Scenario Bias Empirical SE Model SE Coverage
κ  0 non-linear q(·) -0.155 (0.020) 0.909 (0.014) 0.893 (<0.001) 94.5 (0.5)
κ  0.5 linear q(·) -0.169 (0.008) 0.367 (0.006) 0.351 (<0.001) 91.3 (0.6)
κ  0.5 non-linear q(·) -0.137 (0.008) 0.345 (0.005) 0.340 (<0.001) 93.0 (0.6)
κ  1 linear q(·) -0.068 (0.005) 0.227 (0.004) 0.219 (<0.001) 93.2 (0.6)
κ  1 non-linear q(·) -0.052 (0.005) 0.212 (0.003) 0.212 (<0.001) 94.4 (0.5)
dAC(AC) κ  0 linear q(·) -0.030 (0.005) 0.209 (0.003) 0.210 (<0.001) 95.1 (0.5)
κ  0 non-linear q(·) 0.014 (0.006) 0.265 (0.004) 0.264 (<0.001) 94.8 (0.5)
κ  0.5 linear q(·) -0.030 (0.005) 0.209 (0.003) 0.210 (<0.001) 95.0 (0.5)
κ  0.5 non-linear q(·) -0.003 (0.005) 0.244 (0.004) 0.243 (<0.001) 95.0 (0.5)
κ  1 linear q(·) -0.030 (0.005) 0.209 (0.003) 0.210 (<0.001) 95.0 (0.5)
κ  1 non-linear q(·) -0.007 (0.005) 0.237 (0.004) 0.235 (<0.001) 95.2 (0.5)
dBC(AC) κ  0 linear q(·) 0.441 (0.022) 0.997 (0.016) 0.953 (<0.001) 91.8 (0.6)
κ  0 non-linear q(·) 0.169 (0.021) 0.943 (0.015) 0.927 (<0.001) 94.6 (0.5)
κ  0.5 linear q(·) 0.139 (0.010) 0.425 (0.007) 0.408 (<0.001) 92.8 (0.6)
κ  0.5 non-linear q(·) 0.134 (0.009) 0.421 (0.007) 0.415 (<0.001) 93.4 (0.6)
κ  1 linear q(·) 0.038 (0.007) 0.310 (0.005) 0.303 (<0.001) 94.3 (0.5)
κ  1 non-linear q(·) 0.045 (0.007) 0.318 (0.005) 0.315 (<0.001) 94.2 (0.5)
STC dAB(AC) κ  0 linear q(·) -0.464 (0.021) 0.952 (0.015) 0.920 (<0.001) 91.7 (0.6)
κ  0 non-linear q(·) -0.158 (0.020) 0.891 (0.014) 0.885 (<0.001) 94.8 (0.5)
κ  0.5 linear q(·) -0.153 (0.008) 0.361 (0.006) 0.348 (<0.001) 92.4 (0.6)
κ  0.5 non-linear q(·) -0.134 (0.008) 0.339 (0.005) 0.338 (<0.001) 93.7 (0.5)








Method Contrast Scenario Bias Empirical SE Model SE Coverage
κ  1 non-linear q(·) -0.046 (0.005) 0.210 (0.003) 0.210 (<0.001) 94.8 (0.5)
dBC(AC) κ  0 linear q(·) 0.451 (0.022) 0.976 (0.015) 0.943 (<0.001) 92.2 (0.6)
κ  0 non-linear q(·) 0.161 (0.021) 0.930 (0.015) 0.923 (<0.001) 94.9 (0.5)
κ  0.5 linear q(·) 0.140 (0.009) 0.418 (0.007) 0.405 (<0.001) 93.3 (0.6)
κ  0.5 non-linear q(·) 0.127 (0.009) 0.418 (0.007) 0.415 (<0.001) 93.8 (0.5)
κ  1 linear q(·) 0.036 (0.007) 0.307 (0.005) 0.301 (<0.001) 94.3 (0.5)
κ  1 non-linear q(·) 0.038 (0.007) 0.316 (0.005) 0.314 (<0.001) 94.4 (0.5)
MAIC dAB(AC) κ  0 linear q(·) -2.902 (0.087) 3.913 (0.062) - (-) 44.4 (1.1)
κ  0 non-linear q(·) -2.239 (0.084) 3.770 (0.060) - (-) 22.2 (0.9)
κ  0.5 linear q(·) -0.175 (0.010) 0.447 (0.007) 0.447 (0.001) 91.0 (0.6)
κ  0.5 non-linear q(·) -0.135 (0.009) 0.423 (0.007) 0.432 (0.001) 91.7 (0.6)
κ  1 linear q(·) -0.041 (0.005) 0.229 (0.004) 0.228 (<0.001) 93.6 (0.5)
κ  1 non-linear q(·) -0.046 (0.005) 0.213 (0.003) 0.218 (<0.001) 94.7 (0.5)
dBC(AC) κ  0 linear q(·) 2.709 (0.087) 3.872 (0.061) - (-) - (-)
κ  0 non-linear q(·) 2.044 (0.081) 3.643 (0.058) - (-) - (-)
κ  0.5 linear q(·) 0.162 (0.011) 0.490 (0.008) 0.493 (0.001) 93.5 (0.6)
κ  0.5 non-linear q(·) 0.128 (0.011) 0.488 (0.008) 0.495 (0.001) 93.9 (0.5)
κ  1 linear q(·) 0.027 (0.007) 0.313 (0.005) 0.309 (<0.001) 95.5 (0.5)
κ  1 non-linear q(·) 0.038 (0.007) 0.319 (0.005) 0.319 (<0.001) 94.5 (0.5)
Bucher dAB(AC) κ  0 linear q(·) -0.984 (0.005) 0.204 (0.003) 0.202 (<0.001) 0.1 (<0.1)
κ  0 non-linear q(·) -0.670 (0.004) 0.191 (0.003) 0.193 (<0.001) 6.3 (0.5)









Method Contrast Scenario Bias Empirical SE Model SE Coverage
κ  0.5 non-linear q(·) -0.295 (0.004) 0.191 (0.003) 0.193 (<0.001) 66.8 (1.1)
κ  1 linear q(·) -0.084 (0.005) 0.204 (0.003) 0.202 (<0.001) 93.0 (0.6)
κ  1 non-linear q(·) -0.091 (0.004) 0.191 (0.003) 0.193 (<0.001) 92.8 (0.6)
dBC(AC) κ  0 linear q(·) 0.971 (0.007) 0.292 (0.005) 0.290 (<0.001) 8.7 (0.6)
κ  0 non-linear q(·) 0.673 (0.007) 0.326 (0.005) 0.325 (<0.001) 45.6 (1.1)
κ  0.5 linear q(·) 0.296 (0.007) 0.292 (0.005) 0.290 (<0.001) 81.9 (0.9)
κ  0.5 non-linear q(·) 0.288 (0.007) 0.310 (0.005) 0.309 (<0.001) 85.0 (0.8)
κ  1 linear q(·) 0.071 (0.007) 0.292 (0.005) 0.290 (<0.001) 94.5 (0.5)
κ  1 non-linear q(·) 0.083 (0.007) 0.303 (0.005) 0.302 (<0.001) 94.2 (0.5)
402
B.6. SCENARIOS G, H, AND I








Table B.11 Simulation results for scenarios g, h, and i, adjusting for all effect
modifiers. The covariate distributions and correlation structures in each study
are varied jointly. Monte Carlo standard errors for each statistic are shown in
brackets.
Method Contrast Scenario Bias Empirical SE Model SE Coverage
ML-NMR dAB(AB) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.058 (0.005) 0.207 (0.003) 0.207 (<0.001) 94.0 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.058 (0.005) 0.207 (0.003) 0.207 (<0.001) 94.2 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.058 (0.005) 0.207 (0.003) 0.207 (<0.001) 94.4 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.058 (0.005) 0.207 (0.003) 0.207 (<0.001) 94.2 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.058 (0.005) 0.207 (0.003) 0.207 (<0.001) 94.2 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.058 (0.005) 0.207 (0.003) 0.207 (<0.001) 94.1 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.059 (0.005) 0.208 (0.003) 0.207 (<0.001) 94.5 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.059 (0.005) 0.208 (0.003) 0.207 (<0.001) 94.3 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.059 (0.005) 0.208 (0.003) 0.207 (<0.001) 94.5 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.059 (0.005) 0.208 (0.003) 0.207 (<0.001) 94.2 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.059 (0.005) 0.208 (0.003) 0.207 (<0.001) 94.3 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.059 (0.005) 0.208 (0.003) 0.207 (<0.001) 94.4 (0.5)
dAC(AB) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.028 (0.011) 0.476 (0.008) 0.470 (<0.001) 94.8 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.028 (0.011) 0.477 (0.008) 0.470 (<0.001) 95.0 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.028 (0.011) 0.476 (0.008) 0.470 (<0.001) 94.8 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.028 (0.011) 0.477 (0.008) 0.470 (<0.001) 95.0 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.028 (0.011) 0.477 (0.008) 0.470 (<0.001) 94.9 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.028 (0.011) 0.477 (0.008) 0.470 (<0.001) 94.8 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.051 (0.011) 0.478 (0.008) 0.471 (<0.001) 94.9 (0.5)







Method Contrast Scenario Bias Empirical SE Model SE Coverage
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.051 (0.011) 0.478 (0.008) 0.471 (<0.001) 94.6 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.051 (0.011) 0.478 (0.008) 0.472 (<0.001) 94.9 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.051 (0.011) 0.478 (0.008) 0.472 (<0.001) 94.7 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.051 (0.011) 0.478 (0.008) 0.471 (<0.001) 94.8 (0.5)
dBC(AB) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.030 (0.012) 0.516 (0.008) 0.509 (<0.001) 94.5 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 0.030 (0.012) 0.516 (0.008) 0.509 (<0.001) 94.6 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 0.030 (0.012) 0.516 (0.008) 0.509 (<0.001) 94.7 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 0.030 (0.012) 0.516 (0.008) 0.509 (<0.001) 94.7 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 0.029 (0.012) 0.516 (0.008) 0.509 (<0.001) 94.8 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 0.030 (0.012) 0.516 (0.008) 0.509 (<0.001) 94.8 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.008 (0.012) 0.514 (0.008) 0.508 (<0.001) 94.8 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 0.008 (0.012) 0.515 (0.008) 0.508 (<0.001) 94.7 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 0.008 (0.012) 0.514 (0.008) 0.508 (<0.001) 94.5 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 0.008 (0.012) 0.514 (0.008) 0.509 (<0.001) 94.8 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 0.007 (0.012) 0.515 (0.008) 0.509 (<0.001) 94.8 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 0.008 (0.012) 0.514 (0.008) 0.508 (<0.001) 94.5 (0.5)
dAB(AC) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.069 (0.011) 0.470 (0.007) 0.464 (<0.001) 94.2 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.069 (0.011) 0.471 (0.007) 0.464 (<0.001) 94.2 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.069 (0.011) 0.470 (0.007) 0.464 (<0.001) 94.4 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.069 (0.011) 0.471 (0.007) 0.465 (<0.001) 94.2 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.069 (0.011) 0.470 (0.007) 0.464 (<0.001) 94.2 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.069 (0.011) 0.470 (0.007) 0.464 (<0.001) 94.2 (0.5)









Method Contrast Scenario Bias Empirical SE Model SE Coverage
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.047 (0.010) 0.468 (0.007) 0.463 (<0.001) 94.4 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.047 (0.010) 0.468 (0.007) 0.463 (<0.001) 94.5 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.047 (0.010) 0.468 (0.007) 0.463 (<0.001) 94.3 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.047 (0.010) 0.468 (0.007) 0.463 (<0.001) 94.4 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.047 (0.010) 0.468 (0.007) 0.463 (<0.001) 94.3 (0.5)
dAC(AC) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.039 (0.005) 0.219 (0.003) 0.211 (<0.001) 94.0 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.040 (0.005) 0.220 (0.003) 0.211 (<0.001) 94.0 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.039 (0.005) 0.220 (0.003) 0.211 (<0.001) 94.0 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.039 (0.005) 0.220 (0.003) 0.211 (<0.001) 94.3 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.040 (0.005) 0.220 (0.003) 0.211 (<0.001) 93.9 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.039 (0.005) 0.220 (0.003) 0.211 (<0.001) 93.8 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.039 (0.005) 0.219 (0.003) 0.211 (<0.001) 94.1 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.039 (0.005) 0.220 (0.003) 0.211 (<0.001) 94.0 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.039 (0.005) 0.220 (0.003) 0.211 (<0.001) 94.2 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.039 (0.005) 0.220 (0.003) 0.211 (<0.001) 94.2 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.040 (0.005) 0.220 (0.003) 0.211 (<0.001) 94.0 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.039 (0.005) 0.220 (0.003) 0.211 (<0.001) 93.8 (0.5)
dBC(AC) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.030 (0.012) 0.516 (0.008) 0.509 (<0.001) 94.5 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 0.030 (0.012) 0.516 (0.008) 0.509 (<0.001) 94.6 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 0.030 (0.012) 0.516 (0.008) 0.509 (<0.001) 94.7 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 0.030 (0.012) 0.516 (0.008) 0.509 (<0.001) 94.7 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 0.029 (0.012) 0.516 (0.008) 0.509 (<0.001) 94.8 (0.5)







Method Contrast Scenario Bias Empirical SE Model SE Coverage
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.008 (0.012) 0.514 (0.008) 0.508 (<0.001) 94.8 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 0.008 (0.012) 0.515 (0.008) 0.508 (<0.001) 94.7 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 0.008 (0.012) 0.514 (0.008) 0.508 (<0.001) 94.5 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 0.008 (0.012) 0.514 (0.008) 0.509 (<0.001) 94.8 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 0.007 (0.012) 0.515 (0.008) 0.509 (<0.001) 94.8 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 0.008 (0.012) 0.514 (0.008) 0.508 (<0.001) 94.5 (0.5)
STC dAB(AC) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.038 (0.010) 0.458 (0.007) 0.458 (<0.001) 95.2 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.037 (0.010) 0.458 (0.007) 0.458 (<0.001) 95.2 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.037 (0.010) 0.457 (0.007) 0.458 (<0.001) 95.2 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.038 (0.010) 0.458 (0.007) 0.458 (<0.001) 95.2 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.037 (0.010) 0.458 (0.007) 0.458 (<0.001) 95.2 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.037 (0.010) 0.457 (0.007) 0.458 (<0.001) 95.2 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.026 (0.010) 0.457 (0.007) 0.458 (<0.001) 95.1 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.026 (0.010) 0.457 (0.007) 0.458 (<0.001) 95.1 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.026 (0.010) 0.457 (0.007) 0.458 (<0.001) 95.2 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.026 (0.010) 0.457 (0.007) 0.458 (<0.001) 95.1 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.026 (0.010) 0.457 (0.007) 0.458 (<0.001) 95.1 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.026 (0.010) 0.457 (0.007) 0.458 (<0.001) 95.2 (0.5)
dBC(AC) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.023 (0.011) 0.504 (0.008) 0.503 (<0.001) 95.2 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 0.022 (0.011) 0.504 (0.008) 0.503 (<0.001) 95.2 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 0.022 (0.011) 0.504 (0.008) 0.503 (<0.001) 95.3 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 0.023 (0.011) 0.504 (0.008) 0.503 (<0.001) 95.2 (0.5)









Method Contrast Scenario Bias Empirical SE Model SE Coverage
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 0.023 (0.011) 0.504 (0.008) 0.503 (<0.001) 95.3 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.011 (0.011) 0.503 (0.008) 0.503 (<0.001) 95.0 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 0.011 (0.011) 0.503 (0.008) 0.503 (<0.001) 95.0 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 0.011 (0.011) 0.503 (0.008) 0.503 (<0.001) 94.9 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 0.012 (0.011) 0.503 (0.008) 0.503 (<0.001) 95.0 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 0.011 (0.011) 0.503 (0.008) 0.503 (<0.001) 95.0 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 0.011 (0.011) 0.503 (0.008) 0.503 (<0.001) 94.9 (0.5)
MAIC dAB(AC) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.138 (0.019) 0.850 (0.013) - (-) 90.1 (0.7)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.138 (0.019) 0.849 (0.013) - (-) 90.2 (0.7)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.139 (0.019) 0.849 (0.013) - (-) 90.2 (0.7)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.138 (0.019) 0.850 (0.013) 10.701 (4.733) 90.2 (0.7)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.139 (0.019) 0.850 (0.013) 49.602 (22.145) 90.2 (0.7)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.139 (0.019) 0.849 (0.013) - (-) 90.2 (0.7)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.219 (0.024) 1.091 (0.017) - (-) 89.4 (0.7)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.221 (0.025) 1.112 (0.018) - (-) 89.5 (0.7)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.220 (0.024) 1.089 (0.017) - (-) 89.5 (0.7)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.219 (0.024) 1.083 (0.017) - (-) 89.4 (0.7)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.219 (0.024) 1.087 (0.017) - (-) 89.5 (0.7)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.220 (0.025) 1.097 (0.017) - (-) 89.5 (0.7)
dBC(AC) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.123 (0.020) 0.875 (0.014) - (-) 95.4 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 0.123 (0.020) 0.875 (0.014) - (-) 95.1 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 0.124 (0.020) 0.875 (0.014) - (-) 95.1 (0.5)







Method Contrast Scenario Bias Empirical SE Model SE Coverage
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 0.123 (0.020) 0.875 (0.014) 49.603 (22.145) 95.0 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 0.124 (0.020) 0.875 (0.014) - (-) 95.0 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.205 (0.025) 1.106 (0.017) - (-) 96.0 (0.4)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 0.206 (0.025) 1.126 (0.018) - (-) 95.8 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 0.204 (0.025) 1.104 (0.017) - (-) 95.6 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 0.204 (0.025) 1.098 (0.017) - (-) 95.8 (0.4)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 0.204 (0.025) 1.103 (0.017) - (-) 95.9 (0.4)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 0.206 (0.025) 1.112 (0.018) - (-) 95.4 (0.5)
Bucher dAB(AC) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.5 (1.1)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.5 (1.1)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.5 (1.1)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.5 (1.1)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.5 (1.1)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.5 (1.1)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.3 (1.1)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.3 (1.1)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.3 (1.1)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.3 (1.1)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.3 (1.1)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.3 (1.1)
dBC(AC) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.303 (0.007) 0.295 (0.005) 0.291 (<0.001) 81.8 (0.9)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 0.303 (0.007) 0.296 (0.005) 0.291 (<0.001) 81.8 (0.9)









Method Contrast Scenario Bias Empirical SE Model SE Coverage
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 0.304 (0.007) 0.295 (0.005) 0.291 (<0.001) 81.7 (0.9)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 0.303 (0.007) 0.296 (0.005) 0.291 (<0.001) 81.7 (0.9)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 0.303 (0.007) 0.295 (0.005) 0.291 (<0.001) 81.6 (0.9)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.303 (0.007) 0.295 (0.005) 0.291 (<0.001) 81.8 (0.9)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 0.303 (0.007) 0.296 (0.005) 0.291 (<0.001) 81.8 (0.9)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 0.303 (0.007) 0.296 (0.005) 0.291 (<0.001) 81.8 (0.9)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 0.304 (0.007) 0.295 (0.005) 0.291 (<0.001) 81.8 (0.9)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 0.303 (0.007) 0.295 (0.005) 0.291 (<0.001) 81.8 (0.9)






Table B.12 Simulation results for scenarios g, h, and i, only adjusting for one
of two effect modifiers. The covariate distributions and correlation structures
in each study are varied jointly. Monte Carlo standard errors for each statistic
are shown in brackets.
Method Contrast Scenario Bias Empirical SE Model SE Coverage
ML-NMR dAB(AB) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.036 (0.005) 0.204 (0.003) 0.205 (<0.001) 95.2 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.036 (0.005) 0.204 (0.003) 0.205 (<0.001) 95.2 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.036 (0.005) 0.204 (0.003) 0.205 (<0.001) 94.8 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.036 (0.005) 0.204 (0.003) 0.205 (<0.001) 95.0 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.036 (0.005) 0.204 (0.003) 0.205 (<0.001) 95.0 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.036 (0.005) 0.204 (0.003) 0.205 (<0.001) 94.8 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.036 (0.005) 0.205 (0.003) 0.205 (<0.001) 94.9 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.036 (0.005) 0.205 (0.003) 0.205 (<0.001) 94.8 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.036 (0.005) 0.205 (0.003) 0.205 (<0.001) 94.8 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.036 (0.005) 0.205 (0.003) 0.205 (<0.001) 95.0 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.036 (0.005) 0.205 (0.003) 0.205 (<0.001) 94.9 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.036 (0.005) 0.205 (0.003) 0.205 (<0.001) 94.8 (0.5)
dAC(AB) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.113 (0.008) 0.366 (0.006) 0.358 (<0.001) 93.5 (0.6)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 0.112 (0.008) 0.366 (0.006) 0.358 (<0.001) 93.5 (0.6)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 0.112 (0.008) 0.366 (0.006) 0.358 (<0.001) 93.5 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 0.113 (0.008) 0.366 (0.006) 0.358 (<0.001) 93.8 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 0.112 (0.008) 0.366 (0.006) 0.358 (<0.001) 93.5 (0.6)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 0.112 (0.008) 0.366 (0.006) 0.358 (<0.001) 93.7 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.099 (0.008) 0.367 (0.006) 0.359 (<0.001) 94.2 (0.5)









Method Contrast Scenario Bias Empirical SE Model SE Coverage
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 0.099 (0.008) 0.367 (0.006) 0.359 (<0.001) 94.0 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 0.099 (0.008) 0.367 (0.006) 0.359 (<0.001) 94.1 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 0.099 (0.008) 0.367 (0.006) 0.359 (<0.001) 94.2 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 0.099 (0.008) 0.367 (0.006) 0.359 (<0.001) 94.2 (0.5)
dBC(AB) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.148 (0.009) 0.415 (0.007) 0.409 (<0.001) 93.3 (0.6)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 0.148 (0.009) 0.416 (0.007) 0.409 (<0.001) 93.2 (0.6)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 0.148 (0.009) 0.415 (0.007) 0.409 (<0.001) 93.3 (0.6)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 0.148 (0.009) 0.415 (0.007) 0.409 (<0.001) 93.5 (0.6)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 0.148 (0.009) 0.415 (0.007) 0.409 (<0.001) 93.3 (0.6)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 0.148 (0.009) 0.415 (0.007) 0.409 (<0.001) 93.2 (0.6)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.135 (0.009) 0.414 (0.007) 0.409 (<0.001) 93.2 (0.6)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 0.135 (0.009) 0.414 (0.007) 0.409 (<0.001) 93.2 (0.6)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 0.135 (0.009) 0.414 (0.007) 0.409 (<0.001) 93.3 (0.6)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 0.135 (0.009) 0.414 (0.007) 0.409 (<0.001) 93.3 (0.6)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 0.135 (0.009) 0.414 (0.007) 0.409 (<0.001) 93.2 (0.6)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 0.135 (0.009) 0.414 (0.007) 0.409 (<0.001) 93.4 (0.6)
dAB(AC) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.180 (0.008) 0.352 (0.006) 0.352 (<0.001) 92.5 (0.6)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.180 (0.008) 0.352 (0.006) 0.352 (<0.001) 92.5 (0.6)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.179 (0.008) 0.352 (0.006) 0.352 (<0.001) 92.7 (0.6)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.180 (0.008) 0.351 (0.006) 0.352 (<0.001) 92.3 (0.6)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.180 (0.008) 0.352 (0.006) 0.352 (<0.001) 92.3 (0.6)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.180 (0.008) 0.352 (0.006) 0.352 (<0.001) 92.3 (0.6)







Method Contrast Scenario Bias Empirical SE Model SE Coverage
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.167 (0.008) 0.350 (0.006) 0.351 (<0.001) 92.8 (0.6)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.167 (0.008) 0.350 (0.006) 0.351 (<0.001) 92.8 (0.6)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.167 (0.008) 0.350 (0.006) 0.351 (<0.001) 92.8 (0.6)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.167 (0.008) 0.350 (0.006) 0.351 (<0.001) 92.7 (0.6)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.167 (0.008) 0.350 (0.006) 0.351 (<0.001) 92.7 (0.6)
dAC(AC) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.031 (0.005) 0.218 (0.003) 0.210 (<0.001) 94.2 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.032 (0.005) 0.219 (0.003) 0.210 (<0.001) 94.2 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.032 (0.005) 0.218 (0.003) 0.210 (<0.001) 94.2 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.031 (0.005) 0.218 (0.003) 0.210 (<0.001) 94.3 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.032 (0.005) 0.218 (0.003) 0.210 (<0.001) 93.9 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.032 (0.005) 0.218 (0.003) 0.210 (<0.001) 93.9 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.031 (0.005) 0.218 (0.003) 0.210 (<0.001) 94.2 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.032 (0.005) 0.219 (0.003) 0.210 (<0.001) 94.0 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.032 (0.005) 0.218 (0.003) 0.210 (<0.001) 94.2 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.031 (0.005) 0.218 (0.003) 0.210 (<0.001) 94.2 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.032 (0.005) 0.218 (0.003) 0.210 (<0.001) 94.0 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.031 (0.005) 0.218 (0.003) 0.210 (<0.001) 93.8 (0.5)
dBC(AC) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.148 (0.009) 0.415 (0.007) 0.409 (<0.001) 93.3 (0.6)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 0.148 (0.009) 0.416 (0.007) 0.409 (<0.001) 93.2 (0.6)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 0.148 (0.009) 0.415 (0.007) 0.409 (<0.001) 93.3 (0.6)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 0.148 (0.009) 0.415 (0.007) 0.409 (<0.001) 93.5 (0.6)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 0.148 (0.009) 0.415 (0.007) 0.409 (<0.001) 93.3 (0.6)









Method Contrast Scenario Bias Empirical SE Model SE Coverage
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.135 (0.009) 0.414 (0.007) 0.409 (<0.001) 93.2 (0.6)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 0.135 (0.009) 0.414 (0.007) 0.409 (<0.001) 93.2 (0.6)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 0.135 (0.009) 0.414 (0.007) 0.409 (<0.001) 93.3 (0.6)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 0.135 (0.009) 0.414 (0.007) 0.409 (<0.001) 93.3 (0.6)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 0.135 (0.009) 0.414 (0.007) 0.409 (<0.001) 93.2 (0.6)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 0.135 (0.009) 0.414 (0.007) 0.409 (<0.001) 93.4 (0.6)
STC dAB(AC) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.159 (0.008) 0.344 (0.005) 0.348 (<0.001) 94.0 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.159 (0.008) 0.344 (0.005) 0.348 (<0.001) 94.0 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.159 (0.008) 0.344 (0.005) 0.348 (<0.001) 94.0 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.159 (0.008) 0.344 (0.005) 0.348 (<0.001) 94.0 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.159 (0.008) 0.344 (0.005) 0.348 (<0.001) 94.0 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.159 (0.008) 0.344 (0.005) 0.348 (<0.001) 94.0 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.151 (0.008) 0.344 (0.005) 0.348 (<0.001) 94.2 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.151 (0.008) 0.344 (0.005) 0.348 (<0.001) 94.2 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.151 (0.008) 0.344 (0.005) 0.348 (<0.001) 94.2 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.151 (0.008) 0.344 (0.005) 0.348 (<0.001) 94.2 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.151 (0.008) 0.344 (0.005) 0.348 (<0.001) 94.2 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.151 (0.008) 0.344 (0.005) 0.348 (<0.001) 94.2 (0.5)
dBC(AC) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.144 (0.009) 0.408 (0.006) 0.406 (<0.001) 94.0 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 0.143 (0.009) 0.408 (0.006) 0.406 (<0.001) 93.8 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 0.143 (0.009) 0.408 (0.006) 0.406 (<0.001) 93.8 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 0.144 (0.009) 0.408 (0.006) 0.406 (<0.001) 94.0 (0.5)







Method Contrast Scenario Bias Empirical SE Model SE Coverage
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 0.144 (0.009) 0.408 (0.006) 0.406 (<0.001) 93.8 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.136 (0.009) 0.408 (0.006) 0.406 (<0.001) 93.8 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 0.136 (0.009) 0.408 (0.006) 0.406 (<0.001) 93.9 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 0.136 (0.009) 0.408 (0.006) 0.406 (<0.001) 93.8 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 0.136 (0.009) 0.408 (0.006) 0.406 (<0.001) 93.8 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 0.136 (0.009) 0.408 (0.006) 0.406 (<0.001) 93.7 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 0.136 (0.009) 0.408 (0.006) 0.406 (<0.001) 93.8 (0.5)
MAIC dAB(AC) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.165 (0.009) 0.399 (0.006) 0.411 (<0.001) 91.7 (0.6)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.165 (0.009) 0.399 (0.006) 0.411 (<0.001) 91.7 (0.6)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.165 (0.009) 0.399 (0.006) 0.411 (<0.001) 91.7 (0.6)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.165 (0.009) 0.399 (0.006) 0.411 (<0.001) 91.7 (0.6)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.165 (0.009) 0.399 (0.006) 0.411 (<0.001) 91.7 (0.6)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.165 (0.009) 0.399 (0.006) 0.411 (<0.001) 91.7 (0.6)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.176 (0.010) 0.442 (0.007) 0.448 (0.001) 91.2 (0.6)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.176 (0.010) 0.442 (0.007) 0.448 (0.001) 91.2 (0.6)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.176 (0.010) 0.442 (0.007) 0.448 (0.001) 91.2 (0.6)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.176 (0.010) 0.441 (0.007) 0.447 (0.001) 91.3 (0.6)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.176 (0.010) 0.441 (0.007) 0.447 (0.001) 91.3 (0.6)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.176 (0.010) 0.441 (0.007) 0.447 (0.001) 91.3 (0.6)
dBC(AC) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.150 (0.010) 0.453 (0.007) 0.461 (<0.001) 94.1 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 0.150 (0.010) 0.453 (0.007) 0.461 (<0.001) 94.0 (0.5)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 0.150 (0.010) 0.453 (0.007) 0.461 (<0.001) 94.0 (0.5)









Method Contrast Scenario Bias Empirical SE Model SE Coverage
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 0.150 (0.010) 0.453 (0.007) 0.461 (<0.001) 94.2 (0.5)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 0.150 (0.010) 0.453 (0.007) 0.461 (<0.001) 94.1 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.161 (0.011) 0.489 (0.008) 0.494 (0.001) 93.7 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 0.161 (0.011) 0.489 (0.008) 0.494 (0.001) 93.8 (0.5)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 0.161 (0.011) 0.490 (0.008) 0.494 (0.001) 93.8 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 0.161 (0.011) 0.489 (0.008) 0.494 (0.001) 93.5 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 0.161 (0.011) 0.489 (0.008) 0.494 (0.001) 93.8 (0.5)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 0.161 (0.011) 0.489 (0.008) 0.494 (0.001) 93.5 (0.5)
Bucher dAB(AC) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.5 (1.1)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.5 (1.1)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.5 (1.1)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.5 (1.1)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.5 (1.1)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.5 (1.1)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.3 (1.1)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.3 (1.1)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.3 (1.1)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.3 (1.1)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.3 (1.1)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 -0.318 (0.004) 0.199 (0.003) 0.202 (<0.001) 65.3 (1.1)
dBC(AC) X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.303 (0.007) 0.295 (0.005) 0.291 (<0.001) 81.8 (0.9)
X(AB) ∼ Gam X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 0.303 (0.007) 0.296 (0.005) 0.291 (<0.001) 81.8 (0.9)







Method Contrast Scenario Bias Empirical SE Model SE Coverage
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 0.304 (0.007) 0.295 (0.005) 0.291 (<0.001) 81.7 (0.9)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 0.303 (0.007) 0.296 (0.005) 0.291 (<0.001) 81.7 (0.9)
X(AB) ∼ Gam X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0.5 0.303 (0.007) 0.295 (0.005) 0.291 (<0.001) 81.6 (0.9)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0 0.303 (0.007) 0.295 (0.005) 0.291 (<0.001) 81.8 (0.9)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  ρ(AC)  0.25 0.303 (0.007) 0.296 (0.005) 0.291 (<0.001) 81.8 (0.9)
X(AB) ∼ N X(AC) ∼ Gam ρ(AB)  0.25, ρ(AC)  0.5 0.303 (0.007) 0.296 (0.005) 0.291 (<0.001) 81.8 (0.9)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  0.25, ρ(AC)  0 0.304 (0.007) 0.295 (0.005) 0.291 (<0.001) 81.8 (0.9)
X(AB) ∼ N X(AC) ∼ N ρ(AB)  ρ(AC)  0.25 0.303 (0.007) 0.295 (0.005) 0.291 (<0.001) 81.8 (0.9)







Intel i7-6600U CPU, dual core 2.6 GHz. 16 GB RAM.
Desktop
Intel i7-8700 CPU, hex core 3.2 GHz. 16 GB RAM.
BlueCrystal Phase 3 supercomputer
Each node has 16 Sandy Bridge cores at 2.6 GHz, with 64 GB RAM.
C.2Soware
R versions 3.4.1 to 3.5.3 (R Core Team 2018) and Stan versions 2.16.0 to 2.18.1
(Carpenter et al. 2017) were used for analysis.
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